WorldWideScience

Sample records for ampliscreen hbv test

  1. Interpreting Liver Function Test in HIV-HBV Coinfection.

    Directory of Open Access Journals (Sweden)

    Tamal Mukherjee

    2013-08-01

    Such co-infected individuals also face increased risk of hepatotoxicity from anti-retroviral therapy. Individuals with HIV-HBV co-infection should have both the infections completely assessed in order to decide on the best therapeutic option for both viruses. [Natl J Med Res 2013; 3(4.000: 342-345

  2. An in-house real-time polymerase chain reaction: standardisation and comparison with the Cobas Amplicor HBV monitor and Cobas AmpliPrep/Cobas TaqMan HBV tests for the quantification of hepatitis B virus DNA

    Science.gov (United States)

    Santos, Ana Paula de Torres; Levi, José Eduardo; Lemos, Marcilio Figueiredo; Calux, Samira Julien; Oba, Isabel Takano; Moreira, Regina Célia

    2016-01-01

    This study aimed to standardise an in-house real-time polymerase chain reaction (rtPCR) to allow quantification of hepatitis B virus (HBV) DNA in serum or plasma samples, and to compare this method with two commercial assays, the Cobas Amplicor HBV monitor and the Cobas AmpliPrep/Cobas TaqMan HBV test. Samples from 397 patients from the state of São Paulo were analysed by all three methods. Fifty-two samples were from patients who were human immunodeficiency virus and hepatitis C virus positive, but HBV negative. Genotypes were characterised, and the viral load was measure in each sample. The in-house rtPCR showed an excellent success rate compared with commercial tests; inter-assay and intra-assay coefficients correlated with commercial tests (r = 0.96 and r = 0.913, p < 0.001) and the in-house test showed no genotype-dependent differences in detection and quantification rates. The in-house assay tested in this study could be used for screening and quantifying HBV DNA in order to monitor patients during therapy. PMID:26872342

  3. 聚合酶链反应检测血清HBV-DNA的临床价值%Clinical Value of testing Blood HBV-DNA By PCR

    Institute of Scientific and Technical Information of China (English)

    高蓬

    1998-01-01

    @@ 聚合酶链反应(polymerase chain reaction,PCR)是一种体外DNA扩增技术,本文采用PCR技术检测乙型肝炎病毒(HBV-DNA),并与乙肝病毒标志物进行对比,以探讨HBV感染状态及与乙肝标志物(HBV-M)之间的关系.

  4. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg/anti-HBe, and liver function tests.

    Science.gov (United States)

    Hasan, K N; Rumi, M A K; Hasanat, M A; Azam, M G; Ahmed, S; Salam, M A; Islam, L N; Hassan, M S

    2002-03-01

    Serological markers of hepatitis B virus (HBV), liver function tests and quantitative estimation of HBV-DNA are important in the assessment of the state of infection and prognosis following treatment for hepatitis B. This study aimed to determine whether low-cost assays, eg hepatitis B e antigen (HBeAg) and liver function tests, could be used for the assessment of infectivity as an alternative to HBV-DNA estimation. We tested 125 hepatitis B carriers for HBeAg, antibody to HBeAg (anti-HBe), and serum HBV-DNA; we also carried out a range of standard liver function tests. Seventy-three subjects were positive and 52 were negative for HBeAg. Of the HBeAg positive cases, 3 were also positive for anti-HBe; of the HBeAg negative cases, 5 were also negative for anti-HBe. Of these 8 cases, 7 had no detectable HBV-DNA. Most of the HBeAg positive but anti-HBe negative subjects were positive for HBV-DNA (74.3%; 52/ 70) whereas most of the HBeAg negative and anti-HBe positive subjects (93.6%; 44/47) were also negative for HBV-DNA. Of 56 HBV-DNA positive individuals, alanine transaminase (ALT) was found to be raised in 69.6% (p=0.066) and aspartate transaminase (AST) was raised in 66.1% (p=0.011), while 67.9% had normal alkaline phosphatase (ALP) (p=0.054). HBeAg (p=0.018) and raised ALT (p=0.008) were found to be independent predictors for HBV-DNA positivity among HBV carriers. This study suggests that HBeAg positive and anti-HBe negative hepatitis B carriers with raised ALT and AST are likely to be positive for HBV-DNA; the combination of routine serology and biochemical tests may be considered as an alternative to HBV-DNA in evaluating the state of chronic HBV infection. However, HBV-DNA should be specifically assessed if discordance is observed between seromarkers and transaminases.

  5. Clinical Significance of Establishing Relationship between the HBsAg Test and HBV DNA%乙肝五项测定结果与HBV DNA的关系及其临床意义

    Institute of Scientific and Technical Information of China (English)

    李昕; 张荣波

    2011-01-01

    Objective To explore the internal relationship and the clinical significance of HBVM( HBsAg, Anti-HBs,HBeAg,Anti-HBe, Anti-HBc )and HBV DNA( Hepatitis B Virus DNA ). Methods HBVM and HBV-DNA of 300 HBV patients were examined by enzyme linked immunosorbent assay( ELISA )and quantitative fluorescence PCR technique respectively. Results Of all the clinical results of 300 HBV patients,110 patients showed HBsAg( + ),HBeAg( + ),HBcAb( + )( HBV DNA positive rate 99. 1% ),85 patients showing HBsAg( + ), HBeAb( + ),HBcAb( + )( HBV DNA positive rate 69.4% ), 39 patients showing HBsAg( + ),HBcAb( + )( HBV DNA positive rate 53.8% ),53 patients showing HBeAb( + ),HBcAb( + )( HBV DNA positive rate 35.8% ). HBV DNA positive rate of HBsAg( + ),HBeAg( + ),HBcAb( + ) and HBsAg( + ), HBeAb( + ), HBcAb( + ) were different significantly( x2 = 35. 406, P < 0.05 ). Conclusion The results of HBsAg and HBV-DNA are closely related with different clinical meanings,which makes it necessary to combine the two results for a correct diagnosis and treatment.%目的探讨乙型肝炎(乙肝)五项结果和HBV DNA检出情况间的关系和临床意义.方法运用聚合酶链反应法检测300例乙肝血清的HBV DNA,并用酶联免疫吸附实验法进行乙肝五项的测定,对结果进行比较分析.结果 300例乙肝门诊的患者中乙肝五项的结果为110例HBsAg(+)、HBeAg(+)、HBcAb(+)(大三阳),其HBV DNA的阳性率为99.1%,85例HBsAg(+)、HBeAb(+)、HBcAb(+)(小三阳),其HBV DNA的阳性率为69.4%,39例HBsAg(+)、HBcAb(+),其HBV DNA的阳性率为53.8%,53例HBeAb(+)、HBcAb(+),其HBV DNA的阳性率为35.8%.大三阳和小三阳的HBV DNA阳性率比较差异有统计学意义(χ2=35.406,P<0.05).结论乙肝五项的结果与HBV DNA的结果有着密切的联系,并且都具备各自的临床意义,因此两者必须结合才能正确地对乙肝患者的病情作出正确分析和判断.

  6. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors

    Directory of Open Access Journals (Sweden)

    J.S.F. Pereira

    2006-04-01

    Full Text Available Anti-HBc positivity is a frequent cause of donation rejection at blood banks. Hepatitis B virus (HBV infection may also occur in HBsAg-negative patients, a situation denoted occult infection. Similarly, very low levels of HBV-DNA have also been found in the sera of patients with chronic hepatitis C virus (HCV infection, even in the absence of serum HBsAg. Initially we searched for HBV-DNA in serum of 100 blood donors and 50 HCV-infected patients who were HBsAg negative/anti-HBc positive by nested-PCR and by an HBV monitor commercial test for HBV-DNA. Anti-HBs seroconversion rates were measured in 100 blood donors and in 22 patients with chronic HCV infection after HBV vaccination to determine if the HBV vaccination could eliminate an occult HBV infection in these individuals. Occult HBV infection was detected in proportionally fewer blood donors (6/100 = 6% than chronic hepatitis C patients (12/50 = 24% (P 0.05. All subjects who were HBV-DNA(+ before the first dose of HBV vaccine (D1, became HBV-DNA(- after D1, D2, and D3. Among 22 HCV-positive patients, 10 HBV-DNA(+ and 12 HBV-DNA(-, seroconversion was observed in 9/10 (90% HBV-DNA(+ and in 9/12 (75% HBV-DNA(- subjects (P > 0.05. The disappearance of HBV-DNA in the majority of vaccinated patients suggests that residual HBV can be eliminated in patients with occult infection.

  7. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors.

    Science.gov (United States)

    Pereira, J S F; Gonçales, N S L; Silva, C; Lazarini, M S K; Pavan, M H P; Fais, V C; Gonçales Júnior, F L

    2006-04-01

    Anti-HBc positivity is a frequent cause of donation rejection at blood banks. Hepatitis B virus (HBV) infection may also occur in HBsAg-negative patients, a situation denoted occult infection. Similarly, very low levels of HBV-DNA have also been found in the sera of patients with chronic hepatitis C virus (HCV) infection, even in the absence of serum HBsAg. Initially we searched for HBV-DNA in serum of 100 blood donors and 50 HCV-infected patients who were HBsAg negative/anti-HBc positive by nested-PCR and by an HBV monitor commercial test for HBV-DNA. Anti-HBs seroconversion rates were measured in 100 blood donors and in 22 patients with chronic HCV infection after HBV vaccination to determine if the HBV vaccination could eliminate an occult HBV infection in these individuals. Occult HBV infection was detected in proportionally fewer blood donors (6/100 = 6%) than chronic hepatitis C patients (12/50 = 24%) (P 0.05). All subjects who were HBV-DNA(+) before the first dose of HBV vaccine (D1), became HBV-DNA(-) after D1, D2, and D3. Among 22 HCV-positive patients, 10 HBV-DNA(+) and 12 HBV-DNA(-), seroconversion was observed in 9/10 (90%) HBV-DNA(+) and in 9/12 (75%) HBV-DNA(-) subjects (P > 0.05). The disappearance of HBV-DNA in the majority of vaccinated patients suggests that residual HBV can be eliminated in patients with occult infection.

  8. Hepatitis B (HBV)

    Science.gov (United States)

    ... Loss Surgery? A Week of Healthy Breakfasts Shyness Hepatitis B (HBV) KidsHealth > For Teens > Hepatitis B (HBV) Print A A A What's in this ... poisons). There are several different types of hepatitis . Hepatitis B is a type that can move from one ...

  9. Hepatitis B (HBV)

    Science.gov (United States)

    ... Loss Surgery? A Week of Healthy Breakfasts Shyness Hepatitis B (HBV) KidsHealth > For Teens > Hepatitis B (HBV) A A A What's in this article? ... poisons). There are several different types of hepatitis . Hepatitis B is a type that can move from one ...

  10. Analysis by ELISA test important factors of HBV markers%ELISA法检验乙肝标志物影响因素分析

    Institute of Scientific and Technical Information of China (English)

    郭盼

    2013-01-01

    Objective:To analyze by ELISA test important factors of HBV markers specimen storage time and storage conditions on the measurement results .Methods:52 cases in our hospital by ELISA test HBV markers positive sample the retention samples at room tem -perature three days,five days and 10 days,2 ~6℃retention samples 3 days,5 days and 10 days,respectively,again by ELISA assay anal-ysis of specimen storage time and storage conditions on the test results .Results:52 cases of samples using ELISA testing ,store the day samples of HBV markers was positive at room temperature 3 days after the sample was positive ,5 days after four cases of samples into the negative ,and 10 days after 11 cases of sample into a negative .2~6℃for 3 days ,5 days after the samples were positive ,and 10 days af-ter the eight cases of samples into the negative .Conclusion:HBV markers by ELISA test samples at room temperature for 3 days or 2 ~6℃stored for 5 days,had no effect on HBV markers detection results .%目的:分析ELISA法检验乙肝标志物重要影响因素标本存放时间及存放条件对测定结果的影响。方法:对我院52例采用ELISA法检验乙肝标志物为阳性的样本,室温留样3天、5天和10天,2~6℃留样3天、5天和10天,分别再次采用ELISA法检测,分析标本存放时间及存放条件对检测结果的影响。结果:52例样本采用ELISA法检测,当天样本乙肝标志物为阳性,室温存放3天后的样本为阳性,5天后有4例样本转变成阴性,10天后有11例样本转变成阴性。2~6℃存放3天、5天后样本均为阳性,10天后有8例样本转变为阴性。结论:采用ELISA法检验乙肝标志物,样本室温存放3天或2~6℃存放5天,对乙肝标志物检测结果无影响。

  11. 标本前处理方法对乳汁HBV DNA检测的影响%Processing method of samples before the effect on testing milk HBV DNA

    Institute of Scientific and Technical Information of China (English)

    蒋雪纷

    2015-01-01

    Objective:to study the effects and analysis method for detection of HBV dna in milk. Methods:our hospital from 2013 January to 2014 december received 30 deliveries as the main object, pregnant women were serum positive hepatitis B surface antigen, hepatitis B e antigen positive, hepatitis B core antibody positive. take the maternal milk samples, and placed in a temperature of 4 deG in the refrigerator overnight, then take the middle layer of milk three ways parallel detection of milk HBV dna level, including the supernatant, concentrating the supernatant and precipitate detection detection detection. Results:the positive rate of HBV in the comparison of dna, precipitation detection compared to the rest of the two kind of method is high, the obvious differences, P<0.05, suggesting that there was statistical signiifcance in comparison;positive specimens of HBV dna log concentration, precipitation detection compared to the rest of the two kind of method is high, the obvious differences, P<0.05, there is statistical signiifcance indication. Conclusion:the milk samples in the refrigerator overnight after, take the middle layer of milk to give HBV dna detection of centrifugation, precipitation, the result is relatively reliable, worthy of popularization.%目的:探究和分析处理方法对乳汁HBV dna检测的影响。方法选择我院2013年1月份到2014年12月份接收的分娩产妇106例为主要对象,产妇均为血清乙型肝炎表面抗原阳性、乙型肝炎e抗原阳性以及乙型肝炎核心抗体阳性。取产妇乳汁标本,并置于温度为4℃冰箱内过夜,之后取中间层乳汁分三种方法平行检测乳汁HBV dna水平,包括上清液检测、上清液浓缩检测以及沉淀检测。结果在HBV dna阳性率比较上,沉淀检测相比其余两种方法更高,差异明显,P<0.05,提示有统计学意义;在阳性标本HBV dna对数浓度比较上,沉淀检测相比其余两种方法更高,差异明显,P<0.05

  12. HCV and HBV coexist in HBsAg-negative patients with HCV viremia; possibility of coinfection in these patients must be considered in HBV-high endemic area

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Dong Soon [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    1998-01-01

    Hepatocellular carcinoma (HCC) is one of the most common cancers and is highly associated with HBV infection in Korea. It has been suggested that HCV core protein may impair the polymerase activity of HBV in vitro, potentially lowering HBV titre in coinfected patients. The aim of this study was to confirm the coexistence of HBV viremia in HCV infected patients HCC who have apparent HBsAg seronegativity. The serological profiles of HBV and HCV in 616 patients with HCC were analysed and coinfection rate of HBV and HCV investigated. Sera were obtained from 16 patients who were both anti-HCV and HCV RNA positive but HbsAg negative, and tested for HBV BY PCR. As a control group, sera were obtained from 15 patients with HCC and 30 non-A abd non-B chronic hepatitis patients without HCC; both were anti-HCV, HCV-RNA, and HBsAg negative and tested for HBV PCR. Of 616 patients with HCC, 450 (73.1 %) had current HBV infection, 48 (7.8 %) had anti-HCV antibodies, and nine (1.5 %) had viral markers of both HCV abd HBV by serological profiles. Of 27 the patients with HCV viremia and HBsAg seronegativity, 14 (51.9 %) showed HBV viremia by PCR. In contrast, of the 75 patients in the control group who were both HCV PCR negative and HBsAg negative, five (11.1 %) showed HBV viremia by PCR. The PCR for HBV revealed coexistent HBV viremia in HCV viremia patients, despite HBsAg negativity by EIA. In HBV-endemic areas, the possibility of coinfection of HBV in HBsAg-negative patients with HCV viremia should be considered and molecular analysis for HBV-DNA performed. (author). 18 refs., 4 tabs.

  13. Analysis of test results of HBV markers for 482 cases of placental blood and maternal blood%482例胎盘血和母体血 HBV标志物测定结果分析

    Institute of Scientific and Technical Information of China (English)

    吉晓云

    2014-01-01

    Objective:To investigate relationship of HBV markers in placental blood and maternal blood. Methods:The HBV markers in 482 cases of placental blood and maternal blood were determined and analyzed statistically. Results:The test results of the HBV markers in the 482 cases of placental blood and maternal blood were not completely consistent. Conclusions:There is no obvious difference in the HBV markers in placental blood and maternal blood and its reason remains to be further discussed.%目的:探讨胎盘血与母体血HBV标志物的关系。方法:将482例胎盘血与母体血进行HBV标志物测定,然后统计分析。结果:482例人次的胎盘血与母体血HBV标志和检测,发现其结果并非完全一致。结论:胎盘血和母体血二者的结果差异不大,其原因有待进一步探讨。

  14. Prevalence of HBV genotypes in South American immigrants affected by HBV-related chronic active hepatitis

    Directory of Open Access Journals (Sweden)

    Emilio Palumbo

    2007-06-01

    Full Text Available This study evaluated the prevalence of HBV infection in a population of South American immigrants in Italy and to determine in patients with detectable serum HBV-DNA the HBVgenotypes. Between April 2005 and April 2006 a total of 130 South American immigrants were tested for HBsAg. In HBsAg positive patients the biochemical and virological activity of infection and the possible presence of co-infections (HCV, HDV, HIV were evaluated. In patients with detectable serum HBV DNA, the HBV genotype was determined by INNOLiPA. Among the 130 subjects tested, 14 (10.7% resulted HBsAg positive. All were men, with a mean age of 22 years (range 19-37 and 12 (85.7 % came from Brazil, while 2 (14.3% came from Ecuador. All patients infected by HBV had elevated alanine-aminotransferase serum levels (mean level was 127 IU/L, range 74-312 and serum HBV DNA detectable by PCR-Real Time (mean level 1,037,652 copies/mL, range 19,876-1,377,648. Genotype distribution was as follow: genotype D, 9 (64.2%, genotype A, 5 (35.8%. All patients infected by genotype D came from Brazil, while among the patients infected by genotype A, three came from Brazil and two from Ecuador. Our study evidences a moderate prevalence of HBV-infection in South American immigrants with the identification of two genotypes, D and A. These genotypes are not the most prevalent in the South America and this is probably the expression of a possible geographical redistribution of HBV genotypes.

  15. Is Quantitative HBsAg Measurement a Reliable Substitute for HBV DNA Quantitation?

    Directory of Open Access Journals (Sweden)

    Mohammad Reza Mahdavi

    2015-07-01

    Conclusion: There are many factors affecting the correlation between serum HBV DNA copy number and HBsAg level such as genotype of HBV virus, phase of infection, methods of measurement, HBeAg status, and drug and types of treatment procedures. Therefore, these factors should be considered in further studies dealing with the correlation between quantitative HBV DNA and HBsAg tests.

  16. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples.

    Science.gov (United States)

    Fabris, Paolo; Biasin, Maria R; Giordani, Maria T; Berardo, Laura; Menini, Vania; Carlotto, Antonio; Miotti, Maria G; Manfrin, Vinicio; Baldo, Vincenzo; Nebbia, Gaia; Infantolino, Domenico

    2008-03-01

    Prevalence and impact of occult HBV infection in HIV positive patients is controversial. The aims of this study were to determine the prevalence of occult HBV infection and its impact on histological and virological parameters. 52 HIV/HCV (but HBsAg-negative) co-infected patients, 29 HBsAg and anti-HCV negative chronic hepatitis, and 20 HBsAg positive chronic hepatitis controls were studied. DNA was extracted from frozen biopsies and amplified with primers for S, C and X regions, and for (ccc) HBV-DNA. Sera were tested for HBV-DNA with two quantitative assays (Cobas Amplicor HBV Monitor, and the real-time COBAS (r) Taqman HBV Test, Roche Diagnostics, UK). Occult HBV infection was detected in 7 (13.4%) liver biopsies of the study group, and in none case of the non viral chronic hepatitis group (p=0.04). All serum samples were HBV-DNA negative with Cobas Amplicor HBV monitor assay, while 3 cases were found positive with real time PCR. Statistical analysis didn't show any impact of occult HBV infection on liver histology, CD4+ cells count, HIV and HCV load, and ALT levels. Occult B infection is relatively frequent in HIV/HCV co-infected patients, and is underestimated by common HBV-DNA serological assays. However, it doesn't seem to exert a relevant impact.

  17. Occult HBV infection and HCC

    Directory of Open Access Journals (Sweden)

    Isabelle Chemin

    2007-02-01

    Full Text Available

    A number of risk factors appear to play a role in Hepatocellularcinoma (HCC, HBV infection being one of the most important. Chronic inflammation and cytokines are key determinants in the development of fibrosis and liver cell proliferation. HBV DNA integration into host cellular DNA, has been extensively studied and may disrupt or promote expression of cellular genes that are important in cell growth and differentiation. Moreover, expression of HBV proteins may have a direct effect on cellular functions, and some of these gene products may lead to malignant transformation. Several HBV genes have been frequently found in infected tissues including truncated pre-S2/S, hepatitis B X gene, and a novel spliced transcript of HBV (hepatitis B spliced protein. The proteins expressed from these integrated genes have been shown to have intracellular activities, including effects on cellular growth and apoptosis. Occult hepatitis B virus (HBV infection is characterized by persistence of HBV DNA into the tissue of hep atitis B surface antigen-negative individuals. The clinical relevance of this peculiar infection, in particular, the impact of occult HBV infection in cases of HCC has been a matter of debate. Prevalence and molecular status of occult HBV in patients with HCC has been investigated in several studies. HCC patients from Italy, France, Japan, Morocco, the United States, Canada etc…..who had no detectable HBsAg in their serum have been studied. In these HBsAg-negative HCC patients, HBV DNA was detected in tumorous and/or in adjacent non tumorous liver tissue using polymerase chain reaction (PCR in almost half of the patients, being anti-HCV positive or not. Some of the patients are positive for anti-HBc antibodies as the only marker of HBV infection, but not all. Covalently closed circular HBV DNA may be detected indicating that at least some of these patients

  18. HBV-M与定量PCR法检测HBV-DNA相关性探析%The Correlative Analysis between HBV-M and HBV-DNA Detected by Quantitative Fluorescence PCR in Hepatitis B Patients

    Institute of Scientific and Technical Information of China (English)

    刘青鹤

    2014-01-01

    Objective:To discuss the correlation between hepatitis B virus DNA and HBV-M.Method: Five hundred and forty-nine hepatitis B patients were selected in our hospital. Patients’ serum samples were collected, its HBV-DNA and HBV-M were detected by using quantitative PCR and enzyme-linked immunosorbent assay. The correlative between HBV-M and HBV-DNA was analyzed.Result: In HBsAg (+) + HBeAg (+) + HBcAb (+) mode, the positive rate of HBV-DNA was 97.9%. In HBsAg (+) + HBeAg (+) mode, the positive rate of HBV-DNA was 100%. The positive rates were not seen significant difference between the two modes, but they were significantly higher than the other modes(P<0.05).Conclusion: There are some correlations between serological markers of hepatitis B virus and HBV-DNA. HBV-M and HBV-DNA testing are circumstantial evidence and direct evidence of hepatitis B infection, while these two indicators of patient clinical diagnostic testing for hepatitis B, the condition determination, infectious assessment are of great significance.%目的:探讨乙肝病毒DNA(HBV-DNA)与其血清学标志物HBV-M之间的相关性。方法:选取本院收治的乙肝患者183例作为研究对象,采集并分离患者的血清标本,分别采用荧光定量PCR法和酶联免疫吸附法对患者的HBV-DNA、HBV-M进行检测,在不同的HBV-M模式下分析其与HBV-DNA间的关系。结果:在HBsAg(+)+HBeAg(+)+HBcAb(+)的模式下,HBV-DNA的检测阳性率为97.9%;HBsAg(+)+HBeAg(+)模式下,HBV-DNA的检测阳性率是100%;两者比较差异无统计学意义,但这两种模式下的检测阳性率都显著高于其他模式(P<0.05)。结论:乙肝病毒的血清学标志物的模式不同,HBV-DNA的检测阳性率不同,乙肝患者机体内的病毒含量也有差异,HBV-M和HBV-DNA的检测分别是乙肝感染的间接证据和直接证据,同时对患者进行这两项指标的检测对于乙肝的临床诊断、病情判定、传

  19. Presence and integration of HBV DNA in mouse oocytes

    Institute of Scientific and Technical Information of China (English)

    Tian-Hua Huang; Qing-Jian Zhang; Qing-Dong Xie; Li-Ping Zeng; Xi-Fan Zeng

    2005-01-01

    AIM: Hepatitis B is a worldwide public health problem. To explore the feasibility of hepatitis B virus (HBV) vertical transmission via oocytes, the presence and integration of HBV DNA in mouse oocytes were studied. METHODS: Genomic DNA was isolated and metaphases were prepared, respectively from mouse oocytes cocultured with pBR322-HBV DNA plasmids. PCR, Southern blot, dot hybridization and fluorescence in situ hybridization (FISH) were performed to explore the existence and integration of HBV DNA in oocytes.RESULTS: PCR detected positive bands in the tested samples, and then Southern blot revealed clear hybridization signals in PCR products. Final washing solutions were collected for dot hybridization and no signal for HBV DNA was observed, which excluded the possibility that contamination of washing solutions gave rise to positive results of PCR and Southern blot. FISH demonstrated that 36 of 1 000 metaphases presented positive signals. CONCLUSION: HBV DNA sequences are able to pass through the zona and oolemma to enter into oocytes and tointegrate into their chromosomes. HBV DNA sequences might be brought into embryo via oocytes as vectors when they are fertilized with normal spermatozoa.

  20. Hepatitis B virus (HBV) and dual HBV-hepatitis delta virus (HDV) infection in apparently healthy persons.

    Science.gov (United States)

    Brehar-Cioflec, D; Claici, C; Roşiu, N; Negrea, D A; Moldovan, R; Coşniţă, M

    1998-01-01

    The main aims of the present study were to evaluate the transfusional risk concerning HBV and HBV-HDV infections and the prevalence of viral serum markers in apparently healthy persons. Our study included 226 apparently healthy persons in whom we performed tests for HBV (HBsAg, HBsAb, HBcAb) and HDV (Delta Ab) serum markers, using the enzyme immunoassay. In 45 (19.9%) subjects we detected serum HBsAg. In the 181 HBsAg-negative apparently healthy persons, our tests detected HBsAb (31 subjects) and HBcAb (49 subjects). Thus, 125 (55.3%) of the 226 apparently healthy persons had serologic evidence of past HBV infections. Delta Ab were detected in 3 (1.3%) of our subjects. We must state that one of the three Delta Ab-positive apparently healthy persons tested negative for both HBsAg and HBcAb.

  1. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.

    Directory of Open Access Journals (Sweden)

    Prudence Ive

    Full Text Available BACKGROUND: Hepatitis B virus (HBV infection is endemic in South Africa however, there is limited data on the degree of liver disease and geographic variation in HIV/HBV coinfected individuals. In this study, we analysed data from the CIPRA-SA 'Safeguard the household study' in order to assess baseline HBV characteristics in HIV/HBV co-infection participants prior to antiretroviral therapy (ART initiation. METHODS: 812 participants from two South African townships Soweto and Masiphumelele were enrolled in a randomized trial of ART (CIPRA-SA. Participants were tested for hepatitis B surface antigen (HBsAg, hepatitis B e antigen (HBeAg, and HBV DNA. FIB-4 scores were calculated at baseline. RESULTS: Forty-eight (5.9% were HBsAg positive, of whom 28 (58.3% were HBeAg positive. Of those with HBV, 29.8% had an HBV DNA<2000 IU/ml and ALT<40 IU/ml ; 83.0% had a FIB-4 score <1.45, consistent with absent or minimal liver disease. HBV prevalence was 8.5% in Masiphumelele compared to 3.8% in Soweto (relative risk 2.3; 95% CI: 1.3-4.0. More participants in Masiphumelele had HBeAg-negative disease (58% vs. 12%, p = 0.002 and HBV DNA levels ≤2000 IU/ml, (43% vs. 6% p<0.007. CONCLUSION: One third of HIV/HBV co-infected subjects had low HBV DNA levels and ALT while the majority had indicators of only mild liver disease. There were substantial regional differences in HBsAg and HbeAg prevalence in HIV/HBV co-infection between two regions in South Africa. This study highlights the absence of severe liver disease and the marked regional differences in HIV/HBV co-infection in South Africa and will inform treatment decisions in these populations.

  2. Animal models for HCV and HBV studies

    Directory of Open Access Journals (Sweden)

    Isabelle Chemin

    2007-02-01

    develop fulminant hepatitis, acute hepatitis, or chronic liver disease after adoptive transfer, and others spontaneously develop hepatocellular carcinoma (HCC. Among HCV transgenic mice, most develop no disease, but acute hepatitis has been observed in one model, and HCC in another. Although mice are not susceptible to HBV and HCV, their ability to replicate these viruses and to develop liver diseases characteristic of human infections provides opportunities to study pathogenesis and develop novel therapeutics In the search for the mechanism of hepatocarcinogenesis in hepatitis viral infection, two viral proteins, the core protein of hepatitis C virus (HCV and the HBx protein of hepatitis B virus (HBV, have been shown to possess oncogenic potential through transgenic mouse studies, indicating the direct involvement of the hepatitis viruses in hepatocarcinogenesis.

    This may explain the very high frequency of HCC in patients with HCV or HBV infection.

    Chimpanzees remain the only recognized animal model for the study of hepatitis C virus (HCV. Studies performed in chimpanzees played a critical role in the discovery of HCV and are continuing to play an essential role in defining the natural history of this important human pathogen. In the absence of a reproducible cell culture system, the infectivity titer of HCV challenge pools can be determined only in chimpanzees.

    Recent studies in chimpanzees have provided new insight into the nature of host immune responses-particularly the intrahepatic responses-following primary and secondary experimental HCV infections. The immunogenicity and efficacy of vaccine candidates against HCV can be tested only in chimpanzees. Finally, it would not have been possible to demonstrate

  3. Hepatitis B Test

    Science.gov (United States)

    ... helpful? Also known as: HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis B Surface ... including "HBV carrier" state. Hepatitis B surface antibody (anti-HBs) Detects antibody produced in response to HBV surface ...

  4. The Expression of CD2 in Chronic HBV Infection

    Institute of Scientific and Technical Information of China (English)

    Jie Li; Baotai Qi; Ping Chen; Linjing He; Ping Wang; Yuqiang Ji; Ming Xie

    2008-01-01

    It was previously reported that several kinds of intercellular adhesion molecules are closely related to chronic HBV infection. The complex of CD2 and CD58 plays an important role in enhancing the adhesion of T lymphocytes to target cells. and promoting hyperplasia and activation of T lymphocytes. In this study, we detected the level of CD2 expressed on the surface of PBMC, the expression Ievel of CD2 mRNA in PBMC and the percentage of CD2 positive cells in PBMC of patients with chronic HBV infection and compared them with the expression level of normal controls. We also determined the level of serum HBV DNA from patients with chronic HBV infection and from normal controls. The clinical characteristics of hepatic function were tested as well. The results showed that the expression of CD2 significantly increased with the severity of chronic HBV infection, which suggested that CD2 might contribute to the hepatocyte damage in chronic HBV infection. Cellular & Molecular Immunology.2008; 5(1):69-73.

  5. HBV genotypic variability in Cuba.

    Science.gov (United States)

    Loureiro, Carmen L; Aguilar, Julio C; Aguiar, Jorge; Muzio, Verena; Pentón, Eduardo; Garcia, Daymir; Guillen, Gerardo; Pujol, Flor H

    2015-01-01

    The genetic diversity of HBV in human population is often a reflection of its genetic admixture. The aim of this study was to explore the genotypic diversity of HBV in Cuba. The S genomic region of Cuban HBV isolates was sequenced and for selected isolates the complete genome or precore-core sequence was analyzed. The most frequent genotype was A (167/250, 67%), mainly A2 (149, 60%) but also A1 and one A4. A total of 77 isolates were classified as genotype D (31%), with co-circulation of several subgenotypes (56 D4, 2 D1, 5 D2, 7 D3/6 and 7 D7). Three isolates belonged to genotype E, two to H and one to B3. Complete genome sequence analysis of selected isolates confirmed the phylogenetic analysis performed with the S region. Mutations or polymorphisms in precore region were more common among genotype D compared to genotype A isolates. The HBV genotypic distribution in this Caribbean island correlates with the Y lineage genetic background of the population, where a European and African origin prevails. HBV genotypes E, B3 and H isolates might represent more recent introductions.

  6. Real-time PCR per HBV DNA: valutazione del nuovo sistema automatizzato COBAS AMPLIPREP™/COBAS TAQMAN™ HBV

    Directory of Open Access Journals (Sweden)

    Tiziano Allice

    2007-12-01

    Full Text Available Success of antiviral therapy for chronic hepatitis B is supported by highly sensitive PCR-based assays for Hepatitis B virus (HBV DNA. Nucleic acid extraction from biologic specimens is technically demanding and reliable PCR results depend it. Performances of the fully automatic system COBAS AmpliPrep™/COBAS TaqMan™ 48 (CAP/CTM (Roche, Branchburg, NJ for HBV DNA extraction and real -time PCR quantification were assessed and compared with the end-point PCR COBAS AMPLICOR HBV Monitor (CAHBM, Roche. Analytical evaluation with a proficiency panel showed that CAP/CTM quantitated HBV DNA levels in one single run over a wide dynamic range (7 logs with a close correlation between expected and observed values (r=0.976, interassay variability below 5%. Clinical evaluation as tested with samples from 92 HBsAg-positive patients, demonstrated excellent correlation with CAHBM (r=0.966, mean difference in quantitation: 0.36 log10 IU/ml. CAP/CTM detected 10% more viremic patients and longer period of residual viremia in those on therapy. In lamivudine (LAM-resistant patients, reduction of HBV DNA after 12 months of Adefovir (ADF was higher in the combination (LAM+ADF schedule than in ADF monotherapy (5.1 vs. 3.5 logs suggesting a benefit in continuing LAM. In conclusion,CAP/CTM can improve the management of HBV infection, the assessment of antiviral therapy and drug resistance, supporting further insights in the emerging area of drug resistance.

  7. The HBV E Genotype Discover in Dai Nationality in Xishuangbanna, Yunnan Province

    Institute of Scientific and Technical Information of China (English)

    Hai-ping ZHAO; Yuan-ying SHEN; Ru SHEN; Yuan-yi WANG; Mei-ya FU

    2009-01-01

    To investigate the distribution of Hepatitis B virus (HBV) genotypes among the population of Dai nationality in Xishuangbanna, Yurman Province HBV genotypes of the Serum samples were tested by PCR-RFLP. This is the first time to discover the B+E genotypes in China. This finding provides new information for understanding the distribution of HBV genotype in China and a provides a basis for establishing a Chinese gene bank.

  8. HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up

    Directory of Open Access Journals (Sweden)

    Regina Célia Moreira

    2010-02-01

    Full Text Available The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV among haemodialysis (HD subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR in each of the prospective subjects (n = 123 during one year. Additionally, all samples (n = 1,476 were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc, hepatitis B surface antigen (HBsAg and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45 of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.

  9. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (- chronic inactive HBV patients from active carriers

    Directory of Open Access Journals (Sweden)

    Gull Sana

    2011-02-01

    Full Text Available Abstract Background and Aims ELISA is still used as primary test for diagnosis HBV disease. However, ELISA-positive patients were marked as HBV inactive after confirmation with PCR and vice versa. Our aim was to assess the performance of new cut-off value of ALT, HBV DNA load and significance of AST as screening tool for HBeAg (- chronic active or inactive patients in Pakistani population. Materials and methods In a cross-sectional, cohort study, 567 HBeAg (- patients followed for one year were selected. Patients with persistent elevated ALT than normal and HBV DNA ≥ 100,000 copies/mL were taken as active chronic. Diagnostic values for ALT, AST and HBV DNA load in HBV HBeAg (- chronic active and inactive patients compared using receiver operation characteristic (ROC curves. Results Of 567 HBeAg (- patients, 228 were classified as chronic inactive and 339 as active. HBV infection was dominant in male. Serum ALT, AST and HBV DNA levels showed significant and high AUROC to differentiate chronic HBeAg (- inactive patients from active. AUROC for Serum ALT, AST and HBV DNA were observed 0.997, 0.969 and 1.000, respectively. For revised cut off value for ALT (30 IU/L for male and 19 IU/L for female and HBV DNA load ≥100,000 copies/mL, a PPV of 97%, NPV of 94%, a sensitivity of 98%, and a specificity of 92% was observed to discriminate active carriers from inactive carriers. We also observed 93.5% specificity, 83.1% sensitivity, 82% PPV and 89.5% NPV for AST ≤20 IU/L to differentiate inactive carriers from active ones in our study group. Conclusions Revised cut off value of ALT and NIH derived HBV DNA value can better discriminate between HBeAg (- chronic active and inactive patients.

  10. Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype E

    Institute of Scientific and Technical Information of China (English)

    Kei Fujiwara; Atsushi Ozasa; Yuko Sakamoto; Isao Arita; Ahmed El-Gohary; Agossou Benoit; Sophie I Ogoundele-Akplogan; Namiko Yoshihara; Ryuzo Ueda; Masashi Mizokami; Yasuhito Tanaka; Etsuro Orito; Tomoyoshi Ohno; Takanobu Kato; Kanji Sugihara; Izumi Hasegawa; Mayumi Sakurai; Kiyoaki Ito

    2005-01-01

    AIM: To determine the distribution of Hepatitis B virus (HBV) genotypes in Benin, and to clarify the virological characteristics of the dominant genotype.METHODS: Among 500 blood donors in Benin, 21 HBsAg-positive donors were enrolled in the study. HBV genotypes were determined by enzyme immunoassay and restriction fragment length polymorphism. Complete genome sequences were determined by PCR and direct sequencing.RESULTS: HBV genotype E (HBV/E) was detected in 20/21 (95.2%), and HBV/A in 1/21 (4.8%). From the age-specific prevalence of HBeAg to anti-HBe seroconversion (SC) in 19 HBV/E subjects, SC was estimated to occur frequently in late teens in HBV/E.The comparison of four complete HBV/E genomes from HBeAg-positive subjects in this study and five HBV/E sequences recruited from the database revealed that HBV/E was distributed throughout West Africa with very low genetic divers ity (nucleotide homology 96.7-99.2%).Based on the sequences in the basic core promoter (BCP)to precore region of the nine HBV/E isolates compared to those of the other genotypes, a nucleotide substitution in the BCP, G1757A, was observed in HBV/E.CONCLUSION: HBV/E is predominant in the Republic of Benin, and SC is estimated to occur in late teens in HBV/E. The specific nucleotide substitution G1757A in BCP, which might influence the virological characteristics,is observed in HBV/E.

  11. HBV/D1: a major HBV subgenotype circulating in Uyghur patients with chronic HBV infection in Xinjiang, China.

    Science.gov (United States)

    Nie, Jingjing; Li, Jie; Sun, Kuixia; Sun, Mishu; Chen, Jie; Ma, Junfeng; Yan, Ling; Zhuang, Hui

    2012-08-01

    Each hepatitis B virus (HBV) genotype and subgenotype is associated with a particular geographic distribution, ethnicity, and anthropological history. The present study investigated the genomic characteristics of HBV from Uyghur patients with chronic HBV infection in Xinjiang, China. Among the 53 Uyghur patients enrolled, HBV/D was found to be the dominant strain, with 64.2 % (34/53), 60.4 % (32/53) with HBV/D1 and 3.8 % (2/53) with HBV/D3. In addition to these findings, 3.8 % HBV/B (2/53), 5.7 % HBV/C (3/53), 11.3 % C+D (6/53), 7.5 % B+D (4/53), 3.8 % B+C (2/53) and 3.8 % B+C+D (2/53) were also detected. The full-length genome of seven HBV/D1 isolates and 144 reference sequences retrieved from GenBank were compared and analyzed by biological information methods. These results demonstrate that the D1 isolates from Xinjiang and Central Asia show a close genetic proximity (0.013±0.0007). Furthermore, four unique amino acid substitutions (sp82(Asn), sp89(His), rt129(Leu), rt151(Leu)) representing background polymorphisms rather than drug resistance mutations or immune escape variants were found in the Uyghur patients of Xinjiang, but these were seldom found in HBV/D1 strains from other regions (0 %-14.3 %). This study indicates that in Xinjiang, unlike HBV-infected Han patients, HBV/D1 is the predominant strain among HBV-infected Uyghur people. Although genetic distance analysis suggests that the HBV/D1 isolates from Xinjiang are closely related to those from Central Asia, unique amino acid substitutions suggest independent evolution of HBV in the Uyghur patients of Xinjiang.

  12. Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.

    Science.gov (United States)

    Bivigou-Mboumba, Berthold; François-Souquière, Sandrine; Deleplancque, Luc; Sica, Jeanne; Mouinga-Ondémé, Augustin; Amougou-Atsama, Marie; Chaix, Marie-Laure; Njouom, Richard; Rouet, François

    2016-01-01

    Integrated data on hepatitis B virus (HBV) patterns, HBV genotypes and mutations are lacking in human immunodeficiency virus type 1 (HIV-1) co-infected patients from Africa. This survey was conducted in 2010-2013 among 762 HIV-1-positive adults from Gabon who were predominantly treated with 3TC-based antiretroviral treatment. HBV patterns were identified using immunoassays detecting total antibody to hepatitis B core antigen (HBcAb), hepatitis B surface antigen (HBsAg), IgM HBcAb, hepatitis B e antigen (HBeAg), antibody to HBsAg (HBsAb) and an in-house real-time PCR test for HBV DNA quantification. Occult hepatitis B (OBI) was defined by the presence of isolated anti-HBc with detectable serum HBV DNA. HBV genotypes and HBV mutations were analyzed by PCR-direct sequencing method. Seventy-one (9.3%) patients tested positive for HBsAg, including one with acute hepatitis B (0.1%; 95% CI, 0.0%-0.2%), nine with HBeAg-positive chronic hepatitis B (CHB) (1.2%; 95% CI, 0.6%-2.2%), 16 with HBeAg-negative CHB (2.1%; 95% CI, 1.2%-3.3%) and 45 inactive HBV carriers (5.9%; 95% CI, 4.4%-7.8%). Sixty-one (8.0%; 95% CI, 6.2%-10.1%) patients showed OBI. Treated patients showed similar HBV DNA levels to those obtained in untreated patients, regardless of HBV patterns. Around 15.0% of OBI patients showed high (>1,000 UI/mL) viremia. The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04). Our findings encouraged clinicians to promote HBV vaccination in patients with no exposure to HBV and to switch 3TC to universal TDF in those with CHB.

  13. Broad Range of Hepatitis B Virus (HBV Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.

    Directory of Open Access Journals (Sweden)

    Berthold Bivigou-Mboumba

    Full Text Available Integrated data on hepatitis B virus (HBV patterns, HBV genotypes and mutations are lacking in human immunodeficiency virus type 1 (HIV-1 co-infected patients from Africa. This survey was conducted in 2010-2013 among 762 HIV-1-positive adults from Gabon who were predominantly treated with 3TC-based antiretroviral treatment. HBV patterns were identified using immunoassays detecting total antibody to hepatitis B core antigen (HBcAb, hepatitis B surface antigen (HBsAg, IgM HBcAb, hepatitis B e antigen (HBeAg, antibody to HBsAg (HBsAb and an in-house real-time PCR test for HBV DNA quantification. Occult hepatitis B (OBI was defined by the presence of isolated anti-HBc with detectable serum HBV DNA. HBV genotypes and HBV mutations were analyzed by PCR-direct sequencing method. Seventy-one (9.3% patients tested positive for HBsAg, including one with acute hepatitis B (0.1%; 95% CI, 0.0%-0.2%, nine with HBeAg-positive chronic hepatitis B (CHB (1.2%; 95% CI, 0.6%-2.2%, 16 with HBeAg-negative CHB (2.1%; 95% CI, 1.2%-3.3% and 45 inactive HBV carriers (5.9%; 95% CI, 4.4%-7.8%. Sixty-one (8.0%; 95% CI, 6.2%-10.1% patients showed OBI. Treated patients showed similar HBV DNA levels to those obtained in untreated patients, regardless of HBV patterns. Around 15.0% of OBI patients showed high (>1,000 UI/mL viremia. The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4% than in HBV/E isolates (0% (P = .04. Our findings encouraged clinicians to promote HBV vaccination in patients with no exposure to HBV and to switch 3TC to universal TDF in those with CHB.

  14. From HCV To HBV Cure.

    Science.gov (United States)

    Schinazi, Raymond F; Asselah, Tarik

    2017-01-01

    Approximately 170 million people are chronically infected with HCV and 350 million are chronically infected with HBV worldwide. It is estimated that more than one million patients die from complications related to chronic viral hepatitis, mainly HCC which is one of the most frequent cancers in many countries, especially Africa, the Middle East and Asia. HCV drug development has been impressive, and this revolution led to several direct-acting antiviral agents achieving an HCV cure after only 6-12 weeks. This progress could theorically lead to HCV global elimination making HCV and its consequences a rarity. HBV research and development programs can learn from the HCV experience, to achieve an HBV functional or sterilizing cure. This review will summarize key steps which have been realized for an HCV cure, and discuss the next steps to achieve for an HCV elimination. And also, how this HCV revolution has inspired scientists and clinicians to achieve the same for HBV.

  15. HBV And HCV Molecular Evolution

    Directory of Open Access Journals (Sweden)

    Flor H. Pujol

    2007-02-01

    Full Text Available

    Hepatitis B virus (HBV infection is still a significant health concern in in the world, since around 2 billion persons have been infected by this virus (HBV and around 350 millions of them are chronic carriers, in spite of a highly effective vaccine against this virus. Bearing a reverse transcriptase necessary for its replication but with a highly compacted genome, this hepadnavirus exhibits a degree of variability intermediate between DNA and RNA viruses. This plasticiy leads to the generation of several mutants and genotypic variability. HBV mutants develop during the natural course of infection and play an important role in the evasion of the selective pressure applied by the host (immune or chemotherapeutic. Eight HBV genotypes (A-H have been described, based on a minimum divergence of 8% of the complete genome sequences. HBV genotype F is the most divergent of the HBV genotypes, is autochthonous to South America and is highly predominant in the Northen region of South America. The recently described HBV genotype H is closely related to genotype F and seems to be restricted to Central and North America. Recombination among different HBV strains seems to be frequent. Several subgenotypes have also been described inside HBV genotypes, which exhibit a geographic pattern of distribution. The clinical and biologic importance of the genotypic diversity of HBV is of major concern at the present moment and has been studied in Asia and Europe. The origin of HBV is still an open question. Depending on the model used for the phylogenetic analysis, an Asian or an American origin of HBV has been proposed. By revisiting the genotypic diversity of HBV, an alternative explanation is that human HBV genotypes might have emerged by several zoonotic introductions, both in the Old and the New World. Around 170 millions persons in the world are thought to be infected with

  16. High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.

    Directory of Open Access Journals (Sweden)

    John Rusine

    Full Text Available BACKGROUND: Data on prevalence and incidence of hepatitis B virus (HBV and hepatitis C virus (HCV infection in Rwanda are scarce. METHODS: HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART at baseline, and 200 women not yet eligible for ART. RESULTS: Baseline prevalence of active HBV infection (HBsAg positive, past or occult HBV infection (anti-HBc positive and HBsAg negative and anti-HCV was 5.2%, 42.9%, and 5.7%, respectively. The active HBV incidence rate was 4.2/1,000 person years (PY. In a multivariable logistic regression model using baseline data, participants with WHO stage 3 or 4 HIV disease were 4.19 times (95% CI 1.21-14.47 more likely to have active HBV infection, and older patients were more likely to have evidence of past exposure to HBV (aRR 1.03 per year; 95%CI 1.01-1.06. Older age was also positively associated with having anti-HCV antibodies (aOR 1.09; 95%CI 1.04-1.14 while having a higher baseline HIV viral load was negatively associated with HCV (aOR 0.60; 95% CI 0.40-0.98. The median CD4 increase during the first 12 months of ART was lower for those with active HBV infection or anti-HCV at baseline. Almost all participants (88% with active HBV infection who were on ART were receiving lamivudine monotherapy for HBV. CONCLUSION: HBV and HCV are common in HIV-infected patients in Rwanda. Regular HBsAg screening is needed to ensure that HIV-HBV co-infected patients receive an HBV-active ART regimen, and the prevalence of occult HBV infection should be determined. Improved access to HBV vaccination is recommended. Active HCV prevalence and incidence should be investigated further to determine whether HCV RNA PCR testing should be introduced in Rwanda.

  17. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection.

    Science.gov (United States)

    Castillo, Inmaculada; Rodríguez-Iñigo, Elena; López-Alcorocho, Juan Manuel; Bartolomé, Javier; Pardo, Margarita; Carreño, Vicente

    2007-03-01

    Occult hepatitis B virus (HBV) and occult hepatitis C virus (HCV) infection are two recently described different forms of HBV and HCV infections. This work compares the clinical, virologic, and histologic characteristics of patients with occult dual infection to those of patients with single occult HBV or HCV infection. Seventy-six patients with abnormal liver function tests of unknown etiology (serum HBsAg, anti-HCV, HBV-DNA, and HCV-RNA negative) were included in the study. Viral genomes were tested in liver by real-time PCR and confirmed by in situ hybridization. Of the 76 patients, 17 had occult HBV infection (intrahepatic HBV-DNA positive, HCV-RNA negative), 35 had occult HCV infection (intrahepatic HCV-RNA positive, HBV-DNA negative) and 24 occult dual infection (intrahepatic HCV-RNA and HBV-DNA). No differences among the three groups were found regarding clinical and epidemiologic data. The median load of intrahepatic genomic and antigenomic HCV-RNA strands was similar between single occult HCV infection and occult HBV and HCV dual infection. The percentage of HCV-infected hepatocytes did not differ between these groups. In occult single HBV infection, intrahepatic levels of HBV-DNA and percentage of HBV-infected hepatocytes were similar to the group of patients with occult dual infection. Finally, no differences were found in histological liver damage among the three groups. In conclusion, liver disease in patients with occult dual infection was not more severe than in patients with single occult HBV or occult HCV infection. Moreover, in occult dual infection there is no a reciprocal inhibition of the viral genomes.

  18. Acute hepatitis B virus infection with simultaneous high HBsAg and high anti-HBs signals in a previously HBV vaccinated HIV-1 positive patient.

    Science.gov (United States)

    van Dommelen, Laura; Verbon, Annelies; van Doorn, H Rogier; Goossens, Valère J

    2010-03-01

    We present a case of a clinical manifest hepatitis B virus infection and a potentially misleading HBV serological profile in an HIV-1 positive patient despite previous HBV vaccination. The patient presented with an acute hepatitis B and there was no indication of chronic HBV infection or the presence of a mutation in the 'a' determinant. Remarkably, simultaneously with high HBV surface antigen and HBV viral load, high anti-HBs antibodies were present. If, due to previous HBV vaccination only anti-HBs was tested in this patient, the result of the high anti-HBs antibodies could be very misleading and offering a false sense of security. Our findings contribute to the ongoing discussion on how to assess HBV specific immunological memory and determining the role of HBV booster vaccinations in immunocompromised individuals.

  19. Overview of HBV whole genome data in public repositories and the Chinese HBV reference sequences

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    The number of Hepatitis B virus (HBV) whole genomic sequences in public nucleotide databases (GenBank, EMBL, and DDBJ) had reached 866 by January 1, 2007. Coming from 46 countries and regions, these sequences were categorized as eight genotypes (A-H). With the statistical and phylogenetic analysis on all available complete genomic data of HBV, we here present an overview of HBV sequences in public databases. From all registered 229 HBV genomes in Chinese regions as well as 59 sequencing data from our research group, we report the establishment of reference sequences of HBV strains prevailing in China. These analyses provide clues for the effects of HBV genotypes in host clinical progressions, geographic distribution of the infection, and the viral evolutionary history. Moreover, the viral sequence reference would be helpful in the identification of various HBV mutations. Based on the analysis of various public databases,we suggest that the Chinese HBV database with the clinical information should be constructed.

  20. HBV and neurological impairment in HIV-infected patients

    Directory of Open Access Journals (Sweden)

    L Manolescu

    2012-11-01

    Full Text Available Objective: HIV can affect CNS in early stages of disease and determine neurological impairment. HBV DNA was found in CSF of HIV co-infected patients, but little is known about the neurotropic character of this virus. Here we assessed the degree of association between HBV infection and neurological impairment in a large cohort of long-term survivors, HIV-infected patients that experienced multiple therapeutic schemes over time. Methods: A total of 462 HIV-1-infected patients were retrospectively followed up for 10 years for HBV infection and neurological impairment. The patients were tested for immune (flow cytometry and virological parameters of HIV infection (Roche Amplicor, version 1.5/ COBAS AmpliPrep/COBAS TaqMan HIV-1 test and for HBV infection markers (HBsAg, anti HBc: Murex Biotech ELISA tests. Many of these patients have experienced between one and six regimens such as: 2 NRTIs, 3 NRTIs, 2 NRTIs+1 NNRTI, 1 NRTI+1 NNRTI+1 PI, 2 NRTIs+2 PIs. Results: After 10 years 29.87% of the patients presented neurological impairment. Out of them 56.52% were HBV-infected. The prevalence of HIV encephalopathy (HE in our studied cohort was 22.7% and 50.4% of these patients were HBV-infected. The median HIV diagnosis age was 7 and the median age of HE diagnosis was 10. In order to establish a possible correlation between HBV infection and HE we first reviewed and excluded the main risk factors associated with HE at the moment of diagnosis: low weight, anemia, constitutional symptoms, low CD4+count, high plasma HIV-RNA load. No patient was infected with HCV. The groups of patients that presented HE and HBsAg and HE without HBsAg were balanced regarding sex, number of deceased patients, number of class C3 patients, but the patients in first group presented lower CD4 values at HE diagnosis vs patients from second group 2: 44.5 vs 95 cells/µL, p=0.3; lower nadir CD4 count: 38 vs 51 cell/µL, p=0.1; and slightly higher HIV viral load: 5.2 vs 5 log10 copies

  1. Hepatitis B virus (HBV) DNA levels and the management of HBV-infected health care workers

    NARCIS (Netherlands)

    van der Eijk, A A; de Man, R A; Niesters, H G M; Schalm, S W; Zaaijer, H L

    2006-01-01

    Different guidelines exist for the management of hepatitis B virus (HBV)-infected health care workers (HCWs). Various HBV DNA levels are used as a cutoff level to determine whether an HBV-infected HCW is allowed to perform exposure-prone procedures (EPPs) or not. In this paper we discuss the factors

  2. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation.

    Directory of Open Access Journals (Sweden)

    Shi-gui Yang

    Full Text Available BACKGROUND: Hepatitis B virus (HBV infection remains a severe public health problem. Investigating its prevalence and trends is essential to prevention. METHODS: To evaluate the effectiveness of HBV vaccination under the 1992 Intervention Program for infants and predicted HBV prevalence trends under the 2011 Program for all ages. We conducted a community-based investigation of 761,544 residents of 12 counties in Zhejiang Province selected according to their location, population density, and economic development. The HBV prevalence trends were predicted by a time-shifting approach. HBV surface antigen (HBsAg and alanine amino transferase (ALT were determined. RESULTS: Of the 761,544 persons screened for HBsAg, 54,132 were positive (adjusted carrier rate 6.13%; 9,455 had both elevated ALT and a positive HBsAg test (standardized rate 1.18%. The standardized HBsAg carrier rate for persons aged ≤20 years was 1.51%. Key factors influencing HBV infection were sex, age, family history, drinking, smoking, employment as a migrant worker, and occupation. With the vaccination program implemented in 2011, we predict that by 2020, the HBsAg carrier rate will be 5.27% and that for individuals aged ≤34 years will reach the 2% upper limit of low prevalence according to the WHO criteria, with a standardized rate of 1.86%. CONCLUSIONS: The national HBV vaccination program for infants implemented in 1992 has greatly reduced the prevalence of HBV infection. The 2011 program is likely to reduce HBV infection in Zhejiang Province to a low moderate prevalence, and perinatal transmission is expected to be controlled by 2020.

  3. Epidemiology of HBV subgenotypes D.

    Science.gov (United States)

    Ozaras, Resat; Inanc Balkan, Ilker; Yemisen, Mucahit; Tabak, Fehmi

    2015-02-01

    The natural history of hepatitis B virus infection is not uniform and affected from several factors including, HBV genotype. Genotype D is a widely distributed genotype. Among genotype D, several subgenotypes differentiate epidemiologically and probably clinically. D1 is predominant in Middle East and North Africa, and characterized by early HBeAg seroconversion and low viral load. D2 is seen in Albania, Turkey, Brazil, western India, Lebanon, and Serbia. D3 was reported from Serbia, western India, and Indonesia. It is a predominant subgenotype in injection drug use-related acute HBV infections in Europe and Canada. D4 is relatively rare and reported from Haiti, Russia and Baltic region, Brazil, Kenya, Morocco and Rwanda. Subgenotype D5 seems to be common in Eastern India. D6 has been reported as a rare subgenotype from Indonesia, Kenya, Russia and Baltic region. D7 is the main genotype in Morocco and Tunisia. D8 and D9 are recently described subgenotypes and reported from Niger and India, respectively. Subgenotypes of genotype D may have clinical and/or viral differences. More subgenotype studies are required to conclude on subgenotype and its clinical/viral characteristics.

  4. 金标法和ELISA法检测乙型肝炎病毒血清标志物的比较%Comparative Study on Colloidal Gold-labeled Method and ELISA of Testing Five Serological Markers of HBV

    Institute of Scientific and Technical Information of China (English)

    丁邦胜; 潘健

    2012-01-01

    目的 探讨金标法检测乙型肝炎病毒(HBV)HBsAg、HBsAb、HBeAg、HBeAb、HBcAb五项血清标志物的敏感性、特异性.方法 采用ELISA法和金标法对256例血清样本同时进行HBV五项血清标志物的检测,并且对结果进行对比分析.结果 256例样本中:ELISA法“全阴性”(HBsAg,HBsAb,HBeAg,HBeAb,HBcAb均阴性)结果模式,金标法结果相同;ELISA法HBsAg、HBeAb、HBcAb阳性,HBsAb、HBeAg阴性(简称模式1);HBsAg、HBeAg、HBcAb阳性,HBeAb、HBsAb阴性(简称模式2)结果模式,金标法检测样本的结果模式发生改变.256例样本两法各单项指标检测结果经x2检验:HBsAb和HBeAg两项结果的差异无统计学意义(P>0.05);HB-sAg,HBeAb,HBcAb三项结果的差异有统计学意义(P<0.05),少数ELISA法阳性或OD为临界值的样本金标法检测结果为阴性;无ELISA法阴性而金标法为阳性的标本.结论 两种方法对HBV五项血清标志物测定的特异性相近,但是金标法敏感性不如ELISA法.%Objective To investigate the sensitivity and specificity of testing HBsAg. HBsAb, HBeAg, HBeAb and HBcAb with colloidal gold-labeled method. Methods 256 serological cases were tested with both colloidal gold-labeled method and ELISA. The results of two methods were analyzed. Results All five negative results samples by ELISA were the same with colloidal gold-labeled method.but for the results HBsAg. HBeAb, HBcAb are positive)HBsAb,HBeAg are negative and HBsAg.HBeAg. HBcAb are positive; HBeAb.HBsAb are negative by ELISA. some were changed by colloidal gold-labeled method. The chi-aquare test(x2) showed that the result differences of HBsAb and HBeAg were not statistically significant with two methods (P>0.05 ). But X2 test showed the differences were significant on HBsAg,HBeAb and HBcAb with two methods. The weak positive results by ELISA always were negative by colloidal gold-labeled method. but no negative results by ELISA were found positive tested by colloidal gold

  5. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.

    Science.gov (United States)

    Vargas, Jose Ignacio; Jensen, Daniela; Sarmiento, Valeska; Peirano, Felipe; Acuña, Pedro; Fuster, Felipe; Soto, Sabrina; Ahumada, Rodrigo; Huilcaman, Marco; Bruna, Mario; Jensen, Werner; Fuster, Francisco

    2016-04-01

    HBV-HIV coinfection is prevalent. Frequently, anti-HBc is the only serological marker of HBV, which can be indicative of HBV resolved infection, when found together with anti-HBs reactivity; or present as "isolated anti-HBc," related to HBV occult infection with presence of detectable DNA HBV, more prevalent in HIV-positive individuals. Regional data about this condition are scarce. Anti-HBc rapid test has been used as screening, but its performance has not been described in HIV-positive patients. The aim of this study was determine prevalence of anti-HBc in HIV-positive patients, serological pattern of HBV resolved infection and isolated anti-HBc, evaluating presence of HBV occult infection. Assess anti-HBc rapid test compared to ECLIA. Methods included measurement of anti-HBc and anti-HBs in HIV-positive patients with negative HBsAg. Serum HBV DNA quantification and HBV booster vaccination to "isolated anti-HBc" individuals. Detection of anti-HBc by rapid test and ECLIA. In 192 patients, prevalence of anti-HBc was 42.7% (82/192); associated to male gender, drug use, men-sex-men, positive-VDRL, and longer time HIV diagnosis. 34.4% (66/192) had presence of anti-HBs, mean titers of 637 ui/ml. Isolated anti-HBc in 8.3% (16/192), associated to detectable HIV viral load and no-use of HAART; in them, HBV DNA was undetectable, and 60% responded to HBV vaccination booster. Anti-HBc rapid test showed low sensibility (32.9%) compared to ECLIA. These results show that prevalence of anti-HBc in HIV-positive individuals is high, in most cases accompanied with anti-HBs as HBV resolved infection. Low prevalence of "isolated anti-HBc," with undetectable HBV DNA, and most had anamnestic response to HBV vaccination; suggest low possibility of occult HBV infection. Anti-HBc rapid test cannot be recommended as screening method for anti-HBc.

  6. Analysis of HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing%重庆地区乙肝相关性肝癌患者HBV-DNA复制水平分布情况分析

    Institute of Scientific and Technical Information of China (English)

    秦晓波; 胡鹏

    2013-01-01

    Objective To Analyze the HBV-DNA replication level distribution in Hepatitis B associated with Liver Cancer of Chongqing. Methods 238 cases of HCC patients were collected, HBV-DNA replication level detection was tested. Result In 238 cases, HBV-DNA of 202 cases (84.87%) could be detected, except 36 cases (15.13%). The HBV-DNA in 103, 104, 105, 106 copies/mL was the most, that was significantly higher than the others (P<0.05 or 0.01). Conclusion HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing is higher relatively.%目的:分析重庆地区乙肝相关-原发性肝癌(HBV-HCC)患者HBV-DNA复制水平分布情况。方法收集HBV-HCC患者238例,入选者在确诊肝癌时监测HBV-DNA复制水平。结果238例HBV-HCC患者中,检测出外周血检查出HBV-DNA者202例(84.87%)、未检出者36例(15.13%)。HBV-HCC患者HBV-DNA以103、104、105、106拷贝/mL复制水平分布例数较多,显著高于其他HBV-DNA复制水平组(P<0.05或0.01)。结论重庆地区HBV-HCC患者HBV-DNA复制水平较高。

  7. Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV).

    Science.gov (United States)

    Han, Anyue; Li, Lingna; Qing, Kuiyou; Qi, Xiaolu; Hou, Leping; Luo, Xintong; Shi, Shaohua; Ye, Faqing

    2013-03-01

    Hepatitis B virus (HBV) infection causes major public health problems worldwide. Acyclovir (ACV) is mainly used to inhibit herpes simplex virus (HSV) rather than HBV. In this study, we used the combination principle to design and synthesize nucleoside analogues that contain silatrane on the basis of the structure of ACV. We found that the compounds were effective inhibitors of HBV, both in vitro and in vivo. All of the compounds showed suppressive activity on the expression of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the HepG2.2.15 cell line with low cytotoxicity. One of compounds was studied in HBV transgenic mice model, and the test results showed its ability to reduce the levels of HBsAg, HBeAg and HBV DNA by ELASE and qPCR. Furthermore, significant improvement of T lymphocyte was observed after treatment, as evaluated by flow cytometry (FCM).

  8. DETECTION AND SIGNIFICANCE OF HBV IN RENAL TISSUE OF HBV ASSOCIATED GLOMERULONEPHRITIS PATIENTS

    Institute of Scientific and Technical Information of China (English)

    任淑婷; 于琳华; 徐长福; 李恒力; 党双锁; 成少利; 郑黎明

    2002-01-01

    Objective To study the pathogenesis of hepatitis B virus ( HBV ) on kidney tissues. Methods HBsAg and HBcAg in paraffin-embedded renal biopsy tissues from 27 cases of glomerulonephritis with positive serum HBV markers were observed by using immunohistochemistry. In addition, in situ polymerse chain reaction (IS-PCR) was performed in 5 cases with positive HBsAg and HBcAg in renal tissue of the 27-case glomerulonephritis to reveal the state of renal HBV DNA. Results Twenty cases (20/27,74.07%) were positive with HBAg which were mainly diffusely distributed in epithelial cells of renal tubule. Four cases (4/5,80% ) were positive with HBV DNA whose distribution was the same of that of HBAg. Conclusion Renal lesions due to HBV are not only the results of immunologic response, but also the outcome of direct invasion and duplication of HBV in epithelial cells of renal tubule.

  9. 昆明市2008年-2009年从业人员HBV血清学检测结果分析%Analysis of HBV serological test results of employees in Yunnan from 2008 to 2009

    Institute of Scientific and Technical Information of China (English)

    普兴福; 杨文华; 李梅春; 金鑫

    2012-01-01

    目的:为掌握昆明市饮食及公共场所从业人员HBV感染状况.方法:用ELISA法检测HBsAg和HBeAg.结果:①检测40975人次,HBsAg阳性率1.65%( 677/40975),HBsAg、HBeAg两者均阳性的阳性率0.61%(249/40975).②男性HBsAg阳性率和HBsAg、HBeAg两者均阳性的阳性率均明最高于女性,且以男性16岁~19岁年龄组阳性率为最高;男、女16岁~19岁、20岁~ 30岁、31岁~40岁年龄组的HBsAg阳性率及HBsAg、HBeAg两者均阳性的阳性率差别显著,而41岁~56岁年龄组差别无统计学意义.③各年龄组HBsAg阳性率及HBsAg、HBeAg两者均阳性的阳性率差别显著,均以16岁~19岁年龄组为高,而女性自身比较,HBsAg阳性率以41岁~56岁年龄组为高.结论:男性20岁以下,女性20岁以下及41岁~56岁年龄组是防控HBV感染的重点监控对象.%Objective:To master the HBV infection status of employees in catering industry and public place. Methods: ELISA was employed to detect HBsAg and HBeAg in sampled serum. Results; 1. 40975 person were involved in this test, the positive rate of HBsAg was 1. 65% (677/40975) , the rate of both HBsAg and HBeAg positive was 0. 61% (249/40975). 2. The rates of males with HBsAg positive and both HBsAg and HBeAg positive were both higher than those of females, and the highest positive rate was found in males aged 16 to 19. The rates of HBsAg positive and both HBsAg and HBeAg positive had significant difference among the age groups of 16 ~ 19, 20 -30 and 31 ~40 between males and females, while the differences in group 41-56 had no statistical significance. 3. The rates of HBsAg positive and both HBsAg and HBeAg positive had significant difference among different age groups of males and females. In males, the highest positive rates were both found in group agedl6 ~ 19, while in females, HBsAg had the highest positive rate in group aged 41 ~56. Conclusion; Male under 20 years old, females under 20 years old and between 41 - 56 years old

  10. Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR for the quantification of HBV-DNA

    Directory of Open Access Journals (Sweden)

    Varaklioti Agoritsa

    2010-03-01

    Full Text Available Abstract Background Improved sensitivity of HBV-DNA tests is of critical importance for the management of HBV infection. Our aim was to develop and assess a new ultra sensitive in-house real-time PCR assay for HBV-DNA quantification (ultra sensitive RTQ-PCR. Results Previously used HBV-DNA standards were calibrated against the WHO 1st International Standard for HBV-DNA (OptiQuant® HBV-DNA Quantification Panel, Accrometrix Europe B.V.. The 95% and 50% HBV-DNA detection end-point of the assay were 22.2 and 8.4 IU/mL. According to the calibration results, 1 IU/mL equals 2.8 copies/mL. Importantly the clinical performance of the ultra sensitive real-time PCR was tested similar (67% to the Procleix Ultrio discriminatory HBV test (dHBV (70% in low-titer samples from patients with occult Hepatitis B. Finally, in the comparison of ultra sensitive RTQ-PCR with the commercially available COBAS TaqMan HBV Test, the in-house assay identified 94.7% of the 94 specimens as positive versus 90.4% identified by TaqMan, while the quantitative results that were positive by both assay were strongly correlated (r = 0.979. Conclusions We report a new ultra sensitive real time PCR molecular beacon based assay with remarkable analytical and clinical sensitivity, calibrated against the WHO 1st International standard.

  11. The Prevention of Liver Cancer by HBV Vaccine Program

    Institute of Scientific and Technical Information of China (English)

    TAO Xiong

    2002-01-01

    Objective To recognize the HBV vaccine program for prevention of the hepatic cancer.Methods To discuss the relation between the HBV and hepatic cancer arising, and to discuss the immunology respond of the HBV vaccine (HBV surface antigen protein) in our patient group. Result Our data indicates that the predisposing of the HBV infection is required for the hepatic cancer arising and for the high expression of the AFP gene, and our data indicates that the HBV vaccine can induce highly immuno respond in about 78.8 % of the adult for achieving the HBV prevention status and the hepatic cancer prevention status.

  12. Correlation between Serum Markers of Hepatitis B Virus and DNA HBV%乙肝病毒血清标志物与HBV DNA的相关性研究

    Institute of Scientific and Technical Information of China (English)

    张智贤; 何秋莹; 温英梦; 曾华

    2015-01-01

    目的探讨乙型肝炎血清标志物(HBsAg、抗HBs、HBeAg、抗HBe、抗HBc)与乙肝病毒基因(HBV DNA)的相关性和临床意义。方法回顾性分析553例乙肝患者的HBV DNA定量及乙肝两对半定量结果,计算不同乙肝血清学标志物组合模式中HBV DNA阳性率及分布情况,分析乙型肝炎血清标志物与HBV DNA相关性。结果6组血清学模式对应的HBV DNA阳性率在9.5~80.0%不等,以HBsAg(+)HBeAg(+)抗HBc(±)组对应的DNA阳性率及DNA拷贝数为最高。 HBsAg、抗HBs、HBeAg、抗HBe、HBcAg与HBV DNA对数spearman结果分别为r=0.009,>0.05;r=-0.155,>0.05;r=0.541,0.05。结论 HBeAg含量与HBV DNA含量存在正相关(<0.05),抗HBe含量与HBV DNA含量存在负相关(<0.05)。联合检测乙肝血清学标志物定量和HBV DNA定量,可以为乙型肝炎的诊断、治疗及疗效评价提供一个更准确的依据。%Objective To detect and investigate the cor elation and clinical significance of HBV DNA and HBV M in Hepatitis B patients. Methods The test results of the quantity of HBV DNA and HBV M in 553 hepatitis B patients were analyzed retrospectively, and the the correlation between HBV DNA and HBV M was analyzed. Results Al the 6 models held HBV DNA positive rates ranging from 9.5%to 80.0%and 80.0%for the model of positive HBsAg(+)HBeAg(+) Anti-HBc(±). There was statistical significance among the spearman's rank cor elation coef icient between HBV DNA and HBeAg (r=0.541,<0.05) as wel as HBV DNA and Anti-HBe (r=-0.493,<0.05). Conclusion HBV DNA was positively cor elated with HBeAg and negatively cor elated with Anti-HBe statistical y. Combined detection of HBV DNA and HBV M can ef ectively monitor HBV replication,it has important value in monitoring curative ef ect and judging prognosis.

  13. 乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    刘晓燕

    2006-01-01

    目的:孕产妇各种血清学标志的乳汁HBV-DNA与血清HBV-DNA相关性的探讨.方法:用全自动荧光定量分析仪对已确认的乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA的检测.结果:85例乙肝孕产妇其各种血清学标志的血清HBV-DNA与乳汁HBV-DNA是一致的.其同一种血清模式的血清HBV-DNA含量高,则乳汁的HBV-DNA相应高.反之,血清HBV-DNA含量低,则乳汁HBV-DNA含量低.

  14. Occult HBV infection among Egyptian hepatocellular carcinoma patients

    Directory of Open Access Journals (Sweden)

    Mansor Tarek M

    2011-03-01

    Full Text Available Abstract Background Occult HBV infection accelerates the progression of liver fibrosis, cirrhosis, and finally leading to hepatocellular carcinoma (HCC. This study analyzed the occult HBV-genotypes in HCC patients. Methods To achieve our objective, matched serum and tissue samples were collected from 40 HCC patients. Three sets of primers were used for the HBV-DNA detection by nested-PCR, which cover the HBV-genome; Core, Surface and X genes. Genotyping system based on PCR using type-specific primers was applied on HBV-DNA positive samples. Results Intrahepatic occult HBV-DNA was detected in 62.5%, whereas; Serum occult HBV-DNA were detected in only 22.5% of HCC patients. In patients' positive for both anti-HBs and anti-HBc, 10% had occult HBV in serum. In serologically negative HCV patients, 63% had intrahepatic HBV-DNA, and 21% had HBV-DNA in serum samples. HBV-genotype D (32% and B (24% attributed predominantly to intrahepatic HBV infections in HCC patients, whereas HBV-genotype A (4% and C (8% infections were the least observed. Conclusion This is the first study to show the genotypes of occult HBV infection in HCC Patients. We suggest that B or D may influence the outcome of HBV infection which may lead to the development of HCC.

  15. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Zhen [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China); Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Xiang, Wenqing; Guo, Yajuan [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Chen, Zhi [The State Key Laboratory for Infectious Disease, Institute of Infectious Disease, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 (China); Liu, Wei, E-mail: liuwei666@zju.edu.cn [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Lu, Daru, E-mail: drlu@fudan.edu.cn [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China)

    2011-06-10

    Highlights: {yields} LNA-modified oligonucleotides can pass through the plasma membrane of cultured cells even without using transfection machinery. {yields} LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. {yields} LNA-oligonucleotide designed to target nuclear HBV DNA efficiently suppresses HBV replication and transcription in cultured hepatic cells. -- Abstract: Silencing target genes with small regulatory RNAs is widely used to investigate gene function and therapeutic drug development. Recently, triplex-based approaches have provided another attractive means to achieve targeted gene regulation and gene manipulation at the molecular and cellular levels. Nuclear entry of oligonucleotides and enhancement of their affinity to the DNA targets are key points of such approaches. In this study, we developed lipid-based transport of a locked-nucleic-acid (LNA)-modified oligonucleotide for hepatitis B virus (HBV) DNA interference in human hepatocytes expressing HBV genomic DNA. In these cells, the LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. The oligonucleotide specifically targeting HBV DNA clearly interfered with HBV DNA transcription as shown by a block in pregenomic RNA (pgRNA) production. The HBV DNA-targeted oligonucleotide suppressed HBV DNA replication and HBV protein production more efficiently than small interfering RNAs directed to the pgRNA. These results demonstrate that fusion with lipid can carry LNA-modified oligonucleotides to the nucleus where they regulate gene expression. Interfering with HBV DNA transcription by LNA-modified oligonucleotides has strong potential as a new strategy for HBV inhibition.

  16. A real-time quantitative assay for hepatitis B DNA virus (HBV developed to detect all HBV genotypes Ensaio quantitativo em tempo real para o DNA do vírus da hepatite B (HBV desenvolvido para detectar todos os genótipos do HBV

    Directory of Open Access Journals (Sweden)

    Roberta Sitnik

    2010-06-01

    Full Text Available Hepatitis B virus (HBV is a major cause of chronic liver disease worldwide. Besides genotype, quantitative analysis of HBV infection is extensively used for monitoring disease progression and treatment. Affordable viral load monitoring is desirable in resource-limited settings and it has been already shown to be useful in developing countries for other viruses such as Hepatitis C virus (HCV and HIV. In this paper, we describe the validation of a real-time PCR assay for HBV DNA quantification with TaqMan chemistry and MGB probes. Primers and probes were designed using an alignment of sequences from all HBV genotypes in order to equally amplify all of them. The assay is internally controlled and was standardized with an international HBV panel. Its efficacy was evaluated comparing the results with two other methods: Versant HBV DNA Assay 3.0 (bDNA, Siemens, NY, USA and another real-time PCR from a reference laboratory. Intra-assay and inter-assay reproducibilities were determined and the mean of CV values obtained were 0.12 and 0.09, respectively. The assay was validated with a broad dynamic range and is efficient for amplifying all HBV genotypes, providing a good option to quantify HBV DNA as a routine procedure, with a cheap and reliable protocol.O vírus da Hepatite B (HBV é uma das principais causas de doença crônica do fígado no mundo. Além do genótipo, a análise quantitativa do HBV é amplamente utilizada para monitorar a progressão da doença e o tratamento. Em locais com recursos escassos, métodos baratos para o monitoramento da carga viral são desejáveis e, em países em desenvolvimento, sua utilidade já foi demonstrada para outros vírus, como o da Hepatite C e HIV. Neste trabalho, descrevemos a validação de um teste de PCR em Tempo Real para a quantificação do DNA do HBV utilizando sondas Taqman/MGB. Os oligos e sondas foram escolhidos usando um alinhamento contendo seqüências de todos os genótipos do HBV para

  17. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

    Science.gov (United States)

    Parikh, Pathik; Ryan, John D.

    2017-01-01

    Chronic hepatitis B virus (HBV) infection is a major cause of liver morbidity and mortality worldwide. While a proportion of the 250 million individuals chronically infected with HBV will not come to significant harm or require therapy, many others risk developing complications of the end-stage liver disease such as decompensated cirrhosis and hepatocellular carcinoma (HCC), without intervention. Due to the complex natural history of HBV infection, patients require an expert assessment to interpret biochemistry, viral serology and appropriately stage the disease, and to initiate monitoring and/or therapy where indicated. The detection and quantification of liver fibrosis is a key factor for disease management and prognostication for an individual with HBV. The reliance on invasive liver biopsy to stage disease is diminishing with the advent of robust non-invasive blood- and imaging-based algorithms which can reliably stage disease in many cases. These tests are now incorporated into International guidelines for HBV management and relied upon daily to inform clinical judgement. Both blood- and imaging-based approaches have advantages over liver biopsy, including minimal risks, lower cost, better patient acceptance and speed of results, while disadvantages include lower diagnostic accuracy in intermediate disease stages and variability with co-existing hepatic inflammation or steatosis. This review outlines the methods of fibrosis assessment in chronic HBV infection and focuses on the most commonly used blood- and imaging-based non-invasive tests, reviewing their diagnostic performance and applicability to patient care. PMID:28251119

  18. 乙肝血清标志物模式与HBV-DNA含量的关系探讨%Correlation between HBV serological markers and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    张海业; 孙溯荫; 韦兰

    2011-01-01

    Objective To analyze the correlation between the lovel of HBV semiogloat markers and HBV-DNA.Mothods Serum samples of 800 patients from Xinyi Pepole's Hospital clinic department suffering HBV were detected by ELISA and HBV-DNA were detected by FQ-PCR.then analyze the correlation between HBV serological markers and HBV-DNA.Results The HBV-DNA was detoeted in some HBV serological markerg groups and each group was different in the result.HBsAg positive.such as HBsAg,HBeAg and Anti-HBc positive samples has higher amount of copies of HBV-DNA;the low level of HBV-DNA copies were detected in the group of HBsAg.HBeAg or Anti-HBe,Anti-HBo lmsitive; and the HBV-DNA copies rate is 2.98%in the single HBsAg positive.Among 120 HBe Ag positive samples.there were 118 HBV-DNA positive,the positive rate of HBV-DNA was 98.33%and the level of HBeAg positive wail correlated to HBV-DNA(r=0.993).Conclusion Both the detection of HBeAg and HBV-DNA cab reflect the active level of duplicate of HBV-M.The HBV-DNA level showed all obvious correlation to the HBeAg contend in Bera.%目的 探讨不同的乙肝血清标志物(HBV-M)模式与HBV-DNA定量检测结果之间的关系.方法 选择800例经酶联免疫吸附试验(ELISA)检测HBsAg结果为阳性的血清样本,采用实时荧光定量PCR技术(FQ-PCR)检测其HBV-DNA含量;并根据患者HBV-M的不同模式进行分组统计,分析探讨HBV-M模式与HBV-DNA含量之间的关系.结果 不同HBV-M模式中HBV-DNA阳性检出率和含量存在明显差异.①"大三阳"组HBV-DNA含量以中、高拷贝为主;②"小三阳"组及HBsAg(+)&Anti-HBc(+)组HBV-DNA含量以中、低拷贝为主;③单纯HBsAg(+)组HBV-DNA的检出率仅为2.98%.④HBeAg(+)血样中HBV-DNA的阳性检出率高达98.33%(118/120),两者之间存在明显正相关(r=0.993).结论 HBV-M与HBV-DNA的检测都能反映HBV感染、传染性及体内复制的情况;HBeAg与HBV-DNA含量存在明显正相关.两者联合检测对乙肝的临床诊疗具有重要指导意义.

  19. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence.

    Science.gov (United States)

    Karasu, Z; Ozacar, T; Akarca, U; Ersoz, G; Erensoy, S; Gunsar, F; Kobat, A; Tokat, Y; Batur, Y

    2005-03-01

    Anti-HBs immunoglobulins (HBIG) and lamivudine are main options to prevent hepatitis B virus (HBV) reinfection after liver transplantation. Although they are very effective, development of mutant viruses and high cost of treatment are main limitations for their application. Additionally there is an uncertainity for the duration of that prophylaxis regimen and its mostly applied indefinitely. Recently, post-transplant HBV vaccination is reported to be a cheaper alternative prophylaksis strategy, that enables discontinuation of HBIG. To investigate the efficacy of HBV vaccination in patients transplanted for HBV cirrhosis, we administered double course of double dose recombinant HBV vaccine (Genhavac B; containing HBV pre-S1, pre-S2, and S gene products). Vaccination has been started 1 month after HBIg discontinuation, and lamivudine (100 mg/day) was given throughout the study. The first cycle consisted of 0, 1- and 6-month schedule, and, in nonresponders, second cycle 0, 1-, 2-month schedule. Fourteen patients included into the study. Only one patient seroconverted (an anti-HBs titre of 37 IU/L) after the first cycle. No other patient responded to second cycle. HBV vaccination in the post-transplantation setting does not seems like an effective strategy in the prophylaxis of HBV recurrence.

  20. Occult HBV Infection: A Faceless Enemy in Liver Cancer Development

    Directory of Open Access Journals (Sweden)

    Jaime Morales-Romero

    2014-04-01

    Full Text Available The hepatitis B virus (HBV represents a worldwide public health problem; the virus is present in one third of the global population. However, this rate may in fact be higher due to occult hepatitis B virus infection (OBI. This condition is characterized by the presence of the viral genome in the liver of individuals sero-negative for the virus surface antigen (HBsAg. The causes of the absence of HBsAg in serum are unknown, however, mutations have been identified that produce variants not recognized by current immunoassays. Epigenetic and immunological host mechanisms also appear to be involved in HBsAg suppression. Current evidence suggests that OBI maintains its carcinogenic potential, favoring the progression of fibrosis and cirrhosis of the liver. In common with open HBV infection, OBI can contribute to the establishment of hepatocellular carcinoma. Epidemiological data regarding the global prevalence of OBI vary due to the use of detection methods of different sensitivity and specificity. In Latin America, which is considered an area of low prevalence for HBV, diagnostic screening methods using gene amplification tests for confirmation of OBI are not conducted. This prevents determination of the actual prevalence of OBI, highlighting the need for the implementation of cutting edge technology in epidemiological surveillance systems.

  1. HBeAg阴性乙型肝炎患者HBV-LP及HBV-DNA检测分析%Detection of serum HBV-LP and HBV-DNA in hepatitis B patients of negative HBeAg

    Institute of Scientific and Technical Information of China (English)

    刘鸿生; 胡志刚; 俞蕾; 周颖

    2012-01-01

    目的 分析HBeAg阴性的乙型肝炎患者血清HBV-LP及HBV-DNA检测的价值.方法 收集64份HBeAg阴性的乙型肝炎患者血清标本,分别采用实时荧光定量PCR检测HBV-DNA、ELISA法检测HBV-LP.结果 64例HBeAg阴性的乙型肝炎患者血清中,HBV-DNA阳性36例,总检出率为56.3%;HBV-LP阳性44例,总检出率为68.8%;HBV-DNA与PreS1抗原具有较好的相关性,HBeAg阴性的乙型肝炎患者血清HBV-DNA、HBV-LP阳性率差异无统计学意义,HBV-DNA复制拷贝数为<103、103-5、106-7、>107拷贝/ml,HBV-LP 检出率分别为60.7%、82.6%、60.0%、66.7%.结论 HBeAg阴性的乙型肝炎患者血清中HBV-LP检测可以作为HBV-DNA检测的有效补充.%OBJECTIVE To analyze the clinical significance of detection of serum HBV-LP and HBV-DNA in patients with hepatitis B whose HBeAg were negative. METHODS A total of 64 serum specimens of hepatitis B patients with negative HBeAg were collected. HBV-DNA was detected using the real-time fluorescent quantitative PCR and HBV-LP was measured by ELISA. RESULTS Of the 64 serum specimens, 36 were positive for HBV-DNA and 44 were positive for HBV-LP with the detection rates of 56. 3% and 68. 8%, respectively. It showed that HBV-LP and HBV-DNA were related but there was no significant difference between their own positivity. The HBV-DNA copies being 107 copy/ml, the detection rates of HBV-LP were 60. 7%,82. 5%,60. 0% and 66. 7%, respectively. CONCLUSION Detection of HBV-LP can serve as an effective complement to the measurement of HBV-DNA in patients with Hepatitis B whose HBeAg were negative.

  2. Molecular characterization and phylogenetic analysis of full-genome HBV subgenotype D3 sequences from Serbia.

    Science.gov (United States)

    Stanojević, Boban; Osiowy, Carla; Schaefer, Stephan; Bojović, Ksenija; Blagojević, Jelena; Nešić, Milica; Yamashita, Shunichi; Stamenković, Gorana

    2011-08-01

    Hepatitis B virus (HBV) is classified into 8 genotypes with distinct geographical distribution. Genotype D (HBV/D) has the widest distribution area and is comprised of 7 subgenotypes. Subgenotypes D1, D2 and D3 appear worldwide, while D4-D7 have a more restricted distribution. Within the Mediterranean area, HBV/D and subgenotype D3 are the most prevalent. The purpose of this study was to characterize the full genome of Serbian HBV/D3 isolates by comparison and phylogenetic analysis with HBV/D3 sequences (66 samples) found in GeneBank/DDBJ databases from different parts of the world. Isolates were obtained from three patients diagnosed with chronic hepatitis B (HBsAg+). All three isolates have two very rare nucleotide substitutions, A929T and T150A, which indicate the same ancestor. Phylogenetic analysis of HBV/D3 genome sequences throughout the world follows an ethno-geographical origin of isolates with rare exceptions, which could be explained by human travelling and migration. The geographically close but ethnically different Serbian and Italian isolates clustered in the same subnode, and on a common branch with strains from Northern Canada. To test the apparently close HBV phylogenetic relationship between completely separated patients from Serbia and Northern Canada we analyzed in depth a 440 bp region of the HBsAg from Canadian (n=73) and Serbian (n=70) isolates. The constructed parsimony tree revealed that strains from Serbia and Northern Canada fell along the same branch which indicates independent evolution within regions of each country. Considering that HBsAg sequence has limited variability for phylogenetic analyses, our hypothesis needs further confirmation with more HBV complete genome sequences.

  3. Rapid high-throughput genotyping of HBV DNA using a modified hybridization-extension technique.

    Science.gov (United States)

    Bao, Han; Zhao, Wenliang; Ruan, Banjun; Wang, Qing; Zhao, Jinrong; Lei, Xiaoying; Wang, Weihua; Liu, Yonglan; Sun, Jianbing; Xiang, An; Guo, Yanhai; Yan, Zhen

    2013-11-07

    China has the highest incidence of hepatitis B virus (HBV) infection worldwide. HBV genotypes have variable impacts on disease pathogenesis and drug tolerance. We have developed a technically simple and accurate method for HBV genotyping that will be applicable to pre-treatment diagnosis and individualized treatment. Multiple sequence alignments of HBV genomes from GenBank were used to design primers and probes for genotyping of HBV A through H. The hybridization was carried out on nitrocellulose (NC) membranes with probes fixed in an array format, which was followed by hybrid amplification by an extension step with DNA polymerase to reinforce the double-stranded DNA hybrids on the NC membrane and subsequent visualization using an avidin-biotin system. Genotyping results were confirmed by DNA sequencing and bioinformatics analysis using the National Center for Biotechnology Information genotyping database, and compared with results from the line probe assay. The data show that multiple sequence alignment defined a 630 bp region in the HBV PreS and S regions that was suitable for genotyping. All genotyping significant single nucleotides in the region were defined. Two-hundred-and-ninety-one HBV-positive serum samples from Northwest Chinese patients were genotyped, and the genotyping rate from the new modified hybridization-extension method was 100% compared with direct sequencing. Compared with line probe assay, the newly developed method is superior, featuring reduced reaction time, lower risk of contamination, and increased accuracy for detecting single nucleotide mutation. In conclusion, a novel hybridization-extension method for HBV genotyping was established, which represents a new tool for accurate and rapid SNP detection that will benefit clinical testing.

  4. Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.

    Science.gov (United States)

    Peebles, Kathryn; Nchimba, Lweendo; Chilengi, Roma; Bolton Moore, Carolyn; Mubiana-Mbewe, Mwangelwa; Vinikoor, Michael J

    2015-12-01

    Hepatitis B virus (HBV) is endemic in Africa, where it may occur as an HIV coinfection. Data remain limited on HIV-HBV epidemiology in Africa, particularly in children. Using programmatic data from pediatric HIV clinics in Lusaka, Zambia during 2011-2014, we analyzed the prevalence of chronic HBV coinfection (defined as a single positive hepatitis B surface antigen [HBsAg] test) and its impact on immune recovery and liver enzyme elevation (LEE) during the first year of antiretroviral therapy. Among 411 children and adolescents, 10.4% (95% confidence interval, 7.6-14.1) had HIV-HBV. Coinfected patients were more likely to have World Health Organization stage 3/4, LEE and CD4 <14% at care entry (all p < 0.05). During treatment, CD4 increases and LEE incidence were similar by HBsAg status. HBsAg positivity decreased (11.8% vs. 6.6%; p = 0.24) following HBV vaccine introduction. These findings support screening pediatric HIV patients in Africa for HBV coinfection. Dedicated cohorts are needed to assess long-term outcomes of coinfection.

  5. Active co-infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy.

    Science.gov (United States)

    Musyoki, Andrew M; Msibi, Thembeni L; Motswaledi, Mojakgomo H; Selabe, Selokela G; Monokoane, Tshweu S; Mphahlele, M Jeffrey

    2015-02-01

    Human immunodeficiency virus (HIV), Hepatitis B virus (HBV) and Hepatitis C virus (HCV) share routes of transmission. There is limited data on the incidence of active co-infection with HBV and/or HCV in cancer patients infected with HIV in Africa. This was a prospective study based on 34 patients with varied cancer diagnosis, infected with HIV and awaiting cancer therapy in South Africa. HIV viral load, CD4+ cell counts, Alanine-aminotransferase and aspartate aminotransferase levels were tested. Exposure to HBV and HCV was assessed serologically using commercial kits. Active HBV and/or HCV co-infection was detected using viral specific nested PCR assays. HCV 5'-UTR PCR products were sequenced to confirm active HCV infection. Active viral infection was detected in 64.7% of patients for HBV, 38.2% for HCV, and 29.4% for both HBV and HCV. Occult HBV infection was observed in 63.6% of the patients, while seronegative HCV infection was found in 30.8% of patients. In addition, CD4+ cell count HCV or both HBV and HCV co-infections. A total of 72.7%, 18.2% and 9.1% of the HCV sequences were assigned genotype 5, 1 and 4 respectively.The study revealed for the first time a high active HBV and/or HCV co-infection rate in cancer patients infected with HIV. The findings call for HBV and HCV testing in such patients, and where feasible, appropriate antiviral treatment be indicated, as chemotherapy or radiotherapy has been associated with reactivation of viral hepatitis and termination of cancer therapy.

  6. Prevention of de novo HBV infection by the presence of antiHBs in transplanted patients receiving core antibody-positive livers

    Institute of Scientific and Technical Information of China (English)

    Rafael Barcena; Gloria Moraleda; Javier Moreno; M Dolores Martín; Emilio de Vicente; Jesús Nu(n)o; M Luisa Mateos; Santos del Campo

    2006-01-01

    AIM: To analyze whether the presence of anti-HBs in liver transplant recipients is effective in preventing HBV infection.METHODS: Twenty-three patients receiving anti-HBc positive liver were studied. Nine recipients were anti HBc positive as a result of previous HBV infection. Of them, one also received HBV vaccine during the pre-liver transplantation period. Fourteen recipients were anti-HBs positive due to HBV vaccine administered during the pretransplant period. Liver biopsy was obtained in 10/14anti-HBc negative/anti-HBs positive recipients and in 4/9anti-HBc positive recipients.RESULTS: After a mean follow-up period of 46 months,1 recipient with protective serum anti-HBs levels developed de novo HBV infection as a consequence of immune escape HBV mutants. Among the 14 vaccinated anti-HBc negative/anti-HBs positive recipients, 1/10patients with available liver biopsy (10%) had liver HBVDNA at 13 mo post-liver transplantation without serum viral markers and did not develop de novo HBV infection.The vaccinated anti-HBc positive recipient without HBV vaccine response was HBV-DNA positive in serum and liver, viral DNA was continuously negative in the followlng tests, so a spontaneous seroconversion was diagnosed.CONCLUSION: The presence of anti-HBs as a result of HBV vaccine or past HBV infection seems to be effective at protecting patients receiving livers from anti-HBc positive donors. However, the emergence of immune escape HBV mutants, which can evade the anti-HBs protection, should be considered as a risk of HBV infection.

  7. A randomized control trial on interruption of HBV transmission in uterus

    Institute of Scientific and Technical Information of China (English)

    朱启镕; 于广军; 俞蕙; 吕晴; 顾新焕; 董左权; 张秀珍

    2003-01-01

    Objective To study the interruptive effect of hepatitis B virus (HBV) specific immunolobulin (HBIG) before delivery in attempt to prevent intrauterine transmission of HBV.Methods Nine hundred and eighty HBsAg carrier pregnant women were randomly divided into HBIG group and control group. Each subject in the HBIG group received 200 IU or 400 IU of HBIG intramuscularly at 3, 2 and 1 month before delivery. The subjects in the control group did not receive any specific treatment. All newborn infants received 100 IU of HBIG intramascularty after venous blood samples were taken at birth and 2 weeks after birth, followed by 30 μg plasma-derived HB vaccine or 5 μg recombinant yeast-derived hepatitis B vaccine at 1, 2 and 7 months of age. Blood tests were performed for all the lying-in women and their neonates. Blood specimens were tested for HBsAg and HBeAg by enzyme immunoassay. All infants were followed up for 1 year.Results In the HBIG group, 491 neonates were born to 487 HBV carrier mothers; and in the control group, 496 neonates were born to 493 HBV carrier mothers. The rates of intrauterine transmission in the two groups were 14.3% and 5.7% respectively (χ2=20.280, P<0.001), and the rates of chronic hepatitis B in the two groups were 2.2% and 7.3% respectively (χ2=13.696, P<0.001). The high risk factors of intrauterine HBV infection included HBsAg HBeAg double positive and HBV DNA positive in the peripheral blood of pregnant women.Conclusion HBV infection in the uterus may be interrupted by injecting multiple intramuscular HBIG injections before delivery without causing any side-effects.

  8. Evaluation of the effect of three disinfectants on removing HBV contamination

    Directory of Open Access Journals (Sweden)

    Arami S

    2006-06-01

    Full Text Available Background and Aim: Infection control is an important issue in dentistry. Without an efficient infection control, pathogens left on instruments and working surfaces will have potential danger to patients’ health. In this research, antiviral effect of three disinfectants: 0.5% sodium hypochlorite 0.05% sodium hypochlorite and Deconex 50 AF, on HBV was investigated. Materials and Methods: In this interventional (before-after study; serums of 26 HBV positive patients were analyzed by PCR HBV analysis and 9 contaminated species were obtained to test three disinfectants. 36 agar plates were prepared with the contaminated serums. 27 of the plates were disinfected in 3 separate groups with the above mentioned solutions. Nine remaining plates were not disinfected (control. Swabs wetted by BSAS (Bovine Serum Albumin Sodium Chloride medium were applied on the surface of the plates and the were kept in the transferred medium and sent to virology-lab of Pasteur Institute. HBV DNA were detected by commercial kit of HBV PCR (polymerase chain reaction method. Data were analyzed by Cochrane test with p<0.05 as the limit of significance. Results: None of samples disinfected with 0.5% sodium hypochlorite showed contamination. 11/1% of samples disinfected with 0.05% sodium hypochlorite and 44/4% of samples disinfected with Deconex 50 AF remained contaminated. Statistical analysis showed a significant difference between 0.5% sodium hypochlorite and the other groups. Conclusion: Our findings revealed that 0.5% sodium hypochlorite solution is a strong and efficient disinfectant against HBV. Key Words: HBV; Sodium hypochlorite

  9. Innate immune responses in hepatitis B virus (HBV) infection

    OpenAIRE

    Busca, Aurelia; Kumar, Ashok

    2014-01-01

    Hepatitis B virus (HBV) infection has a low rate of chronicity compared to HCV infection, but chronic liver inflammation can evolve to life threatening complications. Experimental data from HBV infected chimpanzees and HBV transgenic mice have indicated that cytotoxic T cells are the main cell type responsible for inhibition of viral replication, but also for hepatocyte lysis during chronic HBV infection. Their lower activation and impaired function in later stages of infection was suggested ...

  10. Breastfeeding and chronic HBV infection: Clinical and social implications

    Institute of Scientific and Technical Information of China (English)

    Mihaela; Petrova; Victor; Kamburov

    2010-01-01

    Mother-to-child transmission of hepatitis B virus (HBV) is among the most important causes of chronic HBV infection and is the commonest mode of transmission worldwide. Currently, the presence of HBsAg, HBeAg and HBV DNA in breast milk is confirmed. Several studies have reported that breastfeeding carries no additional risk that might lead to vertical transmission. Beyond some limitations, the surveys have not demonstrated any differences in HBV transmission rate regarding feeding practices in early childho...

  11. Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Huang De-Rong

    2010-11-01

    Full Text Available Abstract Background Epidemiological studies have clearly validated the association between hepatitis B virus (HBV infection and hepatocellular carcinoma (HCC. Patients with chronic HBV infection are at increased risk of HCC, in particular those with active liver disease and cirrhosis. Methods We catalogued all published interactions between HBV and human proteins, identifying 250 descriptions of HBV and human protein interactions and 146 unique human proteins that interact with HBV proteins by text mining. Results Integration of this data set into a reconstructed human interactome showed that cellular proteins interacting with HBV are made up of core proteins that are interconnected with many pathways. A global analysis based on functional annotation highlighted the enrichment of cellular pathways targeted by HBV. Conclusions By connecting the cellular proteins targeted by HBV, we have constructed a central network of proteins associated with hepatocellular carcinoma, which might be to regard as the basis of a detailed map for tracking new cellular interactions, and guiding future investigations.

  12. The application of combination detection of hepatitis B serological markers quantifi-cation and HBV DNA quantification in the diagnosis of hepatitis B virus infection%乙肝血清学标志物定量和HBV DNA定量联合检测在乙肝病毒感染诊断中的应用

    Institute of Scientific and Technical Information of China (English)

    吴洪秋; 张永良; 黄坚尧; 张汉运

    2016-01-01

    Objective To analyze the application value of combination detection in the diagnosis of hepatitis B virus ( HBV) infection by the quantitative detection of serological markers and HBV DNA of hepatitis B patients. Methods The serum samples of 120 hepatitis B patients from Jun. 2013 to Jun. 2015 were collected, and the ELISA qualitative test and RT-PCR were used to detect the contents of HBV serological markers ( HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc) and HBV DNA. Results The HBV DNA positive rate was 96. 15% in Ⅰ group; the HBV DNA positive rate was 48. 08% in Ⅱ group;the HBV DNA positive rate was 4. 76% inⅢgroup. The quantitative HBV DNA inⅠgroup was significantly higher than that in Ⅱ and Ⅲ groups ( P0. 05). Conclusion The combination detection of HBV serological markers and HBV DNA quantification plays a complementary role in the diagnosis of HBV infection, and has a more accurate diagnosis as well as can provide a more effective reference.%目的:分析乙肝患者的血清标志物和乙肝病毒( HBV) DNA联合检测在HBV感染诊断中的应用价值。方法以2013年6月-2015年6月在珠海市妇幼保健院就诊的120例乙肝患者血清样本作为研究资料,分别采用ELISA定性试验和实时荧光定量PCR( RT-PCR)检测HBV血清标志物( HBsAg、抗-HBs、HBeAg、抗-HBe、抗-HBc)和HBV DNA含量。结果Ⅰ组HBV DNA阳性率为96.15%;Ⅱ组HBV DNA阳性率为48.08%;Ⅲ组HBV DNA阳性率为4.76%。Ⅰ组HBV DNA定量显著高于Ⅱ、Ⅲ两组( P0.05)。结论乙肝血清标志物定量与HBV DNA定量联合检测在诊断HBV感染过程中起互相补充的作用,诊断结果更加准确,可提供更有效的参考依据。

  13. Genotype I of hepatitis B virus was found in east Xishuangbanna, China and molecular dynamics of HBV/I.

    Science.gov (United States)

    Shen, T; Yan, X M; Liu, H X; Zhang, B X; Li, L; Zhang, J P; Wang, J L; Xiao, C J

    2015-01-01

    There is a dearth of data about the prevalence of hepatitis B virus (HBV) infection in Mengla, China; and no detailed analysis of the molecular evolution of genotype I in Asia. In this study, 909 serum samples from ethnic minority people in China were obtained. Serological assay and HBV S-gene amplification were carried out, and phylogenetic and evolutionary dynamics analysis of 62 HBV/I S-gene was performed. On this survey, 153 individuals were tested HBsAg-positive. Genotypes of S-gene were classified into three groups: C, B and I. Under the strict model and the relax model, the estimated evolutionary rates for HBV/I were 3.74 × 10(-4) and 6.93 × 10(-4) substitution/site/year, respectively. However, when the geographic origin was taken into account, the mean substitution rates were increased. Estimated time to most recent ancestor of genotype I varied from ~30 to ~70 years ago. The Bayesian sky plot showed a rapid spread of HBV/I at the end of 1980s. Peculiar nucleotides distributed were observed in the subgenotype I1/I2. In conclusion, higher prevalence of HBV infection was observed in Mengla county. Multifactors like timescale and spatial locations should be integrated to provide a better interpretation of the HBV/I evolutionary history in the region.

  14. Clinical Characteristics in Patients with Liver Cirrhosis Induced by HBV Infection and Combined with Mild Alcohol Intake

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Objective To investigate the differences of clinical and biochemical characteristics between patients with liver cirrhosis induced by HBV infection combined with and without mild alcohol intake. Methods Data of patients with liver cirrhosis who were hospitalized in the First Hospital Afifliated to Xinjiang Medical University were retrospectively analyzed. Patients were divided into three groups: patients with liver cirrhosis induced by HBV infection and combined with mild alcohol intake, patients with HBV-related cirrhosis, and patients with alcohol-related cirrhosis. Biochemical detections including liver function, fasting lipid proifles, lipoprotein, kidney function, glucose, uric acid and regular blood tests were carried out and results were compared among three groups. Data were analyzed through STATA software and co-variant analysis. Results Total of 2 350 patients with liver cirrhosis were included, 732 patients had cirrhosis induced by HBV infection combined with mild alcohol intake, 1 316 patients had HBV-related liver cirrhosis, 302 patients had alcohol-related cirrhosis. The highest mean level of white cell count, mean corpuscular volume,γ-glutamyltranspeptidase and uric acid were observed in HBV infection combined with mild alcohol intake group. Multivariate regression analysis revealed that HBV infection, excessive alcohol intake, male and age were risk factors for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Conclusions HBV infection combined with mild alcoholic-related liver cirrhosis group showed the highest oxidative stress compared with alcoholic liver cirrhosis group, which suggested that mild alcohol intake may increase the incidence of liver cirrhosis in HBV infected patients and may not increase the incidence of HCC.

  15. A new HBV-model applied to an arctic watershed

    Energy Technology Data Exchange (ETDEWEB)

    Bruland, O.

    1995-12-31

    This paper describes the HBV-model, which was developed in the Nordic joint venture project ``Climate change and energy production``. The HBV-model is a precipitation-runoff model made mainly to create runoff forecasts for hydroelectric power plants. The model has been tested in an arctic watershed, the Bayelva drainage basin at Svalbard. The model was calibrated by means of data for the period 1989-1993 and tested on data for the period 1974-1978. For both periods, snow melt, rainfall and glacier melt events are well predicted. The largest disagreement between observed and simulated runoff occurred on warm days with heavy rain. This may be due to the precipitation measurements which may not be representative for such events. Measurements show a larger negative glacier mass balance than the simulated one although the parameters controlling the glacier melt in the model are set high. Glacier mass balance simulations in which the temperature index depends on albedo and radiation are more correct and improve model efficiency. 5 refs., 4 figs., 1 table

  16. HBV Vaccination in Chronic Renal Failure Patients

    OpenAIRE

    Mir-davood Omrani; Mohammad Hassan Khadem Ansari

    2006-01-01

    HBV infection in chronic renal failure (CRF) becomes chronic in 30 to 60% compared with less than 10% in nonuremic patients. Immunological dysfunction in patients on hemodialysis may be related to imbalanced cytokine systems, such as tumor necrosis factor (TNF-|α|) and interleukin (IL) 6,1 by retention of renal metabolite in uremia and chronic inflammation and have a poor immunological reaction to T-cell-dependent antigens, like hepatitis B vaccination. Immunocompromised patients who are unre...

  17. The influence of HLA alleles and HBV subgenotyes on the outcomes of HBV infections in Northeast China.

    Science.gov (United States)

    Li, Xingku; Liu, Wei; Wang, Hongyan; Jin, Xi; Fang, Shaohong; Shi, Yuguang; Liu, Zhen; Zhang, Shuyun; Yang, Shufen

    2012-01-01

    Hepatitis B virus (HBV) infection has a wide variety of clinical outcomes, it could be spontaneouly recovered and also could develop fulminant liver failure or cirrhosis with hepatocellular carcinoma. Human leukocyte antigen (HLA) polymorphism and HBV (sub)genotypes have been speculated to associate with the outcome of HBV infection because the data obtained from various populations who bear different HLA alleles have shown a HLA polymorphism associated outcome of HBV infection. However, as the most important viral and host genetic factors, the impact of HBV (sub)genotypes in combination with HLA polymorphism on the clinical outcomes of HBV infections remains unclear. To demonstrate the association of HLA allele polymorphism in combination with HBV subgenotypes with the outcome of HBV infection in Northeastern Han Chinese population, a total of 230 HBV-infected individuals (Infection group) were compared to 210 random selected controls (Control group) who are negative for HBV infection for their HLA alleles frequency as well as the associations with the virus infection, clearance and persistence in combination with HBV subgenotypes. Of the 230 HBV-infected subjects, 54 were acute self-limited hepatitis (ASH) with HBV subgenotype C2 (ASH-C2), 144 were chronic hepatitis (CH) with HBV subgenotype C2 and B2 (CH-C2 and CH-B2), and 32 were spontaneously recovered (SR) without subgenotype results. When two groups are compared, the results suggest that B*48, B*51 and DRB1*12 carrier may have a high risk for HBV infection, but B*51 is likely association with spontaneous recovery and DRB1*07, 12 may be implied in viral persistence. HLA-B*15, DRB1*11 and 14 associated with viral clearance in the cases of HBV-C2 infection; HLA-B*54 carriers in chronic group are more sensitive to with the infection of HBV subgenotype B2; HLA-B*07 and DRB1*13 may protect subjects from HBV infection. The data presented a link between HLA polymorphism and HBV pathogenesis and suggested potential

  18. Co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors in Kathmandu, Nepal

    Directory of Open Access Journals (Sweden)

    Ashish Chandra Shrestha

    2012-02-01

    Full Text Available Background: HIV, HBV, Syphilis and HCV share common modes of transmission. Objective: The study was aimed to determine the co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors. Methods: The study was conducted on blood samples screened as HCV seropositive at Nepal Red Cross Society, Central Blood Transfusion Service, Kathmandu, Nepal. HCV seropositive samples were further tested for HIV, HBV and Syphilis. Results: Eight co-infections were observed in 139 HCV seropositives with total co-infection rate of 5.75% (95% CI = 2.52-11.03. Conclusion: Co-infection of HIV, HBV and Syphilis with HCV is prevalent in the healthy looking blood donors of Kathmandu, Nepal.

  19. Know HBV: What Every Asian and Pacific Islander Should Know About Hepatitis B and Liver Cancer

    Science.gov (United States)

    ... a hepatitis B carrier). Hepatitis B surface antibody (anti-HBs): Tells if you are protected against HBV. Only ... edu » Get Vaccinated If both your HBsAg and anti-HBs blood tests are negative, then you are not ...

  20. HBV X-gene: A new serum marker for anti-HBV therapy monitoring

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Objective: To address HBV serum nucleic acid markers for stages without apparent replication. Methods: DNA and RNA sequence segments from the X, C and pre C/C regions produced successively during replication were used as targets for quantitative PCR and RT/PCR. Results: The assays confirmed the preferential formation of intermediates blocked at early stages. They persisted as the only detectable type of serum HBV DNA even after one year of therapy. At reentry into viral replication due to emergence of drug resistant mutants, lamivudine resistance produced exclusively incomplete DNA minus strands, whereas the wild type virus immediately synthesized complete DNA minus strands. Conclusion:PCR assays used for monitoring complete suppression of HBV replication must target the X gene region.

  1. HBV cccDNA in patients′ sera as an indicator for HBV reactivation and an early signal of liver damage

    Institute of Scientific and Technical Information of China (English)

    Ying Chen; Johnny Sze; Ming-Liang He

    2004-01-01

    AIM: To evaluate the covalently closed circle DNA (cccDNA)level of hepatitis B virus (HBV) in patients′ liver and sera.METHODS: HBV DNA was isolated from patients′liver biopsies and sera. A sensitive real-time PCR method, which is capable of differentiation of HBV viral genomic DNA and cccDNA, was used to quantify the total HBV cccDNA. The total HBV viral DNA was quantitated by real-time PCR using a HBV diagnostic kit (PG Biotech, LTD, Shenzhen, China)described previously.RESULTS: For the first time, we measured the level of HBV DNA and cccDNA isolated from ten HBV patients′liver biopsies and sera. In the liver biopsies, cccDNA was detected from all the biopsy samples. The copy number of cccDNA ranged from from 0.03 to 173.1 per cell, the copy number of total HBV DNA ranged from 0.08 to 3 717 per cell. The ratio of total HBV DNA to cccDNA ranged from 1 to 3 406. In the sera,cccDNA was only detected from six samples whereas HBV viral DNA was detected from all ten samples. The ratio of cccDNA to total HBV DNA ranged from 0 to 1.77%. To further investigate the reason why cccDNA could only be detected in some patients′sera, we performed longitudinal studies. The cccDNA was detected from the patients′sera with HBV reactivation but not from the patients′sera without HBV reactivation. The level of cccDNA in the sera was correlated with ALT and viral load in the HBV reactivation patients.CONCLUSION: HBV cccDNA is actively transcribed and replicated in some patients′hepatocytes, which is reflected by a high ratio of HBV total DNA vs cccDNA. Detection of cccDNA in the liver biopsy will provide an end-point for the anti-HBV therapy. The occurrence of cccDNA in the sera is an early signal of liver damage, which may be another important clinical parameter.

  2. A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge?

    Directory of Open Access Journals (Sweden)

    Priyanka Banerjee

    Full Text Available BACKGROUND/AIMS: HBV has been classified into ten genotypes (A-J and multiple subgenotypes, some of which strongly influence disease outcome and their distribution also correlate with human migration. HBV infection is highly prevalent in India and its diverse population provides an excellent opportunity to study the distinctiveness of HBV, its evolution and disease biology in variegated ethnic groups. The North-East India, having international frontiers on three sides, is one of the most ethnically and linguistically diverse region of the country. Given the paucity of information on molecular epidemiology of HBV in this region, the study aimed to carry out an in-depth genetic characterization of HBV prevailing in North-East state of Tripura. METHODS: From sera of chronically HBV infected patients biochemical/serological tests, HBV DNA quantification, PCR-amplification, sequencing of PreS/S or full-length HBV genomes were done. HBV genotype/subgenotype determination and sequence variability were assessed by MEGA5-software. The evolutionary divergence times of different HBV subgenotypes were estimated by DNAMLK/PHYLIP program while jpHMM method was used to detect any recombination event in HBV genomes. RESULTS: HBV genotypes D (89.5%, C (6.6% and A (3.9% were detected among chronic carriers. While all HBV/A and HBV/C isolates belonged to subgenotype-A1 and C1 respectively, five subgenotypes of HBV/D (D1-D5 were identified including the first detection of rare D4. These non-recombinant Indian D4 (IndD4 formed a distinct phylogenetic clade, had 2.7% nucleotide divergence and recent evolutionary radiation than other global D4. Ten unique amino acids and 9 novel nucleotide substitutions were identified as IndD4 signatures. All IndD4 carried T120 and R129 in ORF-S that may cause immune/vaccine/diagnostic escape and N128 in ORF-P, implicated as compensatory Lamivudine resistance mutation. CONCLUSIONS: IndD4 has potential to undermine vaccination

  3. Hepatitis B virus (HBV status of children born to HIV/HBV co-infected women in a French hospital: a cross-sectional study

    Directory of Open Access Journals (Sweden)

    Pierre Sellier

    2014-11-01

    Full Text Available Introduction: Human Immunodeficiency Virus (HIV Mother-To-Child-Transmission (MTCT and prevention by combined antiretroviral therapy (cART have been extensively studied. Hepatitis B Virus (HBV MTCT from HIV/HBV co-infected women and prevention by antiretroviral therapy with dual activity have been poorly studied. The aim of the study was to assess HBV MTCT from HIV/HBV co-infected women in a developed country with a large access to cART. Materials and Methods: HIV/HBV co-infected pregnant women attending the Obstetrics Department from 1st January 2000 to 1st January 2012 could be included in the study (NCT02044068. Antiretroviral therapy during pregnancy, injection of immunoglobulin and/or vaccine to newborns was retrospectively recorded. We assessed HBV status of children at least as old as two years. Results: Forty nine (9.2% from 530 HIV-infected women followed in the hospital were HIV/HBV co-infected. 34 (69.4% had given birth to 57 children in the hospital. 13 of these women (22 children were lost-to-follow-up, 21 women (35 children could be studied. Twenty six children (74.3% had HBs Ab at a protective level, 22 of them had received immunoglobulin at birth; 24 had received a complete vaccine schedule during the first six months of life (with immunoglobulin in 21 cases. The women had been given lamivudine or tenofovir/emtricitabine during eight and nine pregnancies respectively. Eight children (22.8% were tested negative for HBs Ag, HBs Ab and HBc Ab: 4 (11.4% had received immunoglobulin and a complete vaccine schedule; in two children, immunoglobulin was uncertain; in one child, the vaccine schedule was incomplete; in the last one, data about immunoglobulin and the vaccine schedule were lacking. The women had been given lamivudine or tenofovir/emtricitabine during five and two pregnancies respectively. One child had HBc Ab and HBs Ab, immunoglobulin was uncertain and the vaccine schedule was incomplete. The woman had been given lamivudine

  4. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

    Science.gov (United States)

    Powell, Eleanor A; Boyce, Ceejay L; Gededzha, Maemu P; Selabe, Selokela G; Mphahlele, M Jeffrey; Blackard, Jason T

    2016-07-01

    Occult hepatitis B is defined by the presence of hepatitis B virus (HBV) DNA in the absence of hepatitis B surface antigen (HBsAg). Occult HBV is associated with the development of hepatocellular carcinoma, reactivation during immune suppression, and virus transmission. Viral mutations contribute significantly to the occult HBV phenotype. Mutations in the 'a' determinant of HBsAg are of particular interest, as these mutations are associated with immune escape, vaccine escape and diagnostic failure. We examined the effects of selected occult HBV-associated mutations identified in a population of HIV-positive South Africans on HBsAg production in vitro. Mutations were inserted into two different chronic HBV backbones and transfected into a hepatocyte-derived cell line. HBsAg levels were quantified by enzyme-linked immunosorbent assay (ELISA), while the detectability of mutant HBsAg was determined using an HA-tagged HBsAg expression system. Of the seven mutations analysed, four (S132P, C138Y, N146D and C147Y) resulted in decreased HBsAg expression in one viral background but not in the second viral background. One mutation (N146D) led to a decrease in HBsAg detected as compared to HA-tag, indicating that this mutation compromises the ability of the ELISA to detect HBsAg. The contribution of occult-associated mutations to the HBsAg-negative phenotype of occult HBV cannot be determined adequately by testing the effect of the mutation in a single viral background, and rigorous analysis of these mutations is required.

  5. Sieroprevalenza di infezione da HBV e HCV tra pazienti in dialisi

    Directory of Open Access Journals (Sweden)

    Rosa Anna Leone

    2003-12-01

    Full Text Available The aim of the present study was to investigate the seroprevalence of HBV and HCV among dialysis patients in the Lamezia Terme (CZ area during the period 1999-2002. Sera from 63 patients in haemodialysis (HD and 10 patients in peritoneal dialysis (PD were analyzed with a follow-up every three months for HBsAg, HBcAb, HBsAb, anti-HCV and anti-HIV (Elisa Test,AxSYM,Abbott;we analyzed reactive sera for anti-HCV by using supplemental test (RIBA Test, Ortho; we also looked for viremia (RT-PCR Amplicor, Roche Diagnostics and HCV genotypes (Inno-Lipa HCV II, Innogenetics.The results show that, among the HD patients, 3 were HBsAg positive (Chronic Infection and 7 HBcAb and HBsAb positive/HBsAg negative (Passed Infection; 14 individuals were anti-HCV positive. No patients in PD were positive for HBV and HCV markers.The prevalence of chronic HBV infection was 4.8% (instead of 3% in other Dialysis Units, that of anti-HCV positive was 22% (in others 24%- 33%; among anti-HCV positive patients, the HCV-RNA prevalence was 79% (instead of 80%; the most recurrent HCV genotype was 2a/2c (instead of 1b in general population.These findings lead us to hypothesize that the environmental transmission in the dialysis setting is tightly correlated to the risk of HBV and HCV infection.

  6. Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.

    Directory of Open Access Journals (Sweden)

    Henry Bautista-Amorocho

    Full Text Available Chronic hepatitis B virus (HBV infection is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV-infected individuals. HIV-positive patients are commonly co-infected with HBV due to shared routes of transmission.Our aim was to determine the risk factors, prevalence, genotypes, and mutations of the Surface S gene of HBV, and occult hepatitis B infection (OBI among patients infected with HIV in a northeastern Colombian city.A cross-sectional study was conducted with 275 HIV-positive patients attending an outpatient clinic in Bucaramanga, Colombia during 2009-2010. Blood samples were collected and screened for serological markers of HBV (anti-HBs, anti-HBc and HBsAg through ELISA assay. Regardless of their serological profile, all samples were tested for the HBV S gene by nested-PCR and HBV genotypes were determined by phylogenetic inference. Clinical records were used to examine demographic, clinical, virological, immunological and antiretroviral therapy (ART variables of HIV infection.Participants were on average 37±11 years old and 65.1% male. The prevalence of HIV-HBV coinfection was 12% (95%CI 8.4-16.4 of which 3.3% had active HBV infection and 8.7% OBI. The prevalence of HIV-HBV coinfection was associated with AIDS stage and ART treatment. Sequence analysis identified genotype F, subgenotype F3 in 93.8% of patients and genotype A in 6.2% of patients. A C149R mutation, which may have resulted from failure in HBsAg detection, was found in one patient with OBI.The present study found a high prevalence of HIV-HBV coinfection with an incidence of OBI 2.6-fold higher compared to active HBV infection. These findings suggest including HBV DNA testing to detect OBI in addition to screening for HBV serological markers in HIV patients.

  7. Progress and Prospects of Anti-HBV Gene Therapy Development

    Directory of Open Access Journals (Sweden)

    Mohube B. Maepa

    2015-07-01

    Full Text Available Despite the availability of an effective vaccine against hepatitis B virus (HBV, chronic infection with the virus remains a major global health concern. Current drugs against HBV infection are limited by emergence of resistance and rarely achieve complete viral clearance. This has prompted vigorous research on developing better drugs against chronic HBV infection. Advances in understanding the life cycle of HBV and improvements in gene-disabling technologies have been impressive. This has led to development of better HBV infection models and discovery of new drug candidates. Ideally, a regimen against chronic HBV infection should completely eliminate all viral replicative intermediates, especially covalently closed circular DNA (cccDNA. For the past few decades, nucleic acid-based therapy has emerged as an attractive alternative that may result in complete clearance of HBV in infected patients. Several genetic anti-HBV strategies have been developed. The most studied approaches include the use of antisense oligonucleotides, ribozymes, RNA interference effectors and gene editing tools. This review will summarize recent developments and progress made in the use of gene therapy against HBV.

  8. Innate immune responses in hepatitis B virus (HBV) infection.

    Science.gov (United States)

    Busca, Aurelia; Kumar, Ashok

    2014-02-07

    Hepatitis B virus (HBV) infection has a low rate of chronicity compared to HCV infection, but chronic liver inflammation can evolve to life threatening complications. Experimental data from HBV infected chimpanzees and HBV transgenic mice have indicated that cytotoxic T cells are the main cell type responsible for inhibition of viral replication, but also for hepatocyte lysis during chronic HBV infection. Their lower activation and impaired function in later stages of infection was suggested as a possible mechanism that allowed for low levels of viral replication. The lack of an interferon response in these models also indicated the importance of adaptive immunity in clearing the infection. Increased knowledge of the signalling pathways and pathogen associated molecular patterns that govern activation of innate immunity in the early stages of viral infections in general has led to a re-evaluation of the innate immune system in HBV infection. Numerous studies have shown that HBV employs active strategies to evade innate immune responses and induce immunosuppression. Some of the immune components targeted by HBV include dendritic cells, natural killer cells, T regulatory cells and signalling pathways of the interferon response. This review will present the current understanding of innate immunity in HBV infection and of the challenges associated with clearing of the HBV infection.

  9. HBV subgenotype misclassification expands quasi-subgenotype A3.

    Science.gov (United States)

    Pourkarim, M R; Amini-Bavil-Olyaee, S; Lemey, P; Maes, P; Van Ranst, M

    2011-06-01

    Recently, we proposed a new classification for 'subgenotype A' of hepatitis B virus (HBV), in which the novel 'quasi-subgenotype A3' group comprising HBV 'subgenotype A3', 'tentative A4', and A5 was introduced. Newly 'Tentative subgenotype A7' strains from Cameroon were introduced by Hubschen et al. However, our meticulous phylogenetic analysis demonstrated that these isolates should also be classified into 'quasi-subgenotype A3'. Such misclassification can be avoided by following established principles for HBV subgenotyping. Moreover, their close evolutionary relationship with A3 highlights our hypothesis that geographical origin may be an important factor in further classification of HBV subgenotypes.

  10. Effects of HBV Genetic Variability on RNAi Strategies

    Directory of Open Access Journals (Sweden)

    Nattanan Panjaworayan

    2011-01-01

    Full Text Available RNAi strategies present promising antiviral strategies against HBV. RNAi strategies require base pairing between short RNAi effectors and targets in the HBV pregenome or other RNAs. Natural variation in HBV genotypes, quasispecies variation, or mutations selected by the RNAi strategy could potentially make these strategies less effective. However, current and proposed antiviral strategies against HBV are being, or could be, designed to avoid this. This would involve simultaneous targeting of multiple regions of the genome, or regions in which variation or mutation is not tolerated. RNAi strategies against single genotypes or against variable regions of the genome would need to have significant other advantages to be part of robust therapies.

  11. 新生期树鼩接种人乙型肝炎病毒的长期实验观察%Long-term observation of hepatitis B virus (HBV) replication in new-born tree shrews inoculated with HBV

    Institute of Scientific and Technical Information of China (English)

    杨芳; 李瑗; 曹骥; 张晶晶; 王琦; 苏建家; 杨春; 欧超; 史俊林; 汪多平

    2009-01-01

    目的 观察新生期树鼩接种HBV后体内HBV感染标志物的长期动态.方法 6只树鼩于新生期接种人HBV DNA阳性血清,每4-6周抽血1次和每6~12周做肝活体组织检查1次,应用巢式聚合酶链反应(nPCR)、荧光定量聚合酶链反应(FQ-PCR)、Southern blot、酶联免疫吸附试验和免疫组织化学染色等方法动态观察血清和肝组织中HBV感染标志物的消长,用电镜寻找肝组织内的HBV颗粒和用光镜观察肝组织病理变化.结果 新生期树鼩接种后48周,3只动物(1、2和6号)血清和肝组织标本经多对引物进行的nPCR,均稳定显示HBV DNA阳性,肝组织HBVcccDNA阳性;FQ-PCR显示血清和肝组织HBV DNA的拷贝数分别为103-104/ml和每微克肝组织总DNA 107~108拷贝;Southern blot检测显示肝组织存在HBV复制中间体HBV cccDNA和HBV单链DNA;酶联免疫吸附试验检测显示血清HBsAg持续阳性;免疫组织化学染色可见数量逐步增多的HBsAg阳性肝细胞.其中的1号动物至接种后2年每微克肝组织总DNA仍可测得107~108拷贝的HBV DNA,电镜下可见疑似HBV颗粒.另3只动物除nPCR显示肝组织HBV DNA阳性条带和FQ-PCR显示低拷贝数(每微克肝组织总DNA103拷贝)HBV DNA外,其余的HBV感染标志物均为阴性或一过性阳性.结论 新生树鼩能够长期感染HBV,并且HBV能够在树鼩体内稳定复制和长期存在.%Objective To observe the hepatitis B virus (HBV) replication in the tree shrews that were inoculated with HBV at neonatal period.Methods Six new-born tree shrews were inoculated with human HBV positive serum.Blood samples and liver biopsies were colleted at different time points after inoculation.The HBV infection markers were tested by nested polymerase chain reaction (nPCR),fluorescence quantitative polymerase chain reaction (FQ-PCR),Southern blot,ELISA and immunohistoehemistry staining.The liver tissues were observed under electron and light microscope.Results 48 weeks after

  12. Evolutionary dynamics of HBV-D7 subgenotype in Tunisia.

    Science.gov (United States)

    Ciccozzi, Massimo; Chaouch, Houda; Lo Presti, Alessandra; Taffon, Stefania; Villano, Umbertina; Equestre, Michele; Bruni, Roberto; Marcantonio, Cinzia; Tritarelli, Elena; Cella, Eleonora; Blasi, Aletheia; Aouni, Mahjoub; Letaief, Amel; Ciccaglione, Anna Rita

    2017-03-01

    Hepatitis B virus (HBV) is the main cause of diseases liver related infecting more than 200 milion persons worldwide. HBV infection shows high level of prevalence in South-East Europe and in Mediterranean basin. In Tunisia, a country with an intermediate level endemicity, HbsAg prevalence ranges from 2 to 5%. Most of the HBV isolates from Tunisia were classified as subgenotype D7 whose circulation is restricted to a specific area of North Africa including Maghreb region. In this paper, the phylogeny of HBV-D7 isolated from 38 Tunisian patients was investigated by analyzing the S gene region of HBV. A Bayesian coalescent-based framework was used to estimate the origin of the HBV-D7 in the country. The Tunisian D7 isolates were found to share a common ancestor whose origin was traced back to 1958. Population dynamics indicated that HBV-D7 epidemic in Tunisia grew exponentially from 1960s to 1990s. After that, the curve reached a plateau around the years 2000 likely due to the implementation of the infant vaccination program in 1996. Epidemiological data suggested that the exponential growth phase was likely sustained by intra-familial transmission events occurring during infancy. Further characterization of HBV-D7 isolates should be performed to evaluate, in the post-vaccination era, the emergence of new transmission routes, and to monitor the efficacy of the vaccination program. J. Med. Virol. 89:469-475, 2017. © 2016 Wiley Periodicals, Inc.

  13. Application of CRISPR/Cas9 Technology to HBV

    Directory of Open Access Journals (Sweden)

    Guigao Lin

    2015-11-01

    Full Text Available More than 240 million people around the world are chronically infected with hepatitis B virus (HBV. Nucleos(tide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA, which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV.

  14. Study on correlation of hepatitis B maternal serum HBV-DNA with HBV-DNA in milk%乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    李国航; 庄桂龙; 瞿志军; 骆欢

    2012-01-01

    目的 探讨乙型病毒性肝炎(乙肝)孕产妇血清HBV-DNA与乳汁HBV-DNA的相关性,以期指导乙肝产妇的喂养方式.方法 选取2008年12月至2009年12月收治的70例血清HBV抗原阳性孕产妇(乙肝组)及20例健康产妇(对照组)为研究对象,采用酶联免疫吸附试验(ELISA)检测血清及乳汁中免疫血清学标志物;采用荧光定量PCR法(FQ-PCR)检测血清及乳汁中HBV-DNA含量情况,并对所检测的指标进行相关性分析.结果 采用ELISA检测到乙肝组产妇大三阳18例,小三阳27例,HBsAg、HBcAb均为阳性的有35例,乳汁HBV-DNA在各组中的检出的阳性率、病毒载量均小于血清HBV-DNA,但两者无显著性差异(P>0.05).乳汁HBV-DNA的含量随血清HBV-DNA含量的升高而增大(P 0.05 ). The level of HBV - DNA in milk was elevated following the increase of serum level of HBV - DNA, P <0.05. Conclusion The choice of feeding mode should be selected according to milk and serum levels of HBV -DNA, and breast feeding can be taking only at the time when HBV - DNA in milk and serum of mother turned to negative level.

  15. Detection of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection

    Institute of Scientific and Technical Information of China (English)

    Li-Zhang Chen; Xue-Gong Fan; Jian-Ming Gao

    2005-01-01

    AIM: To investigate the presence of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection.METHODS: HBsAg and HBcAg were examined in ovarian biopsy tissues from 26 patients with HBV infection by immunocytochemistry, and HBV DNA was detected in ovarian tissues by PCR.RESULTS: HBsAg and HBcAg were present with the same positive rate of 34.6% (9/26). The total positive rate was 46.2% (12/26). HBsAg and HBcAg were positive in 6 (23.1%) of the 26 patients. Brown positive particles were diffusely distributed in ovarian cells. The positive rate of HBV DNA was 58.3% (7/12).CONCLUSION: HBsAg, HBcAg, and HBV DNA can be detected in ovarian tissues from patients with HBV infection. The presence of HBsAg and HBcAg in ovarian tissues does not correlate with the HBV markers in serum.

  16. Adherence to the screening program for HBV infection in pregnant women delivering in Greece

    Directory of Open Access Journals (Sweden)

    Cassimos Dimitrios

    2006-05-01

    Full Text Available Abstract Background Hepatitis B infection (HBV is a major Public Health Problem. Perinatal transmission can be prevented with the identification of HBsAg(+ women and administration of immunoprophylaxis to their newborns. A national prevention programme for HBV with universal screening of pregnant women and vaccination of infants is in effect since 1998 in Greece. Methods To evaluate adherence to the national guidelines, all women delivering in Greece between 17–30/03/03 were included in the study. Trained health professionals completed a questionnaire on demographic data, prenatal or perinatal screening for HBsAg and the implementation of appropriate immunoprophylaxis. Results During the study period 3,760 women delivered. Prenatal screening for HBsAg was documented in 91.3%. Greek women were more likely to have had prenatal testing. HBsAg prevalence was 2.89% (95%CI 2.3–3.4%. Higher prevalence of HBV-infection was noted in immigrant women, especially those born in Albania (9.8%. Other risk factors associated with maternal HBsAg (+ included young maternal age and absence of prenatal testing. No prenatal or perinatal HBsAg testing was performed in 3.2% women. Delivering in public hospital and illiteracy were identifiable risk factors for never being tested. All newborns of identified HBsAg (+ mothers received appropriate immunoprophylaxis. Conclusion The prevalence of HBsAg in Greek pregnant women is low and comparable to other European countries. However, immigrant women composing almost 20% of our childbearing population, have significant higher prevalence rates. There are still women who never get tested. Universal vaccination against HBV at birth and reinforcement of perinatal testing of all women not prenatally tested should be discussed with Public Health Authorities.

  17. Prevalence and characteristics of HIV/HBV and HIV/HCV coinfections in Tuscany

    Directory of Open Access Journals (Sweden)

    Monia Puglia

    Full Text Available Abstract Introduction Worldwide about 30% of HIV-infected patients are coinfected with HCV or HBV. The HIV/HCV coinfection is more common in individuals who have a history of drug addiction. The aims of this study were to assess the HCV and HBV prevalence in HIV-infected patients and analyze their characteristics. Methods We considered the new HIV diagnoses notified by the regional surveillance system of Tuscany from 2009 to 2013. Descriptive analyses were conducted on the socio-demographic characteristics, routes of transmission, and reason to perform the test. In coinfected patients we assessed the risk for being late presenter (LP or the risk of having AIDS. Results In 5 years of surveillance a total of 1354 new HIV diagnoses were notified: 1188 (87.7% were HIV alone, 106 (7.8% HIV/HCV, 56 (4.1% HIV/HBV, and 4 (0.33% HIV/HCV/HBV. The main risk factor was injection drug use in 52.8% of HCV/HIV cases, while in HIV/HBV patients the main risk factor was sexual exposure. HIV/HBV coinfected patients showed worse clinical and immunological features than HIV and HIV/HCV patients: 78.6% had CD4 count less than 350 mm−3 (vs. 54.6% and 62.1%, respectively and 39.4% had AIDS (vs 20.7% and 7.6%. The risk for being LP triples for HIV/HBV (OR 2.98; 95% IC: 1.56–5.70 than patients with HIV alone. Conclusions We have observed less advanced disease in HIV and HCV-HIV patients compared with HBV–HIV coinfected patients. Moreover, our results show a higher prevalence of HIV/HCV among drug addicts and in the age-group 35–59, corresponding to those born in years considered most at risk for addiction. This study also confirms the finding of a less advanced HIV disease in HIV/HCV coinfected patients.

  18. The correlation among HBV DNA load, HBeAg/Anti-HBe and Alanine Aminotransferase in patients with chronic hepatitis B infection%慢性HBV感染者血清HBV DNA载量与HBeAg/抗-HBe、ALT之间的关系

    Institute of Scientific and Technical Information of China (English)

    徐军; 王芳; 杨帆

    2010-01-01

    目的 探讨慢性HBV感染者血清HBV DNA载量与HBeAg/抗-Hbe以及丙氨酸转氨酶(ALT)水平之间的关系.方法 采用酶联免疫吸附法(ELISA)检测134例慢性HBV感染者HBV血清标志物,根据HBeAg/抗-Hbe检测结果将患者分为Ⅰ组(HBeAg+/抗-Hbe-,43例);Ⅱ组(HBeAg-/抗-Hbe+,69例);Ⅲ组(HBeAg-/抗-Hbe-,22例).同时应用实时荧光定量PCR方法以及连续监测法检HBV DNA载量以及ALT水平.结果 Ⅰ组HBV DNA阳性率和HBV DNA载量明显高于Ⅱ、Ⅲ组(P<0.01).HBV DNA阳性患者ALT异常率高于HBV DNA阴性患者(P<0.01).HBV DNA阳性患者HBV DNA载量与ALT水平之间无相关性(r=0.174,P=0.156).结论 血清HBV DNA载量与HBeAg/抗-Hbe以及ALT之间存在一定的关系,但不能单纯依靠HBeAg/抗-Hbe以及ALT来判断HBV在体内的复制情况,三项指标联合检测对HBV慢性感染者的病情检测、治疗具有重要意义.%Objective To explore the relationship among HBV DNA load, HBeAg/Anti-HBe and ALT in patients with chronic hepatitis B infection. Methods HBV markers in 134 patients with chronic HBV infection were detected by ELISA,and patients were divided into group Ⅰ (HBeAg +/Anti-HBe-,43 patients) ,group Ⅱ (HBeAg-/Anti-HBe + ,69 patients)and group Ⅲ (HBeAg-/Anti-Hbe-,22 patients)according to the results of presence of HBeAg/Anti-HBe. HBV DNA load and ALT were tested respectively by fluorescence quantitative polymerase chain reaction technology and successive monitor reaction. Results Both the positive rate and the HBV DNA load quantification in group Ⅰ were higher than in group Ⅱ and Ⅲ (P<0.01). Abnormality rate of ALT in HBV DNA positive patients was higher than the patients with HBV DNA negitive(P<0.01). There was no relationship between HBV DNA load and ALT in HBV DNA positive patients. Conclusion There was a certain corelation among HBV DNA load, HBeAg/Anti-HBe and ALT,but the active degree of HBV replication could not to be assessed by HBeAg/Anti-HBe or ALT alone

  19. Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection.

    Directory of Open Access Journals (Sweden)

    Li-Ping Hu

    Full Text Available The importance of transmission of occult HBV infection (OBI via transfusion, organ transplantation and hemodialysis has been widely recognized. However, data regarding the transmission of OBI through close contact remain limited. In this study, serum samples were obtained from a child and his parents. The child had received the standard vaccination regimen at birth and produced protective antibody. Sera were tested for HBV serological markers. Nested PCR assays were used to detect HBV DNA and the amplicons were cloned and their sequences subjected to phylogenetic analysis. The results showed that both parents had occult infections while the child had an overt infection. Twelve, eleven and nine clones, from the father, mother and son, respectively, were sequenced. Serotypes adrq+, ayw1, ayw and ayr were found in the father and ayw1, adw2 and adwq+ in the mother; adrq+ was the only serotype in son. Genotype B, subgenotype C2 and a recombinant were identified in the father and genotype B, subgenotype C5 and three recombinants were found in the mother. Subgenotype C2 was the only genotype identified in the child. A phylogenetic tree showed that all of the child's sequences and most of the father's sequences clustered together. However, none of mother's sequences clustered with those of the child. The surface gene from the child and his father had the same amino acid substitution pattern (T118K, T123N and G145A. We concluded that the father was the source of the son's HBV infection, suggesting that occult HBV infection may be transmitted through close contact and manifest as an overt infection.

  20. Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection.

    Science.gov (United States)

    Hu, Li-Ping; Liu, De-Ping; Chen, Qin-Yan; Harrison, Tim J; He, Xiang; Wang, Xue-Yan; Li, Hai; Tan, Chao; Yang, Qing-Li; Li, Kai-Wen; Fang, Zhong-Liao

    2015-01-01

    The importance of transmission of occult HBV infection (OBI) via transfusion, organ transplantation and hemodialysis has been widely recognized. However, data regarding the transmission of OBI through close contact remain limited. In this study, serum samples were obtained from a child and his parents. The child had received the standard vaccination regimen at birth and produced protective antibody. Sera were tested for HBV serological markers. Nested PCR assays were used to detect HBV DNA and the amplicons were cloned and their sequences subjected to phylogenetic analysis. The results showed that both parents had occult infections while the child had an overt infection. Twelve, eleven and nine clones, from the father, mother and son, respectively, were sequenced. Serotypes adrq+, ayw1, ayw and ayr were found in the father and ayw1, adw2 and adwq+ in the mother; adrq+ was the only serotype in son. Genotype B, subgenotype C2 and a recombinant were identified in the father and genotype B, subgenotype C5 and three recombinants were found in the mother. Subgenotype C2 was the only genotype identified in the child. A phylogenetic tree showed that all of the child's sequences and most of the father's sequences clustered together. However, none of mother's sequences clustered with those of the child. The surface gene from the child and his father had the same amino acid substitution pattern (T118K, T123N and G145A). We concluded that the father was the source of the son's HBV infection, suggesting that occult HBV infection may be transmitted through close contact and manifest as an overt infection.

  1. The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience.

    Science.gov (United States)

    Sharifian, Afsaneh; Naderi, Nostratollah; Sanati, Azar; Mohebi, Seyed Reza; Azimzadeh, Pedram; Golmohamadi, Ali; Nori, Simin; Khanyaghma, Mahsa; Sheikhesmaeili, Farshad; Zali, Mohamad Reza

    2015-10-01

    BACKGROUND According to the reports of World Health Organization (WHO) and Centers for Disease Control and Prevention, the prevalence of chronic hepatitis B infection in Iran has decreased from 2-7% in 2001 to 1.3-0.8% in children aged 2-14 years. In 2010 the Institute of Medicine recommended more comprehensive screening by primary care physicians (PCPs) for evaluation, vaccination, and management of infected patients for further decrease in the prevalence of chronic HBV infection. Thus, with contribution of the Health Department, we developed a practical flowchart for PCPs to start active screening of hepatitis B virus (HBV) in all visited patients and refer the positive cases for further evaluation and management to Taleghani Hospital. METHODS With collaboration of Health Department of Shahid Beheshti University of Medical Sciences), physicians of health centers were asked to screen all their patients for HBsAg. Positive cases were referred to Taleghani Hospital. They were first registered and educated about their disease, life style, and prevention methods. Their first degree families were screened for HBV infection too and were referred for vaccination if needed. According to the results of lab tests, appropriate management was done by a hepatologist. RESULTS Since implementation of this program, we have encountered a significant rise in patient detection (even in high risk groups). Many of them were not aware of their disease and most of those who were aware of their disease were not managed appropriately. Family screening and vaccination were inadequate and need more emphasis. CONCLUSION Although health system is active about screening of HBV infection in high risk populations, it is not perfect. It seems that health system needs to upgrade the screening and management programs of HBV infection.

  2. [Risk Management of HBV Reactivation: Construction of Check System].

    Science.gov (United States)

    Tanaka, Yasuhito

    2015-09-01

    In recent years, reactivation of HBV in patients receiving cancer chemotherapy or immunosuppressive therapy has been a problem. Generally, HBV-DNA levels are elevated prior to HBsAg concentration, and then hepatic dysfunction is observed in the process of hepatitis by HBV reactivation. Therefore, the monitoring of HBV-DNA is useful for the prediction of hepatic dysfunction, and nucleoside/nucleoside analogue (NA) administration is able to prevent this HBV reactivation. According to these facts, "Guidelines for the Prevention of HBV Reactivation in Patients Receiving Immunosuppressive Therapy or Chemotherapy", 2009 (revised as "JSH Guidelines for the Management of Hepatitis B Virus Infection", 2013) is established, and the diagnostic algorithm of HBsAg, anti-HBc, anti-HBs, and HBV-DNA has relevant descriptions. Combination therapy with rituximab and steroid for malignant lymphoma has a high risk of leading to fulminant hepatitis and, consequently, the guidelines are widely followed in such cases. We introduced the improvement of electronic medical recording and ordering systems in collaboration with hepatologists, and such a system has been widely used. Although the monitoring of HBV-DNA levels is required every 1-3 months, the guidelines are not followed strictly in cases such as rheumatoid disease and solid tumors only with chemotherapy or steroid treatment. Since a DNA assay is complicated and expensive, cost-effective, time-saving, and highly sensitive/specific measurements are required as well. Therefore, Lumipulse HBsAg-HQ (CLIA method) with high sensitivity is expected to be used for the monitoring of HBV reactivation.

  3. The detection of HBV DNA with gold nanoparticle gene probes

    Institute of Scientific and Technical Information of China (English)

    Dong Xi; Xiaoping Luo; Qin Ning; Qianghua Lu; Kailun Yao; Zuli Liu

    2007-01-01

    Objective:Gold nanoparticle Hepatitis B virus (HBV) DNA probes were prepared, and their application for HBV DNA measurement was studied. Methods:Alkanethiol modified oligonucleotide was bound with self-made Au nanoparticles to form nanoparticle HBV DNA gene probes, through covalent binding of Au-S. By using a fluorescence-based method, the number of thiol-derivatized, single-stranded oligonucleotides and their hybridization efficiency with complementary oligonucleotides in solution was determined. With the aid of Au nanoparticle-supported mercapto-modified oligonucleotides serving as detection probes, and oligonucleotides immobilized on a nylon membrane surface acting as capturing probes,HBV DNA was detected visually by sandwich hybridization based on highly sensitive aggregation and silver staining. The modified nanoparticle HBV DNA gene probes were also used to detect the HBV DNA extracted from serum in patients with hepatitis B. Results:Compared with bare Au nanoparticles, oligonucleotide modified nanoparticles had a higher stability in NaCl solution or under high temperature environment and the absorbance peak of modified Au nanoparticles shifted from 520nm to 524nm. For Au nanoparticles, the maximal oligonucleotide surface coverage of hexaethiol 30-mer oligonucleotide was (132 ± 10) oligonucleotides per nanoparticle, and the percentage of hybridization strands on nanoparticles was (22 ± 3% ). Based on a two-probe sandwich hybridization/nanoparticle amplification/silver staining enhancement method, Au nanoparticle gene probes could detect as low as 10-11 mol/L composite HBV DNA molecules on a nylon membrane and the PCR products of HBV DNA visually. As made evident by transmission electron microscopy, the nanoparticles assembled into large network aggregates when nanoparticle HBV DNA gene probes were applied to detect HBV DNA molecules in liquid. Conclusion:Our results showed that successfully prepared Au nanoparticle HBV DNA gene probes could be used to

  4. Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.

    Science.gov (United States)

    Sagnelli, Caterina; Ciccozzi, Massimo; Coppola, Nicola; Minichini, Carmine; Lo Presti, Alessandra; Starace, Mario; Alessio, Loredana; Macera, Margherita; Cella, Eleonora; Gualdieri, Luciano; Caprio, Nunzio; Pasquale, Giuseppe; Sagnelli, Evangelista

    2016-11-02

    In a recent testing in the metropolitan area of Naples, Italy, on 945 irregular immigrants or refugees, 87 HBsAg chronic carriers were identified, 53 of whom were infected by HBV-genotype E. The aim of the present study was to identify the genetic diversity of HBV-genotype E in these 53 immigrants. The 53 immigrant patients with HBV-genotype-E infection were born in Africa, central or eastern Asia, eastern Europe or Latin America. These patients had been seen for a clinical consultation at one of the four first-level units from January 2012 to 2013. The first dataset contained 53 HBV-S gene isolates plus 128 genotype/subgenotype specific reference sequences downloaded from the National Center for Biotechnology Information. The second dataset, comprising the 53 HBV-S gene isolates, previously classified as HBV-genotype E, was used to perform the time-scaled phylogeny reconstruction using a Bayesian approach. Phylogenetic analysis showed that all 53 HBV-S isolates belonged to HBV-genotype E. Bayes factor analysis showed that the relaxed clock exponential growth model fitted the data significantly better than the other models. The time-scaled Bayesian phylogenetic tree of the second dataset showed that the root of the tree dated back to the year 1990 (95% HPD:1984-2000). Four statistically supported clusters were identified. Cluster A dated back to 2012 (95% HPD:1997-2012); cluster B dated back to 2008 (95% HPD:2001-2015); cluster C to 2006 (95% HPD:1999-2013); cluster D to 2004 (95% HPD:1998-2011). This study disclosed the genetic evolution and phylogenesis in a group of HBV-genotype-E-infected immigrants. J. Med. Virol. © 2016 Wiley Periodicals, Inc.

  5. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection.

    Science.gov (United States)

    Rodríguez-Iñigo, E; Bartolomé, J; Ortiz-Movilla, N; Platero, C; López-Alcorocho, J M; Pardo, M; Castillo, I; Carreño, V

    2005-12-01

    In this work, we have shown that hepatitis C virus (HCV) and hepatitis B virus (HBV) can coexist in the same hepatocyte using double fluorescent in situ hybridization in liver biopsy samples from patients with chronic HCV infection with occult HBV infection. Digital image analysis of hybridization signals showed that the HBV DNA levels in coinfected hepatocytes were lower than those in cells infected only with HBV. This finding supports the hypothesis of inhibition of HBV replication by HCV. Furthermore, HCV RNA levels were lower in coinfected cells than in cells infected only with HCV, suggesting that HBV may also inhibit HCV replication.

  6. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

    DEFF Research Database (Denmark)

    Sung, Wing-Kin; Zheng, Hancheng; Li, Shuyu;

    2012-01-01

    To survey hepatitis B virus (HBV) integration in liver cancer genomes, we conducted massively parallel sequencing of 81 HBV-positive and 7 HBV-negative hepatocellular carcinomas (HCCs) and adjacent normal tissues. We found that HBV integration is observed more frequently in the tumors (86.4%) tha...

  7. HBV Vaccination in Chronic Renal Failure Patients

    Directory of Open Access Journals (Sweden)

    Mir-davood Omrani

    2006-12-01

    Full Text Available HBV infection in chronic renal failure (CRF becomes chronic in 30 to 60% compared with less than 10% in nonuremic patients. Immunological dysfunction in patients on hemodialysis may be related to imbalanced cytokine systems, such as tumor necrosis factor (TNF-|α| and interleukin (IL 6,1 by retention of renal metabolite in uremia and chronic inflammation and have a poor immunological reaction to T-cell-dependent antigens, like hepatitis B vaccination. Immunocompromised patients who are unresponsive to hepatitis B vaccination seem to be unable to enhance IL-10 synthesis for control of monokine overproduction. Moreover, human leukocyte antigen (HLA genes, which play a major role in the antigen presentation to immunocompetent cells, have also been shown to modulate this immune response. Unfortunately, seroconversion to anti-HBS has been reported to occur in only 40 to 50% of the vaccine, a significantly lower rate than that observed in healthy adults. Various methods including adjutants such as zinc, gamma interferon, thymopentine, GM-CSF and Levamisol for improving immune responses have been advised. Experience with Pres1/s2, third-generation vaccines is limited and they have not been proven more effective than intradermally (ID administered second-generation S antigen vaccines. Both intramuscular (IM and intradermal (ID vaccinations against hepatitis B have variable efficiency in hemodialysis and non-responders should be retreated by ID route.

  8. Mutation analyses of integrated HBV genome in hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    Peilin Wang; Xiuhai Wang; Shuying Cong; Hongming Ma; Xuecheng Zhang

    2008-01-01

    Little has been learnt in the last 30 years about detection of HBV genome as well as its mutation analysis between hepatitis B fathers (HBF) and their children. In this study, we used nest polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and DNA sequencing analysis, to examine the integrated HBV genome in paraffin-embedded testis tissues, which were taken as samples from HBF, and in peripheral blood mononuclear cells (PBMC) from 74 cases of HBFs and their children who were born after their fathers' HBV infection (caHBF). We found that HBV DNA existed in testis tissues, mainly in the basilar parts of the seminiferous tubules, and also in PBMC of HBF. It was also documented that there were point mutations of poly-loci, insertions and deletions of nucleotides in integrated HBV genomes, and the types of gene mutations in the HBFs were similar to those in caHBF. This study addresses the major types of gene mutations in integrated HBV genome in human patients and also presents reliable evidence of possible genetic transmission of hepatitis B.

  9. TLR3 Plays Significant Roles against HBV-Associated HCC

    Directory of Open Access Journals (Sweden)

    Xiao-lan Chen

    2015-01-01

    Full Text Available Toll-like receptor 3 (TLR3 is a pattern-recognizing receptor that is involved in immune signaling and plays a crucial role in survival by being able to recognize various viral components including double-stranded RNA (dsRNA. The role of TLR3 in hepatocellular carcinoma (HCC with hepatitis B virus (HBV infections is not well understood. To investigate the ability of TLR3 in regulating HBV replication in HCC, 80 cases of human HCC were collected and their tissue microarray was made. In HCC cells, the expression and location of TLR3, hepatitis-associated virus, and interstitial immunoreactive cells were assayed with immunohistochemical staining. The apoptosis of tumor cells was also detected by TUNEL stain. Correlations between TLR3 expression and HBV infection, interstitial immunoreactive cells, and cells apoptosis in HCC were investigated. In addition, we explored whether TLR3 agonist dsRNA can inhibit HepG2.2.15 cells secreting HBV. We found that the cytoplasmic expression of TLR3 in HCC is positively related to HBsAg infection and HCC with cirrhosis and promotes interstitial immunoreactive cells infiltration and cancer cells apoptosis. In HepG2.2.15 cells, dsRNA inhibited the secretion of HBV and induced apoptosis. These results indicate that TLR3 signaling activity may be involved in immune responses against HBV in HCC.

  10. Development and Implementation of Autoverification Rules for ELISA Results of HBV Serological Markers.

    Science.gov (United States)

    Li, Jiancheng; Cheng, Bizhen; Yang, Li; Zhao, Ying; Pan, Meichen; Zheng, Gaozhe; Xu, Xiaoyan; Hu, Jing; Xiao, Tongtong; Cai, Yingmu

    2016-10-01

    Autoverification is a process of using computer-based rules to verify clinical laboratory test results without manual review. But to date, there are few published articles on the use of autoverification over the course of years in a clinical laboratory. In our study, we firstly described the development and implementation of autoverification rules for enzyme-linked immunosorbent assay (ELISA) results of hepatitis B virus (HBV) serological markers in a clinical immunology laboratory. We designed the autoverification rules for HBV by using Boolean logic on five clinically used serological markers in accordance with the framework of AUTO-10A, issued by the American Clinical Laboratory Standards Institute in 2006. The rules were written into the laboratory information system (LIS) and installed in the computer, so we could use the LIS to screen the test results. If the results passed the autoverification rules, they could be sent to doctors immediately. To evaluate the autoverification rules, we applied the real-time data of 11,585 patients with the autoverification rules. The autoverification rate of the five HBV serological markers was 79.5%. Furthermore, the turnaround time (TAT) was reduced by 38% (78 minutes vs. 126 minutes). The error rate was nearly eliminated. These results show that using LIS with autoverification rules can shorten TAT, enhance efficiency, and reduce manual review errors.

  11. HBV/HCV重叠感染的研究进展%Research progress in HBV/HCV co-infection

    Institute of Scientific and Technical Information of China (English)

    何丽; 胡萍; 申焕君; 张野; 黄长形

    2014-01-01

    Hepatitis B virus (HBV)is a hepatotropic DNA virus;HBV DNA and special P protein are covered by capsid proteins to form core particles,which are then covered by lipoprotein to form complete virus particles.Hepatitis C virus (HCV),which belongs to the Flavi-viridae family,is a single-stranded,positive-sense RNA.HBV and HCV are transmitted by parenteral route and may cause co-infection through the same route of transmission.The pathogenesis of HBV/HCV co-infection and its relationship with occult HBV infection,hepato-cellular carcinoma,organ transplantation,and HBV vaccine are reviewed.Meanwhile,the treatment of co -infection is presented.It is shown that HBV and HCV interfere with each other in terms of virology and pathology.%HBV是一种嗜肝DNA病毒,HBV DNA和HBV特异P蛋白由核壳包裹成为核心颗粒,再由脂蛋白外膜包裹成完整的病毒颗粒。HCV是黄病毒科病毒,为单股正链RNA。HBV和HCV均由肠道外途径传播,2种病毒常可由相同途径发生感染。归纳了HBV/HCV重叠感染的发病机制、与隐匿性HBV感染和肝细胞癌以及器官移植、HBV疫苗之间的关系,同时介绍了重叠感染的治疗。指出存在于患者体内的HBV和HCV在病毒学方面相互干扰,在病变方面相互叠加。

  12. Evaluation of the Procleix Ultrio Plus ID NAT assay for detection of HIV 1, HBV and HCV in blood donors

    Directory of Open Access Journals (Sweden)

    Raj Nath Makroo

    2015-01-01

    Full Text Available Introduction: The Procleix Ultrio Plusassay is a new-generation qualitative in vitro nucleic acid amplification test used to screen for human immunodeficiency virus type 1 (HIV-1 RNA, hepatitis C virus (HCV RNA and hepatitis B virus (HBV DNA in blood donors. This study was performed to compare the Procleix Ultrio assay with the new-generation Procleix Ultrio Plus Nucleic Acid Test (NAT assays. Materials and Methods: Ten thousand three hundred and two donor samples were run in parallel for ID NAT using the Procleix Ultrio and the Procleix Ultrio Plus assay. Simultaneously, enzyme-linked immunosorbent assay testing was performed on an EVOLIS Walk away System for HIV, HCV, HBsAg and anti-HBc. Reactive samples were confirmed using polymerase chain reaction. Results: In the 10,302 samples tested during the study period, we identified 15 NAT yields, and all these revealed HBV DNA in the discriminatory assays. Eight of these were exclusive yields from the Ultrio Plus assay and the remaining seven cases were determined as HBV NAT yield, both by the Procleix Ultrio as well as the Ultrio Plus assays, i.e. "Combined" yields. No HCV or HIV 1 yields were detected during the study period by either of two assays. Conclusion: With an overall yield rate of 1 in 687 and an exclusive yield rate of 1 in 1287, the Procleix Ultrio Plus assay proved to be highly sensitive in detecting occult HBV infections.

  13. HBV genotypes prevalence, precore and basal core mutants in Morocco.

    Science.gov (United States)

    Baha, Warda; Ennaji, My Mustapha; Lazar, Fatiha; Melloul, Marouane; El Fahime, Elmostafa; El Malki, Abdelouahad; Bennani, Abdelouaheb

    2012-08-01

    The study of hepatitis B virus (HBV) genomic heterogeneity has become a major issue in investigations aimed at understanding the relationship between HBV mutants and the wide spectrum of clinical and pathological conditions associated with HBV infection. The objective of the current study was to find out the pattern of HBV genotypes circulating in Morocco and to investigate the precore (PC) and basal core promoter (BCP) mutants' status in Moroccan chronic hepatitis B patients. Viral genotypes were determined in 221 chronic carriers using INNO-LiPA HBV assay and hemi-nested PCR. Phylogenetic analysis was performed in 70 samples, and multiplex PCR method was used to confirm some genotyping results. PC and CP mutants were determined using Inno-Lipa. All isolates were successfully genotyped. The genotype distribution was D in 90.45% of cases, A (5.9%), E (1 case), and mixed genotypes (5 A/D and 2 D/F) in 3.17% patients. HBV carried in the HBV/D samples could be assigned to D7 (63.3%), D1 (32.7%) and 2% of strains to each D4 and D5, all HBV/A belonged to A2 subgenotype and HBV/E strain could not be sub-genotyped. In 70 studied strains, HBV mutants were detected in 88.6% of cases; PC mutants were detected in (40%) of patients and 21.5% present a mixture of wild type and G1896A mutation. BCP mutants were observed in 65.7% of cases, 22.9% were found to have the T1762/1764A double mutation, 18.6% had A1762/1764T mutation and 22.9% of patients showed the A1762T/G1764A double mutation with either A1762T/G1764T mutation. Co-infection by PC and BCP mutants was detected in 52.9% of cases. Movement from place to place most likely shapes the observed genotype distribution and consequent prevalence of genotypes other than A2 or D7 in this population. High circulation of PC and BCP mutants is common in chronic hepatitis B infection in Morocco.

  14. Analysis on the Status of HBV, HCV, HIV and Syphilis Infections Among Drug Addicts in Yanfeng District of Hengyang%衡阳市雁峰区吸毒人员HBV/HCV/HIV及梅毒感染状况分析

    Institute of Scientific and Technical Information of China (English)

    欧阳瑞芳

    2011-01-01

    Objective To investigate the status of HBV, HCV, HlV and syphilis infections in drug addicts of a compulsory detoxification center in Hengyang, and to provide a basis for preventing and controlling these diseases among this population. Methods A total of 277 drug users from a compulsory detoxification center in Hengyang were investigated with anonymous questionnaires. Their venous blood samples were collected to test HIV antibody, HBsAg, HCV antibody and syphilis antibody by ELISA method. And the results were analyzed. Results Among the surveyed drug addicts, 15..52% took drug only orally, 64.26% used simple vein injection, and 20.22% used both. The positive rates of HBV, HCV, HIV and syphilis infections among the 277 drug users were 46.21%(128/277), 66.06% (183/277), 6.50% (18/277) and 0.72% (2/277),respectively. The co- infection rates of HBV- HCV, HBV- HIV, HCV- HIV, and HBV- HCV - HIV were 34.66% (96/277),4.33% (12/277), 6.14% (17/277) and3.97% (11/277), respectively. Conclusions The infection rates of HBV, HCV,HIV and syphilis are high among drug users in Hengyang, which have an association with the intravenous drug injection behavior. It is necessary to develop the education program on prevention of the diseases and behavioral intervention for drug addicts in order to reduce the transmission and spread of these diseases in the population.%目的 了解吸毒人群乙肝病毒(HBV)、丙肝病毒(HCV)、人类免疫缺陷病毒(HIV)及梅毒感染情况,为制定预防措施提供参考依据.方法 对某戒毒所的277名吸毒人员进行调杳,并采集静脉血用酶联免疫吸附试验(ELISA)进行血清乙肝表面抗原、HCV抗体、HIV抗体及梅毒检测.结果 277例吸毒者中,吸毒方式以单一静脉注射吸毒为主(64.26%),其次为口吸+注射(占20.22%),单一口吸者最少(占15-52%).吸毒人员的HBV,HCV,HIV和梅毒的感染率分别为46.21% (128/277),66-06% (183/277),6.50% (18/277)和0.72% (2/277).重叠感染HBV

  15. 分析乙肝血清学检验中的三种不常见现象%Analysis of HBV Serological Test Three of the Unusual Phenomenon

    Institute of Scientific and Technical Information of China (English)

    杜琼; 涂云贵

    2015-01-01

    Objective Hepatitis B serology three of the unusual phenomenon. Explore the use of different reagents whether it will affect the test results. Methods Randomly selected in January 2012 to January 2015, January serological examination hospital 200 cases of hepatitis B patients as research subjects. All patients taking 3ml venous blood as the test sample, the same samples were taken to two different ELISA reagents for clinical testing. Analysis of the test results and, and statistical probability of the occur-rence is not common. Results A set of test results showed that a total of 10 patients had three hepatitis B serological testing is not a common phenomenon, Group B test results showed that nine patients had three hepatitis B serological testing is not a common phenomenon. Using statistical software comparison of the two test results showed no significant difference in contrast showed no statistically significant (P>0.05) between the two groups. In which a total of 10 patients had unusual phenomenon, 5.0%of the total number of cases. Conclusion Different reagents will not have hepatitis B serology unusual phenomenon affecting, for hepatitis B serology is not a common phenomenon, should be combined with clinical symptoms and other clinical indicators detect a compre-hensive analysis and review, rule out the possibility everything for interference, for in order to increase the accuracy and reliability of test results.%目的 分析研究乙肝血清学检验中的三种不常见现象. 探究使用试剂的不同是否会对检测结果造成影响. 方法 随机选取2012年1月-2015年1月于该院进行血清学检验的200例乙肝患者作为研究对象. 所有患者取3 mL静脉血作为检验样本,同一样本分别采取两种不同的ELISA试剂进行临床检验. 分析检测结果,并统计不常见现象的发生几率. 结果 A组检测结果显示共有10例患者出现三种乙肝血清检测不常见现象,B组检测结果显示共有9例患者

  16. Seroprevalence of HBV and HCV in blood donors: A study from regional blood transfusion services of Nepal

    Directory of Open Access Journals (Sweden)

    Tiwari B

    2010-01-01

    Full Text Available Background and Objective : Hepatitis B and hepatitis C are significant health problems that might involve the late sequel of liver cirrhosis and hepatocellular carcinoma. A high prevalence of hepatitis B virus (HBV and hepatitis C virus (HCV in blood donors poses an increased risk of window period transmission through blood transfusion. The present study aimed to know the seroprevalence of hepatitis B virus (HBV and hepatitis C virus (HCV among blood donors in regional blood transfusion services of Nepal. Materials and Methods: This was a retrospective study conducted among blood donors in Banke (5,211, Morang (5,351, and Kaski (5,995 blood transfusion services. Serum samples were tested for hepatitis B surface antigen (HBsAg and anti-HCV antibodies using rapid enzyme immunoassays. The donors information was collected via the donor record register through their respective blood transfusion services. The software "Winpepi ver 3.8" was used for statistical analysis. Results: The seroprevalence rate of HBV was highest in the Banke (1.2% followed by Biratnagar (0.87% and Kaski (0.35% (P < 0.0001. The seroprevalence of HCV was highest in the Morang (0.26% followed by Kaski (0.16% and Banke (0.11% (P > 0.05. The seroprevalence of HBV was significantly higher than HCV in all three blood transfusion services. The burden of HBV as well as HCV seems to be higher in male donors (P > 0.05. Conclusion: The study revealed that the seroprevalence of HBV was alarmingly higher in two of the three blood transfusion services. Implementation of community-based preventive measures and improved strategies for safe blood supply might prove useful to decrease the seroprevalence.

  17. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice

    Directory of Open Access Journals (Sweden)

    Wen-Chuan Hsieh

    2013-09-01

    Full Text Available ABSTRACTBackground: Patients with chronic hepatitis B virus (HBV infection are at a high risk to develop hepatocellular carcinoma (HCC. Recently, metabolic syndrome has been found to carry a risk for HCC development. Considering the limitation of chemotherapeutic drugs for HCCs, the development of chemopreventive agents for high risk chronic HBV carriers is urgently demanded. In this study, we used combined silymarin and resveratrol extract which have been shown to exhibit biologic effects on activating peroxisome proliferator activated receptors (PPAR and inhibiting mTOR signaling in a transgenic mice model harboring HBV viral oncoproteins.Methods: The transgenic mice model harboring HBx and pre-S2 mutant constructs which develop HCC was adopted. First, we in vitro tested the ideal combination dosages of the silymarin and resveratrol product, and then we fed the natural product to the transgenic mice.The chemopreventive effects on preventing the development of HCC were evaluated.Results: MTT assay showed an enhanced effect of the combined silymarin and resveratrol product on the reduction of cell proliferation in two hepatoma cell lines, Huh-7 and Hep G2. In vitro reporter assay and Western blot analyses revealed that the combined product couldactivate PPAR/PGC-1 signaling and inhibit mTOR expression. In vivo, the combined products could significantly ameliorate fatty liver and reduce HCCs in transgenic miceharboring HBV oncoproteins.Conclusions: The combined silymarin and resveratrol product exhibits a synergistic effect on the reduction of HCC development in transgenic mice model and may represent a potential agent for the prevention of HCC in high risk chronic HBV carriers.Key words: HBV, HCC, Transgenic mice, Chemoprevention

  18. Analysis of clinical characters of HBV related HCC%HBV相关性HCC的临床特征分析

    Institute of Scientific and Technical Information of China (English)

    张雅芳; 曾庆磊; 徐光华; 李春霞; 古巧燕

    2011-01-01

    Objective To analyze clinical characters of HBV related HCC. Methods 50 patients with HBV related HCC were recruited. The serological indexes including quantity of HBV M, HBV DNA, AFP, HA and ALT were measured. The imaging tests including B ultrasound, CT and MRI were measured. Results The male patients were 88%. The average age was 40-60 year old. 72% cases with the hepatitis B infection most likely acquired at birth or in early childhood. AFP of 74% patients was more than the upper limited normal. 92% of the tumor were in the right lobe of liver. HBsAg, HBeAb and HBcAb positive mode (80%) was the most common mode in HBV related HCC. Statistical analysis showed that HBeAb was positive correlation with HBV DNA ( r= 0. 374, P=0. 018 ). Conclusion The tumor were more likely occurred in male cases who were 40-60 year-old, and always with the hepatitis B infection most likely acquired at birth or in early childhood, not all the cases with high AFP, the mode of HBsAg, HBeAb, HBcAb positive cases always with HBV DNA replication.%目的 探讨HBV相关性HCC的临床特征.方法 收集HBV相关性HCC患者50例资料,检测患者血清HBV M定量、HBV DNA定量、肝纤维化指标、AFP、肝功能指标.用彩色超声、64层螺旋CT、1.5T核磁共振检查患者肝脏影像学情况.用相应的统计学方法对上述指标进行分析.结果 HBV相关性HCC好发于40~60岁男性,72%的患者有乙肝家族史,74%的患者AFP升高,92%的患者肿块发生在肝右叶.HBsAg、HBeAb、HBcAb大于ULN是HBV相关性HCC主要的HBV M模式(80%),这种模式的患者多伴HBV DNA复制(χ2=38.093,P<0.001),且HBeAb定量与HBV DNA定量呈正相关(r=0.374,P=0.018).结论 HBV相关性HCC多发于40~60岁男性,多伴乙肝家族史,且并非所有患者都伴AFP升高,在监测中要高度重视HBsAg、HBeAb、HBcAb大于ULN且有HBVDNA复制的患者,特别注意肝右叶的表现,必要时可缩短其监测周期.

  19. Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis.

    Directory of Open Access Journals (Sweden)

    Dong Lin

    Full Text Available PURPOSE: Excessive brain iron accumulation contributes to cognitive impairments in hepatitis B virus (HBV-related cirrhotic patients. The underlying mechanism remains unclear. Hepcidin, a liver-produced, 25-aminoacid peptide, is the major regulator of systemic iron metabolism. Abnormal hepcidin level is a key factor in some body iron accumulation or deficiency disorders, especially in those associated with liver diseases. Our study was aimed to explore the relationship between brain iron content in patients with HBV-related cirrhosis and serum hepcidin level. METHODS: Seventy HBV-related cirrhotic patients and forty age- sex-matched healthy controls were enrolled. Brain iron content was quantified by susceptibility weighted phase imaging technique. Serum hepcidin as well as serum iron, serum transferrin, ferritin, soluble transferrin receptor, total iron binding capacity, and transferrin saturation were tested in thirty cirrhotic patients and nineteen healthy controls. Pearson correlation analysis was performed to investigate correlation between brain iron concentrations and serum hepcidin, or other iron parameters. RESULTS: Cirrhotic patients had increased brain iron accumulation compared to controls in the left red nuclear, the bilateral substantia nigra, the bilateral thalamus, the right caudate, and the right putamen. Cirrhotic patients had significantly decreased serum hepcidin concentration, as well as lower serum transferring level, lower total iron binding capacity and higher transferrin saturation, compared to controls. Serum hepcidin level negatively correlated with the iron content in the right caudate, while serum ferritin level positively correlated with the iron content in the bilateral putamen in cirrhotic patients. CONCLUSIONS: Decreased serum hepcidin level correlated with excessive iron accumulation in the basal ganglia in HBV-related cirrhotic patients. Our results indicated that systemic iron overload underlined regional

  20. Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression

    Energy Technology Data Exchange (ETDEWEB)

    Hong, Yun; Zhou, Lin; Xie, Haiyang; Wang, Weilin [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Zheng, Shusen, E-mail: shusenzheng@zju.edu.cn [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China)

    2015-06-05

    Chronic infection with hepatitis B virus (HBV) plays an important role in the etiology of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3) inactivation could inhibit the tumor growth of HCC. In this study, differential antiproliferative effect of STAT3 inhibition was observed with HBV-related HCC cells being more resistant than non-HBV-related HCC cells. Resistance of HBV-related HCC cells to STAT3 inhibition was positively correlated to the expression of HBV. Enhanced ERK activation after STAT3 blockade was detected in HBV-related HCC cells but not in non-HBV-related HCC cells. Combined ERK and STAT3 inhibition eliminates the discrepancy between the two types of HCC cells. Moderate reduced HBV expression was found after STAT3 inhibition. These findings disclose a discrepancy in cellular response to STAT3 inhibition between non-HBV-related and HBV-related HCC cells and underscore the complexity of antiproliferative effect of STAT3 inactivation in HBV-related HCC cells. - Highlights: • HBV endows HCC cells with resistance to STAT3 inactivation on proliferation. • Abnormal ERK activation after STAT3 inhibition in HBV-related HCC cells. • Combined ERK and STAT3 inhibition eliminates the discrepancy. • STAT3 inhibition moderately reduces HBV expression.

  1. People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands.

    Directory of Open Access Journals (Sweden)

    Anouk T Urbanus

    Full Text Available BACKGROUND: Although published results are inconsistent, it has been suggested that tattooing and piercing are risk factors for HBV and HCV infections. To examine whether tattooing and piercing do indeed increase the risk of infection, we conducted a study among people with multiple tattoos and/or piercings in The Netherlands who acquired their tattoos and piercings in The Netherlands and/or abroad. METHODS: Tattoo artists, piercers, and people with multiple tattoos and/or piercings were recruited at tattoo conventions, shops (N = 182, and a biannual survey at our STI-outpatient clinic (N = 252 in Amsterdam. Participants were interviewed and tested for anti-HBc and anti-HCV. Determinants of HBV and HCV infections were analysed using logistic regression analysis. RESULTS: The median number of tattoos and piercings was 5 (IQR 2-10 and 2 (IQR 2-4, respectively. Almost 40% acquired their tattoo of piercing abroad. In total, 18/434 (4.2%, 95%CI: 2.64%-6.46% participants were anti-HBc positive and 1 was anti-HCV positive (0.2%, 95%CI: 0.01%-1.29%. Being anti-HBc positive was independently associated with older age (OR 1.68, 95%CI: 1.03-2.75 per 10 years older and being born in an HBV-endemic country (OR 7.39, 95%CI: 2.77-19.7. Tattoo- and/or piercing-related variables, like having a tattoo or piercing in an HBV endemic country, surface percentage tattooed, number of tattoos and piercings etc., were not associated with either HBV or HCV. CONCLUSIONS: We found no evidence for an increased HBV/HCV seroprevalence among persons with multiple tattoos and/or piercings, which might be due to the introduction of hygiene guidelines for tattoo and piercing shops in combination with the low observed prevalence of HBV/HCV in the general population. Tattoos and/or piercings, therefore, should not be considered risk factors for HBV/HCV in the Dutch population. These findings imply the importance of implementation of hygiene guidelines in other countries.

  2. Adaptation of the HBV model for the study of drought propagation in European catchments

    Science.gov (United States)

    van Loon, A. F.; van Lanen, H. A. J.; Seibert, J.; Torfs, P. J. J. F.

    2009-04-01

    "response function" that transforms groundwater recharge into discharge, is replaced by a for this study adapted conceptual research model programmed in R. The structure of this conceptual research model is based on a number of coupled reservoirs representing storage in shallow and deep groundwater, and lakes. The recession characteristics of the catchment determine the model elements: i.e. number of reservoirs, linear vs. non-linear reservoirs, in series vs. parallel connections. We used data from Narsjø (Norway), Metuje and Sázava (Czech Republic) to select the proper configuration for the conceptual research model and to test the combined HBV Light-conceptual research model approach. The influence of different model configurations on drought characteristics is presented. Subsequently, the new approach was applied to 4-5 other European catchments with contrasting climate conditions and physical structures (including Nedožery (Slovakia), and Upper-Guadiana (Spain)). Our adapted model approach finally gives a better representation of groundwater storage during drought periods than the original HBV model, which makes it a useful tool for the study of processes underlying drought propagation. Simulated drought characteristics are shown to illustrate drought propagation for the different catchment conditions. Seibert, J., Unlenbrook, S., Leibundgut, C. and Halldin, S., 2000. Multiscale calibration and validation of a conceptual rainfall-runoff model. Physics and Chemistry of the Earth, Part B: Hydrology, Oceans and Atmosphere, 25(1): 59-64.

  3. Reliable timescale inference of HBV genotype A origin and phylodynamics.

    Science.gov (United States)

    Zehender, Gianguglielmo; Svicher, Valentina; Gabanelli, Elena; Ebranati, Erika; Veo, Carla; Lo Presti, Alessandra; Cella, Eleonora; Giovanetti, Marta; Bussini, Linda; Salpini, Romina; Alteri, Claudia; Lai, Alessia; Tanzi, Elisabetta; Perno, Carlo Federico; Galli, Massimo; Ciccozzi, Massimo

    2015-06-01

    The worldwide distributed Hepatitis B virus (HBV) genotype A is classified into three subgenotypes, and one quasi-subgenotype. The majority of HBV-A subgenotypes are widespread in Africa and in ethnic groups that have relatively recently emigrated from African countries, whereas HBV-A2 is highly prevalent among subjects at high risk for sexual exposure to HBV in north-western Europe and the USA. The aim of this study was to reconstruct the origin and dispersion of HBV-A subgenotypes on a reliable timescale using short-term calibration based on heterochronous sampling for HBV-A2, and long-term calibration based on historical data for the other subgenotypes. To this aim, we analysed 113 newly characterised HBV-A isolates with 247 reference sequences retrieved from a public database. The phylodynamic reconstruction was performed by a Bayesian framework. The common ancestor of the currently circulating A subgenotypes was placed in west-central Africa a mean 1057 years ago. The genotype diverged into two main clades at the beginning of the 13th century: one including all of the west-central African quasi-subgenotypes and the other corresponding to subgenotype A1, originating in east Africa and further segregating into two main subclades: an "African" and a "cosmopolitan" clade. It is likely that the slave trade was the main source the spread of cosmopolitan HBV-A1, which was exported to Asia in the 17th century as a result of Arab or Portuguese trade, and to Latin America in the 18th centuries through the trans-Atlantic slave trade. The origin of the currently circulating A2 strains dates back to the first decades of the 20th century, and the evolutionary demography analysis suggests an exponential growth of infections, between 1970s and the mid-1990s. In conclusion, the very different epidemiological and evolutionary histories of HBV-A subgenotypes justify the use of different calibration approaches to reconstruct their reciprocal phylodynamics.

  4. [HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study].

    Science.gov (United States)

    Cañero-Velasco, M C; Mutti, J E; Gonzalez, J E; Alonso, A; Otegui, L; Adragna, M; Antonuccio, M; Laso, M; Montenegro, M; Repetto, L; Brandi, M; Canepa, J; Baimberg, E

    1998-01-01

    Hemodialized pediatric patients are a risk population for the hepatitis B and C virus infection. The aim of this paper was to study the serum prevalence of HBV and HCV infection in hemodialized children. We study 61 pediatric patients at hemodialisis, 12 on renal transplant, range between 2 and 20 years old (mean: 12.9 years), 23 male and 38 female. The specific anti-HCV IgC were measured by enzyme immunoassay (ELISA Abbott) and confirmed by LIA-TEK (Organon). The anti-HBV were measured by ELISA Abbott and transaminases by cinetic method (ASAT: 29 UI/L and ALT: 33 UI/L). The 19.7% of studied children were HCV (+) and 29.5% were HBV (+), 38.9% of them were HbsAg (+) and 50% anti-HBs (+). The HCV and HBV infection was more elevated in relation to the transfusion number and the hemodilisis time. The elevation of ALT/ASAT activity isn't a right infection index for HCV and HBV in this children.

  5. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants

    Directory of Open Access Journals (Sweden)

    Hong Kim

    2015-06-01

    Full Text Available Occult hepatitis B virus infection (HBV is characterized by HBV DNA positivity but HBV surface antigen (HBsAg negativity. Occult HBV infection is associated with a risk of HBV transmission through blood transfusion, hemodialysis, and liver transplantation. Furthermore, occult HBV infection contributes to the development of cirrhosis and hepatocellular carcinoma. We recently reported the characteristic molecular features of mutations in the preS/S regions among Korean individuals with occult infections caused by HBV genotype C2; the variants of preS and S related to severe liver diseases among chronically infected patients were also responsible for the majority of HBV occult infections. We also reported that HBsAg variants from occult-infected Korean individuals exhibit lower HBsAg secretion capacity but not reduced HBV DNA levels. In addition, these variants exhibit increased ROS-inducing capacity compared with the wild-type strain, linking HBV occult infections to liver cell damage. Taken together, our previous reports suggest the transmission potential of distinct HBV occult infection-related variants in South Korea.

  6. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants.

    Science.gov (United States)

    Kim, Hong; Kim, Bum-Joon

    2015-01-01

    Occult hepatitis B virus infection (HBV) is characterized by HBV DNA positivity but HBV surface antigen (HBsAg) negativity. Occult HBV infection is associated with a risk of HBV transmission through blood transfusion, hemodialysis, and liver transplantation. Furthermore, occult HBV infection contributes to the development of cirrhosis and hepatocellular carcinoma. We recently reported the characteristic molecular features of mutations in the preS/S regions among Korean individuals with occult infections caused by HBV genotype C2; the variants of preS and S related to severe liver diseases among chronically infected patients were also responsible for the majority of HBV occult infections. We also reported that HBsAg variants from occult-infected Korean individuals exhibit lower HBsAg secretion capacity but not reduced HBV DNA levels. In addition, these variants exhibit increased ROS-inducing capacity compared with the wild-type strain, linking HBV occult infections to liver cell damage. Taken together, our previous reports suggest the transmission potential of distinct HBV occult infection-related variants in South Korea.

  7. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa.

    Science.gov (United States)

    Barth, Roos E; Huijgen, Quirine; Tempelman, Hugo A; Mudrikova, Tania; Wensing, Annemarie M J; Hoepelman, Andy I M

    2011-06-01

    Human immunodeficiency (HIV), hepatitis B (HBV), and hepatitis C (HCV) viruses are endemic in Sub-Saharan Africa, but data regarding the prevalence of hepatitis co-infections in HIV-positive individuals residing there are limited. The aim of the study was to determine the prevalence of HBV, HCV, and occult HBV (presence of HBV-DNA in the absence of HBsAg) in a rural, South African cohort. The results were compared to various ethnic groups in a Dutch cohort of people infected with HIV. Antiretroviral-naïve individuals with HIV from both a rural South African clinic (n = 258), and a Dutch University hospital (n = 782), were included. Both serological (HBV and HCV) and molecular (occult HBV) assays were performed. Logistic regression analysis was used to define independent predictors of a hepatitis co-infection. HBV and HCV prevalence rates in the South African cohort were exceptionally low (0.4%, 1/242 and 0.8%, 2/242, respectively), compared to those observed in Caucasians (HBV 4.4% and HCV 10.9%) and African immigrants (HBV 8.9% and HCV 4.8%). Conversely, occult HBV was observed in a considerable proportion (10%, 6/60) of South African patients who were anti-HBc-positive but HBsAg-negative. Occult infections were less frequent in Caucasians and Africans in the Dutch cohort (3.2% and 1.4%, respectively). Independent predictors for occult HBV were not identified, but a trend towards more occult HBV at lower CD4 counts was observed. Local HBV/HCV prevalence data are needed to optimize vaccination and antiretroviral treatment strategies. Occult HBV in patients with HIV may be missed regularly when molecular analyses are not available.

  8. HBV-DNA 定量检测核酸提取过程中影响因素的探讨%Explore the influence factors of hepatitis B virus DNA quantitative testing in nucleic acid extraction process

    Institute of Scientific and Technical Information of China (English)

    彭瑛; 温先勇; 邓正华

    2015-01-01

    between the groups boiling lysis time of 6 min and 10 min group ( P<0 .05) .Conclusion Within a certain range ,changing the dose of the concentrated solution ,mixing mode and the time of boiling lysis in extraction process of HBV‐DNA does not affect the test results ,But mixing ways after a certain period preheating make it easier to mix precipitation and release nucleic acid .

  9. The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers Significado biológico do resultado anti-HBc positivo em doadores de sangue: relação com HBV-DNA e outros marcadores sorológicos

    Directory of Open Access Journals (Sweden)

    Luiz C. Arraes

    2003-06-01

    Full Text Available In order to assess the potential risk of anti-HBc-positive blood donors for post-transfusional hepatitis and to investigate whether other HBV serological markers are capable of identifying the presence of the virus, 1000 first-time blood donors were enrolled between June and July 1997. These donors were screened using routine Brazilian blood center tests (HIV 1 and 2, HTLV 1 and 2, Chagas disease, Syphilis, HCV, HBsAg, anti-HBc and ALT . The 120 (12% found to be anti-HBc-positive underwent further tests: HBe, anti-HBe, anti-HBs and HBV-DNA by PCR. Ten cases were HBsAg positive and all were HBV-DNA positive by PCR. Three HBsAg-negative donors were HBV-DNA-positive. Two HBV-DNA-positive donors were also anti-HBs-positive. All the HBV-positive donors had at least one HBV marker other than anti-HBc. Anti-HBc is an important cause of blood rejection. Testing for HBsAg alone is not fully protective and anti-HBc remains necessary as a screening test. The presence of anti-HBs is not always indicative of absence of the virus. The addition of other HBV serological markers could represent an alternative in predicting the presence of the virus when compared with PCR. It is recommended that other studies should be carried out to confirm this finding.Para verificar o risco potencial para hepatite viral pós-transfusional de doadores anti-HBc positivos e investigar se outros marcadores sorológicos do HBV poderiam identificar a presença ou não do vírus, mil doadores de primeira vez foram recrutados entre junho e julho de 1997. Estes doadores foram testados para os testes de rotina utilizados em centros de transfusão brasileiros. Cento e vinte desses doadores foram anti-HBc positivos (12%. Nestes foram realizados os testes HbeAg, anti-HBc, anti-HBs e a pesquisa do HBV-DNA por PCR. Dez eram HbsAg positivos, todos com presença do HBV-DNA demonstrada por PCR. Três doadores HbsAg negativos foram HBV-DNA positivos. Dois doadores HBV-DNA positivos também o

  10. Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice

    Institute of Scientific and Technical Information of China (English)

    Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Jing-Yuan Fang; Yu-Lin Song; Zhao-Hui Shen; Ai-Ping Cao

    2004-01-01

    AIM: To study the inhibitory effect of oxymatrine on serum hepatitis B virus (HBV) DNA in HBV transgenic mice.METHODS: HBV transgenic mice model was established by microinjection, and identified by HBV DNA integration and replication. Transgenic mice with replicating HBV were divided into 3 groups, and injected with normal saline (group A, n=9), 50 mg/kg (group B, n=8) and 100 mg/kg (group C, n=9) oxymatrine intraperitoneally once a day for 30 d, respectively. Quantitation of serum HBV DNA in HBV transgenic mice was performed by competitive polymerase chain reaction (PCR) in combination with DNA hybridization quantitative detection technique before and after treatment.RESULTS: Compared with pre-treatment, the serum HBV DNA in group A (F=1.04, P=0.9612) and group B (F=1.13,P=0.8739) had no changes after treatment. However, in group C serum HBV DNA was significantly decreased (F=13.97,P=0.0012). The serum HBV DNA after treatment was lower in group C than in groups B and A (F=8.65, P=0.0068;F=12.35, P=0.0018; respectively). The serum HBV DNA after treatment was lower in group B than in group A, but there was no statistical significance (F=1.43, P=0.652).CONCLUSION: Oxymatrine has inhibitory effects on serum HBV DNA in HBV transgenic mice.

  11. Detection of HBV and HCV Coinfection by TEM with Au Nanoparticle Gene Probes

    Institute of Scientific and Technical Information of China (English)

    XI Dong; LUO Xiaoping; NINGQin

    2007-01-01

    Goid(Au) nanoparticle HBV DNA or HCV cDNA gene probes were prepared and were used to detect HBV DNA and HCV RNA extracted from positive serum of patients with HBV and HCV coinfection directly by transmission electron microscopy (TEM). PCR identifying HBV and HCV in serum of patients with HBV and HCV coinfection was established. Alkanethiol-modified oligonueleotide was bound with self-made Au nanoparticles to form nanoparticle HBV DNA or HCV cDNA gene probes through covalent binding of Au-S. HBV DNA and HCV RNA extracted from positive serum of patients with HBV and HCV coinfection was added to the detection system com- posed of nanoparticle HBV DNA and(or) HCV cDNA gene probes. The results showed that HBV DNA and HCV RNA could be specifically amplified by PCR. The zones of DNA amplification ap- peared in 431 lap and 323 bp respectively. When HBV DNA and HCV RNA extracted from positive serum of patients with HBV and HCV coinfection were added to the detection system, TEM dis- played the nanoparticles self-assembled into large network aggregates. It was concluded that the de-tection of HBV and HCV coinfection by TEM was convenient and efficient with high specificity and sensitivity.

  12. Justification for screening programs for early detection of HBV infections

    Directory of Open Access Journals (Sweden)

    Małgorzata Leźnicka

    2014-12-01

    Full Text Available Background: The objective of the study was to collect the data on undetected hepatitis B virus (HBV in the frequently hospitalized (at least twice in the last 5 years population of the Kujawsko-Pomorskie voivodship. The study results could be used by occupational health services and local governments to take preventive actions. Material and Methods: The study focused on empirical data derived from hepatitis B Screening Programme in the Kujawsko-Pomorskie voivodship. The study comprised 6332 people tested for hepatitis B virus surface antigen – HBsAg. They had been hospitalized at least twice. The diagnostic survey was based on an anonymous questionnaire, developed for this study. For the statistical analysis the Statistica 10.0 program was used. A level of statistical significance was assumed at a value of α = 0.05. The results showing that the probability test p satisfy the inequality p < 0.05 were considered to be statistically significant. Results: HBs antigen was detected in 34 patients (0.54%. There was no association between the detected infections and the gender of the respondents. There was no relationship between the detected infections and transfusion of blood and blood products before 1992. Surgical procedures performed in the patients did not increase the risk of hepatitis B infection. Conclusions: Actions aimed at detecting asymptomatic infections should primarily focus on the 35–39 age group. Effective identification of chronically-infected people and application of optimal treatment play a key role in reducing the risk of disease progression in the whole population. Therefore, the implementation of screening programs is warranted for prevention and early detection of hepatitis B. Med Pr 2014;65(6:777–784

  13. Application of CRISPR/Cas9 Technology to HBV

    OpenAIRE

    Guigao Lin; Kuo Zhang; Jinming Li

    2015-01-01

    More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustai...

  14. Polymorphism of TNFα-308 and mutations of HBV C region in patients with chronic HBV infections%慢性HBV感染者TNFα-308位点多态性与HBV C基因区突变的关系

    Institute of Scientific and Technical Information of China (English)

    原津津; 潘晨; 黎环; 许利军

    2010-01-01

    Objective To investigate the association between polymorphism of TNFα-308 and mutations of HBV C region in patients with chronic HBV infection. Methods Ninety-five patients with chronic HBV infection were recruited in the study. The single nucleotide polymorphism(SNP) of TNFα-308 Was determined by restriction fragment length polymorphism(RFLP). Mutations of nt1762/1764, nt1896, nt1899, nt1862, as60, aa87 and as97 in HBV C region were detected by direct sequencing after PCR amplification. Mutations of the above points among different genotypes were compared by Fisher's exget test. Results Three different genotypes G/G(63/95, 66.3%), G/A(28/95, 29.5%) and A/A(4/95, 4.2%) were found in TNFα-308 site. The rates of mutations of aa87 and aa97 points in patients with G/G, G/A and A/A genotype were 39.3%(24/61), 11.5%(3/26) and 50.0% (2/4), respectively(F=7.658, P0.05). Conclusion Compared with G/G genotype, antigenicity of HBV may be more stable in patients with TNFα-308 G/A genotype, which is beneficial to HBV clearance.%目的 研究慢性乙型肝炎病毒(HBV)感染者肿瘤坏死因子α(TNFα)-308位点的基因多态性与HBV C基因区突变的关系.方法 对95例慢性HBV感染者进行研究,采用聚合酶链反应.限制性片断长度多态性(PCR-RFLP)技术分析患者TNFα-308位点的多态性.对PCR产物直接测序,检测HBV C基因区nt1762/1764、nt1896、nt1899、nt1862、aa60、as87及aa97位点是否存在突变.采用Fisher's精确概率法比较TNFα-308位点不同基因型患者HBV C基因区常见突变的检出率.结果 TNFα-308位点共发现3种多态性,分别为G/G型63例(63/95,66.3%),G/A型28例(28/95,29.5%),A/A型4例(4/95,4.2%).TNFα-308位点G/G、G/A、A/A基因型患者HBV C基因区aa87位点及as97位点突变型检出率均分别为39.3%(24/61)、11.5%(3/26)和50.0%(2/4),差异有统计学意义(F=7.658,P0.05).结论 慢性HBV感染者TNFα-308位点G/A基因型相对于G/G基因型不易发生HBV抗原性变异,有利于HBV的清除.

  15. Immunological analysis of a patient with hepatitis B virus (HBV) reactivation after bone marrow transplantation.

    Science.gov (United States)

    Kowazaki, Yuka; Osawa, Yosuke; Imamura, Jun; Ohashi, Kazuteru; Sakamaki, Hisashi; Kimura, Kiminori

    2015-01-01

    Patients with resolved hepatitis B virus (HBV) infection undergoing chemo- or immunosuppressive therapy are at potential risk for HBV reactivation. To determine whether the host immune response contributes to liver injury, we performed an immunological analysis of a patient with HBV reactivation. Consistent with the detection of HBV DNA in the sera, the number of polyclonal HBV-specific cytotoxic T lymphocytes (CTLs) gradually increased; however, the number of CD4(+)CD25(+) regulatory T cells (Treg) decreased. The interaction between HBV-specific CTLs and CD4(+)CD25(+) Treg is an important determinant of liver injury during HBV reactivation. Therefore, monitoring the number of these cells might be a useful modality for the diagnosis of acute hepatitis resulting from HBV reactivation.

  16. Expression and immunoreactivity of HCV/HBV epitopes

    Institute of Scientific and Technical Information of China (English)

    Xin-Yu Xiong; Xiao Liu; Yuan-Ding Chen

    2005-01-01

    AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV)/Hepatitis B virus (HBV) infections.METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system).Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis B patients were determined.RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with antiHCV and anti-HBs antibodies.CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.

  17. Reactivation of HBV infection in low grade lymphoma patient.

    Science.gov (United States)

    Aramă, Victoria; Munteanu, Daniela; Olaru, Ioana; Rădulescu, Mihaela; Mihăilescu, Raluca; Vlădăreanu, Ana-Maria; Onisâi, Minodora; Vintilescu, Anamaria; Dobrea, Camelia; Olariu, M; Aramă, S S

    2011-01-01

    Reactivation of hepatitis B virus is a complication of chronic or HBV infection in patients with malignancies, especially hematological disorders, under cytotoxic or immunosuppressive therapy. The immunosuppression favors HBV replication with the massive infection of hepatocytes. Once immunity is restored when chemotherapy therapy is discontinued, a rapid, immune-mediated destruction of the infected hepatocytes ensues, clinically manifested as hepatitis, liver failure or even death. We report a case of HBV reactivation in a patient with B cells non-Hodgkin lymphoma, with HBsAg negative and protective titre of anti-HBs, after 5 months of combined chemotherapy. Currently, there are no data to support routine pre-emptive anti-HBV therapy in patients with negative HBsAg and undetectable viremia before the initiation of chemotherapy. The case presented in this paper is included in the group of patients that is studied in LIMFOVIR Grant (convention no 41012/2007). This research grant is funded by the National Center of Programs Management, program 4 - Partnerships in Priority Fields. The grant is coordinated by the National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest. The grant team include also the Emergency University Hospital Bucharest, Hematology Department, the "Carol Davila" University of Medicine and Pharmacy, Bucharest, the "Victor Babeş" National Institute of Research and Development, the Institute of Electrotechnical Research, Bucharest and the Polytechnic University, Bucharest. The manager of the grant is Associated Professor dr. Victoria Aramă.

  18. [Control of HCV, HBV and HIV Infections in Hemodialysis].

    Science.gov (United States)

    Fabrizi, Fabrizio; Martin, Paul; Messa, Piergiorgio

    2013-01-01

    Infections with blood-borne pathogens are still common among patients on maintenance dialysis all over the world. The control of infection due to blood-borne viruses (particularly HBV) within dialysis units has been a major goal in the management of patients with chronic kidney disease in the industrialized world. Standard precautions and specific procedures have been recommended to prevent infections with HBV, HCV and HIV within dialysis units. Isolation of HBsAg positive patients by dialysis rooms, staff and machines continues to be an important step to control HBV infection within dialysis units, according to the CDC and other regulatory agencies. Some prospective observational studies have reported the complete prevention of HCV transmission to hemodialysis patients in the absence of any isolation policy, and the use of dedicated dialysis machines for HCV-infected patients is not recommended by clinical guidelines. Isolation of HCV-infected patients should be considered in special circumstances only. Vaccination is an important tool against transmission of HBV among patients on long-term dialysis even if the immune response towards the hepatitis B vaccine remains unsatisfactory. Hemodialysis is considered a low risk setting for the transmission of human immunodeficiency virus (HIV) infection, providing that standard and specific procedures are carefully observed. HIV-infected patients do not have to be isolated from other patients or dialyzed separately on dedicated machines.

  19. 乳汁HBV-DNA定量时标本处理的优选及临床应用%Optimization and clinical application of treatment of specimens in HBV-DNA quantitation

    Institute of Scientific and Technical Information of China (English)

    方有兵; 黄晨艳; 刘贵育

    2011-01-01

    Objective: To choose a method with high sensitivity and good repeatability of drawing HBV - DNA quantitative specimens from colostrum used for colostrum detection of lying - in women with hepatitis B. Methods: 14 colostrum specimens from 14 lying - in women carrying positive HBsAg, HBeAg and HBcAb were selected, and every colostrum specimen was divided into 3 groups: original specimen, centrifugal specimen at middle level and centrifugal sediment at low level, then HBV - DNA was extracted respectively and the content was detected, rank sum test was used to analyze the difference of results; centrifugal specimens at middle level were used to detect the content of HBV - DNA in 316 lying - in women with hepatitis B. Results: The sensitivity of centrifugal specimen at middle level was higher than that of original specimen, and the repeatability of centrifugal specimen at middle level was higher than that of centrifugal sediment at low level. Among 316 lying - in women with hepatitis B, in positive serum HBsAg, HBeAg and HBcAb group, the positive rate of HBV - DNA in colostrum was 77. 60%; in positive serum HBsAg, HBeAb and HBcAb group, the positive rate of HBV - DNA in colostrum was 0. 73%; in positive serum HBsAg and HBeAg group, the positive rate of HBV - DNA in colostrum was 80.00%; in positive serum HBsAg and HBcAb group, the positive rate of HBV -DNA in colostrum was 5.17%; in other groups, the positive rates of HBV - DNA in colostrum were all 0. Conclusion: The colostrum of lying - in women with hepatitis B can be used to assess the safety of breastfeeding. The infants fed with breastfeeding of colostrum from the lying - in women with positive serum HBsAg, HBeAg and HBcAb or positive serum HBsAg, HBeAg have high risk of hepatitis B virus infection.%目的:选择灵敏度高、重复性较好的乳汁HBV-DNA定量标本提取方法应用于乙肝携带产妇的乳汁检测.方法:选择14例乙肝"大三阳"产妇乳汁,每份分为乳汁原标本,乳汁

  20. HBV serological test results comparing the use of chemiluminescence and en-zyme-linked immunosorbent assay of%乙肝病毒血清学检验采用化学发光法与酶联免疫法的效果对比

    Institute of Scientific and Technical Information of China (English)

    张怡莎

    2014-01-01

    目的:探讨化学发光免疫分析技术(ECLIA)和酶联免疫吸附试验(ELISA)在乙肝病毒血清学检验中的应用效果。方法选取2012年1月-2014年1月在我院就诊的疑似乙肝患者150例,分离血清后分别应用ELISA和ECLIA进行检测,比较两种检测方法的效果。结果ELISA和ECLIA检测出HBsAg阳性分别63例和82例,两者比较差异显著(P<0.05),同时ECLIA法检测的批内CV和批间CV的重复性均明显高于ELISA法(P<0.05)。结论与ELISA检验法比较,ECLIA法具有更高的HBsAg阳性检出率,且能进行精确的定性定量检测,值得临床推广应用。%Objective To investigate chemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA) in HBV serological test the application results. Methods Select suspected hepatitis B patients from January 2012 to January 2014 in our hospital 150 cases, respectively, after the application of separation of serum ELISA and ECLIA detection, the effect of two detection methods.Results ELISA and ECLIA detection of HBsAg positive 63 cases and 82 cases respectively,the difference was significant (P<0.05),while intra-assay and inter-assay CV CV ECLIA assay reproducibility were significantly higher than the ELISA method(P<0.05). Conclusion Compared with ELISA test method, ECLIA method has higher HBsAg positive rate,and can be accurate qualitative and quantitative detection,worthy of clinical application.

  1. Detection of HBV DNA by PCR on HBsAg negative blood donors%HBV DNA PCR检测在HBsAg阴性献血人群中的应用

    Institute of Scientific and Technical Information of China (English)

    陈筱华; 林碧; 刘保林; 孔令光

    2008-01-01

    Objective To define the application value of HBV DNA detection on HBsAg-negative blood donors and assess the necessity for nucleic acid detection.Methods Real-time PCR was used to detect HBV DNA on HBsAg negative blood donors.Pools of eight donor samples were used for NAT testing.Viruses were concentrated by centrifugation and the viral DNA extraction was performed using magnetic beads.If HBV DNA wag positive,serological indicators including HBsAg,anti-HBs,HBeAg, anti-Hbe,total anti-HBc was further detected.Results The HBV DNA detection limit was 25 U/ml.There were four HBV DNA positive cases among 23 225 specimens.and the detection rate was 0.17‰ The further serological examination showed anti-Hbe(+),anti-HBc(+) in the two cases and anti-HBc(+) in one case and anti-Hbs(+),anti-HBc(+)in 1 case.The viral load can range form 50 to 200 U/ml. Conclusions The results indicate that there is false negative possibility in blood screening by ELISA.It is necessary to employ anti-Hbe screening or NAT to blood donors screening.%目的 探讨HBsAg阴性献血者HBV DNA榆测的应用价值,评估核酸检测的必要性.方法 采用PCR检测HBsAg阴性献血者HBV DNA.采用8人份混合血样测定,超离心浓缩病毒,磁珠法提取病毒核酸.如HBV DNA为阳性,则进一步检测乙型肝炎病毒血清标志物5项.结果 HBVDNA检测限量为25 U/ml,23 225份标本中有4份为HBV DNA阳性,检出率为0.17‰.进一步检测其他HBV感染的血清学指标,发现这4份标本中有2份为抗HBe和抗HBc阳性,1份为抗HBc阳性,1份为抗HBs、抗HBc阳性.对HBV DNA的定量测定表明,其含量在50~200 U/ml.结论 现行的2次酶联免疫技术的血液筛查存在HBV漏检,有必要在现有的血液筛查模式中增加抗HBc检测,或增加病毒核酸筛查.

  2. A type-specific nested PCR assay established and applied for investigation of HBV genotype and subgenotype in Chinese patients with chronic HBV infection

    OpenAIRE

    Nie Jing-Jing; Sun Kui-Xia; Li Jie; Wang Jie; Jin Hui; Wang Ling; Lu Feng-Min; Li Tong; Yan Ling; Yang Jing-Xian; Sun Mi-Shu; Zhuang Hui

    2012-01-01

    Abstract Background Many studies have suggested that hepatitis B virus (HBV) genotypes show not only geographical distribution and race specificity, but also are associated with disease progression and response to interferon treatment. The objective of this study was to develop a nested polymerase chain reaction (nPCR) assay for genotypes A-D and subgenotypes B1, B2, C1 and C2 of hepatitis B virus (HBV) and to investigate the distribution characteristics of HBV genotypes/subgenotype in China....

  3. Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan.

    Directory of Open Access Journals (Sweden)

    Hisashi Eguchi

    Full Text Available Prejudice and discrimination in the workplace regarding the risk of transmission of Hepatitis B virus (HBV and Hepatitis C virus (HCV are increased by excess concerns due to a lack of relevant knowledge. Education to increase knowledge about HBV and HCV and their prevention could be the first step to reduce prejudice and discrimination. This study aimed to determine the association between the level of knowledge and negative attitudes toward HBV- and HCV-infected colleagues among the Japanese working population. An online anonymous nationwide survey involving about 3,000 individuals was conducted in Japan. The questionnaire consisted of knowledge of HBV and HCV, and attitudes toward HBV- and HCV-infected colleagues in the workplace. Knowledge was divided into three categories: "ensuring daily activities not to be infected"; "risk of infection"; and "characteristics of HBV/HCV hepatitis", based on the result of factor analysis. Multiple logistic regression analysis was applied. A total of 3,129 persons responded to the survey: 36.0% reported they worried about the possibility of transmission of HBV and HCV from infected colleagues; 32.1% avoided contact with infected colleagues; and 23.7% had prejudiced opinions about HBV and HCV infection. The participants were classified into tertiles. A higher level of knowledge of HBV and HCV was significantly associated with these three negative attitudes (P for trend < 0.005. This study suggests that increasing knowledge may decrease individuals' negative attitudes towards HBV- and HCV-infected colleagues. Thus, we should promote increased knowledge of HBV and HCV in stages to reduce negative attitudes toward HBV- and HCV-infected colleagues.

  4. Molecular analysis of hepatitis B virus (HBV in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

    Directory of Open Access Journals (Sweden)

    Costantini Andrea

    2011-11-01

    Full Text Available Abstract Background Occult hepatitis B virus (HBV infection (OBI is characterized by HBV DNA persistence even though the pattern of serological markers indicates an otherwise resolved HBV infection. Although OBI is usually clinically silent, immunocompromised patients may experience reactivation of the liver disease. Case presentation We report the case of an individual with human immunodeficiency virus (HIV infection and anti-HBV core antibody positivity, who experienced severe HBV reactivation after discontinuation of lamivudine-including antiretroviral therapy (ART. HBV sequencing analysis showed a hepatitis B surface antigen escape mutant whose presence in an earlier sample excluded reinfection. Molecular sequencing showed some differences between two isolates collected at a 9-year interval, indicating HBV evolution. Resumption of ART containing an emtricitabine/tenofovir combination allowed control of plasma HBV DNA, which fell to undetectable levels. Conclusion This case stresses the ability of HBV to evolve continuously, even during occult infection, and the effectiveness of ART in controlling OBI reactivation in HIV-infected individuals.

  5. Evaluation for quantitative methods of HBV DNA in serum with very high viral loads%高病毒载量血清HBV DNA定量方法的评价

    Institute of Scientific and Technical Information of China (English)

    李雷; 冯振华; 许碧云; 顾光煜; 张葵; 周乙华

    2012-01-01

    Objective To explore whether quantitative standard curve may be directly extended to determine HBV DNA level in the cases of very high viral loads which was over the upper limit of detection range. Methods A total of 30 serum samples were included. The HBV DNA levels of all the samples were more than 3×107 IU/ml detected by fluorescent quantification kit purchased from Shanghai Shenyou Company. Each samples was quantitatively retested for three times. Both the serum samples and the HBV DNA extracted from serum were further measured in 10-, 100- and 1 000-fold dilution, respectively. After logarithmic conversion the quantitative values were statistically analyzed. Results When the quantitative data of HBV DNA were expressed as logarithm values, the inter-class correlation coefficient was 0.356 (F = 2.66, P 0. 05 ), and the maximum differences were less than 1 in each sample. Conclusion In the determination of HBV DNA by using domestic reagents, direct extension of the quantitative standard curve may be acceptable even if the level of HBV DNA was over the upper limit of detection. For accurate quantification, it is suggested that the serum-extracted DNA with 100-fold dilution should be used as the test materials.%目的 探讨血清HBV DNA定量检测结果高于检测上限时,能否直接延伸标准曲线,用于HBV DNA定量分析.方法 以上海申友生物公司HBV DNA荧光定量检测试剂盒为例,选择HBV DNA>3×107 IU/mL的血清标本30例.每例血清在3个不同时间点提取DNA,或将血清以10、100和1000倍稀释后提取DNA,或将未稀释血清提取的DNA以10、100和1000倍稀释后进行HBV DNA定量检测,检测结果以10为底数进行对数转换后进行统计学分析.结果 经对数转换,3个不同时间点HBV DNA定量检测结果的组间相关系数为0.356(F=2.66,P<0.01);36.7% (11/30)的标本最大差值<0.5,60.0%(18/30)介于0.5~1.0,3.3% (1/30)达1.01;血清稀释后定量检测HBV DNA,96.7%(29/30)

  6. Associated factors for recommending HBV vaccination to children among Georgian health care workers

    Directory of Open Access Journals (Sweden)

    Butsashvili Maia

    2012-12-01

    Full Text Available Abstract Background Most cases of hepatitis B virus (HBV infection and subsequent liver diseases can be prevented with universal newborn HBV vaccination. The attitudes of health care workers about HBV vaccination and their willingness to recommend vaccine have been shown to impact HBV vaccination coverage and the prevention of vertical transmission of HBV. The purpose of this study was to ascertain the factors associated with health care worker recommendations regarding newborn HBV vaccination. Methods A cross-sectional study of prevalence and awareness of hepatitis B and hepatitis B vaccine was conducted among randomly selected physicians and nurses employed in seven hospitals in Georgia in 2006 and 2007. Self-administered questionnaires included a module on recommendations for HBV, HCV and HIV. Results Of the 1328 participants included in this analysis, 36% reported recommending against hepatitis B vaccination for children, including 33% of paediatricians. Among the 70.6% who provided a reason for not recommending HBV vaccine, the most common concern was an adverse vaccine event. Unvaccinated physicians and nurses were more likely to recommend against HBV vaccine (40.4% vs 11.4%, PR 3.54; 95% CI: 2.38, 5.29. Additionally, health care worker age was inversely correlated with recommendations for HBV vaccine with older workers less likely to recommend it. Conclusion Vaccinating health care workers against HBV may provide a dual benefit by boosting occupational safety as well as strengthening universal coverage programs for newborns.

  7. Study on HBV Vertical Transmission via the in vitro Fertilization(IVF)Technique

    Institute of Scientific and Technical Information of China (English)

    Jing-ning YANG; Qing-bin LUO; Chang-jun ZHANG; Hua WANG

    2009-01-01

    Objective To study the hepatitis B virus(HB V)vertical transmission via infected spermatozoa.Methods Eighteen male patients with HBV infection who underwent in vitro fertilization (IVF)were studied,5 HBV negative patients were selected as the control.Fluorescence in situ hybridization(FISH)analysis using the partial-length HBV DNA as the hybridization probe was performed to explore the existence of HBV DNA in the sperm and in the host embryonic genome.Results FISH showed that 5 of 18 patients' sperm presented positive signals and 2 of 18 embryos presented positive signals,while no positive signals were found in control group.Conclusion The HBV DNA was found in human sperm and embryos of HBV patients.These results provide direct evidence that HBV DNA could transmit to foetus via human infected spermatozoa.

  8. The influence of HBV model calibration on flood predictions for future climate

    Science.gov (United States)

    Osuch, Marzena; Romanowicz, Renata

    2014-05-01

    The temporal variability of HBV rainfall-runoff model parameters was tested to address the influence of climate characteristics on the values of model optimal parameters. HBV is a conceptual model with a physically-based structure that takes into account soil moisture, snow-melt and dynamic runoff components. The model parameters were optimized by the DEGL method (Differential Evolution with Global and Local neighbours) for a set of catchments located in Poland. The methodology consisted of the calibration and cross-validation of the HBV models on a series of five-year periods within a moving window. The optimal parameter values show large temporal variability and dependence on climatic conditions described by the mean and standard deviation of precipitation, air temperature and PET. Derived regressions models between parameters and climatic indices were statistically significant at the 0.05 level. The set of model optimal values was applied to simulate future flows in a changed climate. We used the precipitation and temperature series from 6 RCM/GCM models for 2071-2100 following the A1B climate change scenario. The climatic variables were obtained from the KLIMADA project. The resulting flow series for the future climate scenario were used to derive flow indices, including the flood quantiles. Results indicate a large influence of climatic variability on flow indices. This work was partly supported by the project "Stochastic flood forecasting system (The River Vistula reach from Zawichost to Warsaw)" carried out by the Institute of Geophysics, Polish Academy of Sciences by order of the National Science Centre (contract No. 2011/01/B/ST10/06866). The rainfall and flow data were provided by the Institute of Meteorology and Water Management (IMGW), Poland.

  9. Quantitative analysis of plasma HBV DNA for early evaluation of the response to transcatheter arterial embolization for HBV-related hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Ying-Wen Su; Yu-Wen Huang; Sheng-Hsuan Chen; Chin-Yuan Tzen

    2005-01-01

    AIM: To assesse changes in plasma HBV DNA after TAE in HBV-related HCC and correlate the levels with the pattern of lipiodol accumulation on CT.METHODS: Between April and June 2001, 14 patients with HBV-associated HCC who underwent TAE for inoperable or recurrent tumor were studied. Levels of plasma HBV DNA were measured by real-time quantitative PCR daily for five consecutive days after TAE. More than twofold elevation of circulating HBV DNA was considered as a definite elevation. Abdominal CT was performed 1-2 mo after TAE for the measurement of lipiodol retention.RESULTS: Circulating HBV DNA in 10 out of 13 patients was elevated after TAE, except for one patient whose plasma HBV DNA was undetectable before and after TAE.In group Ⅰ patients (n = 6), the HBV DNA elevation persisted for more than 2 d, while in group Ⅱ (n = 7), the HBV DNA elevation only appeared for 1 d or did not reach a definite elevation. There were no significant differences in age or tumor size between the two groups. Patients in group Ⅰ had significantly better lipiodol retention (79.31±28.79%)on subsequent abdominal CT than group Ⅱ (18.43± 10.61%)(P = 0.02).CONCLUSION: Patients with durable HBV DNA elevation for more than 2 d correlated with good lipiodol retention measured 1 mo later, while others associated with poor lipiodol retention. Thus, circulating HBV DNA may be an early indicator of the success or failure of TAE.

  10. Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India.

    Science.gov (United States)

    Saha, Debraj; Pal, Ananya; Biswas, Avik; Panigrahi, Rajesh; Sarkar, Neelakshi; Das, Dipanwita; Sarkar, Jayeeta; Guha, Subhasish Kamal; Saha, Bibhuti; Chakrabarti, Sekhar; Chakravarty, Runu

    2014-01-01

    Previously we reported that the exposure to hepatitis B virus (HBV) infection serves as a major threat among the treatment naive HIV infected population of eastern India. Hence, molecular characterization of these strains is of utmost importance in order to identify clinically significant HBV mutations. A total of 85 treatment naive HIV/HBV co-infected participants were included of whom the complete basal core promoter/precore region, the core and the whole envelope gene could be successfully sequenced for 59, 57 and 39 isolates respectively. Following phylogenetic analysis, it was found that HBV/D was the predominant genotype with HBV/D2 (38.5%) being the most prevalent subgenotype followed by HBV/A1. The major mutations affecting HBeAg expression includes the A1762T/G1764A (13.6%), G1896A (22%) and G1862T mutation (33.9%) which was predominantly associated with HBV/A1. Moreover, the prevalence of G1896A was considerably high among the HBeAg negative HIV/HBV co-infected subjects compared to HBV mono-infection. The main amino acid substitutions within the MHC class II restricted T-cell epitope of HBcAg includes the T12S (15.8%) and T67N (12.3%) mutation and the V27I (10.5%) mutation in the MHC class I restricted T-cell epitope. PreS1/S2 deletion was detected in 3 isolates with all harboring the BCP double mutation. Furthermore, the frequently occurring mutations in the major hydrophilic loop of the S gene include the T125M, A128V and M133I/L. Therefore, this study is the first from India to report useful information on the molecular heterogeneity of the HBV strains circulating among the treatment naive HIV/HBV co-infected population and is thus clinically relevant.

  11. Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India.

    Directory of Open Access Journals (Sweden)

    Debraj Saha

    Full Text Available Previously we reported that the exposure to hepatitis B virus (HBV infection serves as a major threat among the treatment naive HIV infected population of eastern India. Hence, molecular characterization of these strains is of utmost importance in order to identify clinically significant HBV mutations. A total of 85 treatment naive HIV/HBV co-infected participants were included of whom the complete basal core promoter/precore region, the core and the whole envelope gene could be successfully sequenced for 59, 57 and 39 isolates respectively. Following phylogenetic analysis, it was found that HBV/D was the predominant genotype with HBV/D2 (38.5% being the most prevalent subgenotype followed by HBV/A1. The major mutations affecting HBeAg expression includes the A1762T/G1764A (13.6%, G1896A (22% and G1862T mutation (33.9% which was predominantly associated with HBV/A1. Moreover, the prevalence of G1896A was considerably high among the HBeAg negative HIV/HBV co-infected subjects compared to HBV mono-infection. The main amino acid substitutions within the MHC class II restricted T-cell epitope of HBcAg includes the T12S (15.8% and T67N (12.3% mutation and the V27I (10.5% mutation in the MHC class I restricted T-cell epitope. PreS1/S2 deletion was detected in 3 isolates with all harboring the BCP double mutation. Furthermore, the frequently occurring mutations in the major hydrophilic loop of the S gene include the T125M, A128V and M133I/L. Therefore, this study is the first from India to report useful information on the molecular heterogeneity of the HBV strains circulating among the treatment naive HIV/HBV co-infected population and is thus clinically relevant.

  12. HBx M130K and V131I (T-A mutations in HBV genotype F during a follow-up study in chronic carriers

    Directory of Open Access Journals (Sweden)

    Albertazzi Federico

    2005-08-01

    Full Text Available Abstract Background Around 400 million people worldwide are chronically infected with Hepatitis B virus (HBV. An estimated 10% of these chronic patients develop progressive liver damage including cirrhosis and Hepatocellular Carcinoma (HCC. The HBx gene encodes a protein of 154 amino acids which is a transactivator and has been associated with HBV pathogenesis. A change in the amino acid sequences at positions 130 and 131 in the HBV-X protein (M130K and V131I produced by T-A point mutations at the nucleic acids level has been associated with severe liver damage and HCC in patients from China and Africa. Further, such changes have been proposed as a prognostic marker for progressive liver damage and HCC. The purpose of this study was to determine if T-A mutations are present in HBV chronic carriers with genotype F (the major genotype in Costa Rica and further, if these mutations are associated with HBV disease progression in Costa Rica HBV patients from 1972 to 1985. Results Serum samples from 50 HBV positive individuals were amplified and directly sequenced, 48 belonged to genotype F, 1 from genotype D and another was classified as D or E. T-;A mutations were absent in 17 acute patients who recovered, but was present in 12 of 29 chronic carrier samples (42.8%, in one sample the T-A mutations were detected as early as 29 days after clinical onset of disease. In 17 carriers with available liver biopsies, T-;A mutations were found in 8 sera of 13 (61.5% classified as moderate or severe, and none in 4 biopsies with mild liver damage. However, it was not possible to demonstrate a statistical association between the presence of T-A mutations and moderate/severe liver damage, using a Fischer exact test, 1 tail, p = 0.05. In 4 patients HCC was diagnosed, and 2 of them presented the T-A mutations in their sera. Conclusion T-A mutations were found in HBV genotype F in chronic carriers but not in patients who recovered from acute infection. These mutations

  13. 初乳HBV-DNA定量检测对乙肝产妇哺乳的指导价值%The value of colostrum HBV DNA quantities among HBV-positive lying-in women

    Institute of Scientific and Technical Information of China (English)

    邹红霞; 杨庆民; 王金环

    2014-01-01

    Objective The value of colostrum HBV DNA quantities among HBV-positive lying-in Women Methods 325 lying-in women were selected according to the principle of inform consent.These women were classified into 5 groups.Group A:65 lying-in women with strong-infectious HBV (three positives),group B:9 lying-in women with strong-infectious HBV (four positives),group C:152 lying-in women with weak-infectious HBV (three positives),group D:47 lying-in women with the first and the fifth positive HBV,group E:52 HBV-negative lying-in women.The HBV markers in the blood serum and colostrum of selected women were detected by Chemiluminescence (CL).Furthermore PCR was utilized to measure the serum HBV DNA quantities and colostrum HBV DNA quantities from the lying-in women.The data was analyzed after been collected.Results The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group A respectively were 100.00% (65/65)and 83.08% (54/65),and the average colostrum HBV DNA quantity was 3.82 × 104copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group B respectively were 100% (9/9) and 77.78% (7/9),and the average colostrum HBV DNA quantity was 1.26 × 104copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group C respectively were 17.10% (26/152) and 1.97% (3/152),and the average colostrum HBV DNA quantity was 2.31 × 103copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group D respectively were 44.68% (21/47) and 23.40% (11/47),and the average colostrum HBV DNA quantity was 6.17 × 103copies ml-1.The blood serum and colostrum HBV DNA positive-rate among the lying-in women in group E respeetively were 0 (0/52) and 0(0/52) and the average colostrum HBV DNA quantity was < 1.0 × 103copies ml-1.There were significant difference in positive individuals which were detected by colostrum HBV DNA experiments between group A,B and C

  14. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

    Institute of Scientific and Technical Information of China (English)

    Ying Yan; Li Mai; Yu-Bao Zheng; Shao-Quan Zhang; Wen-Xiong Xu; Zhi-Liang Gao; Wei-Min Ke

    2012-01-01

    AIM:To investigate optimal timing for therapeutic efficacy of entecavir for acute-on-chronic hepatitis B liver failure (ACLF-HBV) in hepatitis B e antigen (HBeAg)-negative patients.METHODS:A total of 109 inpatients with ACLF-HBV were recruited from the Department of Infectious Diseases of the Third Affiliated Hospital,Sun Yat-sen University from October 2007 to October 2010.Entecavir 0.5 mg/d was added to each patient's comprehensive therapeutic regimen.Patients were divided into three groups according to model for end-stage liver disease (MELD) score:high (≥ 30,20 males and 4 females,mean age 47.8 ± 13.5 years); intermediate (22-30,49 males and 5 females,45.9 ± 12.4 years); and low (≤22,28 males and 3 females,43.4 ± 9.4 years).Statistical analysis were performed using SPSS 11.0 software.Data with normal distribution were expressed as mean ± SD and comparisons were made with Student's t tests.A value of P < 0.05 was considered statistically significant.Viral loads were related exponentially and logarithmic data were used for analysis.RESULTS:For 24 patients with MELD score ≥ 30,treatment lasted 17.2 ± 16.5 d.Scores before and after treatment were significantly different (35.97 ± 4.87 and 40.48 ± 8.17,respectively,t =-2.762,P =0.011); HBV DNA load was reduced (4.882 ± 1.847 copies log10/mL to 3.685 ± 1.436 copies log10/mL); and mortality rate was 95.83% (23/24).Of 54 patients with scores of 22-30,treatment lasted for 54.0 ± 43.2 d; scores before and after treatment were 25.87 ± 2.33 and 25.82 ± 13.92,respectively (t =-0.030,P =0.976); HBV DNA load decreased from 6.308 ± 1.607 to 3.473 ± 2.097 copies log10/mL; and mortality was 51.85% (28/54).Of 31 patients with scores ≤ 22,treatment lasted for 66.1 ± 41.9 d; scores before and after treatment were 18.88 ± 2.44 and 12.39 ± 7.80,respectively,(t =4.860,P =0.000);HBV DNA load decreased from 5.841 ± 1.734 to 2.657 ± 1.154 copies log10/mL; and mortality was 3.23% (1/31).CONCLUSION:For HBe

  15. A case of Gianotti Crosti syndrome with HBV infection.

    Science.gov (United States)

    Dikici, B; Uzun, H; Konca, C; Kocamaz, H; Yel, S

    2008-01-01

    Gianotti-Crosti syndrome (papular acrodermatitis of childhood), which was first described in 1955, is a nonspecific rash that usually consists of the abrupt onset of pink flesh coloring, smooth or lichenoid, flat-topped papules. It was first related to hepatitis B virus (HBV) infection; however, cases not associated with HBV infection were reported as well. Although a type of delayed hypersensitivity reaction is speculated as a cause, exact pathogenesis still remains unclear. The prognosis is favorable and successful management relies upon general supportive and symptomatic care. We report a seven-year-old boy diagnosed with Gianotti-Crosti syndrome with monomorphous papules on his cheeks, buttocks and extremities associated with hepatitis B virus infection.

  16. HBV infection in relation to consistent condom use: a population-based study in Peru.

    Directory of Open Access Journals (Sweden)

    Antonio Bernabe-Ortiz

    Full Text Available BACKGROUND: Data on hepatitis B virus (HBV prevalence are limited in developing countries. There is also limited information of consistent condom use efficacy for reducing HBV transmission at the population level. The study goal was to evaluate the prevalence and factors associated with HBV infection in Peru, and the relationship between anti-HBc positivity and consistent condom use. METHODS AND FINDINGS: Data from two different surveys performed in 28 mid-sized Peruvian cities were analyzed. Participants aged 18-29 years were selected using a multistage cluster sampling. Information was collected through a validated two-part questionnaire. The first part (face-to-face concerned demographic data, while the second part (self-administered using handheld computers concerned sexual behavior. Hepatitis B core antibody (anti-HBc was tested in 7,000 blood samples. Prevalences and associations were adjusted for sample strata, primary sampling units and population weights. Anti-HBc prevalence was 5.0% (95%CI 4.1%-5.9%, with the highest prevalence among jungle cities: 16.3% (95%CI 13.8%-19.1%. In the multivariable analysis, Anti-HBc positivity was directly associated with geographic region (highlands OR = 2.05; 95%CI 1.28-3.27, and jungle OR = 4.86; 95%CI 3.05-7.74; compared to coastal region; and inversely associated with age at sexual debut (OR = 0.90; 95%CI 0.85-0.97. Consistent condom use, evaluated in about 40% of participants, was associated with reduced prevalence (OR = 0.34; 95%CI 0.15-0.79 after adjusting for gender, geographic region, education level, lifetime number of sex partners, age at sexual debut and year of survey. CONCLUSION: Residence in highlands or jungle cities is associated with higher anti-HBc prevalences, whereas increasing age at sexual debut were associated with lower prevalences. Consistent condom use was associated with decreased risk of anti-HBc. Findings from this study emphasize the need of primary

  17. Inhibition of HBV targeted ribonuclease enhanced by introduction of linker

    Institute of Scientific and Technical Information of China (English)

    Wei-Dong Gong; Jun Liu; Jin Ding; Ya Zhao; Ying-Hui Li; Cai-Fang Xue

    2003-01-01

    AIM: To construct human eosinophil-derived neurotoxin (hEDN) and HBV core protein (HBVc) eukaryotic fusion expression vector with a linker (Gly4 Ser)3 between them to optimize the molecule folding, which will be used to inhibit HBV replication in vitro.METHODS: Previously constructed pcDNA3. 1(-)/TR was used as a template. Linker sequence was synthesized and annealed to form dslinker, and cloned into pcDNA3.1(-)/TR to produce plasmid pcDNA3.1(-)/HBc-linker. Then the hEDN fragment was PCR amplified and inserted into pcDNA3.1(-)/HBc-linker to form pcDNA3.1(-)/TNL in which the effector molecule and the target molecule were separated by a linker sequence. pcDNA3.1(-)/TNL expression was identified by indirect immunofluorescence staining. Radioimmunoassay was used to analyse anti-HBV activity of pcDNA3.1(-)/TNL.Meanwhile, metabolism of cells was evaluated by NTT colorimetry.RESULTS: hEDN and HBVc eukaryotic fusion expression vector with a linker (Gly4Ser)3 between them was successfully constructed. pcDNA3.1(-)/TNL was expressed in HepG2.2.15 cells efficiently. A significant decrease of HBsAg concentration from pcDNA3.1(-)/TNL transfectant was observed compared to pcDNA3. 1(-)/TR (P=0.036, P<0.05).MTT assay suggested that there were no significant differences between groups (P=0.08, P>0.05).CONCLUSION: Linker introduction enhances the inhibitory effect of HBV targeted ribonuclease significantly.

  18. Investigation on HIV/AIDS coinfected with HBV/HCV in acquired immune deficiency syndrome area%某艾滋病治疗示范区HIV/AIDS患者合并HBV/HCV感染调查

    Institute of Scientific and Technical Information of China (English)

    梁红霞; 张倩; 余祖江; 钮正春; 李志勤; 潘延凤; 赵清霞; 李建生; 何云

    2011-01-01

    Objective To investigate the incidence of HIV/AIDS coinfected with HBV and/or HCV in some country of Henan province and the clinical features. Methods Serum samples were obtained from 187 HIV - infected patients who transmitted by paid blood donation. ELISA was used to detect HBV erologic markers( HbsAg, Anti - HBs, HbeAg, anti - Hbe and anti - HBc) and HCV antibody. Flow Cytometry were used to detect CD4 + T cell count. Nested PCR was used to amplify surface protein region of HBV DNA. Results Among 187 HIV - infected patients, 9 patients (4. 81% )were HBsAg positive, 178 patients (95. 19% ) HBsAg negative; 143 patients (76. 47% ) anti - HCV positive, 44 patients( 23. 53% ) anti - HCV negative; 6 patients HIV -1, HBV and HCV triple infection. Of the 143 anti - HCV positive patients, 42 patients (29. 37% ) were coinfected with occult HBV infection, in the 44 anti - HCV negative patients, 11 patients (25. 00% ) were coinfected with occult HBV infection, the disparity had no statistical significance (P > 0. 05 ). The positive patients of HbsAg, anti - HBs, isolated anti - HBc andthe CD4 + cell counts were undifferentiated between anti - HCV positive patients and anti - HCV negative patients ( P > 0. 05 ) . Conclusions In the HIV - infected patients who transmitted by paid blood donation, the HBsAg positive rate is lower than common population, and the HCV infection rate is higher than common population; It is found that occult HBV infection did occurs in HIV - infected patients. HBV DNA testing is necessary in the HIV - infected patients who are HBsAg negative; The occult HBV infection rate of HIV - infected patients who are coinfected with HCV isrit increase.%目的 探讨人免疫缺陷病毒-1 (HIV -1) /AIDS患者合并乙型肝炎病毒(HBV)/丙型肝炎病毒(HCV)感染情况及发病特点.方法 分析国家"十一五重大专项"课题中河南某获得性免疫缺陷综合征(Acquired immunodeficiency syndrome,AIDS)示范区中187

  19. 乙肝两对半与HBV-DNA的血清学检测结果分析%Analysis of serological detection results of HBV-M and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    孔小祥; 王春伟

    2016-01-01

    Objective:To analyze the serological detection results of HBV-M and HBV-DNA.Methods:Serum was collected in 480 cases.We detected hepatitis B surface antigen (HBsAg),hepatitis B core antibody(anti-HBc),anti hepatitis B surface antibody (anti-HBs),hepatitis B E antigen(HBeAg) and hepatitis Be antibody(anti HBe),and detected its HBV-DNA.Results:The hepatitis B virus markers were negative,and the positive rate of HBV-DNA was 10.19%,while the hepatitis B surface antigen was positive, other hepatitis B virus markers were negative,the HBV-DNA detection rate was 38.64%.Hepatitis B surface antigen was negative, other HBV markers were positive,the detection rate of HBV-DNA was 16.22%(P<0.05);hepatitis B surface antigen was positive, other hepatitis B virus markers were positive,the detection rate of HBV-DNA was 73.89%.Its data compared with the HBV-DNA detection rate when hepatitis B surface antigen was positive,and other hepatitis B virus markers were negative has significant differences(P<0.05).Conclusion:The serum HBV markers were closely related to the replication of HBV-DNA,the positive serum hepatitis B virus markers not only on behalf of the patients infected with hepatitis B virus,but also has a certain infectivity.%目的:探析乙肝两对半与 HBV-DNA 的血清学检测结果。方法:采集血清480份,检测乙肝表面抗原(HBsAg)、乙肝核心抗体(抗-HBc)、乙肝表面抗体(抗-HBs)、乙肝E抗原(HBeAg)和乙肝e抗体(抗HBe),同时检测其HBV-DNA。结果:乙肝病毒标志物阴性,HBV-DNA的检出率10.19%,乙肝表面抗原阳性,其他乙肝病毒标志物阴性,HBV-DNA 的检出率38.64%。乙肝表面抗原阴性,其他乙肝病毒标志物阳性,HBV-DNA 的检出率16.22%(P<0.05),乙肝表面抗原阳性,其他乙肝病毒标志物阳性,HBV-DNA的检出率73.89%,其数据与乙肝表面抗原阳性,其他乙肝病毒标志物阴性,HBV-DNA的检出率相比,数据差异有统计学意义(P<0.05)。

  20. Simultaneous detection of HBV and HCV by multiplex PCR normalization

    Institute of Scientific and Technical Information of China (English)

    Ning Wang; Xue-Qin Gao; Jin-Xiang Han

    2004-01-01

    AIM: To design and establish a method of multiplex PCR normalization for simultaneously detecting HBV and HCV.METHODS: Two pairs of primers with a 20 bp joint sequence were used to amplify the target genes of HBV and HCV by two rounds of amplification. After the two rounds of amplification all the products had the joint sequence. Then the joint sequence was used as primers to finish the last amplification. Finally multiplex PCR was normalized to a single PCR system to eliminate multiplex factor interference. Four kinds of nucleic acid extraction methods were compared and screened. A multiplex PCR normalization method was established and optimized by orthogonal design of 6 key factors. Then twenty serum samples were detected to evaluate the validity and authenticity of this method.RESULTS: The sensitivity, specificity, diagnostic index and efficiency were 83.3%, 70%, 153.3% and 72.2%,respectively for both HBsAg and anti-HCV positive patients,and were 78.6%, 80%, 258.6% and 79.2%, respectively for HBsAg positive patients, and were 75%, 90%, 165%and 83.3%, respectively for anti-HCV positive patients.CONCLUSION: The multiplex PCR normalization method shows a broad prospect in simultaneous amplification of multiple genes of different sources. It is practical, correct and authentic, and can be used to prevent and control HBV and HCV.

  1. THE CYTOKINE IP-10 IN CHRONIC HBV AND HCV INFECTION

    Directory of Open Access Journals (Sweden)

    Nina S. Nikolova

    2013-08-01

    Full Text Available Introduction: IP-10 it has been studied as a predictor of treatment response in chronic HCV infected patients. The data for the HBV infection are not enough.Aim: To compare IP-10 levels in patients with chronic HBV /CHB/ and HCV infection /CHC/ and their relation to liver disease and treatment response. Material and methods: 20 patients - with CHC genotype 1 infection /on standard bi-therapy/ and 32 patients with CHB /21 pts - NUC; 11 pts - IFN/. Results: The IP-10 did not correlate with sex, age, ALT and liver fibrosis. The basal IP-10 were lower in patients with CHB (p=0,017. There was a difference in IP-10 baseline levels among the HCV patients with or without RVR (p=0,007. A negative correlation was found between basal IP-10 and RVR (r= -0,508; p=0,008. Conclusion: IP-10 could predict virological response in patients with CHC on standard bi-therapy, but not in HBV infected patients on standard therapy.

  2. Nucleic Acid Sensors Involved in the Recognition of HBV in the Liver–Specific in vivo Transfection Mouse Models—Pattern Recognition Receptors and Sensors for HBV

    Directory of Open Access Journals (Sweden)

    Chean Ring Leong

    2015-04-01

    Full Text Available Cellular innate immune system recognizing pathogen infection is critical for the host defense against viruses. Hepatitis B virus (HBV is a DNA virus with a unique life cycle whereby the DNA and RNA intermediates present at different phases. However, it is still unclear whether the viral DNA or RNA templates are recognized by the pattern-recognition receptors (PRRs to trigger host antiviral immune response. Here in this article, we review the recent advances in the progress of the HBV studies, focusing on the nucleic acid sensors and the pathways involved in the recognition of HBV in the liver–specific in vivo transfection mouse models. Hydrodynamic injection transfecting the hepatocytes in the gene-disrupted mouse model with the HBV replicative genome DNA has revealed that IFNAR and IRF3/7 are indispensable in HBV eradication in the mice liver but not the RNA sensing pathways. Interestingly, accumulating evidence of the recent studies has demonstrated that HBV markedly interfered with IFN-β induction and antiviral immunity mediated by the Stimulator of interferon genes (STING, which has been identified as a central factor in foreign DNA recognition and antiviral innate immunity. This review will present the current understanding of innate immunity in HBV infection and of the challenges for clearing of the HBV infection.

  3. Comparative evaluation of INNO-LiPA HBV assay, direct DNA sequencing and subtractive PCR-RFLP for genotyping of clinical HBV isolates

    Directory of Open Access Journals (Sweden)

    Hasan Fuad

    2010-05-01

    Full Text Available Abstract Genotypes (A to H of hepatitis B virus (HBV influence liver disease progression and response to antiviral therapy in HBV-infected patients. Several methods have been developed for rapid genotyping of HBV strains. However, some of these methods may not be suitable for developing countries. The performance of INNO-LiPA HBV Genotyping assay (LiPA, direct DNA sequencing and subtractive PCR-RFLP of genotype-specific HBV genome regions were evaluated for accurately determining the HBV genotypes by analyzing sera (n = 80 samples from chronic HBV patients. Both, LiPA and DNA sequencing identified 63, 4 and 13 HBV strains as belonging to genotype D, genotype A and mixed genotype A and D, respectively. On the contrary, the PCR-RFLP-based method correctly identified all 4 genotype A but only 56 of 63 genotype D strains. Seven genotype D strains yielded indeterminate results. DNA sequence comparisons showed that a single nucleotide change in the target region generated an additional restriction site for Nla IV that compromised the accuracy of this method. Furthermore, all the mixed genotype A and D strains were identified only as genotype A strains. The data show that the PCR-RFLP-based method incorrectly identified some genotype D strains and failed to identify mixed genotype infections while LiPA and DNA sequencing yielded accurate results.

  4. Cloning, Eukaryotic Expression of Human ISG20 and Preliminary Study on the Effect of Its Anti-HBV

    Institute of Scientific and Technical Information of China (English)

    Youhua HAO; Dongliang YANG

    2008-01-01

    Human ISG20 gene was cloned and the effect of its anti-HBV was primarily studied. The ISG20 gene was amplified from HeLa cells by RT-PCR and recombinant vector expressing ISG20 was constructed by genetic engineering. The overexpression of ISG20 in HepG2 cells was detected by Western blot and the levels of secretion of HBs antigen and HBe antigen tested by ELISA. The results showed that: (1) Sequence of ISG20 cloned was consistent to that published in Genebank; (2) Recombinant vector expressing ISG20 could be expressed in HepG2 cells by transfection; (3) The overexpression of ISG20 protein could reduce the levels of the secretion of HBs antigen and HBe an-tigen in transfected HepG2 cells. It was suggested that the overexpression of recombinant ISG20 in culture cells could reduce the synthesis of HBV proteins.

  5. Long-term hepatitis B virus (HBV response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

    Directory of Open Access Journals (Sweden)

    Woottichai Khamduang

    Full Text Available Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV. In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known.HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030 and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg. At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log(10 IU/mL and 4.47 log(10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24% lost HBsAg and 7 of 8 (88% HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months. HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients

  6. Effects of interferon-α/β on HBV replication determined by viral load.

    Directory of Open Access Journals (Sweden)

    Yongjun Tian

    2011-07-01

    Full Text Available Interferons α and β (IFN-α/β are type I interferons produced by the host to control microbial infections. However, the use of IFN-α to treat hepatitis B virus (HBV patients generated sustained response to only a minority of patients. By using HBV transgenic mice as a model and by using hydrodynamic injection to introduce HBV DNA into the mouse liver, we studied the effect of IFN-α/β on HBV in vivo. Interestingly, our results indicated that IFN-α/β could have opposite effects on HBV: they suppressed HBV replication when viral load was high and enhanced HBV replication when viral load was low. IFN-α/β apparently suppressed HBV replication via transcriptional and post-transcriptional regulations. In contrast, IFN-α/β enhanced viral replication by inducing the transcription factor HNF3γ and activating STAT3, which together stimulated HBV gene expression and replication. Further studies revealed an important role of IFN-α/β in stimulating viral growth and prolonging viremia when viral load is low. This use of an innate immune response to enhance its replication and persistence may represent a novel strategy that HBV uses to enhance its growth and spread in the early stage of viral infection when the viral level is low.

  7. Protection of tree shrews by pVAX-PS DNA vaccine against HBV infection.

    Science.gov (United States)

    Zhou, Feng-Juan; Hu, Zhen-Lin; Dai, Jian-Xin; Chen, Rui-Wen; Shi, Ke; Lin, Yi; Sun, Shu-Han

    2003-07-01

    The immunological protection of pVAX-PS, a DNA vaccine, was assessed in the tree shrews model. pVAX-PS was constructed by inserting the gene encoding the middle (pre-S2 plus S) envelope protein of HBV into a plasmid vector pVAX1. Tree shrews (Tupaia belangeri chinenesis) were experimentally infected with human HBV by inoculation with human serum positive for HBV markers. DNA vaccination-induced seroconversion and antibody to HBV surface antigen (anti-HBs) were analyzed by ELISA, and protective effects elicited by pVAX-PS vaccination against subsequent HBV challenge were evaluated by detection of HBV seromarkers and observation of hepatic lesions in HBV-infected tree shrews. The results shown that anti-HBs were detectable in serum at week 2 after pVAX-PS vaccination and peaked at week 4, and immunization with pVAX-PS decreased the positive conversion rate of HBV seromarkers and relieved hepatic lesions in tree shrews challenged with HBV. These results indicated that pVAX-PS immunization could induce remarkable humoral immune response and prevent the experimental tree shrews from infection of HBV.

  8. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

    Institute of Scientific and Technical Information of China (English)

    Wen-Pin Su; Chiun Hsu; Chih-Hung Hsu; Yen-Shen Lu; Hwei-Fan Tien; Tsu-Yi Chao; Li-Tzong Chen; Jacqueline Whang-Peng; Pei-Jer Chen; Chi-Chung Wen; Chao A. Hsiung; Ih-Jen Su; Ann-Lii Cheng; Ming-Chih Chang; Chao-Jung Tsao; Woei-Yao Kao; Wu-Ching Uen

    2005-01-01

    AIM: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma.METHODS: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy.Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies.RESULTS: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years).There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4% vs 16.7%; P= 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P= 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis.CONCLUSION: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.

  9. Prevalence of HBV Infection and Knowledge of Hepatitis B Among Patients Attending Primary Care Clinics in Poland.

    Science.gov (United States)

    Ganczak, Maria; Dmytrzyk-Daniłów, Gabriela; Korzeń, Marcin; Drozd-Dąbrowska, Marzena; Szych, Zbigniew

    2016-06-01

    It is well known that community awareness of hepatitis B (HB) can lead to vaccination and testing. The study objectives were to assess the prevalence of HBV infection and knowledge of HB among adult patients attending randomly selected primary care clinics. A cross-sectional sero-survey was conducted in March 2013 in the Zgorzelec region, Poland, with the use of an investigator-developed questionnaire containing 22 questions regarding HB knowledge. Serum samples were assayed for anti-HBc total and anti-HBs with enzyme immunoassay. The prevalence of anti-HBc total among 410 participants (median age 56 years) was 10.3 % (95 % CI 7.6-13.8 %), nobody was aware of an infection. The main sources of HB knowledge were the media and medical staff. The mean knowledge score was 14.8 ± 4.9; 76.7 % of the respondents had scores >50 %. Particular gaps were detected relating to knowledge of unprotected sexual intercourse and MTCT; 45.6 % patients were not aware of the potential asymptomatic course of HBV infection, 41.2 % about chronic HB treatment. A patient's low educational level was negatively associated with a high knowledge level; the willingness for further education on HB and HBV vaccination in the past were independently associated with good knowledge. In conclusion, the HBV infection remains a public health threat in Poland, since the prevalence of infection markers in asymptomatic adult patients was high. Knowledge gaps call for awareness campaigns which may increase testing and diagnosis, audiences representing lower education level should be targeted first. Knowledge on HB might serve as an effective tool in decision making regarding vaccination.

  10. HBV-DNA level analysis in serum and breast milk of puerpera with different HBV infection modes%不同HBV感染模式产妇血清及乳汁HBV-DNA检测结果分析

    Institute of Scientific and Technical Information of China (English)

    李文郎; 刘卫东; 吴爱成; 唐恒锋

    2013-01-01

    Objective To explore the hepatitis B virus (HBV) DNA loads in serum and breast milk of puerperal with different HBV infection models and the relationship between them.Methods 385 cases of puerpera with positive HBV markers were divided into 4 groups according to the HBV infection models and detected by fluorescence quantitative assay for the HBV DNA loads in serum and breast milk.The relationship between the HBV DNA loads of serum and breast milk was analyzed.Results In group A,the positive rates of HBV DNA in serum and breast milk were 94.1% and 69.4% ,significantly higher than those in other groups(P< 0.01) ,and the HBV DNA load was significantly higher than those in other groups.In group B,the positive rates of HBV DNA in serum and breast milk were respectively 90.9% and 61.5%,significantly higher than those in group C and group D(P<0.01) ,and the HBV DNA load was significantly higher than those in group C and group D.Conclusion There might be positive correlation between HBV levels in serum and breast milk of puerpera.%目的 了解不同乙型肝炎病毒(HBV)感染模式产妇血清及乳汁HBV-DNA的载量以及两者之间的关系.方法 对385例血清乙肝指标阳性的产妇,应用荧光定量法检测血清和乳汁中的HBV载量,根据产妇HBV血清标志物模式不同分为4组,分析各组血清与乳汁中HBV-DNA含量的关系.结果 A组(HBsAg、HBeAg、HBcAb均为阳性)乙肝大三阳产妇血清和乳汁HBV-DNA阳性率为分别为94.1%和69.4%,明显高于其他模式(P<0.01),且其病毒载量也显著高于其他组;B组(HBsAg、HBeAg为阳性)产妇血清和乳汁HBV-DNA阳性率为分别为90.9%和61.5%,明显高于C组(HBsAg、HBeAb、HBcAb为阳性)和D组(HBsAg、HBcAb为阳性),P<0.01,且其病毒载量也显著高于C组和D组.结论 产妇血清中HBV-DNA水平的高低与乳汁中HBV-DNA呈正相关关系.

  11. An overview of molecular epidemiology of hepatitis B virus (HBV in India

    Directory of Open Access Journals (Sweden)

    Datta Sibnarayan

    2008-12-01

    Full Text Available Abstract Hepatitis B virus (HBV is one of the major global public health problems. In India, HBsAg prevalence among general population ranges from 2% to 8%, placing India in intermediate HBV endemicity zone and the number of HBV carriers is estimated to be 50 million, forming the second largest global pool of chronic HBV infections. India is a vast country, comprised of multiracial communities with wide variations in ethnicity and cultural patterns, which is attributable to its geographical location, gene influx due to invasion and/or anthropological migrations in the past. Moreover, recent increase in trade, trafficking and use of illicit drugs has also considerably influenced the epidemiology of HBV, specifically in the eastern and north eastern parts of India. However, data on the molecular epidemiology of HBV in India is scanty. HBV genotypes A and D have been well documented from different parts of mainland India. Interestingly, in addition to genotypes A and D, genotype C having high nucleotide similarity with south East Asian subgenotype Cs/C1 strain, have been detected exclusively from eastern Indian HBV carriers, suggesting a recent introduction. Thus, compared to other parts of India, the molecular epidemiology of HBV is naturally distinct in eastern India. Very recently, taking the advantage of circulation of three distinct HBV genotypes within the population of eastern India, different aspects of HBV molecular epidemiology was studied that revealed very interesting results. In this study, the clinical significance of HBV genotypes, core promoter and precore mutations, possible routes of introduction of HBV genotype C in eastern India, the clinical implications of x gene variability, prevalence of the AFB1 induced p53 gene codon 249 mutation, the transmission potentiality of HBV among asymptomatic/inactive or occult HBV carriers and the genetic variability of HBV persisting in the PBL was investigated. In this manuscript, the

  12. Association of Chronic HBV Infection with Chronic Lymphoproliferative Disorders: A Review and Case Report

    Directory of Open Access Journals (Sweden)

    Inna M. Mulina

    2016-06-01

    Full Text Available This article presents a clinical report on the associated course of chronic hepatitis B virus (HBV infection with Castleman's disease (CD. We noticed the reactivation of previously latent chronic hepatitis B (CHB with high replicative activity of HBV DNA during the treatment of lymphoproliferative disease. This clinical case dictates the need for pre-emptive therapy of HBV infection with nucleoside analogues in patients who are receiving chemotherapy.

  13. Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB

    OpenAIRE

    Gu Mei-Lei; Li Xiao-Dong; Xing Xiao-Yan; Dong Yi; Duan Zhong-Ping; Song Hong-Bin; Li Jin; Zhong Yan-Wei; Han Yu-Kun; Zhu Shi-Shu; Zhang Hong-Fei

    2011-01-01

    Abstract Background The association of hepatitis B virus (HBV) genotypes/subgenotypes with clinical characteristics is increasingly recognized. However, the virologic and clinical features of HBV genotypes/subgenotypes in pediatric patients remain largely unknown. Methods Four hundred and eighty-seven pediatric inpatients with CHB were investigated, including 217 nucleos(t)ide analog-experienced patients. HBV genotypes/subgenotypes and reverse transcriptase (RT) mutations were determined by d...

  14. Development of fatal acute liver failure in HIV-HBV coinfected patients

    Institute of Scientific and Technical Information of China (English)

    Albert; M; Anderson; Marina; B; Mosunjac; Melody; P; Palmore; Melissa; K; Osborn; Andrew; J; Muir

    2010-01-01

    Coinfection with hepatitis B virus(HBV) is not uncommon in human immunodeficiency virus(HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease.Current guidelines regarding the treatment of HIV infection recommend that patients who are coinfected with HIV and HBV receive highly active antiretroviral therapy(HAART) with activity against hepatitis B.While HIVHBV coinfected patients often experience liver enzyme elevations after starting antiretroviral ...

  15. Development of a Multiplex Real-Time PCR Assay for the Detection of Treponema pallidum, HCV, HIV-1, and HBV.

    Science.gov (United States)

    Zhou, Li; Gong, Rui; Lu, Xuan; Zhang, Yi; Tang, Jingfeng

    2015-01-01

    Treponema pallidum, hepatitis C virus (HCV), human immunodeficiency virus (HIV)-1, and hepatitis B virus (HBV) are major causes of sexually transmitted diseases passed through blood contact. The development of a sensitive and efficient method for detection is critical for early diagnosis and for large-scale screening of blood specimens in China. This study aims to establish an assay to detect these pathogens in clinical serum specimens. We established a TaqMan-locked nucleic acid (LNA) real-time polymerase chain reaction (PCR) assay for rapid, sensitive, specific, quantitative, and simultaneous detection and identification. The copy numbers of standards of these 4 pathogens were quantified. Standard curves were generated by determining the mean cycle threshold values versus 10-fold serial dilutions of standards over a range of 10(6) to 10(1) copies/μL, with the lowest detection limit of the assay being 10(1) copies/μL. The assay was applied to 328 clinical specimens and compared with enzyme-linked immunosorbent assay (ELISA) and commercial nucleic acid testing (NAT) methods. The assay identified 39 T. pallidum-, 96 HCV-, 13 HIV-1-, 123 HBV-, 5 HBV/HCV-, 1 T. pallidum/HBV-, 1 HIV-1/HCV-, and 1 HIV-1/T. pallidum-positive specimens. The high sensitivity of the assay confers strong potential for its use as a highly reliable, cost-effective, and useful molecular diagnostic tool for large-scale screening of clinical specimens. This assay will assist in the study of the pathogenesis and epidemiology of sexually transmitted blood diseases.

  16. Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine.

    Science.gov (United States)

    Dumaidi, Kamal; Al-Jawabreh, Amer

    2014-10-01

    Occult hepatitis B infection is the case with undetectable HBsAg, but positive for HBV DNA in liver tissue and/or serum. Occult hepatitis B infection among hemodialysis patients in Palestine has been understudied. In this study, 148 hemodialysis patients from 2 northern districts in Palestine, Jenin (89) and Tulkarem (59), were investigated for occult hepatitis B, HBV, HCV infections with related risk factors. ELISA and PCR were used for the detection of anti-HBc and viral DNA, respectively. The overall prevalence of occult hepatitis B infection among the study group was 12.5% (16/128). Occult hepatitis B infection is more prevalent among males with most cases (15/16) from Jenin District. About one-third (42/132) of the hemodialysis patients were anti-HBc positive. Approximately 27% of the hemodialysis patients were infected with HCV. Around 20% (28/140) were positive for HBV DNA, but only 8.2% (12/146) of the hemodialysis patients were positive for HBsAg. The comparison between hemodialysis patients with occult hepatitis B infection and those without occult hepatitis B infection for selected risk factors and parameters as liver Enzyme, age, sex, HCV infection, blood transfusion, kidney transplant, anti-HBc, and vaccination showed no statistical significance between both categories. Duration of hemodialysis significantly affected the rate of HCV infection. HCV is significantly higher in hemodialysis patients with both Diabetes mellitus and hypertension. The prevalence of occult hepatitis B infection among hemodialysis patients is high; requiring stringent control policies. HBsAg assay is insufficient test for accurate diagnosis of HBV infection among hemodialysis patients.

  17. Genotyping and Mutation Pattern in the Overlapping MHR Region of HBV Isolates in Southern Khorasan, Eastern Iran

    Science.gov (United States)

    Ziaee, Masood; Javanmard, Davod; Sharifzadeh, Gholamreza; Hasan Namaei, Mohammad; Azarkar, Ghodsiyeh

    2016-01-01

    Background Hepatitis B virus, with 8 known distinct genotypes, is one of the most serious health problems which results to liver injuries. The surface gene of Hepatitis B virus completely overlaps with the polymerase gene. Mutations in the RT gene result in changes in the overlapping hepatitis B surface antigen. Objectives The present study aimed to evaluate the genotypes and prevalence of mutations in a segment of S and RT gene in HBV isolates in Southern Khorasan, Iran. Methods This was a population-based study comprising 5,235 randomized samples for HBV screening. A nested-polymerase chain reaction (PCR) test was followed by direct sequencing, and the sequences blast with present sequences of NCBI database for genotyping. Alignment and phylogenic analysis was performed using MEGA-6 software, and mutation pattern of this segment was finally surveyed in Bioedit software. Results The mean age was 39.07 ± 14.04 years, with 52.2% female and 47.8% male. All isolates belonged to HBV genotype D, sub-genotype D1. The most amino acid substitutions of surface protein were Q129H (34.42%) and A168V (8.2%), other escape mutants observed in this study were P127L/T, S117G, T125M, S143L, D144E and E164D. In the RT gene, Q149K was the most frequently identified amino acid substitution (9.83%), followed by L122F (8.19%), N118D/T (6.55%), L157M (4.91%), and H124Y (3.27%). Conclusions This finding represents an ongoing dominancy of HBV genotype D in Eastern Iran, corresponding to other parts of Iran. There were a lot of variations in the S gene leading to an escape mutation, some of which affected the corresponding area of the RT region. PMID:27882062

  18. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

    Directory of Open Access Journals (Sweden)

    Raul Carlos Wahle

    2015-10-01

    Full Text Available ABSTRACTIn coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess the evolution of HBV viremia after HCV treatment in this special population. Ten hemodialysis patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than 2000 IU/mL and significant fibrosis were treated with interferon-alpha 3 MU 3×/week for 12 months and could be followed for at least 36 months after HCV treatment. Six cases of HBV reactivation (60% during follow-up were observed and 5/6 had been successfully treated for HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary findings indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients may favor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended and prompt anti-HBV therapy should be implemented.

  19. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication

    Directory of Open Access Journals (Sweden)

    Christopher M. Murphy

    2016-09-01

    Full Text Available The hepatitis B virus (HBV regulatory protein X (HBx activates gene expression from the HBV covalently closed circular DNA (cccDNA genome. Interaction of HBx with the DDB1-CUL4-ROC1 (CRL4 E3 ligase is critical for this function. Using substrate-trapping proteomics, we identified the structural maintenance of chromosomes (SMC complex proteins SMC5 and SMC6 as CRL4HBx substrates. HBx expression and HBV infection degraded the SMC5/6 complex in human hepatocytes in vitro and in humanized mice in vivo. HBx targets SMC5/6 for ubiquitylation by the CRL4HBx E3 ligase and subsequent degradation by the proteasome. Using a minicircle HBV (mcHBV reporter system with HBx-dependent activity, we demonstrate that SMC5/6 knockdown, or inhibition with a dominant-negative SMC6, enhance HBx null mcHBV-Gluc gene expression. Furthermore, SMC5/6 knockdown rescued HBx-deficient HBV replication in human hepatocytes. These results indicate that a primary function of HBx is to degrade SMC5/6, which restricts HBV replication by inhibiting HBV gene expression.

  20. High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in shanghai.

    Science.gov (United States)

    Yu, Xuelian; Zhang, Jing; Hong, Liang; Wang, Jiayu; Yuan, Zhengan; Zhang, Xi; Ghildyal, Reena

    2012-01-01

    Human parvovirus 4 (PARV4) has been detected in blood and diverse tissues samples from HIV/AIDS patients who are injecting drug users. Although B19 virus, the best characterized human parvovirus, has been shown to co-infect patients with hepatitis B or hepatitis C virus (HBV, HCV) infection, the association of PARV4 with HBV or HCV infections is still unknown.The aim of this study was to characterise the association of viruses belonging to PARV4 genotype 1 and 2 with chronic HBV and HCV infection in Shanghai.Serum samples of healthy controls, HCV infected subjects and HBV infected subjects were retrieved from Shanghai Center for Disease Control and Prevention (SCDC) Sample Bank. Parvovirus-specific nested-PCR was performed and results confirmed by sequencing. Sequences were compared with reference sequences obtained from Genbank to derive phylogeny trees.The frequency of parvovirus molecular detection was 16-22%, 33% and 41% in healthy controls, HCV infected and HBV infected subjects respectively, with PARV4 being the only parvovirus detected. HCV infected and HBV infected subjects had a significantly higher PARV4 prevalence than the healthy population. No statistical difference was found in PARV4 prevalence between HBV or HCV infected subjects. PARV4 sequence divergence within study groups was similar in healthy subjects, HBV or HCV infected subjects.Our data clearly demonstrate that PARV4 infection is strongly associated with HCV and HBV infection in Shanghai but may not cause increased disease severity.

  1. O-glycosylation inhibition induce HBV release%抑制O-糖基化修饰促进乙型肝炎病毒的释放

    Institute of Scientific and Technical Information of China (English)

    肖凡; 乔雍; 张仁雯; 常路丝; 成军; 魏红山

    2013-01-01

    目的:探讨抑制O-糖基化修饰对乙型肝炎病毒颗粒组装的影响。方法采用O-糖基化修饰抑制剂Benzyl-α-GalNAc干预HepG2.2.15细胞。经7-AAD染色,应用流式细胞仪检测细胞凋亡情况。采用实时荧光定量PCR方法检测上清HBV病毒载量。应用酶联免疫吸附试验(ELISA)检测上清乙型肝炎病毒大蛋白(the hepatitis B virus large surface protein,HBV LHBs)水平。采用蛋白免疫印迹(Western blot)方法检测细胞中LHBs蛋白含量。结果 Benzyl-α-GalNAc能显著促进细胞凋亡,上清中HBV DNA和LHBs水平呈剂量依赖性增加;Benzyl-α-GalNAc抑制细胞中LHBs蛋白表达。结论抑制细胞O-糖基化修饰促进细胞凋亡,从而释放HBV LHBs和病毒颗粒;但在某种程度上抑制细胞O-糖基化修饰能够抑制细胞内LHBs合成。%Objective To investigate the effect of the inhibition of O-glycosylation on HBV assembly. Methods HepG2.2.15 cells treated with O-glycosylation inhibitor, Benzyl-α-GalNAc, were dyed with 7-AAD and examined by FACS for cell apoptosis. HBV DNA loading in cell supernatant was determined by real-time PCR. HBV LHBs levels in cell supernatant was tested by ELISA. LHBs levels in cells was analyzed by Western blot. Results Benzyl-α-GalNAc could signiifcantly induce cell apoptosis. HBV DNA and LHBs levels in cell supernatant were increased in a dose dependent manner. However, Benzyl-α-GalNAc inhibited LHBs synthesis. Conclusions Inhibition of O-glycosylation could induce cell apoptosis and release HBV LHBs and virus. In some extent, inhibition of O-glycosylation may inhibit LHBs synthesis.

  2. 核酸检测在血液HBV筛查中的应用研究%Application of NAT detection for HBV in blood screening

    Institute of Scientific and Technical Information of China (English)

    王芳; 金钊; 林松峰; 栾燕; 刘显智

    2010-01-01

    目的:了解沈阳地区乙型肝炎病毒表面抗原(HBsAg)阴性献血者中乙型肝炎病毒(hepatitis B virus,HBV)感染状况,探讨HBV核酸扩增检测(nucleic acid amplification testing,NAT)技术应用于血液筛查的意义.方法:在酶联免疫法(enzyine immunoassay,EIA)检测的基础上,应用TaqMan实时荧光聚合酶链式反应(PCR)方法对HBsAg EIA阴性血液标本进行HBV DNA的NAT检测.对NAT阳性标本进一步做乙型肝炎病毒血清标志物(HBV Marker,HBV-M)及核酸定量检测.结果:共检测了105,152例HBsAg阴性的血液标本,检出HBV DNA阳性标本15例,阳性率0.014%.Abbott酶联免疫试剂检测发现,15例标本中有6例标本的HBV-M五项指标检测全部阴性,9例为HBsAg阴性但其它标志物阳性.其中10例HBV DNA阳性标本再经Roche试剂进行核酸定量检测,HBV DNA核酸含量最高为149 IU/ml.结论:在HBsAg ELA阴性献血者中仍有极少数的HBV感染者;核酸扩增检测和酶联免疫检测互补,能够缩短血液筛查中HBV检测窗口期,特别是对提高HBsAg阴性血液标本中HBV感染检出率具有重要价值.

  3. Investigation of the relationship between serological markers of hepatitis B virus infection and HBV-DNA%乙型肝炎病毒感染血清学标志物与HBV-DNA的关系探讨

    Institute of Scientific and Technical Information of China (English)

    黄洁; 吴建华

    2014-01-01

    Objective To investigate the relationship between serum hepatitis B virus markers (HBV-M ) and HBV-DNA . Methods Enhanced chemiluminescence enzyme immunoassay (ECLIA ) and real-time fluorescent quantitative polymerase chain re-action(FQ-PCR) were employed to detect HBV-M and HBV-DNA in 262 serum samples ,respectively .HBV surface antigen(HB-sAg) ,anti-HBV surface antibody(HBsAb) ,HBV e antigen(HBeAg) ,anti-HBV e antibody(HBeAb) ,anti-HBV core antibody(HB-cAb) were included in HBV-M .Results Compared the positive rates of HBV-DNA ,HBsAg ,HBeAb in HBeAg-negative patients with those in HBeAg-positive patients ,the differences were statistically significant (P< 0 .01) .29(36 .7% ) patients with HBV-DNA logarithm value not less than 5 were found in HBeAg-negative patients .Differences of HBeAg ,HBeAb positive rates among patients with different ages were statistically significant (P<0 .01) .25 patients with HBsAg less than 250 IU/mL were found in HBV-DNA-positive patients ,12(48 .0% ) of which showed HBV-DNA logarithm value not less than 5 .HBV-DNA logarithm value of HBV-DNA-positive patients was positively correlated to HBeAg and HBeAb (r= 0 .542 ,0 .607 ,P< 0 .01) .Conclusion Com-bined detection of HBV-M and HBV-DNA contributes to estimating the HBV infection .%目的:探讨血清乙型肝炎病毒标志物(HBV-M )与 HBV-DNA之间的关系。方法分别采用增强化学发光酶联免疫分析(ECLIA )技术及实时荧光定量聚合酶链反应(FQ-PCR)对262例血清进行 HBV-M、HBV-DNA检测,HBV-M 包括 HBV表面抗原(HBsAg)、抗HBV表面抗体(HBsAb)、HBV e抗原(HBeAg)、抗 HBV e抗体(HBeAb)、抗 HBV核心抗体(HBcAb)。结果 HBeAg 阴性患者的 HBV-DNA、HBsAg、HBeAb阳性率与 HBeAg 阳性患者比较,差异均有统计学意义( P<0.01)。HBeAg阴性患者 HBV-DNA对数值不低于5的有29例(36.7%)。不同年龄患者 HBeAg、HBeAb阳性率的差异有统计学意义(P<0.01)。HBV

  4. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay.

    Science.gov (United States)

    Park, Yongjung; Hong, Duck Jin; Shin, Saeam; Cho, Yonggeun; Kim, Hyon-Suk

    2012-05-01

    We evaluated quantitative hepatitis B surface antigen (qHBsAg) assays and a hepatitis B virus (HBV) core-related antigen (HBcrAg) assay. A total of 529 serum samples from patients with hepatitis B were tested. HBsAg levels were determined by using the Elecsys (Roche Diagnostics, Indianapolis, IN) and Architect (Abbott Laboratories, Abbott Park, IL) qHBsAg assays. HBcrAg was measured by using Lumipulse HBcrAg assay (Fujirebio, Tokyo, Japan). Serum aminotransferases and HBV DNA were respectively quantified by using the Hitachi 7600 analyzer (Hitachi High-Technologies, Tokyo, Japan) and the Cobas AmpliPrep/Cobas TaqMan test (Roche). Precision of the qHBsAg and HBcrAg assays was assessed, and linearity of the qHBsAg assays was verified. All assays showed good precision performance with coefficients of variation between 4.5% and 5.3% except for some levels. Both qHBsAg assays showed linearity from 0.1 to 12,000.0 IU/mL and correlated well (r = 0.9934). HBsAg levels correlated with HBV DNA (r = 0.3373) and with HBcrAg (r = 0.5164), and HBcrAg also correlated with HBV DNA (r = 0.5198; P HBcrAg assays.

  5. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

    Directory of Open Access Journals (Sweden)

    Asare Isaac

    2008-03-01

    Full Text Available Abstract Background Prisons are known to be high-risk environments for the spread of bloodborne and sexually transmitted infections. Prison officers are considered to have an intermittent exposure potential to bloodborne infectious diseases on the job, however there has been no studies on the prevalence of these infections in prison officers in Ghana. Methods A national multicenter cross-sectional study was undertaken on correlates of human immunodeficiency virus (HIV, hepatitis B virus (HBV, hepatitis C virus (HCV, and syphilis infections in sample of prison inmates and officers from eight of ten regional central prisons in Ghana. A total of 1366 inmates and 445 officers were enrolled between May 2004 and December 2005. Subjects completed personal risk-factor questionnaire and provided blood specimens for unlinked anonymous testing for presence of antibodies to HIV, HCV and Treponema pallidum; and surface antigen of HBV (HBsAg. These data were analyzed using both univariate and multivariate techniques. Results Almost 18% (1336 of 7652 eligible inmates and 21% (445 of 2139 eligible officers in eight study prisons took part. Median ages of inmates and officers were 36.5 years (range 16–84 and 38.1 years (range 25–59, respectively. Among inmates, HIV seroprevalence was 5.9%, syphilis seroprevalence was 16.5%, and 25.5% had HBsAg. Among officers tested, HIV seroprevalence was 4.9%, HCV seroprevalence was 18.7%, syphilis seroprevalence was 7.9%, and 11.7% had HBsAg. Independent determinants for HIV, HBV and syphilis infections among inmates were age between 17–46, being unmarried, being illiterate, female gender, being incarcerated for longer than median time served of 36 months, history of homosexuality, history of intravenous drug use, history of sharing syringes and drug paraphernalia, history of participation in paid sexual activity, and history of sexually transmitted diseases. Independent determinants for HIV, HBV, HCV and syphilis

  6. HBV carriage in children born from HIV-seropositive mothers in Senegal: The need of birth-dose HBV vaccination.

    Science.gov (United States)

    Gueye, Sokhna Bousso; Diop-Ndiaye, Halimatou; Lo, Gora; Mintsa, Sandrine; Guindo, Ibrahima; Dia, Aminata; Sow-Sall, Amina; Gaye-Diallo, Aissatou; Mboup, Souleymane; Touré-Kane, Coumba

    2016-05-01

    Hepatitis B is a major public health problem in Senegal, a country with high prevalence and a transmission occurring mainly during infancy. Only, one 6-8 weeks vaccination campaign was initiated in 2005 and it was part of the expanded program of immunization. The aim of this study was to determine the prevalence of HBsAg in children born from HIV-seropositive mothers by using dried blood specimens. Specimens were collected between July 2007 and November 2012 from children aged 2-48 weeks in Dakar and decentralized sites working on HIV mother-to-child transmission prevention. HBsAg detection was performed using Architect HBsAg Qualitative II kit (Abbott Diagnostics, Ireland) and for all reactive samples confirmation was done using Architect HBsAg Qualitative II Confirmatory kit (Abbott Diagnostics, Ireland). Nine hundred thirty samples were collected throughout the country with 66% out of Dakar, the capital city. The median age was 20 weeks and 88% of children were less than 1 year of age with a sex ratio of 1.27 in favor of boys. HBsAg was detected in 28 cases giving a global prevalence of 3%. According to age, HBsAg prevalences were 5.1% for children less than 6 weeks, 4.1% and 4.6%, respectively, for those aged 12-18 weeks and 18-24 weeks of age. The HIV prevalence was 2.6% with no HIV/HBV co-infection. This study showed a high rate of HBV infection in children under 24 months, highlighting the need to promote birth-dose HBV vaccination as recommended by WHO.

  7. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Yoon Sik, E-mail: yumshak@naver.com; Seo, Hyun Wook, E-mail: suruk@naver.com; Jung, Guhung, E-mail: drjung@snu.ac.kr

    2015-02-13

    Hepatitis B virus (HBV) infection induces reactive oxygen species (ROS) production and has been associated with the development of hepatocellular carcinoma (HCC). ROS are also an important factor in HCC because the accumulated ROS leads to abnormal cell proliferation and chromosome mutation. In oxidative stress, heat shock protein 90 (Hsp90) and glutathione (GSH) function as part of the defense mechanism. Hsp90 prevents cellular component from oxidative stress, and GSH acts as antioxidants scavenging ROS in the cell. However, it is not known whether molecules regulated by oxidative stress are involved in HBV capsid assembly. Based on the previous study that Hsp90 facilitates HBV capsid assembly, which is an important step for the packing of viral particles, here, we show that ROS enrich Hsp90-driven HBV capsid formation. In cell-free system, HBV capsid assembly was facilitated by ROS with Hsp90, whereas it was decreased without Hsp90. In addition, GSH inhibited the function of Hsp90 to decrease HBV capsid assembly. Consistent with the result of cell-free system, ROS and buthionine sulfoximine (BS), an inhibitor of GSH synthesis, increased HBV capsid formation in HepG2.2.15 cells. Thus, our study uncovers the interplay between ROS and Hsp90 during HBV capsid assembly. - Highlights: • We examined H{sub 2}O{sub 2} and GSH modulate HBV capsid assembly. • H{sub 2}O{sub 2} facilitates HBV capsid assembly in the presence of Hsp90. • GSH inhibits function of Hsp90 in facilitating HBV capsid assembly. • H{sub 2}O{sub 2} and GSH induce conformation change of Hsp90.

  8. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line

    Institute of Scientific and Technical Information of China (English)

    Wei He; Li-Xia Li; Qing-Jiao Liao; Chun-Lan Liu; Xu-Lin Chen

    2011-01-01

    AIM: To analyze the antiviral mechanism of Epigallocatechin gallate (EGCG) against hepatitis B virus (HBV) replication. METHODS: In this research, the HBV-replicating cell line HepG2.117 was used to investigate the antiviral mechanism of EGCG. Cytotoxicity of EGCG was analyzed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Hepatitis B virus e antigen (HBeAg) and hepatitis B virus surface antigen (HBsAg) in the supernatant were detected by enzyme-linked immunosorbent assay. Precore mRNA and pregenomic RNA (pgRNA) levels were determined by semi-quantitative reverse transcription polymerase chain reaction (PCR) assay. The effect of EGCG on HBV core promoter activity was measured by dual luciferase reporter assay. HBV covalently closed circular DNA and replicative intermediates of DNA were quantified by real-time PCR assay. RESULTS: When HepG2.117 cells were grown in the presence of EGCG, the expression of HBeAg was suppressed, however, the expression of HBsAg was not affected. HBV precore mRNA level was also downregulated by EGCG, while the transcription of precore mRNA was not impaired. The synthesis of both HBV covalently closed circular DNA and replicative intermediates of DNA were reduced by EGCG treatment to a similar extent, however, HBV pgRNA transcripted from chromosome-integrated HBV genome was not affected by EGCG treatment, indicating that EGCG targets only replicative intermediates of DNA synthesis. CONCLUSION: In HepG2.117 cells, EGCG inhibits HBV replication by impairing HBV replicative intermediates of DNA synthesis and such inhibition results in reduced production of HBV covalently closed circular DNA.

  9. Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines.

    Science.gov (United States)

    Wu, Yong; Zhang, Tian-Ying; Fang, Lin-Lin; Chen, Zi-Xuan; Song, Liu-Wei; Cao, Jia-Li; Yang, Lin; Yuan, Quan; Xia, Ning-Shao

    2016-08-01

    The stable HBV-replicating cell lines, which carry replication-competent HBV genome stably integrated into the genome of host cell, are widely used to evaluate the effects of antiviral agents. However, current methods to generate HBV-replicating cell lines, which are mostly dependent on random integration of foreign DNA via plasmid transfection, are less-efficient and time-consuming. To address this issue, we constructed an all-in-one Sleeping Beauty transposon system (denoted pTSMP-HBV vector) for robust generation of stable cell lines carrying replication-competent HBV genome of different genotype. This vector contains a Sleeping Beauty transposon containing HBV 1.3-copy genome with an expression cassette of the SV40 promoter driving red fluorescent protein (mCherry) and self-cleaving P2A peptide linked puromycin resistance gene (PuroR). In addition, a PGK promoter-driven SB100X hyperactive transposase cassette is placed in the outside of the transposon in the same plasmid.The HBV-replicating stable cells could be obtained from pTSMP-HBV transfected HepG2 cells by red fluorescence-activated cell sorting and puromycin resistant cell selection within 4-week. Using this system, we successfully constructed four cell lines carrying replication-competent HBV genome of genotypes A-D. The replication and viral protein expression profiles of these cells were systematically characterized. In conclusion, our study provides a high-efficiency strategy to generate HBV-replicating stable cell lines, which may facilitate HBV-related virological study.

  10. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro.

    Science.gov (United States)

    Li, Xuefen; Tian, Li; Dong, Yuejiao; Zhu, Qiaoyun; Wang, Yiyin; Han, Wenzheng; Liu, Xia; Ni, Qin; Chen, Yu; Li, Lanjuan

    2015-09-01

    Interleukin (IL)-35 is an inhibitory cytokine consisting of IL-12A and Epstein-Barr virus-induced gene 3 (Ebi3) and is required by regulatory T-cells (Tregs) for maximal activity. During chronic hepatitis B virus (HBV) infection, Tregs have immunosuppressive effects on HBV-specific T helper (Th) cells, yet little is known about the complex regulation of Tregs and their contribution to the inadequate immune system response to the virus. In the present study, we investigated whether IL-35 is involved in HBV-related cellular immune responses. Cluster of differentiation (CD)4(+) T-cells from peripheral blood were derived from healthy volunteers, resolved HBV individuals and chronic active hepatitis B patients and stimulated with CD3/28-conjugated beads. We analysed mRNA and protein levels of IL-35 and assessed the inhibitory effect of IL-35 on HBV core antigen-specific cytotoxic T lymphocytes (CTLs), dendritic cells (DCs) and effector T-cells (Teffs). Correlation analyses between liver inflammation and HBV DNA load were conducted. Results show that chronic HBV patients harbour significantly higher levels of Ebi3 mRNA and protein in CD4(+) T-cells compared with healthy volunteers and resolved HBV individuals. IL-35 suppressed the proliferation of HBV antigen-specific CTLs and interferon (IFN)-γ production in vitro. Ex vivo, IL-35 decreased the proliferation of CD4(+)CD45RA(+) naïve T-cells, especially in CD4(+)CD25(-)CD45RA(+) naïve Teffs. IL-35 inhibited the expansion of CD11c(+) DCs. Our data indicate that IL-35 is highly expressed in chronic HBV CD4(+) T-cells and plays an important role in the inhibition of the cellular immune response in chronic HBV.

  11. 携带乙型肝炎病毒产妇血清与初乳HBV DNA载量关联性研究%The Relationship between Serum HBV DNA Quantities and Colostrum HBV DNA Quantities among HBV-positive Lying-in women

    Institute of Scientific and Technical Information of China (English)

    黄晨艳; 陶芳标; 方有兵; 蔡娟; 黛垠之; 陆天慧; 王黎; 李启发; 孟祥莲; 张育苗

    2011-01-01

    目的 研究产妇血清与其初乳汁乙型肝炎病毒(HBV) DNA载量的关联性.方法 选取住院分娩产妇共522例,依据HBV五项血清学指标,分为A组:乙肝"HBsAg、HBeAg、HBcAb均阳性"103例,B组:乙肝"HBsAg、HBeAb、HBcAb均阳性"221例,C组:HBsAg、HBeAg阳性20例,D组:HBsAg、HBcAb阳性43例,E组:乙肝其他血清模式49例,另选F组:HBV模式全阴性的产妇86例作为对照组;均采用ELISA法检测产妇血清、乳汁中HBV标志物HBsAg、HBsAb、HBeAg、HBeAb、HBcAb,阳性者采用该项目胶体金标试纸复核,同时采用实时荧光定量PCR检测产妇血清和乳汁HBV DNA载量,对相关数据进行统计分析.结果 对年龄18~44岁围产期妇女体检乙肝感染指标,A组乙肝"HBsAg、HBeAg、HBcAb均阳性"产妇血清和乳汁HBV DNA诊断灵敏度分别为100.00%(103/103)和86.41%(89/103)、血清HBV DNA载量平均为4.11×108 copies/ml;B组乙肝"HBsAg、HBeAb、HBcAb均阳性"产妇血清和乳汁HBV DNA诊断灵敏度分别为19.46%(43/221)和2.71%(6/221),血清HBV DNA载量平均为6.85×104 copies/ml ;C组乙肝HBsAg、HBeAg阳性产妇血清和乳汁HBV DNA诊断灵敏度分别为100.00%(20/20)和80.00%(16/20),血清HBV DNA载量平均为8.27×106 copies/ml ;D组HBsAg、HBcAb阳性产妇血清和乳汁HBV DNA诊断灵敏度分别为65.12%(28/43)和25.58%(11/43),血清HBV DNA载量平均为2.89×105 copies/ml ;E组HBV其他模式产妇血清和乳汁HBV DNA诊断灵敏度分别为10.20%(5/49)和2.04%(1/49),血清HBV DNA载量平均为1.59×104 copies/ml ;F组乙肝五项全阴性产妇血清和乳汁HBV DNA诊断灵敏度分别为1.16%(1/86)和0(0/86),血清HBV DNA载量<1.00×103 copies/ml.A组与B组间乳汁HBV DNA实验诊断阳性差异有统计学意义(χ2=237.45,P<0.01).HBV携带者乳汁HBV DNA载量与其血液HBV DNA载量呈正相关(r=0.721).结论 携带HBV产妇乳汁HBV DNA载量远低于血液HBV DNA载量;乳汁中HBV传染性也低于血液传染性;研究证实A组产

  12. 皖北地区乙型肝炎患者HBV血清标志物与HBV-DNA定量检测的比较%Comparison of HBV-M and HBV-DNA detection in HBV infectors in the North of Anhui

    Institute of Scientific and Technical Information of China (English)

    昝丽娜; 石秀芳; 孙峰

    2013-01-01

    Objective: To compare the detection results of HBV-M and HBV-DNA. Methods: All 388 HBV patients were detected for the HBV-M by ELISA and HBV-DNA by FQ-PCR. Results:The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(+)/ HBcAb(+) was 91.25% ,and the majority of the virus replication was 107 IU/ml; while the majority of the virus replication in the group of HBsAg(+)/HBeAb(+)/ HBcAb(+) was 103 IU/ml. The positive rate of HBV-DNA in the group of HBsAgAb(+)/ HBeAg(+)/HBc(+) was higher than that in the group of HBsAg(+)/HBeAb(+)/HBcAb(+) (P <0.05) . The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(±)/ HBc(+) Ab was 66. 67% . The majority of the virus replication was 105 IU/ml and 106 IU/ml in patients with positive HBsAg(+)/HBeAg(+)/HBc(-) Ab. The positive rate of HBV-DNA in the group of HBsAg (+)/HBeAg(-)/HBcAb(+) was 30.77%. Conclusions: Patients with HBeAg(+) have the highest replication level in all the groups,which is closely associated with HBV-DNA. Virus replication in patients with HBeAb(+) and HBcAb(+) does not stop completely, but obviously decreases. Combination detection of HBV-M and HBV-DNA may display the immune status and virus replication level of patients with hepatitis B, which would provide experimental basis for clinical monitoring and drug administration.%目的:比较乙型肝炎病毒血清标志物(HBV-M)与HBV-DNA定量检测的结果.方法:采用酶联免疫法检测388例患者血清HBV-M,同时用荧光定量-聚合酶链反应检测其HBV-DNA含量.结果:乙型肝炎大三阳组患者血清HBV-DNA阳性率为91.25%,阳性患者中HBV拷贝数为107 IU/ml的所占比例最多,小三阳组阳性患者中HBV拷贝数以103 IU/ml为主,大三阳组患者血清HBV-DNA阳性率高于小三阳组(P<0.05);HBsAg(+)、HBeAg(±)、抗-HBc(+)组阳性率为66.67%;HBsAg(+)、HBeAg(+)、抗HBc(-)组阳性患者中以105 IU/ml和106 IU/ml为主;HBsAg(+)、HBeAg(-)、HBcAb(+)组阳性率为30.77%.结论:乙型肝炎患者中HBeAg(+)者

  13. BCG vaccine combined with dipyridamole in the treatment of HBV infection

    Institute of Scientific and Technical Information of China (English)

    Xu Wen Gao; Shi Ying Jia; Xue Mei Liu

    2000-01-01

    AIM To investigate the effect of BCG vaccine and dipyridamole in treating hepatitis B due to their anti-virus effects.METHODS Among 602 patients with positive HBeAg, 512 were allocated to the treatment group and 90patients to the control group. There was no significant difference in disease and age between the two groups.All the patients in the treatment group with no abnormal findings by chest X-ray fluoroscopy, whose localskin scleromata diameters were less than 7 mm after the 1:2000 OT test, were given BCG vaccine 0.1 mlintracutaneously at the deltoid once a month, and simultaneously took dipyridamole 50 mg twice a day forfour to eight months. The hepatic function, B-mode ultrasound and the five markers of hepatitis B wereroutinely examined before each injection. The results at one month after the last injection in the treatmentgroup were compared with those of the control group.RESULTS The recovery rates of hepatic functions and the rates of improvement of the symptoms and signsin the treatment group were better than those in the control group. The negative transformation rates ofHBeAg and the positive transformation rates of HBeAb were 60.3% and 31.6% in the treatment group vs.13.3% and 13.0% in the control group (P0.05. Test x2, x2=1.11, 0.22).CONCLUSION The application of BCG vaccine in combination with dipyridamole increased the negativetransformation rate of HBeAg and the positive transformation rate of HBeAb, improved the clinicalsymptoms, signs and hepatic function of the patients. These two drugs had significant anti-HBV effect andshowed good efficacy in the treatment of HBV infection.

  14. Cloning analysis of HBV-specific CD8 T cell receptor gene in patients with acute hepatitis B

    Directory of Open Access Journals (Sweden)

    Ning DING

    2011-05-01

    Full Text Available Objective To investigate the molecular mechanism of T cell receptor(TCR in CD8 T cell-mediated immune response to HBV in patients with acute hepatitis B(AHB.Methods Peripheral blood mononuclear cells(PBMCs were collected from HLA-A2-positive AHB patients.To determine HBsAg183-191 and HBsAg335-343-specific CD8 T cell frequencies,the PBMCs were stained by fluorescence-labeled anti-CD3,anti-CD8 and pentamers,and analyzed by flow cytometry.PBMCs from 6 patients were stimulated with epitopic peptide HBsAg335-343 in vitro for 3 to 4 weeks.HBV-specific CD8 T cells were isolated by magnetic activated cell sorting followed by flow florescence activated cell sorting.The mRNA of sorted cells was extracted after expanding by IL-2,anti-CD3 and anti-CD8.The full-length gene fragments of variable region of TCR α and β chains were gained by 5’-RACE,and then cloned and sequenced(≥50 clones for single chain of each sample.The gene families of TCR α and β chains were identified and the sequence characters of CDR3 were compared.Results Analysis of more than 600 cloned gene sequences of TCR α and β chains showed that the proliferated HBV-specific CD8 T cells from 6 AHB patients presented a predominant expression in TCR α and chains,with 2-4 α chain families and 1-4 chain families in each case.The α2,α14,α15,β3,β13 and 23 families were detected in more than one case.The chain genes were all 13 for all tested clones in one case.For the same α chain or-chain family,CDR3 sequences tended to be identical in one case but different among cases.Conclusions HBV-specific CD8 T cells with antigenic peptide-induced proliferation present predominance in the usage of TCR α and β chains.This property might be one of the important molecular factors influencing anti-HBV immunity.

  15. Sieropositivitá per HIV, HBV e HCV negli utenti del Servizio di Tossicodipendenza di Formia (ASL di Latina

    Directory of Open Access Journals (Sweden)

    G. La Torre

    2003-05-01

    Full Text Available

    Obiettivi: valutare la prevalenza sieropositività per HIV, HBV e HCV nei tossicodipendenti afferenti al Ser.T di Formia (LT.

    Materiali e metodi: sono state consultate le cartelle cliniche degli afferenti al Ser.T. nel 2002, estraendo dati relativi ai parametri socio-demografici ed alle sieropositività. L’analisi statistica ha previsto l’impiego del test del χ2 e della regressione logistica multipla.

    Risultati: sono stati presi in considerazione 135 tossicodipendenti, di cui 103 (76.3% maschi e 32 (23.7% femmine. L’età mediana dell’inizio della tossicodipendenza e della presa in carico presso il servizio erano, rispettivamente, di 18 e di 23 anni. Il 94.1% dei tossicodipendenti risulta dipendente primariamente da eroina, il 5.2% da cocaina e lo 0.7% da alcol. Relativamente alle positività per i virus considerati, 7 soggetti (5.2% sono risultati positivi all’HIV, 23 (17% sieropositivi per HBV e 50 (37% sieropositivi per HCV. L’analisi multivariata mostra che sono associate alla sieropositività per HCV la sieropositività per HBV (OR = 3.87 e l’età della presa in carico presso il servizio superiore a 25 anni (OR = 1.88; alla sieropositività per HBV l’occupazione saltuaria (OR = 4.58, la HCV positività (OR = 4.41 e la HIV positività (OR = 5.39; alla sieropositività per HIV l’età della presa in carico presso il servizio superiore a 25 anni (OR = 4.94.

    Discussione: l’indagine ha messo in evidenza prevalenze di sieropositività per HCV, HBV e HIV decisamente inferiori a quelle registrate in altre realtà italiane ed internazionali. Una possibile spiegazione potrebbe essere ricercata nei bassi livelli di sieropositività per questi virus nella popolazione generale del Basso Lazio, o nella scarsa abitudine di scambiarsi le siringhe fra tossicodipendenti di questa area geografica.

  16. Molecular characterization of hepatitis B virus (HBV) strains circulating in the northern coast of the Persian Gulf and its comparison with worldwide distribution of HBV subgenotype D1.

    Science.gov (United States)

    Pourkarim, Mahmoud Reza; Vergote, Valentijn; Amini-Bavil-Olyaee, Samad; Sharifi, Zohre; Sijmons, Steven; Lemey, Philippe; Maes, Piet; Alavian, Seyed Moayed; Van Ranst, Marc

    2014-05-01

    Iran is a large country that covers the northern coast of the Persian Gulf. Iranian residents of this coastal region interact closely with people from neighboring countries because of historical and cultural relationships, as well as economic activities. In addition, the inhabitants of this border region have experienced several wars, which have affected public health infrastructures. This study characterized for the first time, the evolution of the full-length genome of HBV strains in asymptomatic carrier patients living in this particular region. In addition, this study was compared and complemented by a comprehensive evolutionary analysis of the worldwide geographical distribution of HBV subgenotype D1. Evolutionary analysis demonstrates that patients living in the northern coast of the Persian Gulf are mainly infected with HBV subgenotype D1, subtype ayw2. Specific mutations related to advanced liver disease were found more frequently in these strains compared to other strains isolated from asymptomatic carriers from other regions of Iran. This global comprehensive analysis showed that HBV subgenotype D1 strains have a worldwide distribution and that human mobility and immigration had a large impact on dispersal of HBV subgenotype D1, subtype ayw2 in Middle Eastern countries such as Iran, Syria, and Turkey. In addition to association of subtype ayw2 with subgenotype D1, it was demonstrated that other HBV subtypes like adw2, ayw1, and ayw3 are associated with HBV subgenotype D1 in different regions of the world. This study also revealed a remarkable distribution of subgenotype D1, subtype ayw4 although this particular subtype is associated with subgenotype D4 of HBV in European countries.

  17. Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives.

    Science.gov (United States)

    Liu, Sheng; Li, Yubin; Wei, Wanxing; Wang, Kuiwu; Wang, Lisheng; Wang, Jianyi

    2016-05-01

    In this work, a series of phenylpropanoid derivatives were synthesized, and their anti-hepatitis B virus (HBV) activity was evaluated. Most of the synthesized derivatives showed effective anti-HBV activity. And compound 4d-3 showed the most effective anti-HBV activity, performing strong potent inhibitory not only on the secretion of HBsAg (IC50 = 58.28 μM, SI = 23.26) and HBeAg (IC50 = 97.21 μM, SI = 13.95), but also on the HBV DNA replication (IC50 = 42.28 μM, SI = 32.06). The structure-activity relationships (SARs) of the derivatives had been discussed, which were useful for developing phenylpropanoid derivatives as novel anti-HBV agents. Moreover, the docking study of all synthesized compounds inside the HLA-A protein (PDB ID: 3OX8) active site was carried out to explore the molecular interactions and a molecular target for activity and a modified assay method measuring the interaction between our derivatives and HBcAg was investigated, indicating that the HBV core protein might be their potential target for anti-HBV. This study identified a new class of potent non-nucleoside anti-HBV agents.

  18. HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review

    Directory of Open Access Journals (Sweden)

    Xiu-Li Chen

    2013-01-01

    Full Text Available A number of nucleoside analogues such as lamivudine (LAM, actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg clearance. The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative. However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous. The aim of this meta-analysis is to determine more precise estimations of the relationship. All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative through June 2013 were collected. Relative risk (RR with 95% confidence intervals (95% CI was calculated in fixed or random model, was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software. Overall, for HBeAg clearance and genotype B/C, the RR (95% CI was 1.27 (0.94–1.71, while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI was 1.07 (0.98–1.17. HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative.

  19. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

    Science.gov (United States)

    Holt, Stephen G; Gracey, David M; Levy, Miriam T; Mudge, David W; Irish, Ashley B; Walker, Rowan G; Baer, Richard; Sevastos, Jacob; Abbas, Riaz; Boyd, Mark A

    2014-01-01

    A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir and lopinavir) or apparent changes in renal function (e.g. cobicistat, ritonavir, rilpivirine and dolutegravir). Patients with HIV are at higher risk of acute and chronic renal dysfunction, so baseline assessment and ongoing monitoring of renal function is an important part of routine management of patients with HIV. Given the paucity of evidence in this area, we sought to establish a consensus view on how routine monitoring could be performed in Australian patients on ART regimens, especially those involving TDF. A group of nephrologists and prescribers (an HIV physician and a hepatologist) were assembled by Gilead to discuss practical and reasonable renal management strategies for patients particularly those on TDF-based combination regimens (in the case of those with HIV-infection) or on TDF-monotherapy (in the case of HBV-mono infection). The group considered which investigations should be performed as part of routine practice, their frequency, and when specialist renal referral is warranted. The algorithm presented suggests testing for serum creatinine along with plasma phosphate and an assessment of urinary protein (rather than albumin) and glucose. Here we advocate baseline tests of renal function at initiation of therapy. If creatinine excretion inhibitors (e.g. cobicistat or rilpivirine) are used as part of the ART regimen, we suggest creatinine is rechecked at 4 weeks and this value used as the new baseline. Repeat testing is suggested at 3-monthly intervals for a year and then at least yearly thereafter if no abnormalities are detected. In patients with abnormal baseline results, renal function assessment should be performed at least 6 monthly. In HBV mono-infected patients advocate that a similar testing

  20. Relationship between heterogeneity of HBV preS/S gene and intrauterine transmission

    Institute of Scientific and Technical Information of China (English)

    LI Duan; YAN Yong-ping; XU De-zhong; ZHANG Jing-xia

    2002-01-01

    Objective: To study the relationship of the mutation of HBV preS/S gene in HBsAg carrying pregnant women and intrauterine transmission. Methods: Polymerase chain reaction (PCR) was used to amplify HBV preS/S gene from sera of 8 HBsAg carrying pregnant women, 4 women's neonates infected with HBV,and the other's neonates non-infected with. The PCR products were cloned and 5 clones were chosen from every woman for DNA sequencing. Results: Heterogeneity of HBV preS/S gene in HBsAg carrying pregnant women having intrauterine transmission was much higher than that from having not intrauterine transmission, and the divergence rate of nucleotide sequences also higher strikingly. Conclusion: High heterogeneity of HBV preS/S gene of HBsAg positive pregnant women may be relative to high rate of intrauterine transmission.

  1. Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey.

    Science.gov (United States)

    Ciccozzi, Massimo; Ciccaglione, Anna Rita; Lo Presti, Alessandra; Equestre, Michele; Cella, Eleonora; Ebranati, Erika; Gabanelli, Elena; Villano, Umbertina; Bruni, Roberto; Yalcinkaya, Tulay; Tanzi, Elisabetta; Zehender, Gianguglielmo

    2014-01-01

    Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). Turkey, seems to have played an important role in the penetration of HBV-D1 in the Mediterranean area. The importance of Turkey in the European epidemiology of HBV is also suggested by the observation that the highest spread of HBV infection in the Continent are reported in Turkey with Romania, Bulgaria, Greece, Albania and some southern regions of Italy. In this paper the molecular epidemiology and the epidemiological history of HBV-D in Turkey was studied, by characterizing 34 new Turkish isolates and performing a phylogeographic reconstruction. By using a phylodynamic and phylogeographic Bayesian approach, the analysis suggested that HBV-D1 originated in Turkey about in the early 1940s. The large prevalence of D1 in comparison to the other subgenotypes in Turkey confirms the importance of this Country as epidemiological reservoir of HBV-D1 dispersion. The phylogeny suggests that after each initial introduction of the virus in a specific population, separate transmission clusters have been evolving along independent phylogenetic lineages. Better characterization and continuous monitoring of such groups are going to be crucial to understand in detail the epidemiology of HBV-D1 subgenotype in Turkey and to assess the efficacy of prevention, vaccination and therapy in controlling the epidemic.

  2. An HBV model with diffusion and time delay.

    Science.gov (United States)

    Xu, Rui; Ma, Zhien

    2009-04-07

    In this paper, a hepatitis B virus (HBV) model with spatial diffusion and saturation response of the infection rate is investigated, in which the intracellular incubation period is modelled by a discrete time delay. By analyzing the corresponding characteristic equations, the local stability of an infected steady state and an uninfected steady state is discussed. By comparison arguments, it is proved that if the basic reproductive number is less than unity, the uninfected steady state is globally asymptotically stable. If the basic reproductive number is greater than unity, by successively modifying the coupled lower-upper solution pairs, sufficient conditions are obtained for the global stability of the infected steady state. Numerical simulations are carried out to illustrate the main results.

  3. Effects of temporal variability on HBV model calibration

    Directory of Open Access Journals (Sweden)

    Steven Reinaldo Rusli

    2015-10-01

    Full Text Available This study aimed to investigate the effect of temporal variability on the optimization of the Hydrologiska Byråns Vattenbalansavedlning (HBV model, as well as the calibration performance using manual optimization and average parameter values. By applying the HBV model to the Jiangwan Catchment, whose geological features include lots of cracks and gaps, simulations under various schemes were developed: short, medium-length, and long temporal calibrations. The results show that, with long temporal calibration, the objective function values of the Nash-Sutcliffe efficiency coefficient (NSE, relative error (RE, root mean square error (RMSE, and high flow ratio generally deliver a preferable simulation. Although NSE and RMSE are relatively stable with different temporal scales, significant improvements to RE and the high flow ratio are seen with longer temporal calibration. It is also noted that use of average parameter values does not lead to better simulation results compared with manual optimization. With medium-length temporal calibration, manual optimization delivers the best simulation results, with NSE, RE, RMSE, and the high flow ratio being 0.563 6, 0.122 3, 0.978 8, and 0.854 7, respectively; and calibration using average parameter values delivers NSE, RE, RMSE, and the high flow ratio of 0.481 1, 0.467 6, 1.021 0, and 2.784 0, respectively. Similar behavior is found with long temporal calibration, when NSE, RE, RMSE, and the high flow ratio using manual optimization are 0.525 3, −0.069 2, 1.058 0, and 0.980 0, respectively, as compared with 0.490 3, 0.224 8, 1.096 2, and 0.547 9, respectively, using average parameter values. This study shows that selection of longer periods of temporal calibration in hydrological analysis delivers better simulation in general for water balance analysis.

  4. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).

    Science.gov (United States)

    Dhillon, Sohita

    2010-10-01

    Infanrix hexa, administered intramuscularly, is a diphtheria, tetanus, acellular pertussis, hepatitis B (HBV), inactivated poliomyelitis and Haemophilus influenzae type b (Hib) conjugate vaccine, indicated for primary and booster vaccination of infants. Infanrix hexa should be administered as a two- or three-dose primary vaccination course in infants aged hexa. Infanrix hexa as primary and booster vaccination was safe and highly immunogenic for all its component toxoids/antigens in infants aged hexa elicited a strong immune response against vaccine toxoids/antigens, as indicated by high seroprotection/seropositivity/vaccine response rates and geometric mean titers. Moreover, antibodies against vaccine toxoids/antigens persisted for up to a mean of approximately 6 years after booster vaccination, and the vaccine induced long-term immune memory against hepatitis B surface antigen and Hib antigen. A strong immune response against Infanrix hexa toxoids/antigens after primary vaccination was also induced in infants who had received a dose of HBV vaccine at birth and in pre-term infants, although the response in the latter group was somewhat lower than that in full-term infants. In addition, when coadministered with other childhood vaccines, the immunogenicity of Infanrix hexa or that of the concomitantly administered vaccine was generally not altered. Hexavalent vaccines, including Infanrix hexa, were protective against invasive Hib disease; Infanrix hexa is also expected to be protective against pertussis. Most solicited local and general symptoms with Infanrix hexa were mild to moderate in intensity and the vaccine was associated with few unsolicited adverse events. Available clinical data from more than 10 years' experience with the vaccine suggest that Infanrix hexa as primary and booster vaccination is a safe and useful option for providing protection against the common childhood diseases of diphtheria, tetanus, poliomyelitis, pertussis, hepatitis B and invasive

  5. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies?

    Directory of Open Access Journals (Sweden)

    Ali Acar

    2010-02-01

    Full Text Available The national blood transfusion policies have been changed significantly in recent years in Turkey. The purpose of this study was to determine the prevalence of HBV, HCV, and HIV in blood donors at the Red Crescent Center in Istanbul and to evaluate the effect of changes in the national blood transfusion policies on the prevalence of these infections. The screening results of 72695 blood donations at the Red Crescent Center in Istanbul between January and December 2007 were evaluated retrospectively. HBsAg, anti-HCV, and anti-HIV-1/2 were screened by microparticle enzyme immunoassay (MEIA method. Samples found to be positive for anti-HIV 1/2 and anti-HCV were confirmed by Inno-Lia HCV Ab III and Inno-Lia HIV I/II Score, respectively. The seropositivity rates for HBsAg, anti-HCV, and anti-HIV-1/2 were determined as 1.76%, 0.07%, and 0.008%, respectively. Compared to the previously published data from Red Crescent Centers in Turkey, it was found that HBV and HCV seroprevalances decreased and HIV seroprevalance increased in recent years. In conclusion, we believe that the drop in HBV and HCV prevalence rates are likely multifactorial and may have resulted from more diligent donor questioning upon screening, a higher level of public awareness on viral hepatitis as well as the expansion of HBV vaccination coverage in Turkey. Another factor to contribute to the decreased prevalence of HCV stems from the use of more sensitive confirmation testing on all reactive results, thereby eliminating a fair amount of false positive cases. Despite similar transmission routes, the increase in HIV prevalence in contrast to HBV and HCV may be linked to the increase in AIDS cases in Turkey in recent years.

  6. Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk

    Science.gov (United States)

    Ye, Fei; Fan, Qing-Min; Yu, Guo-Feng; Yu, Dan-Dan; Gao, Lu; Sun, Kai; Han, Zhi-Peng; Li, Rong; Yang, Yang; Zhao, Qiu-Dong; Wu, Meng-Chao; Wang, Hong-Yang; Wei, Li-Xin

    2015-01-01

    Hepatitis B virus (HBV) infection is a risk factor for hepatocarcinogenesis and recurrence. Here, we sought to characterize intratumoral and peritumoral expression of HBsAg and its specific receptors in HBsAg-positive hepatocellular carcinoma (HCC) patients and further examined their correlation with the recurrence-free survival (RFS). HCC tissue and adjacent normal tissue specimens were acquired from HBsAg-positive patients. The presence of HBsAg and receptors, as well as hepatic progenitor cells (HPCs) were detected by tissue microassay and immunohistochemistry. Necroinflammatory activity was evaluated by HE staining. The mean IOD of HBsAg and HBV DNA in the intratumoral tissues was markedly lower than that in the peritumoral tissues (P ASGPR (r = 0.506, P < 0.001) in peritumoral tissues. And the peritumoral HBsAg and receptors presented a positive association with necroinflammatory activity (P < 0.05). Inflammation induced by HBV infection presented a positive association with HPCs activation (P < 0.05). Additionally, due to lack of HBV receptors, HPCs was not preferentially infected with HBV, but activated HPCs had a significant correlation with HBsAg expression in peritumoral tissues, and the peritumoral HPCs activation was associated with RFS of HCC patients, therefore, the overexpression of HBsAg and receptors in peritumor were also with higher recurrence risk (P < 0.05). In conclusion, lack of HBV receptors resulted in scant HBV infection in tumor cells, and overexpression of HBsAg and receptors in peritumor was strongly associated with higher recurrence risk in HCC patients. PMID:26515593

  7. A type-specific nested PCR assay established and applied for investigation of HBV genotype and subgenotype in Chinese patients with chronic HBV infection

    Directory of Open Access Journals (Sweden)

    Nie Jing-Jing

    2012-06-01

    Full Text Available Abstract Background Many studies have suggested that hepatitis B virus (HBV genotypes show not only geographical distribution and race specificity, but also are associated with disease progression and response to interferon treatment. The objective of this study was to develop a nested polymerase chain reaction (nPCR assay for genotypes A-D and subgenotypes B1, B2, C1 and C2 of hepatitis B virus (HBV and to investigate the distribution characteristics of HBV genotypes/subgenotype in China. Methods After redesigning the primers and optimizing the reaction conditions using common Taq polymerase, the sensitivity, specificity and reproducibility of the method were evaluated using plasmids and serum samples. In total, 642 serum samples from patients with chronic HBV infection were applied to investigate the distribution of HBV genotype and subgenotype in China. Results The genotype and subgenotype could be identified when the HBV DNA load of a sample was ≥102.3 IU/mL. For the 639 successfully genotyped samples, the sequencing results of 130 randomly selected samples (20.3%, 130/639 were consistent with those of the nPCR method. The present study showed that HBV genotype B (11.2%, 72/642, C (68.2%, 438/642 and D (7.2%, 46/642 were circulating in China, while genotype C was the dominant strain except for western region where genotype D was the prevalent strain. The main subgenotypes of genotypes B and C were B2 (87.5%, 63/72 and C2 (92.9%, 407/438, respectively. Conclusions The low-cost nPCR method would be a useful tool for clinical and epidemiological investigation in the regions where genotypes A-D are predominant.

  8. The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China.

    Directory of Open Access Journals (Sweden)

    Hui Wang

    Full Text Available This study aimed to investigate the virological status in liver (both tumor and adjacent non-tumor tissue, the clinical features and the contribution of occult HBV infection (OBI to postoperative prognosis in HBeAg-negative(- hepatocellular carcinoma (HCC patients in China. Using quantitative TaqMan fluorescent real-time PCR assays, HBV covalently closed circular DNA (cccDNA and total DNA (tDNA were both quantified in 11 (HBsAg(- and 57 (HBsAg-positive(+ pairs of tumor tissue (TT and adjacent non-tumor tissue (ANTT obtained from HBeAg(- HCC patients who received no antiviral treatment and were negative for anti-HCV before surgical treatment. Of 11 HBsAg(- patients, 36% were with HBsAb(+ HBeAb(+ HBcAb(+. However, only 9% of the HBsAg(- patients were HBsAb(- HBeAb(+ HBcAb(+, which accounted for the majority (93% in the HBsAg(+ group. TT and ANTT HBV tDNAs in 11 HCC patients with HBsAg (- and HBeAg (- were all detectable. HBV cccDNA and tDNA were all lower in the HBsAg(- group than those in the HBsAg(+ group. By Kaplan-Meier analysis, patients with OBI were associated with a lower risk of cirrhosis and better overall survival (OS. The intracellular HBV DNAs, such as HBV cccDNA and tDNA are valuable biological markers for the diagnosis of occult HBV infection in HCC patients. This would assist the clinical implementation of a more personalized therapy for viral re-activation control and improve the survival rate of OBI patients.

  9. Association of an HLA-G 14-bp Insertion/Deletion polymorphism with high HBV replication in chronic hepatitis.

    Science.gov (United States)

    Laaribi, A B; Zidi, I; Hannachi, N; Ben Yahia, H; Chaouch, H; Bortolotti, D; Zidi, N; Letaief, A; Yacoub, S; Boudabous, A; Rizzo, R; Boukadida, J

    2015-10-01

    Identification of an HLA-G 14-bp Insertion/Deletion (Ins/Del) polymorphism at the 3' untranslated region of HLA-G revealed its importance in HLA-G mRNA stability and HLA-G protein level variation. We evaluated the association between the HLA-G 14-bp Ins/Del polymorphism in patients with chronic Hepatitis B virus (HBV) infection in a case-control study. Genomic DNA was extracted from 263 patients with chronic HBV hepatitis and 246 control subjects and was examined for the HLA-G 14-bp Ins/Del polymorphism by PCR. The polymorphic variants were genotyped in chronic HBV seropositive cases stratified according to HBV DNA levels, fibrosis stages and in a control population. There was no statistical significant association between the 14-bp Ins/Del polymorphism and increased susceptibility to HBV infection neither for alleles (P = 0.09) nor for genotypes (P = 0.18). The stratification of HBV patients based on HBV DNA levels revealed an association between the 14-bp Ins/Del polymorphism and an enhanced HBV activity with high HBV DNA levels. In particular, the Ins allele was significantly associated with high HBV DNA levels (P = 0.0024, OR = 1.71, 95% CI 1.2-2.4). The genotype Ins/Ins was associated with a 2.5-fold (95% CI, 1.29-4.88) increased risk of susceptibility to high HBV replication compared with the Del/Del and Ins/Del genotypes. This susceptibility is linked to the presence of two Ins alleles. No association was observed between the 14-bp Ins/Del polymorphism and fibrosis stage of HBV infection. We observed an association between the 14-bp Ins/Del polymorphism and high HBV replication characterized by high HBV DNA levels in chronic HBV patients. These results suggest a potential prognostic value for disease outcome evaluation.

  10. Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area

    Institute of Scientific and Technical Information of China (English)

    Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang

    2003-01-01

    AIM: To investigate the clinical and virological course of coinfection by hepatitis B virus (HBV) and hepatitis C virus (HCV) in China.METHODS: We enrolled 40 patients with chronic HBV and HCV coinfection (Group BC), 16 patients with chronic HBV infection (Group B) and 31 patients with chronic HCV infection (Group C). They infected HBV and/or HCV during 1982 to 1989.Sera of all the 87 patients were collected in 1994 and 2002respectively. We detected biochemical and virologic markers and serum HBV DNA and HCV RNA levels of all the patients. Btype ultrasound detection was performed in some patients.RESULTS: In Group BC, 67.5% of the patients cleared HBsAg,and 92.5% of the patients cleared HBeAg. The clearance rate of HBV DNA was 87.5%. There was no significant difference of HBV clearance between Group BC and Group B. In Group BC, 85.7% of males and 47.4% of females cleared HBV, and males were easier to clear HBV (x2=6.686, P=0.010). Such a tendency was also found in Group B. The clearance rate of HCV RNA in Group BC was 87.5%, significantly higher than that in Group C (x2=22.963, P<0.001). Less than 40% of the patients in all groups had elevated liver enzyme values. The highest value of alanine aminotransferase (ALT) was 218 u/L (normal range for ALT is 0-40 u/L). In most patients the ultrasonogram presentations changed mildly.CONCLUSION: The clinical manifestations of patients with HBV/HCV coinfection are mild and occult. High clearance rate of HBV and easy to clear HBV in male patients are the characteristics of HBV infection in adults in China. HBV can inhibit HCV replication, but no evidence has been found in our data that HCV suppresses HBV replication.

  11. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma.

    Science.gov (United States)

    She, Sha; Xiang, Yi; Yang, Min; Ding, Xiangchun; Liu, Xiaoyan; Ma, Lina; Liu, Qing; Liu, Bin; Lu, Zhenhui; Li, Shiying; Liu, Yi; Ran, Xiaoping; Xu, Xiaoming; Hu, Huaidong; Hu, Peng; Zhang, Dazhi; Ren, Hong; Yang, Yixuan

    2015-08-01

    Hepatocellular carcinoma (HCC) is one of the most aggressive cancers worldwide and is associated with the high rates of morbidity and mortality. α-fetoprotein (AFP) is common used in diagnosis of HCC; however, a growing body of research is questioning the diagnostic power of AFP. There is, therefore, an urgent need to develop additional novel non-invasive techniques for the early diagnosis of HCC, particularly for patients with AFP-negative [AFP(-)] HCC. Accordingly, in the present study, we employed iTRAQ-based mass spectro-metry to analyze the plasma proteins of subjects with AFP(-) HBV-related HCC, AFP(+) HBV-related HCC and non-malignant cirrhosis. We identified 14 aberrantly expressed proteins specific to the HCC patients, including 10 upregulated and 4 downregulated proteins. We verified C-reactive protein (CRP) overexpression by ELISA and immunohistochemical staining of clinical samples. Per ROC curve analyses, CRP was positive in 73.3% of patients with HBV-related HCC, and CRP overexpression had significant diagnostic power for AFP(-) HBV-related HCC. Furthermore, we found that silencing CRP caused a >2-fold decease in HBV replication. Additionally, we determined that this reduction in HBV replication involved the interferon-signaling pathway. However, silencing CRP also promoted HCC invasion and migration in vitro. In conclusion, we demonstrated that CRP can serve as a diagnostic biomarker for AFP(-) HBV-related HCC.

  12. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.

    Science.gov (United States)

    Guarino, Maria; Picardi, Marco; Vitello, Anna; Pugliese, Novella; Rea, Matilde; Cossiga, Valentina; Pane, Fabrizio; Caporaso, Nicola; Morisco, Filomena

    2017-01-01

    HBV and HCV reactivation has been widely reported in patients undergoing immunosuppressive therapy for oncohaematological diseases. We aimed to evaluate the HBV and HCV reactivation events in patients with non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) underwent cytotoxic chemotherapy containing or not rituximab. This is a retrospective observational study, including all patients with NHL and HL attending an Italian tertiary referral hospital, the University of Naples "Federico II". A total of 322 patients were enrolled. We evaluated serum HBV and HCV markers. A total of 47 (38%) patients with occult HBV infection were enrolled. Seven/47 were treated with therapeutic cytotoxic schedule containing rituximab. Of them, 6/7 received prophylaxis with lamivudine. HBV reactivation was observed in two patients treated with rituximab. A reactivation was observed in the only patient (HBcAb+/HBsAb+) not receiving lamivudine prophylaxis, and the other one was observed in 1 patient with isolated HBcAb positivity during lamivudine prophylaxis. Moreover, 8 patients with HCV-Ab positivity were enrolled. No viral reactivation was observed in these patients. In conclusion, patients with occult HBV infection receiving chemotherapy containing rituximab for lymphoma without antiviral prophylaxis are at risk of viral reactivation. On the contrary, there is no risk of reactivation in patients undergoing rituximab-free schedule. Our findings suggest that there is also very low risk of HCV reactivation. This preliminary report underlines the concept that HBV reactivationis strongly related to the type of immunosuppressive therapy administered and that antiviral prophylaxis needs to be tailored.

  13. Non-invasive optical detection of HBV based on serum surface-enhanced Raman spectroscopy

    Science.gov (United States)

    Zheng, Zuci; Wang, Qiwen; Weng, Cuncheng; Lin, Xueliang; Lin, Yao; Feng, Shangyuan

    2016-10-01

    An optical method of surface-enhanced Raman spectroscopy (SERS) was developed for non-invasive detection of hepatitis B surface virus (HBV). Hepatitis B virus surface antigen (HBsAg) is an established serological marker that is routinely used for the diagnosis of acute or chronic hepatitis B virus(HBV) infection. Utilizing SERS to analyze blood serum for detecting HBV has not been reported in previous literature. SERS measurements were performed on two groups of serum samples: one group for 50 HBV patients and the other group for 50 healthy volunteers. Blood serum samples are collected from healthy control subjects and patients diagnosed with HBV. Furthermore, principal components analysis (PCA) combined with linear discriminant analysis (LDA) were employed to differentiate HBV patients from healthy volunteer and achieved sensitivity of 80.0% and specificity of 74.0%. This exploratory work demonstrates that SERS serum analysis combined with PCA-LDA has tremendous potential for the non-invasive detection of HBV.

  14. [Evaluation of high-sensitivity HBsAg quantitative assay for HBV genotype].

    Science.gov (United States)

    Takagi, Kazumi; Tanaka, Yasuhito; Hiramatu, Kumiko; Kani, Satomi; Tatematsu, Kanako; Naganuma, Hatsue; Ueno, Tetsuo; Gotou, Takaaki; Wakimoto, Yukio; Mizokami, Masashi

    2009-07-01

    The clinical implication of the hepatitis B surface antigen (HBsAg) concentrations has been reported in HBV-infected patients during anti-viral treatment. HBV genotypes A and D are ubiquitous and scattered worldwide, especially northern America as well as Europe, whereas genotypes B and C are common in Asia. The aim of this study was to evaluate a new version of the Sysmex HBsAg quantitative kit based on Chemiluminescence Enzyme Immunoassay. Sera collected from 172 patients infected with any of the four major genotypes A to D (HBV/A, n = 18; B, n = 25; C, n = 84; D, n = 45), including the genotype D cases with weak reaction in the previous version of the kit. The new version of the kit having additional monoclonal antibody, showed improved sensitivity compared to the previous version as well as robust correlation with another quantitative HBsAg assay: the Abbot Architect. Observed during lamivudine therapy, increase in HBsAg and HBV DNA concentrations preceded the aminotransferase (ALT) elevation associated with drug-resistant HBV variant emergence (breakthrough hepatitis). In conclusion, reliability of the Sysmex HBsAg quantitative assay was confirmed for the four HBV genotypes common worldwide. Monitoring of serum HBsAg concentrations in addition to HBV DNA quantification, is helpful in evaluation of the response or resistance to anti-viral therapy.

  15. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis:A comparative study

    Institute of Scientific and Technical Information of China (English)

    Ioan; Sporea; Roxana; Sirli; Alexandra; Deleanu; Adriana; Tudora; Alina; Popescu; Manuela; Curescu; Simona; Bota

    2010-01-01

    AIM:To assess the values of liver stiffness (LS) in pa-tients with hepatitis B virus (HBV) chronic hepatitis and to compare them with those in patients with hepatitis C virus (HCV) chronic hepatitis. METHODS: The study included 140 patients with HBV chronic hepatitis, and 317 patients with HCV chronic hepatitis, in which LS was measured (FibroScan-Echo-sens) and liver biopsy was performed in the same session (assessed according to the Metavir score). RESULTS:According to the Metavir score of the 140 HBV p...

  16. Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    AIM:To establish the more feasible and sensitive assessment approach to the detection of adefovir (ADV) resistance-associated hepatitis B virus (HBV) quasispecies.METHODS: Based on the characteristics of rtA181V/T and rtN236T mutations, a new approach based on real-time fluorescent quantitative polymerase chain reaction (RT-PCR) was established for the detection of ADV-resistant HBV quasispecies, total HBV DNA, rtA181 and rtN236 mutations in blood samples from 32 chronic hepatitis B (CHB) patients with unsa...

  17. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis.

    Science.gov (United States)

    Landrum, Michael L; Hullsiek, Katherine Huppler; Chun, Helen M; Crum-Cianflone, Nancy F; Ganesan, Anuradha; Weintrob, Amy C; Barthel, R Vincent; O'Connell, Robert J; Agan, Brian K

    2011-01-01

    To assess associations between the timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and vaccine effectiveness, US Military HIV Natural History Study cohort participants without HBV infection at the time of HIV diagnosis were grouped by vaccination status, retrospectively followed from HIV diagnosis for incident HBV infection, and compared using Cox proportional hazards models. A positive vaccine response was defined as hepatitis B surface antibody level ≥ 10 IU/L. Of 1,877 participants enrolled between 1989 and 2008, 441 (23%) were vaccinated prior to HIV diagnosis. Eighty percent of those who received vaccine doses only before HIV diagnosis had a positive vaccine response, compared with 66% of those who received doses both before and after HIV and 41% of those who received doses only after HIV (P HIV only). Compared with the unvaccinated, persons vaccinated only before HIV had reduced risk of HBV infection after HIV diagnosis (hazard ratio = 0.38, 95% confidence interval: 0.20, 0.75). No reduction in HBV infection risk was observed for other vaccination groups. These data suggest that completion of the vaccine series prior to HIV infection may be the optimal strategy for preventing this significant comorbid infection in HIV-infected persons.

  18. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment

    Directory of Open Access Journals (Sweden)

    Zhang Dake

    2012-12-01

    Full Text Available Abstract Background Hepatitis B virus (HBV, because of its error-prone viral polymerase, has a high mutation rate leading to widespread substitutions, deletions, and insertions in the HBV genome. Deletions may significantly change viral biological features complicating the progression of liver diseases. However, the clinical conditions correlating to the accumulation of deleted mutants remain unclear. In this study, we explored HBV deletion patterns and their association with disease status and antiviral treatment by performing whole genome sequencing on samples from 51 hepatitis B patients and by monitoring changes in deletion variants during treatment. Clone sequencing was used to analyze preS regions in another cohort of 52 patients. Results Among the core, preS, and basic core promoter (BCP deletion hotspots, we identified preS to have the highest frequency and the most complex deletion pattern using whole genome sequencing. Further clone sequencing analysis on preS identified 70 deletions which were classified into 4 types, the most common being preS2. Also, in contrast to the core and BCP regions, most preS deletions were in-frame. Most deletions interrupted viral surface epitopes, and are possibly involved in evading immuno-surveillance. Among various clinical factors examined, logistic regression showed that antiviral medication affected the accumulation of deletion mutants (OR = 6.81, 95% CI = 1.296 ~ 35.817, P = 0.023. In chronic carriers of the virus, and individuals with chronic hepatitis, the deletion rate was significantly higher in the antiviral treatment group (Fisher exact test, P = 0.007. Particularly, preS2 deletions were associated with the usage of nucleos(tide analog therapy (Fisher exact test, P = 0.023. Dynamic increases in preS1 or preS2 deletions were also observed in quasispecies from samples taken from patients before and after three months of ADV therapy. In vitro experiments demonstrated that

  19. Establishment of a new Scorpion real-time fluorescence PCR method to detect the mutation of HBV%建立一种HBV突变检测的蝎子实时荧光PCR新方法

    Institute of Scientific and Technical Information of China (English)

    张余兵

    2014-01-01

    目的:为 HBV 突变检测建立一种有效、快速、简捷的蝎子实时荧光 PCR 新方法。方法同时用蝎子实时荧光 PCR 新方法和 Sanger 测序法对比:对157例 HBV 患者的血清的 DNA 进行 HBV 基因rtN236T 突变检测,统计其符合率;通过对混有不同比例的 HBV 基因 rtN236T 突变核酸的样本进行对照检测来比较两者的灵敏度。结果在157例 HBV 患者的血清样本中,蝎子实时荧光PCR 新方法检测到 rtN236T 突变的有69例,而 Sanger 测序法检测的有68例,其符合率为98.6%;蝎子实时荧光PCR 新方法能检测出混有5%突变的样本,其灵敏度达5%,比 Sanger 测序法高。结论蝎子实时荧光 PCR 新方法能有效检测到 HBV 突变,且比 Sanger 测序法更为简单、快速、灵敏度高,适合临床应用。%Objective To establish an effective, rapid and simple Scorpion real-time PCR method to detect the mutation of HBV. Methods The rtN236T mutation of HBV was detected by Scorpion real-time PCR and Sanger sequencing method, respectively. 157 patients were tested and coincidence rate was calculated. The samples which mixed with different proportions of HBV mutant DNA were tested to compare the sensitivity of Scorpion real-time PCR method and Sanger sequencing method. Results In the DNA of 157 HBV patients, 69 cases with the rtN236 mutation of HBV were detected by Scorpion real-time PCR method while 68 cases were detected by Sanger sequencing method. The coincidence rate of the two methods was 98.6%. The Scorpion real-time PCR method can detect the samples which mixed with 5%HBV mutant DNA , and its sensitivity was 5%, which was higher than that of Sanger sequencing method. Conclusion The mutation of HBV can be detected by the Scorpion real-time PCR. It is more simple, convenient, high sensitivity than Sanger sequencing method. Scorpion real-time PCR method is suitable for clinical applications.

  20. Detection of HBV - DNA content in serum and breast milk of parturient women carrying HBV and its clinical significance%HBV携带产妇血清及乳汁中HBV- DNA含量检测及其临床意义

    Institute of Scientific and Technical Information of China (English)

    黄珍贞

    2012-01-01

    目的:探讨HBV携带产妇的血清及乳汁中HBV -DNA含量,以期指导母乳喂养.方法:选取HBV携带产妇100例,采用荧光定量PCR技术检测其血清、乳汁中HBV -DNA含量.结果:HBsAg、HBeAg双阳性组和HBsAg单阳性组中血清HBV-DNA含量、阳性率均高于乳汁,差异有统计学意义(P<0.05),且乳汁HBV-DNA阳性率随着母血清HBV-DNA含量的增加而增加;100例产妇中乳汁HBV-DNA检测阴性及血清病毒含量<104 copy/ml的母乳喂养儿未见婴儿发生乙肝病毒感染.结论:HBV携带产妇乳汁具有一定的传染性,但乳汁的传染性低于血液,血清HBV-DNA阳性产妇在哺乳时应进行HBV -DNA检测,以保证婴儿的安全哺乳环境.%Objective: To explore the contents of HBV - DNA in serum and breast milk of parturient women carrying HBV, in order to direct breast feeding. Methods: 100 parturient women carrying HBV were selected, fluorescence quantitative PCR technique was used to detect the contents of HBV - DNA in serum and breast milk. Results; In positive HBsAg + positive HBeAg group and positive HBsAg group, the contents and positive rates of HBV - DNA in serum were significantly higher than those in breast milk (P < 0.05 ) . The positive rate of HBV - DNA in breast milk increased with the increase of HBV - DNA content in maternal serum; 100 infants who were bom by the parturient women with negative HBV - DNA in breast milk and serum viral content < 104 copy/ml were not found with HBV infection. Conclusion; The breast milk of parturient women carrying HBV have infectivity, but the infectivity of breast milk is lower than that of serum, the parturient women with positive HBV - DNA in serum should receive HBV - DNA detection when they suckle their infants to ensure a safe lactation environment of infants.

  1. Analysis of Real-time Fluorescence Quantitative PCR Detection of HBV DNA Indoor Quality Control%实时荧光定量PCR检测HBV DNA室内质控分析

    Institute of Scientific and Technical Information of China (English)

    陆小玲; 周鸣桢

    2014-01-01

    目的探讨实时荧光定量PCR在HBV DNA定量检测过程中的室内质控问题。方法用实时荧光定量PCR法检测2013年1~7月自制的乙肝阳性室内质控血清,与临床标本同步检测,计算每次阳性质控结果的常用对数、标准曲线的斜率、截距和相关系数(r)及相关结果的均值(x)、标准差(s)和变异系数(cv),利用EXCEL折线散点图画出质控图进行质控。结果本室2013年1~7月测定自制的阳性室内质控结果测定值均在控,标准差和变异系数均在允许范围内,符合要求。结论本实验室采用实时荧光定量PCR检测HBV-DNA定量检测过程中,选用的质控方法和自制的质控品稳定性良好,能可靠有效地为临床提供准确的检验结果。%Objective To explore the indoor quality controlproblems in HBV DNA quantitative detection of real-time fluorescence quantitative PCR. Indoor quality control serum HBsAg positive self detection.Methods For 1~7 months of 2013 by real-time fluorescence quantitativePCR method and clinical specimens, synchronous detection, curve of standard logarithm, calculated for eachpositive quality control results of the slope, intercept and correlation coefficient (R) value and related results ,standard deviation (s) and the coefficient of variation(CV), scat er picture quality control chart for quality control by using the EXCEL line. Results The 1~7 months of 2013 were positive results of internal quality control of homemade measured values are in control, the standard deviation and variation coefficient were within the al owable range, meet the requirements. Conclusion This laboratory detection of HBV-DNA quantitative real-time fluorescence quantitative PCR detection process,quality control methods and quality control of homemadegood stability, can provide valid and reliable accurate test results for clinical.

  2. 乙肝携带产妇血清、乳汁及新生儿血清中HBV DNA载量的关系探讨%The correlation between HBV DNA in serum, breast milk of HBV-carring parturient women and the one in serum of newborn

    Institute of Scientific and Technical Information of China (English)

    夏伟; 陈芳

    2012-01-01

    目的 探讨乙型肝炎病毒携带产妇血清及乳汁中HBV DNA载量与新生儿血清中HBV DNA载量的关系,以指导临床采取正确的孕期处理和母乳喂养措施.方法 选择乙型肝炎病毒携带产妇293例,采用荧光定量PCR技术测定产妇血清、母乳和新生儿血清HBV DNA载量,并将产妇血清HBV DNA载量分为血清阴性组(HBV DNA<103 copies/mL)、血清低拷贝组(103 copies/mL≤HBV DNA≤106 copies/mL)和血清高拷贝组(HBV DNA>106copies/mL),并按标本类型和HBV DNA水平进行比较.结果 293例HBV感染产妇中,HBV DNA阴性组、低拷贝组和高拷贝组分别占50.2% 、21.8%和28.0%.血清HBV DNA阴性组产妇乳汁中HBV DNA检出率为0.而血清低拷贝组和高拷贝组产妇乳汁HBV DNA的阳性检出率分别为12.5%和76.8%,前者明显低于后者(P<0.01).而血清HBVDNA阴性组、低拷贝组和高拷贝组之间新生儿血清HBV DNA阳性率差异均无统计学意义(P>0.05).结论 产妇血清中HBV DNA载量与乳汁中HBV DNA阳性率呈正相关.产妇血清HBV DNA载量与胎儿宫内感染无明显相关性.%Objective To discuss the correlation between HBV DNA in serum, breast milk of HBV-earring parturient women and the one in serum of newborn for supplying a correct clinic guidance of pregnancy management and breast feeding measures. Methods HBV DNA in serum, breast milk of HBV-earring parturient women (n=293) and serum of newborn were detected by fluorescence quantitative PCR. 293 cases of parturient women were divided into three groups according to HBV DNA load: serum negative group (HBV DNA106copies/mL). Then a comparision between them was carried out. Results In 293 cases of HBV-carring parturient women, HBV DNA negative group, low copies group and high copies group account for 50.2%, 21.8% and 28.0% respectively. The positive rate for detection of HBV DNA in breast milk in serum negative group was 0. But in serum low copies group and high copies group

  3. 慢性乙型肝炎病毒感染产妇乳汁传染性的探讨%The prediction of maternal HBV transmission by breast milk of postpartum women with chronic HBV infection

    Institute of Scientific and Technical Information of China (English)

    门娅玲; 刘聪; 赵连三; 曾义岚; 李嘉; 付稼虹; 邹光友; 曾雪梅; 李睿; 王辉; 刘丽

    2008-01-01

    目的 研究慢性HBV感染产妇乳汁的传染性及可能的预测指标.方法 慢性HBV感染产妇64例,采用荧光定量PCR技术检测其外周血血清和乳汁中的HBV DNA水平,以其≥1.0×103拷贝/ml判为阳性,并进行相关性分析.结果 64例慢性HBV感染产妇血清和乳汁中HBV DNA的阳性检出率分别为78.1%和62.5%.其中,乳汁HBV DNA水平在1.05×103~3.87×1044拷贝/ml.分析结果显示,当血清HBV DNA水平在105~107拷贝/ml时,乳汁HBV DNA的阳性率高达94.9%;而当血清HBV DNA水平在103~104拷贝/ml时,乳汁HBV DNA的阳性率则仅为18.2%.结论 慢性HBV感染产妇的乳汁HBV DNA阳性检出率随着血清中HBV DNA拷贝数的增加而升高;血清HBV DNA水平≥105拷贝/ml的产妇,应避免母乳喂养.%Objective To investigate the prediction of maternal HBV transmission by breast milk of postpartum women with chronic HBV infection.Methods HBV DNA levels in serum and breast milk were detected by fluorescent quantitative polymerase chain reaction in 64 postpartum women with chronic HBV infection.HBV DNA≥1.0×103copies/ml was defined as positive,and correlation analysis was conducted.Results HBV DNA positive rate was 78.1%and 62.5%in serum and breast milk respectively,with a HBV DNA range of 1.05×103~3.87 ×104copies/ml in breast milk.When HBV DNA in serum was 1.0×105~1.0×107copies/ml,the HBV DNA positive rate in breast milk reached to 94.9%;however,when HBV DNA in serum was 1.0×103~1.0×104copies/ml,the positive rate in breast milk was only 18.2%.Conclusion The HBV DNA positive rate of breast milk in postpartum women with chronic HBV infection is correlated with the HBV DNA levels in serum;and breast-feeding should be avoided for postpartum women with HBV DNA≥1.0×105copies/ml in the serum.So serum HBV DNA detection is necessary in antenatal care for women with chronic HBV infection.

  4. HBV pathogenesis in animal models: recent advances on the role of platelets.

    Science.gov (United States)

    Iannacone, Matteo; Sitia, Giovanni; Ruggeri, Zaverio M; Guidotti, Luca G

    2007-04-01

    Hepatitis B virus (HBV) causes acute and chronic necroinflammatory liver diseases and hepatocellular carcinoma (HCC). HBV replicates noncytopathically in the hepatocyte, and most of the liver injury associated with this infection reflects the immune response. While the innate immune response may not contribute significantly to the pathogenesis of liver disease or viral clearance, the adaptive immune response, particularly the cytotoxic T lymphocyte (CTL) response, contributes to both. Recent observations also reveal that antigen-nonspecific inflammatory cells enhance CTL-induced liver pathology and, more surprisingly, that platelets facilitate the intrahepatic accumulation of CTLs, suggesting that the host response to HBV infection is a highly complex but coordinated process. The notion that platelets contribute to liver disease and viral clearance by promoting the recruitment of virus-specific CTLs into the liver is a new concept in viral pathogenesis, which may prove useful to implement treatments of chronic HBV infection in man.

  5. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDT protein chip technology

    Institute of Scientific and Technical Information of China (English)

    Xiao-Dong Zhu; Wei-Hua Zhang; Cheng-Lin Li; Yang Xu; Wei-Jiang Liang; Po Tien

    2004-01-01

    AIM: To find new serum biomarkers for liver cirrhosis (LC)in chronic carriers of hepatitis B virus (HBV).METHODS: Surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry was used to discover biomarkers for differentiating HBV induced LC from non-cirrhotic cohorts. A training population of 25 patients with HBV-induced LC, 20 patients with HCC, and 25 closely age-matched healthy men, was studied.RESULTS: Two biomarkers with Mr 7 772 and 3 933 were detected in sera of non-cirrhotic cohorts, but not in patients with HBV-induced LC. A sensitivity of 80% for all LC patients,a specificity of 81.8% for all non-cirrhotic cohorts and a positive predictive value of 75% for the study population were obtained.CONCLUSION: These two serum biomarkers for HBVinduced LC might be used for diagnosis and assessment of disease progression.

  6. 慢性乙肝HBV DNA含量与临床的关系

    Institute of Scientific and Technical Information of China (English)

    任贵英; 蒋音; 伍利军

    2005-01-01

    目的探讨慢性乙型肝炎病人HBV DNA含量与临床的关系。方法检测360例未经抗病毒治疗的慢性乙型肝炎病人HBV DNA含量,肝功能和肝纤维化指标。结果HBV DNA含量与肝功能(ALT、AST、TBiL)水平无明显关系,也与肝脏的纤维化指标(LN、HA、PCⅢ、IV-C)无相关性。结论不能完全以HBV DNA含量来判断病人肝功能的好坏和肝纤维化程度。

  7. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients

    Institute of Scientific and Technical Information of China (English)

    Timothée Noterdaeme; Luc Longrée; Christian Bataille; Arnaud Deroover; Anne Lamproye; Jean Delwaide; Yves Beguin; Pierre Honoré; Olivier Detry

    2011-01-01

    Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good.

  8. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis

    Institute of Scientific and Technical Information of China (English)

    Meng-Lan Wang; Hong Tang

    2016-01-01

    BACKGROUND: The long-term use of nucleos(t)ide analogues causes drug resistance and mutations in the HBV reverse tran-scriptase (RT) region of the polymerase gene. The RT region overlaps the HBV surface gene (S gene) and therefore, the mutations in the RT region simultaneously modify S gene se-quence. Certain mutations in the RT region bring about trun-cated S proteins because the corresponding changed S gene en-codes a stop codon which results in the loss of a large portion of the C-terminal hydrophobic region of HBV surface protein. The rtA181T/sW172*, rtM204I/sW196* and rtV191I/sW182*are the most frequently reported drug-resistant mutations with C-terminal truncation, these mutations have oncogenic potential. DATA SOURCES: PubMed and Web of Science were searched using terms: “hepatitis B virus”, “HBV drug resistance muta-tion”, “HBV surface protein”, “HBV truncation”, “hepatocel-lular carcinoma”, “rtA181T/sW172*”, “rtM204I/sW196*”,“rtV191I/sW182*”, and relevant articles published in English in the past decades were reviewed. RESULTS: The rtA181T/sW172* and rtV191I/sW182* mu-tants occurred more frequently than the rtM204I/sW196* mu-tant both in chronic hepatitis B patients and the HBV-related hepatocellular carcinoma tissues. Although these mutations occur naturally, nucleos(t)ide analogues therapy is the main driving force. These mutations may exist alone or coexist with other HBV mutations. All these three mutants impair the vi-rion secretion and result in HBV surface protein retention and serum HBV DNA level reduction. These mutations possess potential carcinogenic properties. The three mutations are re-sistant to more than one nucleos(t)ide analogue and therefore, it is dififcult to treat the patients with the truncated mutations. CONCLUSIONS: Nucleos(t)ide analogues induce drug resis-tance and HBV S gene truncated mutations. These mutations have potential carcinogenesis.

  9. HBx truncation mutants differentially modulate SREBP-1a and -1c transcription and HBV replication.

    Science.gov (United States)

    Wu, Qi; Liu, Qiang

    2015-12-01

    As master transcription factors for lipogenesis, sterol regulatory element-binding protein-1 (SREBP-1) has two isoforms, SREBP-1a and SREBP-1c. Hepatitis B virus X (HBx) can up-regulate the transcription of both SREBP-1a and SREBP-1c. HBx is a small protein consisting of 154 amino acids. Truncated forms of HBx, often found in the tissues after HBV infection, may have a role in the pathogenesis associated with HBV infection. In this study, we examined the effects of two HBx truncation mutants, HBx aa. 1-127 and HBx aa. 43-154, on the transcription of SREBP-1a and SREBP-1c. HBx 1-127 can up-regulate SREBP-1c, but not SREBP-1a transcription, whereas HBx 43-154 can activate SREBP-1a, but not SREBP-1c transcription. We further determined the activities of two HBV enhancers after the expression of the truncated HBx proteins. HBx 1-127 and HBx 43-154 can only up-regulate HBV enhancer I or HBV enhancer II, respectively. Knocking down SREBP-1 abrogates enhancer activation by HBx proteins, suggesting a role of SREBP-1. In addition, using HBV enhancer mutants, we found that the binding sequence for AP-1 on enhancer I is essential for its activation by HBx 1-127, whereas C/EBP and Sp1 sites are required for enhancer II activation by HBx 43-154. Finally, we showed that both HBx 1-127 and HBx 43-154 can increase HBV transcription and HBV replication dependent upon SREBP-1 because knocking down SREBP-1 abrogates the up-regulation. Furthermore, upon ectopic expression of either SREBP-1a or SREBP-1c, we showed that SREBP-1a is involved in HBV transcription and replication up-regulation by HBx 43-154, whereas SREBP-1c is involved in HBV transcription and replication up-regulation by HBx 1-127. Our results should help understand the interactions between HBV and the SREBP-1-mediated lipogenic pathway.

  10. Detection of soluble TRAIL in HBV infected patients and its clinical implications

    Institute of Scientific and Technical Information of China (English)

    Li-Hui Han; Wen-Sheng Sun; Chun-Hong Ma; Li-Ning Zhang; Su-Xia Liu; Qiu Zhang; Li-Fen Gao; You-Hai Chen

    2002-01-01

    AIM: To detect the expression of soluble TRAIL (TNF-related apoptosis inducing ligand, TRAIL) in the peripheral blood of HBV infected patients and try to elucidate whether the expression level of sTRAIL have any correlativity with the clinical staging, the expression level of HBV markers and the degree of liver damage.METHODS: 52 cases of HBV infected patients were investigated, induding 8 HBV carriers, 30 chronic hepatitis B, 11 drrhotics and 3 HBV infection related hepatocellular carcinoma. Expression of soluble TRAIL and markers of the hepatitis B were mearsured by enzyme-linked immunosorbent assay.RESULTS: The expression level of sTRAIL in the peripheral blood of the HBV infected patients was significantly higher than that of healthy controls (1378.35±540.23 pg/ml vs 613.75±175.80 pg/ml, P<0.001). In the group of chronic hepatitis, the expression level of sTRAIL was coincident with the status of the disease and was significantly correlated with the level of ALT. In the group of cirrhosis and liver cancer, its expression level was significantly higher than that of the healthy persons and HBV carriers, but lower than that of the hepatitis B patients; meanwhile, the expression of siRAIL did not have any correlativity with the functional indexes of the liver. CONCLUSION: The soluble TRAIL in the HBV infected people may participate in the liver damage. Our results indicated that the expression level of soluble TRAIL may reflect the ravage of liver caused by host immune reaction to a certain degree.

  11. Urban-Rural Comparison of HBV and HCV Infection Prevalence in Eastern China

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    The present study was initiated to make an urban-rural comparison of the prevalence of cases positive to hepatitis B and C virus (HBV and HCV, respectively) infection markers in densely populated eastern half of China. For this purpose, 10 survey sites were selected, i.e., six sites in urban areas (the city group; Beijing, Shanghai and four provincial capitals) and four sites in rural areas (the village group ; one village each in Jilin and Shandong Provinces, and two villages in Shaanxi Province). About 50 adult women per site volunteered to participate, from whom 494 valid blood samples were collected. Positivities to HBsAg (HBsAg+), anti-HBs (anti-HBs+) and anti-HBc (anti-HBc+) were examined by RIA methods, and that to anti-HCV (anti-HCV+) by either EIA or RIA. Those positive to any one of the three HBV infection markers were taken as HBV infection-positive (HBV+). The prevalence of HBsAg+, HBV+ and anti-HBc+ was 8%, 70% and 2.7% in the city group, and 8%, 65% and 2.0% in the village group, and no significant difference was found between the two groups. The overall prevalence was 8% for HBsAg+, 68% for HBV+, and 2.4% for anti-HCV+. The results were discussed in reference to some 20 papers each on HBV+ and anti-HCV+ prevalence in China published since 1991. The reviewing of these papers confirmed that the prevalence of HBV was high (i.e., in excess of 50%), whereas the prevalence of anti-HCV was low (well below 5%), and that no substantial difference was found between the rural and urban populations.

  12. HBV-DNA levels in serum and saliva of hepatitis B patients%乙型肝炎患者血清和唾液中HBV-DNA的水平

    Institute of Scientific and Technical Information of China (English)

    刘纯成; 李桂珍; 徐云芳

    2012-01-01

    [Objective]To explore the HBV-DNA levels in serum and saliva of hepatitis B patients, and provide clinical evidence for HBV spreading by saliva[ Methods] Real-time PCR was adopted for the determination of HBV-DNA levels in serum and saliva of hepatitis B patients. [ Results ] The positive rate of in serum and saliva of 99 cases of hepatitis B patients was 90.9% (90 cases) and 65.7 % (65 cases). [ Conclusion]The difference of HBV-DNA positive rate between serum and saliva of hepatitis B patients is significant(P <0.01) , and HBV-DNA levels in serum and saliva showed a significant positive correlation (r=0.82).%目的 探讨乙型肝炎(乙肝)患者唾液中HBV-DNA水平,为乙型肝炎病毒(HBV)经唾液传播提供临床依据.方法 采用实时荧光定量PCR法检测乙肝患者血清和唾液中HBV-DNA含量.结果 99例乙肝患者血清和唾液中HBV-DNA的阳性率分别为90例(90.9%)、65例(65.7%).结论 乙肝患者唾液中HBV-DNA的阳性率与血清HBV-DNA的阳性率之间差异有统计学意义(P<0.01),乙肝患者唾液中HBV-DNA含量与血清HBV-DNA含量呈显著正相关(r=0.82).

  13. New therapeutic perspectives in HBV: when to stop NAs.

    Science.gov (United States)

    Pérez-Cameo, Cristina; Pons, Mònica; Esteban, Rafael

    2014-02-01

    The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg. Nucleos(t)ide analogues (NAs) are one of the first-line treatments for CHB. NAs produce a potent suppression of viral replication but are associated with a low rate of HBsAg seroclearance and a high risk of virological relapse after discontinuation. Because of these reasons, long-term treatment is needed. They are well-tolerated oral drugs, and it seems they do not produce important side-effects in long-term administration. The duration of NA treatment remains unclear, nevertheless, in some patients NAs can be stopped with a low rate of relapse. HBeAg-positive patients could discontinue NA therapy if they achieved HBeAg seroclearance and maintain undetectable HBV DNA. For HBeAg-negative patients, to stop NA treatment is not recommended. In addition to other factors, serum HBsAg titres during treatment have recently been proposed to guide NA-based therapy duration in selected patients. All patients could be stopped from taking treatment if they achieve HBsAg loss.

  14. Molecular mechanism of hepatitis B virus (HBV) on suppression of raf kinase inhibitor protein (RKIP) expression

    Science.gov (United States)

    Cheng, Xiao-Ke; Yu, Guo-Zheng; Li, Xiao-Dong; Ren, Xue-Qun

    2017-01-01

    Raf kinase inhibitor protein (RKIP) has been shown to be a suppressor of the mitogen-activated protein kinase pathway and is reported to be involved in human malignancy. However, the molecular mechanism of hepatitis B virus (HBV) in regulating RKIP expression is not yet clarified. In this study, we compared RKIP expression in 107 pairs of matched liver cancer and adjacent non-cancerous liver tissues. Among seven HBV-encoded proteins, we found HBV X (HBX) protein could significantly inhibit the expression level of RKIP, indicating that HBV could suppress RKIP expression through regulating HBX. To further elucidate the mechanism, analyses on transcriptional regulation and promoter methylation inhibition were conducted in Huh7 cells. Our results showed that HBX can interact with AP1 protein to inhibit the RKIP transcription. Moreover, we observed that the promoter methylation level of RKIP could be enhanced by HBV. In conclusion, our study revealed that RKIP could act as a molecular marker for HBV-infected liver cancer, but had no tumor-suppressing effect. PMID:27902472

  15. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

    Institute of Scientific and Technical Information of China (English)

    Cheng; Peng; Mengji; Lu; Dongliang; Yang

    2015-01-01

    Hepatitis B virus(HBV) infection remains a major global health problem because current therapies rarely eliminate HBV infections to achieve a complete cure. A different treatment paradigm to effectively clear HBV infection and eradicate latent viral reservoirs is urgently required. In recent years, the development of a new RNA-guided gene-editing tool, the CRISPR/Cas9(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system, has greatly facilitated site-specific mutagenesis and represents a very promising potential therapeutic tool for diseases, including for eradication of invasive pathogens such as HBV. Here, we review recent advances in the use of CRISPR/Cas9, which is designed to target HBV specific DNA sequences to inhibit HBV replication and to induce viral genome mutation, in cell lines or animal models. Advantages, limitations and possible solutions, and proposed directions for future research are discussed to highlight the opportunities and challenges of CRISPR/Cas9 as a new, potentially curative therapy for chronic hepatitis B infection.

  16. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization

    Institute of Scientific and Technical Information of China (English)

    Yui-Jie Bai; Jin-Rong Zhao; Guan-Ting Lv; Wen-Hong Zhang; Yan Wang; Xiao-Jun Yan

    2003-01-01

    AIM: To develop a simple and rapid detection of HBV gene variants and prediction of lamivudine-resistance in patients.METHODS: Initially, plasmids harboring the wild-type or mutant HBV DNA fragments were used in a model system.The technique was then applied to clinical samples for an analysis of YMDD mutations. The sera were extracted from chronic hepatitis patients who had received lamivudine treatment for more than one year. P region gene of HBV was amplified by polymerase chain reaction. The excess primers and dNTPs in PCR products were removed by cleaning-up reagents. Template-directed dye-terminator incorporation reaction was performed and R110 or TAMRA labeled acyclo-terminator was added on the 3' end of TDIprimer specifically. Fluorescence polarization value was measured with Victor 2 multilabel counter and the genotypes of HBV were analyzed.RESULTS: The YMDD genotypes in recombined positive plasmid and 56 serum samples of HBV infected patients were analyzed by using our TDI-FP method and the specificity and sensitivity were confirmed by DNA sequencing. Five of 56 serum samples showed YVDD phenotype (9%), including 1 YMDD and YVDD mixed infection. Four of 56 showed YIDD phenotype (7.1%).CONCLUSION: This is a simple, rapid, low cost and high throughput assay to detect HBV polymerase gene variants and suitable for large-scale screening and prediction of the lamivudine-resistance in clinical samples.

  17. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination.

    Science.gov (United States)

    Xu, Libin; Wei, Yong; Chen, Taoyang; Lu, Jianhua; Zhu, Chang-Lin; Ni, Zhengping; Huang, Fei; Du, Jun; Sun, Zongtang; Qu, Chunfeng

    2010-08-23

    Previous follow-up on our neonatal HB vaccination cohorts with 80,000 individuals in Qidong, China, showed significant protective efficacy of immunization against HBV infection in childhood. However, some vaccinees were found to be HBsAg negative, but anti-HBs positive and anti-HBc positive at age 10-11 years. To study this phenomenon, 2919 vaccinees at age 19-21 years were sampled from the cohort. HBsAg(-), anti-HBs(+) and anti-HBc(+) were found in 124/2919 (4.2%) of the vaccinees. HBV DNA was detectable in 81/106 sample sera by using nested PCR. The PreS-S regions of HBV were sequenced in 41 randomly sampled sera. All the HBV isolates were HBV genotype C. Twenty one isolates (21/41, 51.2%) were identical to an HBV isolated in this area (GU434374). Only 4/41 (9.8%) showed mutations at the "a" epitope and three of them were G145A. The other mutations were found outside of the "a" epitope. Most of the sera contained anti-HBs(+) and anti-HBc(+) status, who received neonatal vaccination in Qidong.

  18. Rapid detection of hepatitis B virus DNA in liver tissue by in situ hybridisation and its combination with immunohistochemistry for simultaneous detection of HBV antigens.

    OpenAIRE

    Lau, J. Y.; Naoumov, N V; Alexander, G J; Williams, R

    1991-01-01

    A rapid technique using a non-radioactive receptor molecule (digoxigenin) for intrahepatic hepatitis B virus (HBV) DNA detection using in situ hybridisation was developed. It can be adapted for use in combination with standard immunohistochemistry for simultaneous detection of both HBV DNA and HBV antigens. The total time required for dual detection of HBV antigens and HBV DNA starting from paraffin wax liver sections was two working days. A good signal to background ratio for the detection o...

  19. [Private companies: an opportunity for hepatitis B virus (HBV) prevention and care in Ivory Coast in the wake of HIV/AIDS?].

    Science.gov (United States)

    Bekelynck, A

    2015-02-01

    In the 1990s, defenders of "aids exceptionnalism" have promised that the inequities caused by HIV/AIDS could provide leverage in the care of other health issues later. Fifteen years later, this argument can be rethought at the light of the current context of hepatitis B virus (HBV) in Ivory Coast. In fact, in this country, the challenges caused by HBVecho those of HIV/AIDS fifteen years ago: high prevalence (8-10%), ignorance of the disease, and high cost of care. To this end, this article compares the role of private companies in the fights against HIV/AIDS in the 2000s and its role in the fight against HBV today. Although some private firms played a critical role in the promotion of universal access to ART, today, they are one of the few places where HBV screening, vaccination and treatment are offered in the country. HIV/AIDS opened the door for private companies to address other diseases through their health care systems. However, many challenges still need to be met: the absence of qualitative ongoing training for health professionals, illness representations and the costs of treatments, which are all related to the lack of international and national collective action. In Ivory Coast, at the early stage of the HIV/AIDS epidemic, national authorities took up the leadership in the fight against AIDS in West Africa, by developing extraverted strategies (Xth ICASA's organization, Unaids initiative hosting). The exceptional international mobilization and the creation of innovative funding mechanisms [International Therapeutic Solidarity Fund (ITSF), Global Fund (GM), and President's Emergency Plan for AIDS Relief (PEPFAR)] have facilitated easy access to ARV. Although 380 million people are infected by chronic HBV in the world, even so, international and national collective actions are fledgling and remained weak. Moreover, private firms have represented leverage for testing, treatment, and the provision of universal access to medication in the context of the HIV

  20. Genotype-dependent activation or repression of HBV enhancer Ⅱ by transcription factor COUP-TF1

    Institute of Scientific and Technical Information of China (English)

    Silke F Fischer; Katja Schmidt; Nicola Fiedler; Dieter Glebe; Christian Schüttler; Jianguang Sun; Wolfram H Gerlich; Reinald Repp; Stephan Schaefer

    2006-01-01

    AIM: To study the expression of HBV enhancer Ⅱ by transcription factor COUP-TF1.METHODS: In order to study the regulation of HBV variants in the vicinity of the NRRE we cloned luciferase constructs containing the HBV enhancer Ⅱ from variants and from HBV genotypes A and D and cotransfected them together with expression vectors for COUP-TF1 into HepG2 cells.RESULTS: Our findings show that enhancer Ⅱ of HBV genotype A is also repressed by COUP-TF1. In contrast,two different enhancer Ⅱ constructs of HBV genotype D were activated by COUP-TF1. The activation was independent of the NRRE because a natural variant with a deletion of nt 1763-1770 was still activated by COUP-TF1.CONCLUSION: Regulation of transcription of the HBV genome seems to differ among HBV genomes derived from different genotypes. These differences in transcriptional control among HBV genotypes may be the molecular basis for differences in the clinical course among HBV genotypes.

  1. ORIGINAL ARTICLE: Blood Donor’s Status of HIV, HBV, HCV and Syphilis in this Region of Marathwada, India

    Directory of Open Access Journals (Sweden)

    Rangrao H. Deshpande

    2012-07-01

    Full Text Available Aims & Objectives: Blood transfusion can cause the transmission of infections to recipients. This is an important mode of infection. The aim of study was to assess the prevalence of such type of infections among blood donors and to compare the seroprevalence of transfusion transmitted diseases in voluntary donors and replacement donors. Retrospective study of five years from Jan. 2007 to Dec. 2011 was done. This study was conducted at Blood bank, MIMSR Medical College Latur, Govt. Medical College, Latur and Bhalchandra Blood bank, Latur. Material & Methods: Total 10, 4925 donors were tested. Donors were screened for seroprevalence of HIV, HBC, HCV and Syphilis. Screening of HIV, HBV & HCV was done by ELISA method & Syphilis was screened by RPR type. Results: The comparison of seroprevalence of HIV, HBV, HCV & Syphilis in voluntary donors and replacement donors showed significant difference only for HIV in the years 2007, 2010, and 2011. Conclusion: The seroprevalence of transfusion transmitted diseases in the study is very low or negligible in voluntary donors as compared to replacement donors. There was a declining trend of seroprevalence for all the disease screened. But in our study the difference is not significant, which indicates that the selection of donors is of low quality. The selection of high quality voluntary donors should be achieved by creation of awareness by education of the prospective donor populations.

  2. HBV X Gene Transfection Upregulates IL-1β and IL-6 Gene Expression and Induces Rat Glomerular Mesangial Cell Proliferation

    Institute of Scientific and Technical Information of China (English)

    Hongzhu LU; Jianhua ZHOU

    2008-01-01

    The X gene of HBV encodes a 17-KD protein, termed HBx, which has been shown to function as a transcriptional trans-activator of a variety of viral and cellular promoter/enhancer elements. The aim of this study was to investigate the effect of HBx on gene expression of interleukin (IL)-1β and IL-6, and proliferation of rat mesangial cells in vitro. The X gene of HBV was amplified by PCR assay, and inserted into the eukaryotic expression vector pCI-neo. The structure of recombinant pCI-neo-X plasmid was proved by restrict endonuclease digestion and sequencing analysis. pCI-neo-X was transfected into cultured rat mesangial cell line in vitro via liposome. HBx expression in transfected mesangial cells was detected by Western blot. The IL-1β and IL-6 mRNA expression in those cells was assayed by semiquantitative RT-PCR. Mesangial cell proliferation was tested by MTT. The results showed that HBx was obviously expressed in cultured mesangial cell line at 36th and 48th h after transfection. The expression of IL-1β and IL-6 mRNA was simultaneously increased. The cell proliferation was also obvious at the same time. It was concluded that HBx gene transfection could induce IL-1β and IL-6 gene expression and mesangial cell proliferation. HBx may play a critical role in mesangial cell proliferation through upregulation of the IL-1β and IL-6 gene expression.

  3. An assay for screening anti-HBV in vitro%一种体外初筛抗乙型肝炎病毒药物实验方法

    Institute of Scientific and Technical Information of China (English)

    吴淑坤; 林雨霖; 姚学军; 刘学峰; 李晖

    2001-01-01

    OBJECTIVE A safe,convenient and semi-quantitative technique wasdeveloped to screen anti-HBV in vitro.METHODS The screening system was consisted of cell culture of 2.2.15. PCR with end-point dilution and MTT assay. RESULTS The sensitivity of the system to test HBV DNA was 0.01pg which was identified by using a standard HBV plasmid DNA. By using the PCR with end-point dilution, the content of HBV DNA tested in supernatant of 4×106 2.2.15 cells was around 1.2×106 copies. To confirm the reliability of the method, the anti-HBV effects of (-)FTC known as an effective anti-HBV compound was detected and the results showed that the EC50 of the compound against HBV DNA in the intro- and extro- cellular were 0.5 μm and 0.045 μm,respectively. And the seletive index(SI) were >800 and >8888.9.CONCLUSIONS The results revealed that the technique for screening anti-HBV compounds was specific and sensitive.%目的:建立一个操作简便,灵敏度高且可半定量的体外初筛抗HBV药物实验方法。方法:实验利用2.2.15细胞、终点稀释PCR和MTT实验等技术。结果:用标准HBV质粒PTHBV-1DNA证实该方法检测HBVDNA灵敏度达0.01pg级,利用终点稀释PCR检测未用药处理的4×1062.2.15细胞上清中HBVDNA水平约有1.2×106拷贝;利用已知有效抗HBV药物(-)FTC验证了该方法可靠性,结果显示(-)FTC抑制2.2.15细胞内及上清HBVDNA的EC50分别为0.5μm和0.045μm,选择抑制指数(SI)分别为>800和>8888.9。结论:能敏感区分药物作用效果,为抗HBV药物初筛研究的一种方法。

  4. A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains.

    Science.gov (United States)

    Abdou Chekaraou, Mariama; Brichler, Ségolène; Mansour, Waël; Le Gal, Frédéric; Garba, Aminata; Dény, Paul; Gordien, Emmanuel

    2010-06-01

    Niger is a west African country that is highly endemic for hepatitis B virus (HBV) infection. The seroprevalence for HBV surface antigen (HBsAg) is about 20%; however, there are no reports on the molecular epidemiology of HBV strains spreading in Niger. In the present study, HBV isolates from the sera of 58 consecutive, asymptomatic, HBsAg-positive blood donors were characterized. Genotype affiliation was determined by amplification, sequencing and phylogenetic analysis of the preS1, polymerase/reverse transcriptase (RT/Pol) and precore (preC)/C regions. The first series of results revealed that different genomic fragments clustered with different genotypes on phylogenetic trees, suggesting recombination events. Twenty-four complete genomic sequences were obtained by amplification and sequencing of seven overlapping regions covering the whole genome, and were studied by extensive phylogenetic analysis. Among them, 20 (83.3%) were classified unequivocally as genotype E (HBV/E). The remaining four (16.7%) clustered on a distinct branch within HBV/D with strong bootstrap and posterior probability values. Complete molecular characterization of these four strains was achieved by the Simplot program, bootscanning analysis and cloning experiments, and enabled us to identify an HBV/D-E recombinant that formed a new HBV/D subgenotype spreading in Niger, tentatively named D8. Moreover, 20 new complete HBV/E nucleotide sequences were determined that exhibited higher genetic variability than is generally described in Africa. One was found to be a recombinant containing HBV/D sequences in the preS2 and RT/Pol regions. Taken together, these data suggest that, in Niger, genetic variability of HBV strains is still evolving, probably reflecting ancient endemic HBV infection.

  5. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV

    Institute of Scientific and Technical Information of China (English)

    Jing Jin; Jian-Ying Yang; Jing Liu; Yu-Ying Kong; Yuan Wang; Guang-Di Li

    2002-01-01

    AIM: Both Hepatitis B virus (HBV) and Hepatitis C virus(HCV) are major causative agents of transfusion-associatedand community-acquired hepatitis worldwide. Developmentof a HCV vaccine as well as more effective HBV vaccines isan urgent task. DNA immunization provides a promisingapproach to elicit protective humoral and cellular immuneresponses against viral infection. The aim of this study is toachieve immune responses against both HCV and HBV by DNAimmunization with fusion constructs comprising various HCVE2 gene fragments fused to HBsAg gane of HBV.METHODS: C57BL/6 mice were immunized with plasmid DNAexpressing five fragments of HCV E2 fused to the gene forHBsAg respectively. After one primary and one boostingimmunizations, antibodies against HCV E2 and HBsAg weretested and subtyped in ELISA. Splenic cytokine expressionof IFN-γ and IL-10 was analyzed using an RT-PCR assay.Post-immune mouse antisera also were tested for theirability to capture HCV viruses in the serum of a hepatitis Cpatient in vitro.RESUTLTS: After immunization, antibodies against bothHBsAg and HCV E2 were detected in mouse sera, withIgG2a being the dominant immunoglobulin sub-class. High-level expression of INF-γ was deuetected in cultured splenic cells.Mouse antisera against three of the five fusion constructs wereable to capture HCV viruses in an in vitro assay.CONCLUSION: The results indicate that these fusionconstructs could efficiently elicit humoral and Th1 dominantcellular immune responses against both HBV S and HCV E2antigens in DNA-immunized mice. They thus could serve ascandidates for a bivalent vaccine against HBV and HCVinfection. In addition, the capacity of mouse antisera againstthree of the five fusion constnucts to capture HCV virusses invitro suggested that neutralizing epitopes may be present inother regions of E2 besides the hypervariable region 1.

  6. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.

    Directory of Open Access Journals (Sweden)

    Edouard Tuaillon

    Full Text Available BACKGROUND: The decline in hepatitis B virus surface antigen (HBsAg may be an early predictor of the viral efficacy of Hepatitis B virus (HBV therapy. The HBsAg levels obtained by different immunoassays now need comparing and the relationships between levels of HBsAg and HBV DNA alongside HBsAg and genotype must be evaluated. METHODOLOGY/PRINCIPAL FINDINGS: HBsAg levels were compared among 80 patients using the Abbott Architect assay, a commercial immunoassay approved for HBsAg detection and quantitation, and three other assays derived from immunoassays approved for HBsAg detection (manufactured by Diasorin, Bio-Rad and Roche. Good correlation was found between the Abbot vs. Diasorin, Bio-Rad and Roche assays with narrow 95% limits of agreement and small mean differences: -0.06 to 0.11, -0.09 log(10 IU/mL; -0.57 to 0.64, -0.04 log(10 IU/mL; -0.09 to 0.45, -0.27 log(10 IU/mL, respectively. These agreements were not affected by genotypes A or D. HBsAg was weakly correlated with HBV DNA, whatever the HBsAg assay used: Abbott, ρ = 0.36 p = 0.001, Diasorin ρ = 0.34, p = 0.002; Bio-Rad ρ = 0.37, p<0.001; or Roche ρ = 0.41, p<0.001. This relationship between levels of HBsAg and HBV DNA seemed to depend on genotypes. Whereas HBsAg (Abbott assay tended to correlate with HBV DNA for genotype A (ρ = 0.44, p = 0.02, no such correlation was significant for genotypes D (ρ = 0.29, p = 0.15. CONCLUSION/SIGNIFICANCE: The quantitation of HBsAg in routine clinical samples is comparable between the reference assay and the adapted assays with acceptable accuracy limits, low levels of variability and minimum discrepancy. While HBsAg quantitation is not affected by HBV genotype, the observed association between levels of HBsAg and HBV DNA seems genotype dependent.

  7. Hepatitis B virus infection in blood donors in Argentina: prevalence of infection, genotype distribution and frequency of occult HBV infection.

    Science.gov (United States)

    Pisano, María Belén; Blanco, Sebastián; Carrizo, Horacio; Ré, Viviana Elizabeth; Gallego, Sandra

    2016-10-01

    This study describes the prevalence of HBV infection based on detection of HBsAg and HBV-DNA by NAT in 70,102 blood donors in Argentina (Córdoba province) and shows the viral genotype distribution and frequency of occult HBV infection (OBI) in this population. Forty-two donors were confirmed positive for HBV infection (0.06 %), and four had OBI. Genotype F was the most prevalent (71.4 %), followed by A (14.3 %), C (7.1 %) and D (7.1 %). This is the first report of the prevalence of confirmed HBV infection and the high frequency of occult HBV infection in a blood bank in Argentina.

  8. HBV 感染不同阶段病毒特异性T 细胞反应评估%HBV-specific T lymphocyte responses during different stages of hepatitis B virus infection

    Institute of Scientific and Technical Information of China (English)

    覃岭; 赵艳; 王熠; 黄雁翔; 刘金花; 张永宏

    2014-01-01

    目的:探讨HBV感染不同阶段病毒特异性T细胞反应特征。方法对北京佑安医院84例HBV感染者进行研究,分为急性乙型肝炎组(8例)、慢性乙型肝炎组(39例)、肝硬化组(17例)和HBV相关肝癌组(20例)。采用ELISPOT方法与磁珠细胞分选方法检测外周血中HBV特异性T细胞。结果(1)急性乙型肝炎组、慢性乙型肝炎组、肝硬化组及肝癌组HBV特异性T 细胞反应强度分别为(2067.00±1029.00) SFU/106 PBMCs、(288.50±57.69) SFU/106 PBMCs、(96.25±31.06) SFU/106 PBMCs、(71.47±14.26) SFU/106 PBMCs,急性乙型肝炎组病毒特异性T细胞反应最强,组间比较差异有统计学意义(P<0.01)。(2)急性乙型肝炎组中,HBV Core(C)蛋白诱导的T 细胞释放IFN-γ反应强度为(323.90±130.30) SFU/106 PBMCs,明显高于S蛋白、P蛋白及X蛋白诱导的T细胞反应强度,组间比较差异有统计学意义(P=0.0037);在慢性乙型肝炎组HBV P蛋白诱导的T细胞反应最强,为(127.20±54.42) SFU/106 PBMCs,其次为S蛋白、C蛋白、X蛋白,差异有统计学意义(P=0.0159)。(3)在肝硬化组和肝癌组,HBV X蛋白、P蛋白、S蛋白及C蛋白诱导的T细胞释放IFN-γ反应强度无明显差别,并且均低于慢性乙型肝炎患者组。结论 HBV感染者随着病情由急性乙型肝炎向慢性乙型肝炎、肝硬化、肝癌进展,病毒特异性T 细胞反应逐渐减低,不同的感染阶段病毒蛋白诱导的T细胞反应可能发挥不同的作用。%Objective To analyze hepatitis B virus ( HBV)-specific T lymphocyte responses dur-ing different stages of HBV infection.Methods Eighty-four patients with HBV infection were recruited in this study.They were divided into four groups including acute HBV infection group (8 cases), chronic HBV infection group (39 cases), hepatocirrhosis group (17 cases) and

  9. Serum neopterin levels in patients with replicative and nonreplicative HBV carriers

    Directory of Open Access Journals (Sweden)

    Yılmaz Mustafa

    2006-10-01

    Full Text Available Abstract Background Infection by hepatitis B virus (HBV causes complicated biochemical, immunological and histological changes in host immune response against the virus which can be specific or non-specific. Recent attention has focused on neopterin as a marker for the activation of cell mediated immunity. The aim of this study was to define the pattern of neopterin levels in replicative and nonreplicative HBV carriers. Methods Thirty HBV replicative carriers and 25 nonreplicative HBV carriers and 30 healthy adult patients were included this study. Hepatitis markers were determined by commercial kit based on chemilumminesans assay. HBV DNA was quantified by hybrid capture system. Serum neopterin levels were measured by the method of competitive enzyme-linked immunosorbent assay. Results were expressed as mean ± SD and ranges. Results In the nonreplicative group, except for one patient, all the patients' HBeAg were negative and anti-HBe were positive. That particular patient was HBeAg positive and anti-HBe negative. In the replicative group, 23 out of 30 patients have positive HBeAg and negative anti-HBe; 7 out of 30 patients have negative HBeAg and positive anti-HBe. Serum neopterin concentrations were 14.5 ± 10.0 (4.2–41 nmol/L in replicative HBV carriers, 8.9 ± 4.3 (2.1–22 nmol/L in nonreplicative HBV carriers and 7.1 ± 2.2 (4.0–12 nmol/L in the control group. Serum neopterin levels and the rates of abnormal serum neopterin levels in the replicative group were higher than the control group (P . In the nonreplicative group, serum neopterin levels were not different from those of the control. There was a difference between replicative and nonreplicative groups in the respect of neopterin levels. Conclusion In the hepatitis B infected carriers, elevated neopterin levels may be an indicator of the presence of replication.

  10. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA

    Science.gov (United States)

    Seeger, Christoph; Sohn, Ji A

    2016-01-01

    Hepatitis B virus (HBV) causes chronic infections that cannot yet be cured. The virus persists in infected hepatocytes, because covalently closed circular DNA (cccDNA), the template for the transcription of viral RNAs, is stable in nondividing cells. Antiviral therapies with nucleoside analogues inhibit HBV DNA synthesis in capsids in the cytoplasm of infected hepatocytes, but do not destroy nuclear cccDNA. Because over 200 million people are still infected, a cure for chronic hepatitis B (CHB) has become one of the major challenges in antiviral therapy. As a first step toward the development of curative therapies, we previously demonstrated that the CRISPR/Cas9 system can be used to functionally inactivate cccDNA derived from infectious HBV. Moreover, some evidence suggests that certain cytokines might induce an APOBEC-mediated cascade leading to the destruction of cccDNA. In this report we investigated whether a combination of the two mechanisms could act synergistically to inactivate cccDNA. Using next generation sequencing (NGS), we determined the complete spectrum of mutations in cccDNA following Cas9 cleavage and repair by nonhomologous end joining (NHEJ). We found that over 90% of HBV DNA was cleaved by Cas9. In addition our results showed that editing of HBV DNA after Cas9 cleavage is at least 15,000 times more efficient that APOBEC-mediated cytosine deamination following treatment of infected cells with interferon alpha (IFNα). We also found that a previously used method to detect cytosine deaminated DNA, termed 3D-PCR, overestimates the amount and frequency of edited HBV DNA. Taken together, our results demonstrated that the CRISPR/Cas9 system is so far the best method to functionally inactivate HBV cccDNA and provide a cure for CHB. PMID:27203444

  11. Urban-Rural Comparison of HBV and HCV Infection Prevalence in Eastern China

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    The present study was initiated to make and urban-rural comparison of the prevalence of cases positive to hepatitis B and C virus(HBV and HCV,respectively)infection markers in densely populated eastern half of China.For this purpose.10 survey sites were selected,i.e.,six sites in urban areas(the city group;Beijing,shangahi and four provincial capitals)and four sites in rural areas(the village group;one village each in Jilin and Shandong provinces,and two villages in Shaanxi Province),About 50 adult women per site volunteered to participate,from whom 494 valid bllod samples were collected.Positivities to HBsAg(HBsAg+),anti-HBs(anti-HBs+)and antiHBc(anti-HBc+)were examined by RIA methods.and that to anti-HCV(anti-HCV+)by either EIA or RIA.Those positive to any one of the three HBV infection markers were taken as HBV infection-positive(HBV+).The prevalence of HBsAg+,HBV+ and anti-HBc+ was 8%,70%and 2.7% in the city group,and 8%,65% and 2.0%in the village group,and no significant difference was found between the two groups.The overall prevalence was 8% for HBsAg+,68% for HBV+,and 2.4% for anti-HVC+,The results were discussed in reference to some 20 papers each on HBV+ and anti-HCV+ prevalence in China published since(1991),The reviewing of these papers of anti-HCV was low(well below 5%),and that no substantial difference was found between the rural and urban populations.

  12. HBVPathDB: A database of HBV infection-related molecular interaction network

    Institute of Scientific and Technical Information of China (English)

    Yi Zhang; Xiao-Chen Bo; Jing Yang; Sheng-Qi Wang

    2005-01-01

    AIM: To describe molecules or genes interaction between hepatitis B viruses (HBV) and host, for understanding how virus' and host's genes and molecules are networked to form a biological system and for perceiving mechanism of HBV infection.METHODS: The knowledge of HBV infection-related reactions was organized into various kinds of pathways with carefully drawn graphs in HBVPathDB. Pathway information is stored with relational database management system (DBMS), which is currently the most efficient way to manage large amounts of data and query is implemented with powerful Structured Query Language (SQL). The search engine is written using Personal Home Page (PHP) with SQL embedded and web retrieval interface is developed for searching with Hypertext Markup Language (HTML).RESULTS: We present the first version of HBVPathDB,which is a HBV infection-related molecular interaction network database composed of 306 pathways with 1050molecules involved. With carefully drawn graphs, pathway information stored in HBVPathDB can be browsed in an intuitive way. We develop an easy-to-use interface for flexible accesses to the details of database. Convenient software is implemented to query and browse the pathway information of HBVPathDB. Four search page layout options-category search, gene search, description search,unitized search-are supported by the search engine ofthe database. The database is freely available at http://www.bio-inf, net/HBVPathDB/HBV/.CONCLUSION: The conventional perspective HBVPathDB have already contained a considerable amount of pathway information with HBV infection related, which is suitable for in-depth analysis of molecular interaction network of virus and host. HBVPathDB integrates pathway data-sets with convenient software for query, browsing,visualization, that provides users more opportunity to identify regulatory key molecules as potential drug targets and to explore the possible mechanism of HBV infection based on gene expression datasets.

  13. HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.

    Science.gov (United States)

    Akhtar, Ali; Khan, Amer Hayat; Sulaiman, Syed Azhar Syed; Soo, Chow Ting; Khan, Kashifullah

    2016-03-01

    According to WHO, Malaysia has been classified as a concentrated epidemic country due to progression of HIV infection in the population of injecting drug users. The main objectives of current study are to determine the prevalence of HBV among HIV-positive individuals in a tertiary care hospital of Malaysia and to assess the predictors involved in the outcomes of HIV-HBV co-infected patients. A retrospective, cross-sectional study is conducted at Hospital Palau Pinang, Malaysia. The collection of socio-demographic data as well as clinical data is done with the help of data collection form. Data were analyzed after putting the collected values of required data by using statistical software SPSS version 20.0 and P > 0.05 is considered as significant. Results show that the overall prevalence of HBV was 86 (13%) including 495 (74.5%) males and 169 (25.5%) females among a total of 664 HIV-infected patients. It was observed that there is a high prevalence of HIV-HBV co-infection in males 76 (11.4%) as compared to females 10 (1.5%) (P = 0.002). The median age of the study population was 39 years. The statistical significant risk factors involved in the outcomes of HIV-HBV co-infected patients were observed in the variables of gender, age groups, and injecting drug users. The findings of the present study shows that the prevalence of HBV infection among HIV-positive patients was 13% and the risk factors involved in the outcomes of HIV-HBV co-infected patients were gender, age, and intravenous drug users.

  14. KIR : HLA association with clinical manifestations of HBV infection in Madurai, south India

    Indian Academy of Sciences (India)

    Narayanan Kalyanaraman; Lakshmikanthan Thayumanavan; Mariakuttikan Jayalakshmi

    2016-03-01

    The antiviral action of natural killer (NK) cells is regulated by a wide repertoire of germ-line encoded membrane receptors which recognize the expression of certain self-molecules on target cells. Among the receptors, killer cell immunoglobulinlikereceptor (KIR) which recognizes the expression of human leukocyte antigen (HLA) class I has a predominant role in regulating the effector functions of NK cells, particularly in viral infections. We studied a total of 128 hepatitis B virus (HBV)patients (15 acute, 43 asymptomatic, 27 chronic and 43 with other liver diseases) while attending the Department of Medical Gastroenterology, Government Rajaji Hospital, Madurai, India, and 128 ethnic matched control to find the association between the KIR : HLA genes and differential manifestations of HBV. KIR and its ligand HLA polymorphism were identified by DNAPCR methods. The activatory receptor KIR-2DS1 was significantly elevated in various disease categories, namely asymptomatic, chronic and other HBV, except acute HBV infection. Whereas, KIR 2DS3 in acute and chronic patients and KIR 2DS5 and 3DS1 in asymptomatic individuals. Among various KIR–HLA combinations, homozygous 2DS2:C1 and individuals with 3DSI:BW4 (OR = 3.23, CI = 1.55–6.7, Pc = 0.02) are associated with HBV asymptomatism, while most of the two domain inhibitory receptors with their ligands showed significant risk in other liver diseases. Further, KIR3DL1 : HLA Bw4Iso80 (OR = 3.89, 95% CI = 1.58–9.55, Pc = 0.004) is related with higher risk for asymptomatic infection when compared with chronic HBV. Thus, the select KIR : HLA alleles and combinations seem to direct the NK cell activities and immune response in different directions resulting in varied symptoms and manifestations in the subgroups of HBV-infected patientsstudied.

  15. MCM3AP,a Novel HBV Integration Site in Hepatocellular Carcinoma and Its Implication in Hepatocarcinogenesis

    Institute of Scientific and Technical Information of China (English)

    王晶; 林菊生; 常莹; 黎培元; 杨玉珍

    2010-01-01

    A novel HBV integration site involved in hepatocarcinogenesis was investigated. The HBV DNA integration sites were detected by Alu-PCR in hepatocellular carcinoma tissues, matched surrounding liver tissues in 30 patients with hepatitis B-related hepatocellular carcinoma (HCC) and 3 cases of normal liver tissues. The integration sites and flanking sequences in human genome were sequenced and blasted, and the expression of integrated HBV genes was determined by reverse transcriptase-polymerase chain reaction ...

  16. Analysis on HBV DNA copies in the serum and breast milk of parturients with HBsAg positive%HBsAg阳性产妇血清和乳汁中HBV DNA载量分析

    Institute of Scientific and Technical Information of China (English)

    邹军; 汪永强

    2015-01-01

    Objective To study the relationship and correlation between serum HBV DNA and breast milk HBV DNA of HBsAg(+) parturients, and to provide evidence of guiding breast feeding for women infected by chronic hepatitis B virus (HBV). Methods A total of 148 parturients with HBsAg(+) of HBV were divided into the four groups according to the copies of HBV DNA in serum:<420 IU/ml group, 420~104 IU/ml group, 105~106 IU/ml group, 107~108 IU/ml group. The HBV DNA copies in the serum and breast milk from the four groups of women were detect-ed by fluorescence quantitative PCR (FQ-PCR) technique respectively. And the relationship and correlation of the load of HBV DNA were performed between in serum and breast milk from the four groups. Results The HBV positive rate of women with HBsAg (+) was 31.8%(47/148) in serum and 16.2%(24/148) in breast milk (χ2=7.355, P<0.05). In the parturients with serum HBV DNA<420 IU/ml, the corresponding breast milk was negative for the expression of HBV DNA. In the women with serum HBV DNA of 420~104 IU/ml, 105~106 IU/ml, 107~108 IU/ml, the corresponding HBV DNA positive rate in breast milk was 14.3%(3/18), 71.4%(5/7) and 84.2%(16/19), respectively (χ2=20.88, P<0.05). When serum HBV DNA load increased, the content of breast milk increased accordingly, which showed a mod-erate correlation (r=0.628, P<0.05). Conclusion HBV DNA is detected in breast milk of HBsAg(+) parturients. Its content is lower than that in the corresponding serum, and it increases when the load of HBV DNA in serum increases, which indicates that baby may be get infected through breast feeding.%目的:探讨HBsAg(+)产妇血清和乳汁中HBV DNA载量关系及相关性,为慢性乙型肝炎产妇母乳喂养提供实验依据。方法对148例HBsAg(+)产妇血清和乳汁中乙肝病毒采用实时荧光定量PCR (FQ-PCR)方法检测HBV DNA,按产妇血清HBV载量分为HBV DNA载量<420 IU/ml组、420~104 IU/ml组、105~106 IU/ml组、107~108 IU/ml组,并同时收取产妇乳汁进行HBV

  17. Analysis the situation of HIV, syphilis and HBV testing services among pregnant women in Guangdong, 2012-2013%广东省2012-2013年孕产妇接受HIV梅毒和HBV检测服务情况

    Institute of Scientific and Technical Information of China (English)

    汤柳英; 赵庆国; 李兵; 高爽; 马远珠; 赖科峰; 夏建红

    2015-01-01

    目的 了解广东省各地区孕产妇接受艾滋病病毒(HIV)、梅毒和乙型肝炎病毒(HBV)检测服务状况,及各地区检测服务的差异,为各地区持续改进HIV、梅毒和HBV检测服务能力提供参考依据.方法 常规收集广东省各地区2012年与2013年孕产妇在医疗保健机构接受HIV、梅毒和HBV检测与咨询服务的相关信息,并通过国家预防艾滋病、梅毒和乙型肝炎母婴传播管理信息系统报告与收集相关数据,采用描述性统计分析与卡方检验分析各地市分娩产妇HIV、梅毒和HBV检测率及孕期检测率.结果 广东省各地区2012-2013年分娩产妇共计3 530 186人,其中,2012年为1 763 034人,2013年为1 767 152人.2013年广东省孕产妇HIV、梅毒和HBV检测率分别为93.33%、83.02%和84.30%,均显著高于2012年的孕产妇检测率.两年间,珠三角地区、东翼地区、西翼地区和山区HIV、梅毒和HBV的检测率分别为97.77%、83.15%和84.48%,74.72%、76.15%和77.14%,92.97%、83.93%和85.60%,94.67%、88.22%和89.24%;珠三角地区HIV、梅毒和HBV检测率显著高于其他地区.结论 广东省孕产妇孕期检测率不高,各地区项目检测现状不均衡,预防梅毒和乙型肝炎母婴传播有待进一步加强.

  18. A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Chun-Hong Ma; Xiao-Hong Liang; Wen-Sheng Sun; Pei-Kun Tian; Li-Fen Gao; Su-Xia Liu; Xiao-Yan Wang; Li-Ning Zhang; Ying-Lin Cao; Li-Hui Han

    2003-01-01

    AIM: To construct a novel HBV antisense RNA delivery system targeting hapatocellular carcinoma and study its inhibitory effect in vitro and in vivo.METHODS: GE7,a 16-peptide specific to EGFR, and HA20,a homologue of N-terminus of haemagglutinin of influenza viral envelope protein, were synthesized and conjugated with polylysin. The above conjugates were organized into the pEBAF-as-preS2, a hepatocarcinoma specific HBV antisense expression vector, to construct a novel HBV antisense RNA delivery system, named AFP-enhancing 4-element complex. Hepatocelluar carcinoma HepG2.2.15 cells was used to assay the in vitro inhibition of the complex on HBV. Expression of HBV antigen was assayed by ELISA. BALB/c nude mice bearing HepG2.2.15 cells were injected with AFP-enhancing 4-element complex. The expression of HBV antisense RNA was examined by RT-PCR and the size of tumor in nude mice were measured.RESULTS: The AFP-enhancing 4-element complex was constructed and DNA was completely trapped at the slot with no DNA migration when the ratio of polypeptide to plasmid was 1:1.The expression of HBsAg and HBeAg of HepG2.2.15 cells was greatly decreased after being transfected by AFP-enhancing 4-element complex. The inhibitory rates were 33.4 % and 58.5 % respectively. RTPCR showed HBV antisense RNA expressed specifically in liver tumor cells of tumor-bearing nude mice. After 4injections of AFP-enhancing 4-element complex containing 0.2 μg DNA, the diameter of the tumor was 0.995 cm±0.35,which was significantly smaller than that of the control groups (2.215 cm±0.25, P<0.05).CONCLUSION: AFP-enhancing 4-element complex could deliver HBV antisense RNA targeting on hepatocarcinoma and inhibit both HBV and liver tumor cells in vitro and in vivo.

  19. Evolution of Hepatitis B Virus in a Chronic HBV-Infected Patient over 2 Years

    Directory of Open Access Journals (Sweden)

    Tao Shen

    2011-01-01

    Full Text Available Mutations in full-length HBV isolates obtained from a chronic HBV-infected patient were evaluated at three time points: 1 day, 6 months, and 31 months. While 5 nucleotides variation, and an 18 bp deletion of preS1 have been kept in during at least the first two years, C339T mutation occurring in the hydrophilic region of HBsAg and T770C that caused polymerase V560A substitution were the new point mutations found existing in sequenced clones of the 3rd time point. Internal deletion of coding region obviously appeared in the 3rd time point. The splicers included two new 5′-splice donors and three new 3′-splice acceptors besides the reported donors and acceptors and may have produced presumptive HBV-spliced proteins or truncated preS proteins. ALT, HBeAg and viral DNA load varied during the follow-up years. These data demonstrated the diversity of genomes in HBV-infected patient during evolution. Combined with clinical data, the HBV variants discovered in this patient may contribute to viral persistence of infection or liver pathogenesis.

  20. Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR

    Institute of Scientific and Technical Information of China (English)

    Jun Liu; Ying-Hui Li; Jin Ding; Wei-Dong Gong; Cai-Fang Xue; Ya Zhao; Yu-Xiao Huang

    2004-01-01

    AIM: To quantify the inhibition of HBV replication by targeted ribonuclease by using real-time fluorescent PCR.METHODS: Targeted ribonuclease was introduced into 2.2.15cells by liposome-mediated transfection or HIV-TAT mediated protein transduction. Forty-eight hours after the transfection and 24 h after the transduction, supernatants of 2.2.15 cells were collected and HBV DNA in the supernatants was quantified by real-time fluorescent PCR with a commercial kit.RESULTS: HBV DNA concentrations in the supernatants of2.2.15 cells transfected or transducted with targeted ribonuclease were 4.9±2.4×108 copies/L and 8.3±4.0×108copies/L, respectively. Compared with controls, transfection or transduction of targeted ribonuclease reduced HBV DNA concentration in the supernatants of 2.2.15 cells by 90.4%and 90.1%, respectively (P<0.05).CONCLUSION: Targeted ribonuclease can inhibit HBV replication in 2.2.15 cells.

  1. HBV感染者血清标志物与HBV DNA的关系

    Institute of Scientific and Technical Information of China (English)

    李君莲; 李东军

    2007-01-01

    目的 了解乌鲁木齐地区HBV感染者血清学标志物与HBV DNA的关系.方法 检测234例HBV感染者血清标志物,并用实时荧光定量PCR法检测HBV DNA.结果 在本组234例HBV感染者中,血清前S1抗原阳性率为62.39%(146/234);前S2抗原阳性率为85.47%(200/234);HBV DNA阳性率为49.57%(116/234).在HBsAg/HBeAg/Anti-HBc阳性组,前S1抗原和HBV DNA阳性率较高.结论 前S1抗原和HBV DNA能反映病毒的复制状态.

  2. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant

    Institute of Scientific and Technical Information of China (English)

    Tatehiro Kagawa; Kazuo Shimamura; Shohei Matsuzaki; Tetsuya Mine; Norihito Watanabe; Hisashi Kanouda; Ichiro Takayama; Tadahiko Shiba; Takashi Kanai; Kazuya Kawazoe; Shinji Takashimizu; Nobue Kumaki

    2004-01-01

    We report a case of fatal liver failure due to reactivation of lamivudine-resistant HBV. A 53-year-old man was followed since 1998 for HBV-related chronic hepatitis. Serum HBVDNA was 150 MEq/mL (branched DNA signal amplification assay) and ALT levels fluctuated between 50-200 IU/L with no clinical signs of liver cirrhosis. Lamivudine (100 mg/d)was started in May 2001 and serum HBV-DNA subsequently decreased below undetectable levels. In May 2002, serum HBV-DNA had increased to 410 MEq/mL, along with ALT flare (226 IU/L). The YMDD motif in the DNA polymerase gene had been replaced by YIDD. Lamivudine was continued and ALT spontaneously decreased to the former levels. On Oct 3 the patient presenting with general fatigue, nausea and jaundice was admitted to our hospital. The laboratory data revealed HBV reactivation and liver failure (ALT: 1828IU/L, total bilirubin: 10 mg/dL, and prothrombin INR: 3.24).For religious reasons, the patient and his family refused blood transfusion, plasma exchange and liver transplantation.The patient died 10 d after admission. The autopsy revealed remarkable liver atrophy.

  3. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV

    Institute of Scientific and Technical Information of China (English)

    Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu

    2006-01-01

    AIM: To study the prevalence and clinical effects of occult HBV infection in haemodialysis patients with chronic HCV.METHODS: Fifty chronic hemodialysis patients with negative HbsAg, and positive anti-HCV were included in the study. These patients were divided into two groups:HCV-RNA positive and HCV-RNA negative, based on the results of HCV-RNA PCR. HBV-DNA was studied using the PCR method in both groups.RESULTS: None of the 22 HCV-RNA positive patients and 28 HCV-RNA negative patients revealed HBV-DNA in serum by PCR method. The average age was 47.2 ± 17.0 in the HCV-RNA positive group and 39.6 ± 15.6 in the HCV-RNA negative group.CONCLUSION: The prevalence of occult HBV infection is not high in haemodialysis patients with chronic HCV in our region. This result of our study has to be evaluated in consideration of the interaction between HBsAg positivity (8%-10%) and frequency of HBV mutants in our region.

  4. Association of the Cellular Apoptosis Susceptibility Protein with HBV Infection in Hepatocellular Carcinoma

    Institute of Scientific and Technical Information of China (English)

    Hong Zang; Dong Ji; Qing Shao; Guang-de Zhou; Deng Pan; Shao-jie Xin; Jing-min Zhao; Guo-feng Chen

    2014-01-01

    Objective The cellular apoptosis susceptibility (CAS) protein plays a regulatory role in the induction of cell death in tumor cells. The objective of this study was to investigate the association of the expression of CAS protein with HBV infection in the development of HCC. Methods The expression level of CAS was measured with immunohistochemistry. The occurrence of HBsAg, HBeAg and HBV DNA in HCC were concurrently examined with immunohistochemistry and in situ hybridization, respectively. Results The results showed that the CAS protein was detected in 86% (43/50), 70% (7/10), 15% (3/20) and none (0/20) of livers from patients with HCC, cholangiocarcinoma, cirrhosis and hepatitis, respectively. Furthermore, the level of CAS protein was higher in poorly differentiated tumors than moderately or well differentiated HCC. Interestingly, the CAS was stained significantly stronger in HBV-infected HCC than in non-HBV infected tissues (P < 0.01). Conclusions The expression of CAS is facilitated by HBV infection in HCC, suggesting that CAS might be a prognostic marker and a putative therapeutic target for HCC.

  5. The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

    Science.gov (United States)

    Daffis, Stephane; Ramakrishnan, Dhivya; Burdette, Dara; Peiser, Leanne; Salas, Eduardo; Ramos, Hilario; Yu, Mei; Cheng, Guofeng; Strubin, Michel; Delaney IV, William E.; Fletcher, Simon P.

    2017-01-01

    The structural maintenance of chromosome 5/6 complex (Smc5/6) is a restriction factor that represses hepatitis B virus (HBV) transcription. HBV counters this restriction by expressing HBV X protein (HBx), which targets Smc5/6 for degradation. However, the mechanism by which Smc5/6 suppresses HBV transcription and how HBx is initially expressed is not known. In this study we characterized viral kinetics and the host response during HBV infection of primary human hepatocytes (PHH) to address these unresolved questions. We determined that Smc5/6 localizes with Nuclear Domain 10 (ND10) in PHH. Co-localization has functional implications since depletion of ND10 structural components alters the nuclear distribution of Smc6 and induces HBV gene expression in the absence of HBx. We also found that HBV infection and replication does not induce a prominent global host transcriptional response in PHH, either shortly after infection when Smc5/6 is present, or at later times post-infection when Smc5/6 has been degraded. Notably, HBV and an HBx-negative virus establish high level infection in PHH without inducing expression of interferon-stimulated genes or production of interferons or other cytokines. Our study also revealed that Smc5/6 is degraded in the majority of infected PHH by the time cccDNA transcription could be detected and that HBx RNA is present in cell culture-derived virus preparations as well as HBV patient plasma. Collectively, these data indicate that Smc5/6 is an intrinsic antiviral restriction factor that suppresses HBV transcription when localized to ND10 without inducing a detectable innate immune response. Our data also suggest that HBx protein may be initially expressed by delivery of extracellular HBx RNA into HBV-infected cells. PMID:28095508

  6. 两类 HBV 感染终末患者CRP、PCT 、IL-6水平及临床特征的比较%Comparison of CRP,PCT and IL-6 in patients with two types of ends of HBV infection

    Institute of Scientific and Technical Information of China (English)

    王宇; 陈龙琴; 张自豪; 田丽媛

    2016-01-01

    目的:观察炎性反应指标C反应蛋白(CRP)、白细胞介素‐6(IL‐6)、降钙素原(PCT )对 HBV病毒感染不同终末期患者的可能影响。方法收集48例HBV相关原发性肝细胞癌及48例肝硬化失代偿患者临床数据及外周血清,检测 HBV拷贝数、PCT、IL‐6、CRP、丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、凝血酶原时间(PT )等指标用于组间比较及相关性分析。结果原发性肝细胞癌与肝硬化失代偿组间 HBV拷贝数、PCT、CRP、淋巴细胞及单核细胞计数无明显差异,而肝硬化失代偿期IL‐6较肝细胞癌组水平高,中性粒细胞绝对数较肝细胞癌组减少。结论 IL‐6水平升高可能与HBV感染终末结局有关,动态监测IL‐6有助于评估 HBV感染终末的转归。%Objective We investigate the possible effect of inflammative indicator C reactive protein(CRP) ,interleukin‐6(IL‐6) and procalcitonin(PCT) on the outcome of HBV infection .Methods The clinical data and peripheral serum of 48 patients with HBV related hepatocellular carcinoma and 48 patients with decompensated cirrhosis were collected ,HBV copy numbers ,PCT ,IL‐6 , CRP ,ALT ,AST ,prothrombin time(PT ) and other indicators were tested for comparison and correlative analysis .Results HBV copy numbers ,PCT ,CRP ,lymphocytes and mononuclear cells showed no significant difference between primary hepatocellular car‐cinoma and decompensated cirrhosis group;however ,IL‐6 level was significantly higher in decompensated liver cirrhosis than in hep‐atocellular carcinoma ,as opposed to the absolute number of neutrophils .Conclusion IL‐6 increase may be related to final outcome of HBV infection ,dynamic monitoring IL‐6 is helpful to evaluate the prognosis of HBV infection .

  7. Values of TTV, NLR, and HBV-DNA in predicting tumor recurrence on patients with HCC after cura-tive hepatectomy%术前TTV、NLR及HBV-DNA定量对预测肝癌术后复发的价值

    Institute of Scientific and Technical Information of China (English)

    袁琳; 万磊; 陈佳佳; 刘建军; 阚和平; 谭永法

    2015-01-01

    Objective To investigate the values of total tumor volume (TTV), preoperative peripheral blood neutrophil to lymphocyte ratio (NLR),and hepatitis B virus (HBV-DNA) level in predicting the tumor recurrence of patients with HBV-related hepatocellular carcinoma (HCC) after curative hepatectomy. Methods Clinical data of 180 patients with HBV-related HCC who underwent curative hepatectomy were retrospective-ly analyzed. All patients were followed up after hepatectomy, and their tumor recurrence and survival time were recorded. TTV and NLR were calculated according to the clinical data. Receiver operating characteristic (ROC) curves of TTV and NLR for predicting tumor recurrence were plotted, and the cut-off values were de-fined,respectively. The cut-off value of HBV-DNA for predicting tumor recurrence after hepatectomy was defined at 1,000 ng/mL in advance. The patients were divided into low TTV group and high TTV group, low NLR group and high NLR group, low HBV-DNA group and high HBV-DNA group respectively according to the cut-off values of TTV, NLR, and HBV-DNA. The differences of disease-free survival and cumulative survival rates between groups were compared with survival analysis. Clinical data were included as the factors influencing patients′disease-free survival rates by Cox proportional-hazards regression model. Survival anal-ysis was conducted using Kaplan-Meier method and Log-rank test. Survival prognosis was analyzed using Cox′s proportional-hazard model. Results When the cut-off value of TTV was defined at 183.59 cm3, the sensitivity was 0.492, and specificity was 0.964. When the cut-off value of NLR for predicting tumor recur-rence after operation was defined at 2.215, the sensitivity was 0.637, and specificity was 0.679. The 1,2,3-year disease-free survival and cumulative survival rates in low TTV group, low NLR group, and low HBV-DNA group were higher than those in high TTV group, high NLR group, and high HBV-DNA group respectively. The differences

  8. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Yong-dong Niu

    2011-08-01

    Full Text Available Farnesoid X receptor (FXR, also termed nuclear receptor NR1H4 is critically involved in the regulation of nascent bile formation and bile acid enterohepatic circulation. FXR and bile acids have been shown to play roles in liver regeneration and inflammatory responses. There is increasing evidence suggesting that FXR and the FXR signaling pathway are involved in the pathophysiology of a wide range of liver diseases, such as viral hepatitis, cirrhosis, and hepatocellular carcinoma (HCC. Here we discuss the latest discoveries of FXR functions with relevance to bile acid metabolism and HBV-associated HCC. More specifically, the goal of this review is to discuss the roles of FXR and bile acids in regulating HBV replication and how disregulation of the FXR-bile acid signaling pathway is involved in HBV-associated hepatocarcinogenesis.

  9. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    Nian-cai Peng; Chun-lin Wang; Li-li Zhang; Mao-li Lu; Zhen-xi Zhang

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50 : 1, 100 : 1) and concentrations (13. 0 pmol/25μL and 0.14 pmol/25μL, 19. 5 pmol/25μL and 0. 21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio of 50 : 1 provided better yield and concentration of 19. 5 pmol/25μL and 0. 21 pmol//25μL generated a clearer band. Conclusion A simple and feasible method to produce HBV ssDNA for pyrosequencing in batch is established.

  10. Antigen-induced regulatory T cells in HBV chronically infected patients.

    Science.gov (United States)

    Barboza, Luisa; Salmen, Siham; Goncalves, Loredana; Colmenares, Melisa; Peterson, Darrell; Montes, Henry; Cartagirone, Raimondo; Gutiérrez, Maria del Carmen; Berrueta, Lisbeth

    2007-11-10

    T cell response against HBV is vigorous in patients with acute hepatitis who clear the virus, whereas it is weak and narrowly focused in patients with chronic disease. We report that following incubation with HBcAg, a population of CD4+FoxP3+ cells expressing phenotypic markers of both natural and induced Tregs, can be antigen-induced from peripheral mononuclear cells. Conversely, naive and naturally immune subjects did not increase CD4+FoxP3+ Tregs following stimulation with HBcAg, supporting the idea that natural Tregs are able to respond specifically to HBV antigen. Furthermore, increased frequencies of antigen-induced CD4+FoxP3+IL-10+ Tregs correlated with viral load, suggesting that antigen-induced Tregs could contribute to an inadequate response against the virus, leading to chronic infection and support the view that specific natural Tregs may be implicated in host immune tolerance during HBV infection.

  11. HBV and HIV co-infection: Impact on liver pathobiology andtherapeutic approaches

    Institute of Scientific and Technical Information of China (English)

    Mohammad Khalid Parvez

    2015-01-01

    The consequences of hepatitis B virus (HBV) andhuman immunodeficiency virus (HIV) co-infection onprogression of severe liver diseases is a serious publichealth issue, worldwide. In the co-infection cases,about 90% of HIV-infected population is seropositivefor HBV where approximately 5%-40% individuals arechronically infected. In HIV co-infected individuals, liverrelatedmortality is estimated over 17 times higher thanthose with HBV mono-infection. The spectrum of HIVinducedliver diseases includes hepatitis, steatohepatitis,endothelialitis, necrosis, granulomatosis, cirrhosis andcarcinoma. Moreover, HIV co-infection significantlyalters the natural history of hepatitis B, and thereforecomplicates the disease management. Though severalstudies have demonstrated impact of HIV proteins onhepatocyte biology, only a few data is available oninteractions between HBV and HIV proteins. Thus,the clinical spectrum as well as the complexity of theco-infection offers challenging fronts to study theunderlying molecular mechanisms, and to designeffective therapeutic strategies.

  12. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: a nationwide study.

    Science.gov (United States)

    Pourkarim, Mahmoud Reza; Sharifi, Zohre; Soleimani, Ali; Amini-Bavil-Olyaee, Samad; Elsadek Fakhr, Ahmed; Sijmons, Steven; Vercauteren, Jurgen; Karimi, Gharib; Lemey, Philippe; Maes, Piet; Alavian, Seyed Moayed; Van Ranst, Marc

    2014-01-01

    The genetic diversity of the HBV S gene has a significant impact on the prophylaxis and treatment of hepatitis B infection. The effect of selective pressure on this genetic alteration has not yet been studied in Iranian blood donors. To explore HBV evolution and to analyze the effects and patterns of hepatitis B surface antigen (HBsAg) mutations on blood screening assays, 358 Iranian blood donors diagnosed as asymptomatic HBV carriers were enrolled in this nationwide study. Large S and partial S genes were amplified and sequenced. HBV (sub) genotypes and synonymous and nonsynonymous mutations were investigated. The impact of naturally occurring mutations on HBsAg ELISA results was explored. Phylogenetic analyses revealed that isolated strains were of genotype D. The dominant subgenotype/subtype was D1/ayw2. Deletions and naturally occurring stop codons in the pre-S1 and major hydrophilic region (MHR) were identified. In total, 32.8% of the studied strains harbored 195 single or multiple mutations in the MHR, the majority of which were located at the first loop of the "a determinant" domain. The ayw2 subtype showed a significant effect on the ELISA signal/cut-off value and carried fewer mutations in the MHR. Nonsynonymous/synonymous substitution value indicated that negative selection was the dominant evolutionary force in the HBV S gene. This nationwide study revealed that mutation frequency of HBsAg among Iranian blood donors was much higher than previous reports from the different local regions. These findings regarding the significant differences in reactivity of ELISA among different subtypes of HBV and its correlation with the number of mutations at the MHR will be valuable to public health authorities.

  13. Association of interleukin-10 with hepatitis B virus (HBV mediated disease progression in Indian population

    Directory of Open Access Journals (Sweden)

    Roli Saxena

    2014-01-01

    Full Text Available Background & objectives: Interleukin (IL-10, an anti-inflammatory Th2 cytokine, is one of the key coordinators of the inflammatory responses involved. The present study was designed to evaluate the impact of IL-10 (-819/-592 genotypes, haplotypes, mRNA and the protein levels with risk for hepatitis B virus (HBV related hepatocellular carcinoma (HCC development in India. Methods: A total of 390 subjects (145 controls, 62 inactive HBV-carriers, 64 chronic-active HBV patients, 60 HBV related cirrhotics and 59 HBV- HCC subjects were enrolled in the study. Allele specific (AS-PCR, ELISA and RT-PCR methods were used for assessing polymorphism, spontaneous blood levels and the mRNA expression, respectively of IL-10. Results: The study revealed that the CC/TA genotype acted as a risk factor for cirrhosis (OR a =2.02; P<0.05 and the subsequent HCC development (OR a =2.20; P<0.05, with controls as reference. However, no significant association was found between the two haplotypes (CC and TA observed and HCC risk. Moreover, the IL-10 protein and mRNA levels in peripheral blood mono nuclear cells (PBMCs showed a significant elevation as the disease progressed to cirrhosis. But, no variation was observed in the IL-10 levels in subjects with different IL-10 genotypes. Interpretation & conclusions: These preliminary results suggest a strong association of IL10 (-819/-592 with the HBV infection mediated disease progression, from inactive carrier state to malignancy, in Indian population.

  14. Moving horizon estimation for assimilating H-SAF remote sensing data into the HBV hydrological model

    Science.gov (United States)

    Montero, Rodolfo Alvarado; Schwanenberg, Dirk; Krahe, Peter; Lisniak, Dmytro; Sensoy, Aynur; Sorman, A. Arda; Akkol, Bulut

    2016-06-01

    Remote sensing information has been extensively developed over the past few years including spatially distributed data for hydrological applications at high resolution. The implementation of these products in operational flow forecasting systems is still an active field of research, wherein data assimilation plays a vital role on the improvement of initial conditions of streamflow forecasts. We present a novel implementation of a variational method based on Moving Horizon Estimation (MHE), in application to the conceptual rainfall-runoff model HBV, to simultaneously assimilate remotely sensed snow covered area (SCA), snow water equivalent (SWE), soil moisture (SM) and in situ measurements of streamflow data using large assimilation windows of up to one year. This innovative application of the MHE approach allows to simultaneously update precipitation, temperature, soil moisture as well as upper and lower zones water storages of the conceptual model, within the assimilation window, without an explicit formulation of error covariance matrixes and it enables a highly flexible formulation of distance metrics for the agreement of simulated and observed variables. The framework is tested in two data-dense sites in Germany and one data-sparse environment in Turkey. Results show a potential improvement of the lead time performance of streamflow forecasts by using perfect time series of state variables generated by the simulation of the conceptual rainfall-runoff model itself. The framework is also tested using new operational data products from the Satellite Application Facility on Support to Operational Hydrology and Water Management (H-SAF) of EUMETSAT. This study is the first application of H-SAF products to hydrological forecasting systems and it verifies their added value. Results from assimilating H-SAF observations lead to a slight reduction of the streamflow forecast skill in all three cases compared to the assimilation of streamflow data only. On the other hand

  15. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50∶1, 100∶1) and concentrations (13.0 pmol/25μL and 0.14 pmol/25μL, 19.5 pmol/25μL and 0.21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio ...

  16. HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

    Directory of Open Access Journals (Sweden)

    Ambreen Ayub

    2013-01-01

    Full Text Available Hepatocellular carcinoma (HCC is a deadly and emerging disease leading to death in Asian countries. High hepatitis B virus (HBV load and chronic hepatitis B (CHB infection increase the risk of developing HCC. HBV is a DNA virus that can integrate DNA into host genome thereby increase the yield of transactivator protein HBxAg that may deregulate many pathways involving in metabolism of cells. Several monogenic and polygenic risk factors are also involved in HCC development. This review summarizes the mechanism involved in HCC development and discusses some promising therapies to make HCC curative.

  17. Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC

    Directory of Open Access Journals (Sweden)

    Charing Ching-Ning Chong

    2016-03-01

    Full Text Available There have been major advances recently on the therapeutic approaches of hepatitis B virus (HBV-related hepatocellular carcinoma (HCC. Surgical treatments are the key curative treatments of HCC, whereas local ablative treatments may also achieve clinical remission in selected cases. Trans-arterial locoregional therapies are regarded as palliative but still lead to improved survival. There have been major breakthroughs in the systemic therapies for HCC. The first marketed targeted therapy, sorafenib, was shown to improve survival in patients with advanced HCC. Studies on other targeted therapies also showed promising results. Suppressing HBV with effective antiviral treatment would also benefit HCC patients by reducing recurrence and improving liver function.

  18. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens

    Directory of Open Access Journals (Sweden)

    Cui GY

    2015-06-01

    Full Text Available Guangying Cui,1,2 Jianing Chen,1,2 Jianqin He,1,2 Chong Lu,1,2 Yingfeng Wei,1,2 Lin Wang,1,2 Xuejun Xu,3 Lanjuan Li,1,2 Toshimitsu Uede,4 Hongyan Diao1,2 1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 3Department of Oral Orthodontics, Affiliated Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan Purpose: Dendritic cells (DCs play critical roles in promoting innate and adaptive immunity in microbial infection. Functional impairment of DCs may mediate the suppression of viral-specific T-cell immune response in chronic hepatitis B (CHB patients. Osteopontin (OPN is involved in several liver diseases and infectious diseases. However, whether OPN affects DC function in hepatitis B virus (HBV infection is unknown.Methods: Twenty CHB patients and 20 healthy volunteers were recruited. OPN secreted by DCs was compared. Peripheral blood mononuclear cells cultured with OPN antibody were examined to study the costimulatory molecular expression and interleukin (IL-12 production of DCs after HBV antigenic stimulation. OPN-deficient mice were used to investigate the influence of OPN on DC maturation and function after HBV antigenic stimulation in vitro and in vivo. Exogenous OPN was administrated to further verify the functioning of DCs from CHB patients upon HBV antigenic stimulation.Results: We found that OPN production of DCs from CHB patients was significantly lower than those from healthy volunteers. The absence of OPN impaired IL-12 production and costimulatory molecular expression of DCs upon stimulation with HBV antigens. Defective DC function led to reduced activation of Th1 response to

  19. Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection.

    Science.gov (United States)

    Mareddy, Aswani Srinivas; Rangaswamy, Dharshan; Vankalakunti, Mahesha; Attur, Ravindra Prabhu; Nagaraju, Shankar Prasad; Koti, Neeraja

    2016-01-01

    Hepatitis B virus (HBV) infection presenting as crescentic glomerulonephritis in the absence of cryoglobulinemia is an extremely rare phenomenon. We report a case of a 44-year-old male with HBV infection, who underwent kidney biopsy for rapidly progressive renal failure and nephrotic range proteinuria. Histopathological evaluation of the kidney biopsy was consistent with immune complex mediated crescentic membranoproliferative glomerulonephritis (MPGN). The patient achieved complete renal and virological remission with steroids, plasmapheresis and antiviral therapy. This case report summarises the importance of early initiation of immunosuppression and plasmapheresis under antiviral coverage for improved clinical outcomes.

  20. Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection

    Directory of Open Access Journals (Sweden)

    Aswani Srinivas Mareddy

    2016-01-01

    Full Text Available Hepatitis B virus (HBV infection presenting as crescentic glomerulonephritis in the absence of cryoglobulinemia is an extremely rare phenomenon. We report a case of a 44-year-old male with HBV infection, who underwent kidney biopsy for rapidly progressive renal failure and nephrotic range proteinuria. Histopathological evaluation of the kidney biopsy was consistent with immune complex mediated crescentic membranoproliferative glomerulonephritis (MPGN. The patient achieved complete renal and virological remission with steroids, plasmapheresis and antiviral therapy. This case report summarises the importance of early initiation of immunosuppression and plasmapheresis under antiviral coverage for improved clinical outcomes.

  1. GLOBAL ASYMPTOTICAL PROPERTIES FOR A DIFFUSED HBV INFECTION MODEL WITH CTL IMMUNE RESPONSE AND NONLINEAR INCIDENCE

    Institute of Scientific and Technical Information of China (English)

    Wang Shaoli; Feng Xinlong; He Yinnian

    2011-01-01

    This article proposes a diffused hepatitis B virus (HBV) model with CTLimmune response and nonlinear incidence for the control of viral infections.By means of different Lyapunov functions,the global asymptotical properties of the viral-free equilibrium and immune-free equilibrium of the model are obtained.Global stability of the positive equilibrium of the model is also considered.The results show that the free diffusion of the virus has no effect on the global stability of such HBV infection problem with Neumann homogeneous boundary conditions.

  2. The association of complex liver disorders with HBV genotypes prevalent in Pakistan

    Directory of Open Access Journals (Sweden)

    Qureshi Huma

    2007-11-01

    Full Text Available Abstract Background Genotyping of HBV is generally used for determining the epidemiological relationship between various virus strains and origin of infection mostly in research studies. The utility of genotyping for clinical applications is only beginning to gain importance. Whether HBV genotyping will constitute part of the clinical evaluation of Hepatitis B patients depends largely on the availability of the relevance of the evidence based information. Since Pakistan has a HBV genotype distribution which has been considered less virulent as investigated by earlier studies from south East Asian countries, a study on correlation between HBV genotypes and risk of progression to further complex hepatic infection was much needed Methods A total of 295 patients with HBsAg positive were selected from the Pakistan Medical Research Council's (PMRC out patient clinics. Two hundred and twenty six (77% were males, sixty nine (23% were females (M to F ratio 3.3:1. Results Out of 295 patients, 156 (53.2% had Acute(CAH, 71 (24.2% were HBV Carriers, 54 (18.4% had Chronic liver disease (CLD Hepatitis. 14 (4.7% were Cirrhosis and HCC patients. Genotype D was the most prevalent genotype in all categories of HBV patients, Acute (108, Chronic (39, and Carrier (53. Cirrhosis/HCC (7 were HBV/D positive. Genotype A was the second most prevalent with 28 (13% in acute cases, 12 (22.2% in chronics, 14 (19.7% in carriers and 5 (41.7 in Cirrhosis/HCC patients. Mixed genotype (A/D was found in 20 (12.8% of Acute patients, 3 (5.6% of Chronic and 4 (5.6% of carriers, none in case of severe liver conditions. Conclusion Mixed HBV genotypes A, D and A/D combination were present in all categories of patients except that no A/D combination was detected in severe conditions. Genotype D was the dominant genotype. However, genotype A was found to be more strongly associated with severe liver disease. Mixed genotype (A/D did not significantly appear to influence the clinical outcome.

  3. DNA Double-Strand Breaks,Potential Targets for HBV Integration

    Institute of Scientific and Technical Information of China (English)

    胡晓文; 林菊生; 谢琼慧; 任精华; 常莹; 吴文杰; 夏羽佳

    2010-01-01

    Hepatitis B virus(HBV)-induced hepatocellular carcinoma(HCC) is one of the most fre-quently occurring cancers.Hepadnaviral DNA integrations are considered to be essential agents which can promote the process of the hepatocarcinogenesis.More and more researches were designed to find the relationship of the two.In this study,we investigated whether HBV DNA integration occurred at sites of DNA double-strand breaks(DSBs),one of the most detrimental DNA damage.An 18-bp I-SceI homing endonuclease recognition site...

  4. Dynamics of an HBV/HCV infection model with intracellular delay and cell proliferation

    Science.gov (United States)

    Zhang, Fengqin; Li, Jianquan; Zheng, Chongwu; Wang, Lin

    2017-01-01

    A new mathematical model of hepatitis B/C virus (HBV/HCV) infection which incorporates the proliferation of healthy hepatocyte cells and the latent period of infected hepatocyte cells is proposed and studied. The dynamics is analyzed via Pontryagin's method and a newly proposed alternative geometric stability switch criterion. Sharp conditions ensuring stability of the infection persistent equilibrium are derived by applying Pontryagin's method. Using the intracellular delay as the bifurcation parameter and applying an alternative geometric stability switch criterion, we show that the HBV/HCV infection model undergoes stability switches. Furthermore, numerical simulations illustrate that the intracellular delay can induce complex dynamics such as persistence bubbles and chaos.

  5. HBV genotype C is independently associated with cirrhosis in community-based population

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    AIM:To determine the association of hepatitis B virus (HBV) genotypes with probable cirrhosis and fatty liver in community-based populations.METHODS: A multi-stage cluster probability sampling method was applied to recruit 10 167 subjects aged between 6 and 72 years from our epidemiological bases in Eastern China. After excluding the subjects co-infected with hepatitis C or hepatitis D viruses, the hepatitis B surface antigen (HBsAg)-positive subjects were examined for HBV genotype, serum viral load, alanin...

  6. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population.

    Science.gov (United States)

    Tang, Shengli; Yuan, Yufeng; He, Yueming; Pan, Dingyu; Zhang, Yongxi; Liu, Yuanyuan; Liu, Quanyan; Zhang, Zhonglin; Liu, Zhisu

    2014-04-01

    As a multifunctional cytokine, interleukin-6 (IL-6) plays a key role in chronic inflammation as well as tumor growth and progression of hepatitis B virus (HBV) infection. Recent studies have implicated that single nucleotide polymorphism (SNP) -572C>G (rs1800796) located within the promoter region of IL-6 gene was associated with susceptibility to several diseases. Here, a case-control study was undertaken to investigate the association between this polymorphism and HBV-related hepatocellular carcinoma (HCC) susceptibility in a Chinese Han population. A total of 900 patients with chronic HBV infection, including 505 HBV-related HCC patients and 395 HBV infected patients without HCC were enrolled, and rs1800796 polymorphism was genotyped by the TaqMan method and DNA sequencing technology. The results indicated no significant association between rs1800796 polymorphism and the risk of HBV-related HCC in all subjects; however, a significant difference was identified in male subjects. Under the dominant model, male subjects with the G allele (CG/GG) have higher susceptibility to HBV-related HCC than those with CC genotype after adjusting confounding factors (P=0.012, odds ratio [OR] 1.68, 95% confidence interval [95% CI] 1.15-2.42). Our results suggested that rs1800796 polymorphism of IL-6 gene was associated with susceptibility to HBV-related HCC in a male Chinese Han population.

  7. HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers.

    Science.gov (United States)

    Kay, A; Melo da Silva, E; Pedreira, H; Negreiros, S; Lobato, C; Braga, W; Muwonge, R; Dény, P; Reis, M; Zoulim, F; Trepo, C; D'Oliveira, A; Salcedo, J M; Schinoni, M I; Parana, R

    2014-12-01

    HDV infection still remains a serious public health problem in Amazonia. There are few data regarding the biomolecular aspects of HBV/HDV co-infection in this region. We studied 92 patients HBsAg(+) /anti-HDV IgG(+) followed at the Hepatitis Referral Centers of Porto Velho (RO), Rio Branco and Cruzeiro do Sul (AC), Brazil, from March 2006 to March 2007 for whom the HDV and/or the HBV genotype could be determined. The HDV genotype could be determined in 90 patients, while the HBV genotypes could be positively determined in 74. HBV subgenotype F2 is the most prevalent (40.2%), followed by the subgenotypes A1 (15.2%) and D3 (8.7%), while 16.4% were other subgenotypes or genotypes, 4.3% were discordant and 15.2% were unamplifiable. Surprisingly, HDV genotype 3 (HDV-3) was found in all of the HBV/HDV-infected patients that could be genotyped for HDV, confirming that HDV-3 can associate with non-F HBV genotypes. However, a HDV-3 mutant was found in 29.3% of patients and was more frequently associated with non-F HBV genotypes (P HBV genotypes.

  8. 基于同位素标记相对和绝对定量技术筛选乙型肝炎慢加急性肝衰竭患者的血清生物标志物%Screening of serum biomarkers by isobaric tags for relative and absolute quantitation in patients with HBV-related acute-on-chronic liver failure

    Institute of Scientific and Technical Information of China (English)

    刘慧敏; 高方媛; 于浩; 孟培培; 江宇泳; 王宪波

    2016-01-01

    Objective To investigate the screening of serum biomarkers in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) by isobaric tags for relative and absolute quantitation (iTRAQ).Methods Gel electrophoresis was used to isolate and remove high-abundant proteins.Each group ofpeptides was labeled by the iTRAQ reagents and then tested with an UltiMateTM 3000 nanoliter high-performance liquid chromatograph,and a Q-Exactive tandem mass spectrometer.The Protein Discovery software was used to analyze mass spectrometry data and perform bioinformatic analysis for differentially expressed proteins.Results Ten samples each were included in the HBV-ACLF group and the chronic hepatitis B (CHB) group,and six samples each were included in the HBV-ACLF survival group and the HBV-ACLF death group.Compared with the CHB group,the HBV-ACLF group had 43 differentially expressed proteins,among which 34 were downregulated and 9 were upregulated.Compared with the HBV-ACLF survival group,the HBV-ACLF death group had 33 differentially expressed proteins,among which 18 were upregulated and 15 were downregulated.Conclusion Keratin,α1-acid glycoprotein,and zinc-α2-glycoprotein identified in the serum may be used as potential biomarkers for predicting the prognosis of patients with HBV-ACLF.%目的 采用核素标记相对和绝对定量(iTRAQ)技术筛选乙型肝炎慢加急性肝衰竭(HBV-ACLF)患者的血清生物标志物. 方法 本实验采用凝胶电泳法分离、去除高丰度蛋白质,用iTRAQ试剂标记每组肽段后采用UltiMateTM 3000纳升高效液相色谱仪、Q-Exactive串联质谱仪进行检测,Protein Discovery软件分析质谱数据,并对差异表达的蛋白质进行生物信息学分析.结果 HBV-ACLF组、慢性乙型肝炎(CHB)组各纳入10例样本,HBV-ACLF组生存组和死亡组各纳入6例样本.与CHB组比较,HBV-ACLF组差异表达的蛋白共有43个,其中下调的34个,上调的9个;与HBV-ACLF生存组比较,死亡组的差异蛋

  9. Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).

    Science.gov (United States)

    Martel, Nora; Gomes, Selma A; Chemin, Isabelle; Trépo, Christian; Kay, Alan

    2013-11-01

    For functional analysis of HBV isolates, epidemiological studies and correct identification of recombinant genomes, the amplification of complete genomes is necessary. A method for completely in vitro amplification of full-length HBV genomes starting from serum RC-DNA is described. This uses in vitro completion/ligation of plus-strand HBV RC-DNA and amplification using Rolling-Circle Amplification, eventually followed by a genomic PCR. The method can amplify complete HBV genomes from sera with viral loads ranging from >1.0E+8 IU/ml down to 1.0E+3 IU/ml. The method can be applied to archived sera that have undergone long-term storage or to archived DNA serum extracts. The genomes can easily be cloned. HBV genotypes A-G can all be amplified with no apparent problems. A recombinant subgenotype A3/genotype E genome was identified and fully sequenced.

  10. Correlation analysis of hepatic fibrosis related indicators with HBV-DNA level in patients with hepatitis B

    Institute of Scientific and Technical Information of China (English)

    Xiao-Yan Zhang; Bo Wu

    2017-01-01

    Objective:To observe the correlation of HBV-DNA level with hepatic fibrosis related indicators in patients with chronic hepatitis B.Methods: Real-time RT-PCR was used to detect HBV-DNA level. Chemiluminescence was used to detect the hepatic fibrosis related indicators, including PCⅢ, HA, CⅣ, and LN.Results:The serum HBV-DNA level, PCⅢ, HA, CⅣ, and LN in the observation group were significantly higher than those in the control group (P0.05). The serum HBV-DNA level had no linear correlation with HA, PCⅢ, and CⅣ, but was positively correlated with LN (r=0.290,P<0.05).Conclusions:Effective anti-viral therapy and controlling of serum HBV-DNA level can play a positive role in delaying the hepatic fibrosis progression in patients with chronic hepatitis B.

  11. 乙型肝炎血清标志物和HBV-DNA载量相关性分析%Study on the correlation between serum markers of hepatitis B and HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    罗慧琴; 王志刚; 李玲; 刘付芹

    2013-01-01

    目的 探讨乙肝血清标志物与病毒DNA水平之间的相关性.方法 采用实时荧光定量PCR对874例HBV感染者血清中HBV-DNA含量进行检测,同时运用ELISA法检测HBV血清标志物,并统计分析患者乙型肝炎血清标志物、病毒DNA之间的相关性及分布特点.结果 在受检的874例标本中,男性533例,阳性率58.16% (310/533);女性341例,阳性率50.44%(172/341),男性和女性阳性率比较差异有统计学意义(X2=5.01,P<0.05),男性和女性HBV-DNA水平差异无统计学意义(t =0.117,P=0.907).乙肝总阳性率和HBV-DNA水平均随年龄的增长呈下降趋势,不同年龄组间比较差异有统计学意义.同一年龄段的大三阳与小三阳、两头阳和三抗阳之间比较差异有统计学意义;其中男性和女性HBV-DNA水平随年龄增长均呈下降趋势,差异有统计学意义.≤20岁以下人群HBV-DNA阳性率最高达82.86%.结论 HBV-DNA阳性率和HBV-DNA水平都随年龄增长呈下降趋势,其中≤20岁年龄段HBV-DNA阳性率最高达82.86%;男性HBV-DNA的阳性率高于女性.%Objective To investigate the correlation between HBV serum markers and HBV DNA levels.Methods HBV-DNA and serum markers in 874 cases of HBV infected persons were detected by real-time fluorescence quantitative PCR and ELISA,respectively.SPSS 16.0 was used to analyze the correlation and distribution characteristics.Results In 874 cases,533 positive cases were male,the positive rate was 58.16% (310/533).341 positive cases were female,the positive rate was 50.44% (172/341).There was statistical difference (x2 =5.01,P <0.05) comparing male with female.But there was no statistical difference (t =0.117,P =0.907) in HBV-DNA level between male and female.The total positive rate and HBV-DNA level showed descending tendency with age,and there were statistical differences among different age groups.When comparing big 3 this world,small 3 this world,two head positive and three antibody positive

  12. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.

    Directory of Open Access Journals (Sweden)

    Ying Yin

    Full Text Available BACKGROUND: Typically, DNA immunization via the intramuscular route induces specific, Th1-dominant immune responses. However, plasmids expressing viral proteins fused to cytotoxic T lymphocyte antigen 4 (CTLA-4 primed Th2-biased responses and were able to induced effective protection against viral challenge in the woodchuck model. Thus, we addressed the question in the mouse model how the Th1/Th2 bias of primed immune responses by a DNA vaccine influences hepatitis B virus (HBV clearance. PRINCIPAL FINDINGS: Plasmids expressing HBV core protein (HBcAg or HBV e antigen and HBcAg fused to the extracellular domain of CTLA-4 (pCTLA-4-HBc, CD27, and full length CD40L were constructed. Immunizations of these DNA plasmids induced HBcAg-specific antibody and cytotoxic T-cell responses in mice, but with different characteristics regarding the titers and subtypes of specific antibodies and intensity of T-cell responses. The plasmid pHBc expressing HBcAg induced an IgG2a-dominant response while immunizations of pCTLA-4-HBc induced a balanced IgG1/IgG2a response. To assess the protective values of the immune responses of different characteristics, mice were pre-immunized with pCTLA-4-HBc and pHBc, and challenged by hydrodynamic injection (HI of pAAV/HBV1.2. HBV surface antigen (HBsAg and DNA in peripheral blood and HBcAg in liver tissue were cleared with significantly accelerated kinetics in both groups. The clearance of HBsAg was completed within 16 days in immunized mice while more than 50% of the control mice are still positive for HBsAg on day 22. Stronger HBcAg-specific T-cell responses were primed by pHBc correlating with a more rapid decline of HBcAg expression in liver tissue, while anti-HBs antibody response developed rapidly in the mice immunized with pCTLA-4-HBc, indicating that the Th1/Th2 bias of vaccine-primed immune responses influences the mode of viral clearance. CONCLUSION: Viral clearance could be efficiently achieved by Th1/Th2-balanced

  13. Inhibition of Hepatitis B Virus Replication by Rheum palmatum L. Ethanol Extract in a Stable HBV-producing Cell

    Institute of Scientific and Technical Information of China (English)

    Yan SUN; Li-jun LI; Jing LI; Zhi LI

    2007-01-01

    Hepatitis B virus(HBV) infection is a severe health problem in the world.However,there is still not a satisfactory therapeutic strategy for the HBV infection.To search for new anti-HBV agents with higher efficacy and less side-effects,the inhibitory activities of traditional Chinese medicine Rheum palmatum L.ethanol extract(RPE) against HBV replication were investigated in this study.Quantitative real-time polymerase chain reaction(PCR) was employed to analyze the inhibitory activity of RPE against HBV-DNA replication in a stable HBV-producing cell line HepAD38; the expression levels of HBV surface antigen(HBsAg) and e antigen(HBeAg) were also determined by enzyme linked immunosorbent assay(ELISA) after RPE treatment.RPE could dose-dependently inhibit the production of HBV-DNA and HBsAg.The concentration of 50% inhibition(IC50) was calculated at 209.63,252.53 μg/mL,respectively.However,its inhibitory activity against HBeAg expression was slight even at high concentrations.RPE had a weak cytotoxic effect on HepAD38 cells(CC50 = 1 640 μg/mL) and the selectivity index(SI) was calculated at 7.82.Compared with two anthraquinone derivatives emodin and rhein,RPE showed higher ability of anti-HBV and weaker cytotoxicity.So Rheum palmatum L.might possess other functional agents which could effectively inhibit HBV-DNA replication and HBsAg expression.Further purification of the active agents,identification and modification of their structures to improve the efficacy and decrease the cytotoxicity are required.

  14. 乙型肝炎病毒分子生物学检测研究进展%Advancement in molecular microbiological researches of HBV

    Institute of Scientific and Technical Information of China (English)

    乔宏; 马彦

    2003-01-01

    乙型肝炎病毒(HBV)的分子生物学检测主要是HBV DNA的检测,HBV DNA常用分子杂交法或聚合酶链反应(PCR)法检测.文中对近年来HBV DNA分子生物检测方法的改进作了介绍,并对其中存在的问题予以探讨.

  15. 聚集性HBV感染家系中父亲HBsAg阳性家庭传播特点分析%Characteristics of HBV transmission in families with HBsAg-positive fathers and familial clustering of HBV infection

    Institute of Scientific and Technical Information of China (English)

    杨瑗; 金李; 何英利; 刘锦锋; 王静; 王科; 马晓华; 李倩; 冯玉岭

    2016-01-01

    Objective To investigate the characteristics of hepatitis B virus (HBV) transmission among family members in families with familial clustering of HBV infection and poor outcomes,as well as the prevalence and distribution characteristics of HBsAg in offspring with different parental HBsAg status.Methods The general information of each member in families with poor outcomes were collected from 2007 to 2010,and serological test was performed to analyze the prevalence and distribution of HBsAg in family members.The chi-square test or Fisher's exact test was used to analyze and compare the sex of offspring and the prevalence of HBsAg in them in 266 nuclear families with different paternal and maternal HBsAg status.Results The positive rates of HBsAg in parents,siblings,children,and spouses of the probands were 20%,88.2%,76.8%,and 9.5%,respectively.The nuclear families with HBsAg-positive fathers and HBsAg-negative mothers had a significantly increased proportion of male offspring (male/female ratio =2.02) compared with those with HBsAg-positive mothers and HBsAg-negative fathers (1.22) or those with HBsAg-negative fathers and mothers (0.96).In addition,in the nuclear families with HBsAg-positive fathers and HBsAg-negative mothers,the male offspring had a significantly higher HBsAg positive rate than female offspring (37.4% vs 13.8%),while in those with HBsAg-positive mothers and HBsAg-negative fathers or those with HBsAg-negative fathers and mothers,HBsAg positive rate showed no significant difference between male and female offspring.Conclusion In families with familial clustering of HBV infection and poor outcomes,mother-to-child transmission is still the major route of HBV transmission,but father-to-child transmission also plays a role in HBV transmission in this special population.Positive HBsAg in fathers is associated with the increased proportion of male offspring,and father-to-son transmission of HBV is higher than father-to-daughter transmission

  16. 慢性乙型肝炎患者乙型肝炎病毒外膜大蛋白与病毒复制的相关性研究%Relativity between large protein of HBV membrane and virus replication in patients with HBV infection in Lanzhou

    Institute of Scientific and Technical Information of China (English)

    李彩东; 吴斌; 段正军; 田鹏飞

    2014-01-01

    目的:探讨慢性乙型肝炎病毒(HBV)感染患者血清乙型肝炎病毒外膜大蛋白(HBV-LP)与 HBV-DNA、HBeAg之间的关系及临床应用价值。方法2010年10月-2011年5月采用酶联免疫吸附法(ELISA )检测乙型肝炎病毒患者血清中 HBV-LP ,化学发光免疫分析法(CLIA)检测乙型肝炎病毒标志物(HBV-M ),实时荧光定量PCR法(RT-PCR)检测HBV DNA载量,比较分析三者间的阳性率及相关性,数据采用SPSS17.0软件进行统计分析。结果1036例慢性 HBV感染者中,HBV-LP阳性率为84.36%,较 HBV-DNA阳性率72.01%与HBeAg阳性率54.44%均高,差异有统计学意义(P<0.01);HBV-LP与 HBV-DNA和 HBeAg的总符合率分别为78.19%、64.48%,HBV-LP与 HBV-DNA和 HBeAg阳性符合率分别为93.43%、94.86%;HBV-LP表达与HBV-DNA和HBeAg之间均显著关联(χ2=101.67,χ2=65.35),差异有统计学意义(P<0.01)。结论 HBV-LP是反映HBV感染者体内复制程度的良好血清免疫学指标,血清中 HBV-LP与 HBV-DNA具有较好的相关性,特别是可作为 HBeAg阴性患者检测病毒复制及预后判断的良好的指标。%OBJECTIVE To discuss the relationship between HBV-LP , HBV-DNA and HBeAg in patients with HBV infection in Lanzhou ,and its clinical application .METHODS ELISA ,CLIA and RT-PCR were used to detect HBV-LP ,HBV-M and HBV DNA ,respectively ,and the relativity between them was analyzed .The data were analyzed by SPSS17 .0 software .RESULTS In 1036 patients ,the positive rate of HBV-LP was 84 .36% ,higher than HBV DNA (72 .01% ) and HBeAg (54 .44% ) ,the difference was significant(P<0 .01) .The total consistent rates of HBV-LP to HBV-DNA and HBeAg were 78 .19% ,64 .48% .The positive consistent rates of HBV-LP to HBV-DNA and HBeAg were 93 .43% ,94 .86% . HBV-LP expression with HBV-DNA and HBeAg showed significant correlation (χ2 = 101 .67 ,χ2 = 65 .35) ,and the difference

  17. MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication

    Directory of Open Access Journals (Sweden)

    Ying Yang

    2017-01-01

    Full Text Available Background/Aims: About 400 million individuals are chronically infected with hepatitis B virus, at high risk of developing liver cirrhosis and hepatocellular carcinoma. Recent studies have demonstrated an interaction between hepatitis B virus replication and autophagy activity of hepatocytes. In the present study, we aimed to investigate the role of miR-141 in regulating autophagy and hepatitis B virus replication. Methods: The expression of HBV-DNA, miR-141 and Sirt1 mRNA was determined by quantitative real-time PCR analysis. The expression of HBsAg and HBeAg was determined by ELISA. Western blotting was performed to detect protein expression. The LC3 puncta was determined by immunofluorescence. To test whether miR-141 directly regulate the expression level of Sirt1 mRNA, dual-luciferase reporter gene assay was performed. Results: In vitro studies showed that miR-141 mimic inhibited the autophagic response, hepatitis B virus and the expression of Sirt1 in hepatocytes. And transfection with miR-141 inhibitor enhanced autophagic response and Sirt1 expression. The autophagy induced by overexpression of Sirt1 was inhibited by miR-141 mimic. In addition, miR-141 mimic also decreased the expression of Sirt1 mRNA. Sirt1 was predicted as a potential miR-141 target by bioinformatic analysis of its 3'-UTR, and confirmed by luciferase reporter assays which analyzing the interaction of miR-141 with the wild- type or the mutated Sirt1 3’-UTR. Conclusion: We have therefore demonstrated a role of miR-141 in regulating autophagy-mediated hepatitis B virus inhibition by targeting Sirt1, and may provide potential targets for drug development.

  18. 探讨乙型肝炎病毒携带产妇HBV-DNA水平对新生儿的影响

    Institute of Scientific and Technical Information of China (English)

    曹玲; 朱凡; 曾崇亮

    2014-01-01

    Objective To explore the effect on the newborn of maternal HBV-DNA levels in HBV carriers.So as to guide the treatment during pregnancy and breast feeding.Methods 120 cases of puerperas carried HBV were chosen from January 2012 to December 2012.The HBV-DNA levels in maternal serum,breast milk and neonatus serum were detected.And the results were an-alyzed comprehensively.Results The maternal serum HBV-DNA quantity of 64 cases were lower than 500 copies/mL.There was one case of breast milk HBV-DNA positive and one case of neonatal serum HBV-DNA positive.The maternal serum HBV-DNA quantity of 29 cases ranged from 500 copies/mL to <1.0×106 copies/mL,4 cases showed HBV-DNA positive in breast milk,and no one showed HBV-DNA positive in neonatal serum.The maternal serum HBV-DNA quantity of 27 cases were ≥1.0×106 cop-ies/mL,25 cases showed HBV-DNA positive in breast milk,and one case showed HBV-DNA positive in neonatal serum.ConclusionWhen maternal serum HBV-DNA quantity was 1.0×106 copies/mL,the HBV-DNA positive rate in breast milk increases sharp-ly,and breastfeeding should be prohibited.Maternal serum HBV-DNA concentration has little effect on intrauterine transmission.%目的:探讨乙型肝炎病毒携带产妇血清 HBV-DNA水平对乳汁和新生儿 HBV-DNA水平的影响,以此指导孕期处理和喂养方式。方法选择2012年1~12月的乙型肝炎病毒携带产妇120例,检测产妇血清、乳汁和新生儿血清中的 HBV-DNA水平,对结果进行综合分析。结果64例产妇血清 HBV-DNA<500 copies/mL,其乳汁 HBV-DNA 检出阳性为1例,新生儿血清 HBV-DNA 检出阳性1例;29例产妇血清 HBV-DNA水平为500 copies/mL至1.0×106 copies/mL,其中4例乳汁HBV-DNA检出阳性,新生儿血清 HBV-DNA检测均为阴性;27例产妇血清 HBV-DNA水平大于或等于1.0×106 copies/mL,其中25例乳汁 HBV-DNA阳性,1例新生儿血清 HBV-DNA检测阳性。结论产妇血清 HBV-DNA 水平大于或等于1.0

  19. Preparation and Determination of Immunological Activities of Anti-HBV Egg Yolk Extraction

    Institute of Scientific and Technical Information of China (English)

    Yanping Xu; Weimin Zou; Xuejun Zhan; Shuhua Yang; Daze Xie; Sailiang Peng

    2006-01-01

    To prepare an effective immune preparation to treat hepatitis B, hens were immunized with hepatitis B vaccines,and then anti-HBV egg yolk extraction (anti-HBV EYE) was refined from egg yolk by a dialyzable method. Its chemical characteristics were identified by ultraviolet spectrum, HPLC, Lowry analysis and pharmacopocia-raleted methods. The specific immunological activity was examined by leukocyte adherence inhibition (LAI) in vitro and delayed type hypersensitivity (DTH) in vivo. Anti-HBV EYE was a small dialyzable substance with molecular weight less than 12 kD containing 18 kinds of amino acids. The preparation could obviously inhibit LAI and DTH which was similar to hepatitis B virus-specific transfer factor of pig spleen. However, there were no similar effects observed in the nonspecific transfer factor (NTF) group, control egg yolk extraction (CEYE) group and hepatitis A virus (HAV) group. The results suggested that anti-HBV EYE contained hepatitis B virus-specific transfer factor(STF) and had the antigen-specific cell immune activity similar to PSHBV-TF. The STF obtained from egg yolk of the hens immunized with specific antigen, might be a potential candidate for immunoregulation in hepatitis B prevention and treatment.

  20. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine.

    Science.gov (United States)

    Tsai, Horng-Jyh

    2015-04-01

    Approximately 2 million new cancer cases are attributed to infectious agents each year worldwide. Vaccines for the hepatitis B virus (HBV), a risk factor of hepatocellular cancer, and human papillomavirus (HPV), a risk factor of cervical cancer, are considered major successes in clinical chemoprevention of cancer. In Taiwan, the first evidence of cancer prevention through vaccinations was provided by HBV vaccination data in infants. The Taiwanese HBV vaccination program has since become a model immunization schedule for newborns worldwide. Persistent infection with high-risk HPV is generally accepted as prerequisite for cervical cancer diagnosis; however, cervical cancer is a rare complication of HPV infections. This is due to the fact that such infections tend to be transient. The safety and efficacy of both available HPV quadrivalent vaccine and bivalent vaccine are not in doubt at the present time. Until a human cytomegalovirus (CMV) vaccine becomes available, simple hygienic practices, such as hand washing, can prevent CMV infection both before and during pregnancy. Each country should establish her official guidelines regarding which vaccines should be used to treat various conditions, the target population (i.e., universal or limited to a selected population), and the immunization schedules. After a vaccine is recommended, decisions regarding reimbursement by the public health care fund are evaluated. The guidelines become part of the immunization schedule, which is updated annually and published in the official bulletin. In conclusion, both HBV and HPV vaccines are considered major successes in the chemoprevention of cancer.

  1. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV

    Institute of Scientific and Technical Information of China (English)

    Di-Peng Ou; Lian-Yue Yang; Geng-Wen Huang; Yi-Ming Tao; Xiang Ding; Zhi-Gang Chang

    2005-01-01

    AIM: To comprehend the risk factors of recurrence of hepatocellular carcinoma (HCC) and its relationship with the infection patterns of hepatitis B virus (HBV). METHODS: All materials of 270 cases of postoperative HCC were statistically analyzed by SPSS software. Recurrence and metastasis were classified into early (≤2 years) and late phase (>2 years). Risk factors for recurrence and metastasis after surgery in each group were analyzed.RESULTS: Out of 270 cases of HCC, 162 cases were followed up in which recurrence and metastasis occurred in 136 cases. There were a lot of risk factors related to recurrence and metastasis of HCC; risk factors contributing to early phase recurrence were serum AFP level, vascular invasion, incisal margin and operative transfusion, gross tumor classification and number of intrahepatic node to late phase recurrence. The HBV infective rate of recurrent HCC was 94.1%, in which "HBsAg, HBeAb, HBcAb" positive pattern reached 45.6%. The proportion of HBV infection in solitary large hepatocellular carcinoma (SLHCC) evidently decreased compared to nodular hepatocellular carcinoma (NHCC) (P<0.05).CONCLUSION: The early and late recurrence and metastasis after hepatectomy of HCC were associated with different risk factors. The early recurrence may be mediated by vascular invasion and remnant lesion, the late recurrence by tumor's clinical pathology propert, as multicentric carcinogenesis or intrahepatic carcinoma denovo. HBV replication takes a great role in this process. From this study, we found that SLHCC has more satisfactory neoplasm biological behavior than NHCC.

  2. Thermodynamics and NMR studies on Duck, Heron and Human HBV encapsidation signals

    NARCIS (Netherlands)

    Girard, F.C.; Ottink, O.M.; Ampt, K.A.; Tessari, M.; Wijmenga, S.S.

    2007-01-01

    Hepatitis B virus (HBV) replication is initiated by binding of its reverse transcriptase (P) to the apical stem-loop (AL) and primer loop (PL) of epsilon, a highly conserved RNA element at the 5'-end of the RNA pregenome. Mutation studies on duck/heron and human in vitro systems have shown similarit

  3. Study on the risk factors related vertical transmission of HBV positive couples to their infant

    Institute of Scientific and Technical Information of China (English)

    张荣莲

    2013-01-01

    Objective To explore the risk factors and the rate of HBV vertical transmission from HBsAg-positive couple to their infant. Methods 46 families who had antenatal examination at Fujian Provincial Maternal and Child Health Hospital during August 2010 and November 2011 were

  4. Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV.

    Science.gov (United States)

    Qin, Yannan; Zhong, Yaogang; Ma, Tianran; Wu, Fei; Wu, Haoxiang; Yu, Hanjie; Huang, Chen; Li, Zheng

    2016-04-01

    The incidence of hepatocellular carcinoma (HCC) is closely correlated with hepatitis B virus (HBV)-induced liver cirrhosis. Structural changes in the glycans of serum and tissue proteins are reliable indicators of liver damage. However, little is known about the alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV infection. This study compared the differential expression of liver glycopatterns in 7 sets of normal pericarcinomatous tissues (PCTs), cirrhotic, and tumor tissues from patients with liver cirrhosis and HCC induced by HBV using lectin microarrays. Fluorescence-based lectin histochemistry and lectin blotting were further utilized to validate and assess the expression and distribution of certain glycans in 9 sets of corresponding liver tissue sections. Eight lectins (e.g., Jacalin and AAL) revealed significant difference in cirrhotic tissues versus PCTs. Eleven lectins (e.g., EEL and SJA) showed significant alteration during cirrhotic and tumor progression. The expression of Galα1-3(Fucα1-2)Gal (EEL) and fucosyltransferase 1 was mainly increasing in the cytoplasm of hepatocytes during PCTs-cirrhotic-tumor tissues progression, while the expression of T antigen (ACA and PNA) was decreased sharply in cytoplasm of tumor hepatocytes. Understanding the precision alteration of liver glycopatterns related to the development of hepatitis, cirrhosis, and tumor induced by HBV infection may help elucidate the molecular mechanisms underlying the progression of chronic liver diseases and develop new antineoplastic therapeutic strategies.

  5. Expression of HLA class Ⅰ and Ⅱ on peripheral blood lymphocytes in HBV infection

    Institute of Scientific and Technical Information of China (English)

    WANG Chuan-xin; WANG Jin-feng; LIU Min; ZOU Xiong; YU Xiu-ping; YANG Xiao-jing; ZHENG Gui-xi

    2006-01-01

    @@ Persistent hepatitis B virus (HBV) infection is the most important reason for chronic hepatitis B,hepatic cirrhosis, and hepatocellular carcinoma.1 T lymphocytes, including CD4+ and CD8+ T cells, are major composition of host cellular immunity.Furthermore, CD8+ cells play a primary role in host immune reaction of anti-tumor and anti-infection.

  6. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy.

    Science.gov (United States)

    Dini, Guglielmo; Toletone, Alessandra; Barberis, Ilaria; Debarbieri, Nicoletta; Massa, Emanuela; Paganino, Chiara; Bersi, Francesca; Montecucco, Alfredo; Alicino, Cristiano; Durando, Paolo

    2017-02-01

    Vaccination against Hepatitis B Virus (HBV) became mandatory in Italy for all newborns and 12 years-old individuals in the 1991. The immunogenicity of HBV vaccine and the effectiveness of the universal immunization strategy have been widely demonstrated. However the need to assess the antibody concentrations above the well known serological correlate of protection for HBV infection (≥10 mIU/mL), established in individuals immunized with a 3 doses vaccination course, is still recommended in subjects exposed to occupational risks in different settings, particularly the healthcare services. This practice has to be performed during the preventive medical examination, before the worker's exposure to biological hazards, as a fundamental part of Occupational Health Surveillance Programs in several Countries, including Italy: the goal is to assure individual protection, also providing booster doses when needed, after many years following the primary vaccination. During the 2011-2013 period, an observational study was performed in Healthcare students (HCSs) trained at a regional university acute-care hospital in North-Western Italy, properly immunized against HBV during infancy or adolescence, in order to evaluate the persistence of seroprotection and to assess the anamnestic response to booster vaccination. Data from 717 subjects undergoing HbsAg Ab and HBc Ab testing during the preventive medical examination, and receiving a booster dose of HBV vaccine when resulting with a non-protective titer (<10 mIU/mL), were collected and analyzed. Most of the HCSs (74.6%) included in the survey, mean age 24.8 y ( ± 4.6 SD), had received the primary vaccination course during the first year of life (3-5-11 months). Globally, 507 (70.7%) HCSs showed protective antibody titres, and an anamnestic response was observed in more than 95% subjects receiving the booster dose. Our study demonstrated the long-term persistence of protection of HBV vaccine, more than 20 y following the

  7. Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy

    Science.gov (United States)

    Dini, Guglielmo; Toletone, Alessandra; Debarbieri, Nicoletta; Massa, Emanuela; Bersi, Francesca; Montecucco, Alfredo; Alicino, Cristiano; Durando, Paolo

    2017-01-01

    ABSTRACT Vaccination against Hepatitis B Virus (HBV) became mandatory in Italy for all newborns and 12 years-old individuals in the 1991. The immunogenicity of HBV vaccine and the effectiveness of the universal immunization strategy have been widely demonstrated. However the need to assess the antibody concentrations above the well known serological correlate of protection for HBV infection (≥10 mIU/mL), established in individuals immunized with a 3 doses vaccination course, is still recommended in subjects exposed to occupational risks in different settings, particularly the healthcare services. This practice has to be performed during the preventive medical examination, before the worker's exposure to biological hazards, as a fundamental part of Occupational Health Surveillance Programs in several Countries, including Italy: the goal is to assure individual protection, also providing booster doses when needed, after many years following the primary vaccination. During the 2011–2013 period, an observational study was performed in Healthcare students (HCSs) trained at a regional university acute-care hospital in North-Western Italy, properly immunized against HBV during infancy or adolescence, in order to evaluate the persistence of seroprotection and to assess the anamnestic response to booster vaccination. Data from 717 subjects undergoing HbsAg Ab and HBc Ab testing during the preventive medical examination, and receiving a booster dose of HBV vaccine when resulting with a non-protective titer (<10 mIU/mL), were collected and analyzed. Most of the HCSs (74.6%) included in the survey, mean age 24.8 y ( ± 4.6 SD), had received the primary vaccination course during the first year of life (3–5–11 months). Globally, 507 (70.7%) HCSs showed protective antibody titres, and an anamnestic response was observed in more than 95% subjects receiving the booster dose. Our study demonstrated the long-term persistence of protection of HBV vaccine, more than 20

  8. [Requirement of standardizing anti-HBs assay methods in Japan for HBV infection-preventing strategy--discrepancy of anti-HBs measurements among three different kits widely used in Japan].

    Science.gov (United States)

    Ogata, Norio

    2006-09-01

    The strategy to eliminate hepatitis B virus (HBV) infection by administrating an HB vaccine is changing worldwide; however, this is not the case in Japan. An important concern about the HBV infection-preventing strategy in Japan may be that the assay methods for the antibody to hepatitis B surface antigen (anti-HBs) are not standardized. The minimum protective anti-HBs titer against HBV infection has been established as 10 mIU/ml by World Health Organization (WHO) -standardized assay methods worldwide, but that is still determined as a "positive" test result by the passive hemagglutination (PHA) method in Japan. We compared anti-HBs measurements in given samples among PHA(Mycell II, Institute of Immunology), chemiluminescent enzyme immunoassay (CLEIA) (Lumipulse, Fujirebio), and chemiluminescent immunoassay (CLIA) (Architect, Abbott), all of which are currently in wide use in Japan. First, anti-HBs measurements in serum from individuals who received a yeast-derived recombinant HB vaccine composed of the major surface protein of either subtype adr or subtype ayw were compared. The results clearly showed that in subtype adr-vaccinees CLIA underestimated the anti-HBs amount compared with CLEIA and PHA, but in ayw-vaccinees, the discordance in the measurements among the three kits was not prominent. Second, anti-HBs measurements in standard or calibration solutions of each assay kit were compared. Surprisingly, CLEIA showed higher measurements in all three kit-associated standard or calibration solutions than CLIA. Thus, the anti-HBs titer of 10 mIU/ml is difficult to introduce in Japan as the minimum protective level against HBV infection. Efforts to standardize anti-HBs assay methods are expected to share international evidence about the HBV infection-preventing strategy.

  9. Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70

    Directory of Open Access Journals (Sweden)

    Bian Zhongqi

    2012-11-01

    Full Text Available Abstract Background Hepatitis B virus (HBV infection is a major health concern with more than two billion individuals currently infected worldwide. Because of the limited effectiveness of existing vaccines and drugs, development of novel antiviral strategies is urgently needed. Heat stress cognate 70 (Hsc70 is an ATP-binding protein of the heat stress protein 70 family. Hsc70 has been found to be required for HBV DNA replication. Here we report, for the first time, that combined siRNAs targeting viral gene and siHsc70 are highly effective in suppressing ongoing HBV expression and replication. Methods We constructed two plasmids (S1 and S2 expressing short hairpin RNAs (shRNAs targeting surface open reading frame of HBV(HBVS and one plasmid expressing shRNA targeting Hsc70 (siHsc70, and we used the EGFP-specific siRNA plasmid (siEGFP as we had previously described. First, we evaluated the gene-silencing efficacy of both shRNAs using an enhanced green fluorescent protein (EGFP reporter system and flow cytometry in HEK293 and T98G cells. Then, the antiviral potencies of HBV-specific siRNA (siHBV in combination with siHsc70 in HepG2.2.15 cells were investigated. Moreover, type I IFN and TNF-α induction were measured by quantitative real-time PCR and ELISA. Results Cotransfection of either S1 or S2 with an EGFP plasmid produced an 80%–90% reduction in EGFP signal relative to the control. This combinational RNAi effectively and specifically inhibited HBV protein, mRNA and HBV DNA, resulting in up to a 3.36 log10 reduction in HBV load in the HepG2.2.15 cell culture supernatants. The combined siRNAs were more potent than siHBV or siHsc70 used separately, and this approach can enhance potency in suppressing ongoing viral gene expression and replication in HepG2.2.15 cells while forestalling escape by mutant HBV. The antiviral synergy of siHBV used in combination with siHsc70 produced no cytotoxicity and induced no production of IFN-α, IFN-β and TNF

  10. Molecular analysis of HBV genotypes and subgenotypes in the Central-East region of Tunisia

    Directory of Open Access Journals (Sweden)

    Gharbi Jawhar

    2010-11-01

    Full Text Available Abstract Background In Tunisia, country of intermediate endemicity for Hepatitis B virus (HBV infection, most molecular studies on the virus have been carried out in the North of the country and little is known about other regions. The aim of this study was to determine HBV genotype and subgenotypes in Central-East Tunisia. A total of 217 HBs antigen positive patients were enrolled and determination of genotype was investigated in 130 patients with detectable HBV DNA. HBV genotyping methods were: PCR-RFLP on the pre-S region, a PCR using type-specific primers in the S region (TSP-PCR and partial sequencing in the pre-S region. Results Three genotypes (D, B and A were detected by the PCR-RFLP method and two (D and A with the TSP-PCR method, the concordance between the two methods was 93%. Sequencing and phylogenetic analysis of 32 strains, retrieved the same genotype (D and A for samples with concordant results and genotype D for samples with discordant results. The sequences of discordant genotypes had a restriction site in the pre-S gene which led to erroneous result by the PCR-RFLP method. Thus, prevalence of genotype D and A was 96% and 4%, respectively. Phylogenetic analysis showed the predominance of two subgenotypes D1 (55% and D7 (41%. Only one strain clustered with D3 subgenotype (3%. Conclusions Predominance of subgenotype D7 appears to occur in northern regions of Africa with transition to subgenotype D1 in the East of the continent. HBV genetic variability may lead to wrong results in rapid genotyping methods and sequence analysis is needed to clarify atypical results.

  11. Correlation of Primary Hepatocellular Carcinoma with HBV Genotypes, Subgenotypes and Gene Mutations in Gansu Province

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Objective To investigate the occurrence of basal core promoter (BCP) and pre-C mutations in patients with hepatitis B virus (HBV) infection in Gansu Province, China, and to analyze the correlation of HBV mutation and HBV genotype with primary hepatocellular carcinoma (HCC). Methods PCR-RFLP was applied to detect HBV subgenotypes, and the presence of the pre-C and BCP mutations in 62 patients with HCC, 70 patients with hepatitis B induced liver cirrhosis (LC) and 90 patients with chronic hepatitis B (CHB). Results In HCC patients, genotype C was the major genotype (70.97%). The pre-C mutation was found in 59.68%, 31.43% and 16.67% patients with HCC, LC and CHB, respectively. The frequency of BCP mutations was signiifcantly different between patients with HCC, LC and CHB (74.19%, 51.43% and 37.78%, respectively;χ2=30.727, 19.540, respectively,P < 0.01). Patients in HCC group had a higher incidence of pre-C as well as BCP mutations compared to the other groups. The prevalence of pre-C and BCP mutations was signiifcantly higher in patients with genotype C1 (44.32% and 69.32%, respectively) compared to patients with other subgenotypes (P < 0.05). Conclusions The incidence of pre-C and BCP mutations increases with disease progression. Pre-C and BCP mutations frequently occur in patients with genotype C1. HBV genotype C, pre-C mutations and BCP mutations are closely related to the occurrence of HCC.

  12. Synergistic Action of Clonorchiasis,HBV Infection and Alcohol Consumption on Primary Hepatocellular Carcinoma

    Institute of Scientific and Technical Information of China (English)

    Shengkui Tan; Xiaoqiang Qiu; Hongping Yu; Xiaoyun Zeng; Zengming Xiao; Lequn Li; Qiuan Zhong

    2009-01-01

    OBJECTIVE It has been recognized that HBV infection and alcohol consumption are two important risk factors for primary hepatocellular carcinoma(HCC).Recently,the role of clonorchiasis as a risk factor for HCC is controversial.We aimed to investigate whether these factors increase the risk of HCC in Guangxi,China.METHODS A hospital-based,case-control study of HCC was conducted from July 2005 to July 2007.We enrolled 500consecutive patients with HCC as an experimental group and 500patients without tumor in liver as a control group.nle risk factors that the patients were exposed to were assessed.RESULTS Comparing the risks of developing the HCC,we found out the following results.The risk of developing HCC for the patients with clonorchiasis was 5 folds of that for the patients without clonorchiasis(OR=5.0;95%CI:3.1-8.1),and the risk for the patients with alcohol consumption was 3 folds of that for the patients without drinking alcohol(OR=3.4;95%CI:2.3-4.9),and similarly,the risk for the patients with HBV infection was 21 times of that for the patients without HBV infection (OR=20.6;95% CI:14.3-29.7).According to crossover analysis,there was significant interaction among clonorchiasis,HBV infection and alcohol consumption,with synergistic indices greater than 1.The etiologic fractions attributed to these interactions [EF(A x B)] are 0.7465,0.5789 and 0.5506,respectively.CoNCLUSION Clonorchiasis,HBV infection and heavy alcohol consumption are independent risk factors for developing HCC in our population in Guangxi,and as they can interact synergistically,the risk of developing HCC is increased.Data from this study may indicate new prevention strategies of developing HCC in hish-risk individuals.

  13. Blocking peptides against HBV: PreS1 protein selected from a phage display library

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Wei; Liu, Yang; Zu, Xiangyang; Jin, Rui [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China); Xiao, Gengfu, E-mail: xiaogf@wh.iov.cn [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China)

    2011-09-09

    Highlights: {yields} Successfully selected specific PreS1-interacting peptides by using phage displayed library. {yields} Alignment of the positive phage clones revealed a consensus PreS1 binding motif. {yields} A highly enriched peptide named P7 had a strong binding ability for PreS1. {yields} P7 could block PreS1 attachment. -- Abstract: The PreS1 protein is present on the outermost part of the hepatitis B virus (HBV) surface and has been shown to have a pivotal function in viral infectivity and assembly. The development of reagents with high affinity and specificity for PreS1 is of great significance for early diagnosis and treatment of HBV infection. A phage display library of dodecapeptide was screened for interactions with purified PreS1 protein. Alignment of the positive phage clones revealed a putative consensus PreS1 binding motif of HX{sub n}HX{sub m}HP/R. Moreover, a peptide named P7 (KHMHWHPPALNT) was highly enriched and occurred with a surprisingly high frequency of 72%. A thermodynamic study revealed that P7 has a higher binding affinity to PreS1 than the other peptides. Furthermore, P7 was able to abrogate the binding of HBV virions to the PreS1 antibody, suggesting that P7 covers key functional sites on the native PreS1 protein. This newly isolated peptide may, therefore, be a new therapeutic candidate for the treatment of HBV. The consensus motif could be modified to deliver imaging, diagnostic, and therapeutic agents to tissues affected by HBV.

  14. TGF-β suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex.

    Directory of Open Access Journals (Sweden)

    Guoxin Liang

    2015-04-01

    Full Text Available Transforming growth factor (TGF-β inhibits hepatitis B virus (HBV replication although the intracellular effectors involved are not determined. Here, we report that reduction of HBV transcripts by TGF-β is dependent on AID expression, which significantly decreases both HBV transcripts and viral DNA, resulting in inhibition of viral replication. Immunoprecipitation reveals that AID physically associates with viral P protein that binds to specific virus RNA sequence called epsilon. AID also binds to an RNA degradation complex (RNA exosome proteins, indicating that AID, RNA exosome, and P protein form an RNP complex. Suppression of HBV transcripts by TGF-β was abrogated by depletion of either AID or RNA exosome components, suggesting that AID and the RNA exosome involve in TGF-β mediated suppression of HBV RNA. Moreover, AID-mediated HBV reduction does not occur when P protein is disrupted or when viral transcription is inhibited. These results suggest that induced expression of AID by TGF-β causes recruitment of the RNA exosome to viral RNP complex and the RNA exosome degrades HBV RNA in a transcription-coupled manner.

  15. Incidence of HBV variants with a mutation at nt551 among hepatitis B patients in Nanjing and its neighbourhood

    Institute of Scientific and Technical Information of China (English)

    Chun-Ling Ma; De-Xing Fang; Kun Yao; Fa-Qing Li; Hui-Ying Jin; Su-Qin Li; Wei-Guo Tan

    2005-01-01

    AIM: To investigate the epidemiology of hepatitis B virus (HBV) strains with a mutation at nt551 in surface gene among hepatitis B patients in Nanjing and its neighbourhood.METHODS: By using mutation-specific polymerase chain reaction (msPCR) established by our laboratory for amplifying HBV DNAs with a mutation at nt551, 117 serum samples taken from hepatitis B patients were detected.RESULTS: The results showed that 112 samples were positive for nt551A, 4 samples were positive for nt551G.One sample was positive for nt551T. No nt551C of HBV DNA was found. The incidence of HBsAg mutants with G,C, T, A at nt551 among 117 samples was 3.42%, 0%, 0.85%,95.73%, respectively.CONCLUSION: In Nanjing and its neighbourhood, hepatitis B patients are mainly infected with wild genotype HBV.The incidence of mutants with a mutation at nt551 in HBV genome is significantly lower than that in wild genotype HBV DNA (P<0.01). The necessity of adding components of HBsAg mutants to HBV vaccine needs further investigation.

  16. Cytoplasm-translocated Ku70/80 complex sensing of HBV DNA induces hepatitis-associated chemokine secretion

    Directory of Open Access Journals (Sweden)

    Haiming Wei

    2016-12-01

    Full Text Available Chronic hepatitis B remains a serious disease, mainly owing to the severe pathological consequences of persistent hepatitis B virus (HBV infection of carriers, which is difficult to cure using current therapies. When the immune system responds to hepatocytes experiencing rapid HBV replication, effector cells (such as HBV-specific CD8+ T cells, NK cells, NKT cells and other subtypes of immune cells infiltrate the liver and cause hepatitis. However, precisely how these cells are recruited remains unclear. In the present study, we found that the cytoplasm-translocated Ku70/80 complex in liver-derived cells sensed cytosolic HBV DNA and promoted hepatitis-associated chemokine secretion. Upon sensing HBV DNA, DNA-dependent protein kinase catalytic subunit (DNA-PKcs and PARP1 were assembled. Then IRF1 was activated and translocated into the nucleus, which upregulated CCL3 and CCL5 expression. Because CCR5, a major chemokine receptor for CCL3 and CCL5, is known to be critical in hepatitis B, Ku70/80 sensing of HBV DNA likely plays a critical role in immune cell recruitment in response to HBV infection.

  17. Cytoplasm-Translocated Ku70/80 Complex Sensing of HBV DNA Induces Hepatitis-Associated Chemokine Secretion

    Science.gov (United States)

    Li, Young; Wu, Yang; Zheng, Xiaohu; Cong, Jingjing; Liu, Yanyan; Li, Jiabin; Sun, Rui; Tian, Zhigang G.; Wei, Haiming M.

    2016-01-01

    Chronic hepatitis B virus (HBV) infection remains a serious disease, mainly due to its severe pathological consequences, which are difficult to cure using current therapies. When the immune system responds to hepatocytes experiencing rapid HBV replication, effector cells (such as HBV-specific CD8+ T cells, NK cells, NKT cells, and other subtypes of immune cells) infiltrate the liver and cause hepatitis. However, the precise recruitment of these cells remains unclear. In the present study, we found that the cytoplasm-translocated Ku70/80 complex in liver-derived cells sensed cytosolic HBV DNA and promoted hepatitis-associated chemokine secretion. Upon sensing HBV DNA, DNA-dependent protein kinase catalytic subunit and PARP1 were assembled. Then, IRF1 was activated and translocated into the nucleus, which upregulated CCL3 and CCL5 expression. Because CCR5, a major chemokine receptor for CCL3 and CCL5, is known to be critical in hepatitis B, Ku70/80 sensing of HBV DNA likely plays a critical role in immune cell recruitment in response to HBV infection. PMID:27994596

  18. The Role of the Innate Immune System of the Liver in the Control of HBV and HCV

    Institute of Scientific and Technical Information of China (English)

    Jun Wu; Ruth Br(o)ring; J(o)rg F. Schlaak

    2008-01-01

    Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection are among the most frequent causes of chronic liver disease worldwide. As recent studies suggested that Toll like receptor (TLR)-based therapies may represent a promising approach in the treatment of HBV infection, we have studied the role of the local innate immune system of the liver as possible mediator of this effect. Murine non-parenchymal liver cells (NPC; Kupffer cells, KC; sinusoidal endothelial cells, LSEC) were isolated from C57/BL6 and stimulated by TLR 1-9 agonists. Supernatants were harvested and assayed for their antiviral activity against HBV in HBV-Met cells and HCV in the murine HCV replicon cell line MH1. Only supernatants from TLR 3 and -4 stimulated KC and TLR 3 stimulated LSEC were able to potently suppress HBV and HCV replication. By using neutralizing antibodies we could demonstrate that the TLR 3- but not the TLR 4 mediated effect is exclusively mediated through IFN-β. Our data indicate that TLR 3 and -4 mediated stimulation of NPC leads to production of IFN-β which can potently suppress HBV and HCV replication. This is of relevance for the local control of viral hepatitis infection by the innate immune system of the liver, the development of novel TLR-based therapeutic approaches and sheds new light on the viral crosstalk between HCV (TLR 3 stimulator) and HBV.

  19. Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Hua Dong

    2015-12-01

    Full Text Available Interaction between HBV and host genome integrations in hepatocellular carcinoma (HCC development is a complex process and the mechanism is still unclear. Here we described in details the quality controls and data mining of aCGH and transcriptome sequencing data on 50 HCC samples from the Chinese patients, published by Dong et al. (2015 (GEO#: GSE65486. In additional to the HBV-MLL4 integration discovered, we also investigated the genetic aberrations of HBV and host genes as well as their genetic interactions. We reported human genome copy number changes and frequent transcriptome variations (e.g. TP53, CTNNB1 mutation, especially MLL family mutations in this cohort of the patients. For HBV genotype C, we identified a novel linkage disequilibrium region covering HBV replication regulatory elements, including basal core promoter, DR1, epsilon and poly-A regions, which is associated with HBV core antigen over-expression and almost exclusive to HBV-MLL4 integration.

  20. Variations of HBV-DNA quantification and concentration of α-L-fucosidase and alpha fetal protein%HBV-DNA、AFU和AFP水平与肝损害的相关性

    Institute of Scientific and Technical Information of China (English)

    欧超伟; 陈绍鹏; 雷耀珍; 郝彦强

    2011-01-01

    目的 探讨HBV-DNA定量与α-L-岩藻糖苷酶(AFU)和甲胎蛋白(AFP)浓度变化的关系.方法 对373例慢性乙型肝炎患者血清进行HBV-DNA定量、AFU与AFP浓度检测,根据HBV-DNA水平分为3组:HBV-DNA 1×10copies/ml以下为阴性组;HBV-DNA 1×10~1×10copies/ml为低病毒量组;HBV-DNA 1×10~1×10copies/ml为高病毒量组进行分析.结果不同病毒量组的AFU、AFP浓度变化显示HBV-DNA低病毒量组和高病毒量组与正常对照组比较的差异则有统计学意义(P<0.05).AFU与AFP的阳性比例随病毒复制量的增加而升高.结论 对乙型肝炎病毒感染者,应定期进行血清HBV-DNA定量检测,评估病毒的复制状况,并同时检测AFU和AFP浓度,尽早发现肝组织的损害程度及演变过程,达到早期治疗的目的.%Objective To investigate the relationship between HBV-DNA quantification and concentration variation of α-L-fucosidase(AFU) and alpha fetal protein(AFP). Methods The levels of AFU,AFP and HBV-DNA in the serum of 373 chronic hepatitis B patients were determined. The 373 chronic hepatitis B patients were divided into 3 groups based the levels of HBV-DNA,that is the negative group(HBV-DNA <1×103 copies/ml(the low viral load group(HBV-DNA 1 ×104 ~1 ×105copies/ml); high viral load group (HBV-DNA 1×106~1×108copies/ml). Results The levels of AFU and AFP in low and high viral load groups were significantly different as compared with that of the norrmal control group (P<0.05).The positive rates of AFU and AFP increases along with the increase of virus replication. Conclusion HBV-DNA in the HBV carriers should be determined at regular intervals,the replication of HBV-DNA be assessed and the levels of AFU and AFP be simultaneously detected to diagnose the ealy liver lesions for early treatment.

  1. The prevalence of HBV infection in the cohort of IDPs of war against terrorism in Malakand Division of Northern Pakistan

    Directory of Open Access Journals (Sweden)

    Akbar Haji

    2011-06-01

    Full Text Available Abstract Background Hepatitis B is an important public health problem in the Pakistani population and is the major cause of chronic hepatitis, cirrhosis, fibrosis and hepatocellular carcinoma. High prevalence of HBV infections has been observed especially in areas of low economic status. In spite of effective immunization programs, no significant change has been observed in the epidemiology of HBV in the rural areas of Pakistan (~67.5% of the total population mainly due to lack of interest from government authorities and poor hygienic measures. The current study was aimed at estimating the prevalence and risk factors associated with HBV infection within internally displaced persons (IDPs due to war against terrorism in the Malakand Division of Northern Pakistan. Methods Blood samples from 950 IDPs suspected with HBV infection (including both males and females were collected and processed with commercial ELISA kits for HBsAg, Anti HBs, HBeAg, Anti HBe antibodies. The samples positive by ELISA were confirmed for HBV DNA by real-time PCR analysis. Results The overall prevalence of HBV observed was 21.05% of which 78.5% were males and 21.5% were females. Most confirmed HBV patients belong to the Malakand and Dir (lower district. High-risk of infection was found in the older subjects 29.13% (46-60 years, while a lower incidence (11.97% was observed in children aged Conclusion The present study, revealed for the first time a high degree of prevalence of HBV infection in rural areas of Northern Pakistan. The noticed prevalence is gender- and age-dependent that might be due to their high exposures to the common risk factors. To avoid the transmission of HBV infection proper awareness about the possible risk factors and extension of immunization to the rural areas are recommended.

  2. Species association of hepatitis B virus (HBV in non-human apes; evidence for recombination between gorilla and chimpanzee variants.

    Directory of Open Access Journals (Sweden)

    Sinéad Lyons

    Full Text Available Hepatitis B virus (HBV infections are widely distributed in humans, infecting approximately one third of the world's population. HBV variants have also been detected and genetically characterised from Old World apes; Gorilla gorilla (gorilla, Pan troglodytes (chimpanzee, Pongo pygmaeus (orang-utan, Nomascus nastusus and Hylobates pileatus (gibbons and from the New World monkey, Lagothrix lagotricha (woolly monkey. To investigate species-specificity and potential for cross species transmission of HBV between sympatric species of apes (such as gorillas and chimpanzees in Central Africa or between humans and chimpanzees or gorillas, variants of HBV infecting captive wild-born non-human primates were genetically characterised. 9 of 62 chimpanzees (11.3% and two from 11 gorillas (18% were HBV-infected (15% combined frequency, while other Old world monkey species were negative. Complete genome sequences were obtained from six of the infected chimpanzee and both gorillas; those from P. t .ellioti grouped with previously characterised variants from this subspecies. However, variants recovered from P. t. troglodytes HBV variants also grouped within this clade, indicative of transmission between sub-species, forming a paraphyletic clade. The two gorilla viruses were phylogenetically distinct from chimpanzee and human variants although one showed evidence for a recombination event with a P.t.e.-derived HBV variant in the partial X and core gene region. Both of these observations provide evidence for circulation of HBV between different species and sub-species of non-human primates, a conclusion that differs from the hypothesis if of strict host specificity of HBV genotypes.

  3. 1 018例孕妇血清HBV DNA荧光定量PCR检测分析

    Institute of Scientific and Technical Information of China (English)

    蔡筠; 金晴; 卢妙娟

    2005-01-01

    目的:探讨荧光定量PCR法检测乙肝病毒DNA与ELISA检测的乙肝病毒标志物之间的关系,拟在为乙肝病毒母婴传播的判断提供更为可靠的实验依据.方法:1 018例孕妇血清同时进行乙肝病毒标志物和HBV DNA的检测,按照不同的乙肝病毒标志物情况分组后,进行HBV DNA与乙肝病毒标志物之间的分析研究.结果:HBsAg、HBeAg、Anti-HBcAg阳性组和HBsAg、HBeAg组的HBV DNA阳性检出率分别为93.52%和100.00%,拷贝数大多数在5×105以上;HBsAg、Anti-HBeAg、Anti-HBcAg组的HBV DNA阳性检出率低于阴性检出率;HBsAg、Anti-HBcAg阳性组HBV DNA阳性检出率比单纯HBsAg组高:HBeAg和HBeAg、Anti-HBcAg组HBV DNA检出率仍较高,但拷贝数多数在5×105~5×102之间;Anti-HBsAg、AntiHBcAg阳性组及单纯Anti-HBcAg阳性组仍可检到HBV DNA;另有42例ELISA全阴性的仍有2例HBV DNA检出阳性,占4.76%.孕妇血清HBV DNA阳性检出率低于其他文献报道.结论:HBV DNA在各种乙肝病毒血清标志物模式中均可检出.乙肝病毒标志物中HBsAg和/或HBeAg阳性者HBV DNA拷贝数也较高,HBsAg及其抗体阳性者甚至全阴性者仍可检出HBV DNA.应将FQ-PCR的检测和ELISA检测结果结合来诊断患者的病况和是否有传染性.

  4. RNA-seq based transcriptome analysis of hepatitis E virus (HEV) and hepatitis B virus (HBV) replicon transfected Huh-7 cells.

    Science.gov (United States)

    Jagya, Neetu; Varma, Satya Pavan Kumar; Thakral, Deepshi; Joshi, Prashant; Durgapal, Hemlata; Panda, Subrat Kumar

    2014-01-01

    Pathogenesis of hepatitis B virus (HBV) and hepatitis E virus (HEV) infection is as varied as they appear similar; while HBV causes an acute and/or chronic liver disease and hepatocellular carcinoma, HEV mostly causes an acute self-limiting disease. In both infections, host responses are crucial in disease establishment and/or virus clearance. In the wake of worsening prognosis described during HEV super-infection over chronic HBV hepatitis, we investigated the host responses by studying alterations in gene expression in liver cells (Huh-7 cell line) by transfection with HEV replicon only (HEV-only), HBV replicon only (HBV-only) and both HBV and HEV replicons (HBV+HEV). Virus replication was validated by strand-specific real-time RT-PCR for HEV and HBsAg ELISA of the culture supernatants for HBV. Indirect immunofluorescence for the respective viral proteins confirmed infection. Transcription profiling was carried out by RNA Sequencing (RNA-Seq) analysis of the poly-A enriched RNA from the transfected cells. Averages of 600 million bases within 5.6 million reads were sequenced in each sample and ∼15,800 genes were mapped with at least one or more reads. A total of 461 genes in HBV+HEV, 408 in HBV-only and 306 in HEV-only groups were differentially expressed as compared to mock transfection control by two folds (preplicon transfected RNA-Seq based transcriptome analysis to understand the host responses against HEV and HBV.

  5. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.

    Science.gov (United States)

    Mowa, Mohube Betty; Crowther, Carol; Ely, Abdullah; Arbuthnot, Patrick

    2014-01-01

    Research on applying RNA interference (RNAi) to counter HBV replication has led to identification of potential therapeutic sequences. However, before clinical application liver-specific expression and efficient delivery of these sequences remain an important objective. We recently reported short-term inhibition of HBV replication in vivo by using helper dependent adenoviral vectors (HD Ads) expressing anti-HBV sequences from a constitutively active cytomegalovirus (CMV) promoter. To develop the use of liver-specific transcription regulatory elements we investigated the utility of the murine transthyretin (MTTR) promoter for expression of anti-HBV primary microRNAs (pri-miRs). HD Ads containing MTTR promoter effected superior expression of anti-HBV pri-miRs in mice compared to HD Ads containing the CMV promoter. MTTR-containing HD Ads resulted in HBV replication knockdown of up to 94% in mice. HD Ads expressing trimeric anti-HBV pri-miRs silenced HBV replication for 5 weeks. We previously showed that the product of the codelivered lacZ gene induces an immune response, and the duration of HBV silencing in vivo is likely to be attenuated by this effect. Nevertheless, expression of anti-HBV pri-miRs from MTTR promoter is well suited to countering HBV replication and development of HD Ads through attenuation of their immunostimulatory effects should advance their clinical utility.

  6. HBsAg阴性献血者输血HBV感染残余风险分析%Residual Risk of Transfusion-transmitted HBV Infection in HBsAg-negative Blood Donors

    Institute of Scientific and Technical Information of China (English)

    方昌志; 傅颖媛; 钱榕; 熊丽红

    2012-01-01

    目的 分析HBsAg ELISA法检测阴性献血者的输血HBV感染残余风险,评价其感染状况.方法 采用瑞士罗氏诊断公司的Cobas s201核酸检测平台对2011年1月1日至12月31日57 141人份2遍ELISA检测阴性标本进行HBV DNA/HCV RNA/HIV-1,-2 RNA三项联合核酸检测(Cobas TaqScreen MPX 试剂),检测模式为混样检测+拆分检测,即先进行6标本混样检测,再对检测阳性标本进行拆分检测;对127人份拆分检测阳性标本进行分项鉴别试验及乙型肝炎两对半检测.结果 1)2遍ELISA法共检测标本60 037人份,检出HBsAg阴性标本57 141人份;2)对57 141人份阴性标本进行HBV DNA/HCV RNA/HIV-1,-2 RNA三项联检,共检出127人份病毒核酸阳性标本;3)127人份病毒核酸阳性标本进行分项鉴别试验,共检出HBV DNA 阳性标本69人份,输血HBV残余风险为0.12%,其定量检测结果以<20 U·mL-1为主(51人份,占73.9%);4)69人份HBV DNA阳性标本进行乙型肝炎两对半检测,发现乙型肝炎可疑窗口期感染6人份(占8.7%),隐匿性感染 52人份(占75.4%).结论 HBsAg ELISA法检测阴性献血者的输血HBV感染残余风险依然存在,其感染状况多以隐匿性感染为主,将核酸检测纳入血液筛查常规模式,可降低输血残余风险,提高输血安全.%Objective To analyze the residual risk of transfusion-transmitted HBV infection by ELISA method in HBsAg-negative blood donors,and to assess the infection status. Methods TaqScreen MPX test was performed for the detection of HBV DNA/HCV RNA/HIV-1,-2 RNA on a Cobas s201 system (Swiss Roche Diagnosis Company) in 57 141 HBsAg-negative blood donations. The detection was repeated two times. The detection mode was a combination of 6-sample minipool and individual positive donation test. Then, subentry identification and HBV marker detection were conducted in the 127 positive individual donations. Results A total of 60 037 samples were detected by twice ELISA test and 57 141 of them were

  7. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients

    Institute of Scientific and Technical Information of China (English)

    Etsuro Orito; Kei Fujiwara; Hiroshi Kanie; Tesshin Ban; Tomonori Yamada; Katsumi Hayashi

    2012-01-01

    AIM:To analysis the factors that predict the response to entecavir therapy in chronic hepatitis patients with hepatitis B virus (HBV) genotype C.METHODS:Fifty patients [hepatitis B e antigen (HBeAg)-negative:HBeAg-positive =26:24] with HBV genotype C,who received na(i)ve entecavir therapy for > 2 years,were analyzed.Patients who showed HBV DNA levels ≥3.0 log viral copies/mL after 2 years of entecavir therapy were designated as slow-responders,while those that showed < 3.0 log copies/mL were termed rapidresponders.Quantitative hepatitis B surface antigen (HBsAg) levels (qHBsAg) were determined by the Architect HBsAg QT immunoassay.Hepatitis B core-related antigen was detected by enzyme immunoassay.Pre-C and Core promoter mutations were determined using by polymerase chain reaction (PCR).Drug-resistance mutations were detected by the PCR-Invader method.RESULTS:At year 2,HBV DNA levels in all patients in the HBeAg-negative group were < 3.0 log copies/mL.In contrast,in the HBeAg-positive group,41.7% were slow-responders,while 58.3% were rapid-responders.No entecavir-resistant mutants were detected in the slow-responders.When the pretreatment factors were compared between the slow-and rapid-responders;the median qHBsAg in the slow-responders was 4.57log IU/mL,compared with 3.63 log IU/mL in the rapidresponders (P < 0.01).When the pretreatment factors predictive of HBV DNA-negative status at year 2 in all 50 patients were analyzed,HBeAg-negative status,low HBV DNA levels,and low qHBsAg levels were significant (P < 0.01).Multivariate analysis revealed that the low qHBsAg level was the most significant predictive factor (P =0.03).CONCLUSION:Quantitation of HBsAg could be a useful indicator to predict response to entecavir therapy.

  8. Verification of the interaction between ASGPR and HBV preS1 protein%ASGPR 与 HBV preS1蛋白之间相互作用的验证

    Institute of Scientific and Technical Information of China (English)

    张曦; 刘小静; 陈云茹; 孔颖; 杨雪亮; 叶峰; 蔺淑梅

    2016-01-01

    目的:验证去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)与乙肝病毒前 S1蛋白(HBV preS1蛋白)之间的相互作用,确认 ASGPR 作为乙肝病毒肝细胞膜受体在介导乙肝病毒感染的分子机制中的作用。方法分别用哺乳动物双杂交及体外免疫共沉淀技术验证 ASGPR 与 HBV preS1蛋白之间的相互作用,操作方法参照试剂盒说明书进行。结果哺乳动物双杂交实验结果提示,ASGPR 与 HBV preS1蛋白在细胞环境中具有相互作用;免疫共沉淀实验结果提示,ASGPR 与 HBV preS1蛋白在非细胞环境中具有相互作用。结论ASGPR 可能是介导 HBV 入侵的肝细胞膜受体之一。%Objective To verify the interaction between asialoglycoprotein receptor (ASGPR)and hepatitis B virus (HBV)preS1 protein in vivo and in vitro ,and identify ASGPR as a cell-surface receptor for HBV,which could elucidate the molecular mechanism of HBV infection.Methods The preS1-ASGPR interaction was examined in mammalian two-hybrid and coimmunoprecipitation system by strictly following the manufacturer’s instructions.Results ASGPR interacted specifically and directly with the preS1 domain of HBV in vivo and in vitro .Conclusion ASGPR may be a candidate receptor for HBV that mediates further step of HBV entry.

  9. ANALYSIS OF POINT MUTATION IN SITE 1896 OF HBV PRECORE AND ITS DETECTION IN THE TISSUES AND SERUM OF HCC PATIENTS

    Institute of Scientific and Technical Information of China (English)

    Wang Yuan; Liu Hu; Zhou Qing; Li Xu

    1999-01-01

    Aim The 3' -base specific polymerase chain reaction (3' - BS- PCR) method was established to investigate the relationship between the mutation of precore region of Hepatitis B virus (HBV) and the liver damage to the patients caused by HBV and the possibility of HBV precore gene integration in liver cells. Mdthods According to the DNA sequence of precore region of HBV, the method of 3' - BS- PCR is applied to analyze the point mutation site 1896 of HBV precore in 126 clinical serum specimens and 23 hepatocellular carcinoma (HCC) patients' tissues and serum whose trmors have been surgically excised and pathologically diagnosed. Rdsults The point mutation in site 1896 of HBV precore has been successfully rates of preore gene of HBV in the 23 patients' tissues and serum are 52.2 96 (12/23) and 30.4 96 (7/23) respectively. Conclusion The established method for HBV precore mutation analysis is simple and results can well repeated. It has provided a new approach to clinical HBV research and its relationship to liver damage. The results obtained suggested that HBV precore mutation exists in a wide range among serum and tissue of the patients infected by HBV and HCC patients, and the pre-c gene of HBV can not be detected in the serum of 21.8% of the HCC patients (tissue HBV precore gene positive). We may deduce that there may be the integration of HBV precore gence in the genome of liver cells, which may play an important role in the carcinogenesis of HCC.

  10. Detection of Hepatitis B Virus (HBV) Genotype E Carried—Even in the Presence of High Titers of Anti-HBs Antibodies—by an Argentinean Patient of African Descent Who Had Received Vaccination against HBV

    Science.gov (United States)

    Mathet, Verónica L.; Cuestas, María L.; Ruiz, Vanesa; Minassian, María L.; Rivero, Cintia; Trinks, Julieta; Daleoso, Graciela; León, Liliana M.; Sala, Andrea; Libellara, Beatriz; Corach, Daniel; Oubiña, José R.

    2006-01-01

    Genotype E hepatitis B virus (HBV) was detected in two Argentine sisters exhibiting an African mitochondrial lineage. One of them (who had been vaccinated against HBV) exhibited anti-HBs cocirculating antibodies without HBsAg escape mutants, while her unvaccinated sister showed a D144A HBsAg escape mutant without anti-HBs antibodies. Both sisters carried an unusual L209V substitution within HBsAg. PMID:16954295

  11. Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

    Science.gov (United States)

    Uphoff, Cord C; Denkmann, Sabine A; Steube, Klaus G; Drexler, Hans G

    2010-01-01

    The high prevalence of contaminated cell cultures suggests that viral contaminations might be distributed among cultures. We investigated more than 460 primate cell lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus I and II (HTLV-I/-II), and squirrel monkey retrovirus (SMRV) infections for risk assessment. None of the cell lines were infected with HCV, HIV-1, or HTLV-I/-II. However, one cell line displayed reverse transcriptase activity. Thirty-nine cell lines harbored EBV DNA sequences. Studies on the lytic phase of EBV revealed that five cell lines produce EBV particles and six further cell lines produced EBV upon stimulation. One cell line contained an integrated HBV genome fragment but showed no virus production. Six cell lines were SMRV-infected. Newly established cell lines should be tested for EBV infections to detect B-lymphoblastoid cell lines (B-LCL). B-LCLs established with EBV from cell line B95-8 should be tested for SMRV infections.

  12. Seroprevalencia de VHB, VHC y VIH en donadores de sangre en Irapuato, México Seroprevalence of HBV, HCV and HIV in blood donors in Irapuato, Mexico

    Directory of Open Access Journals (Sweden)

    Miguel Angel Carreto-Vélez

    2003-01-01

    General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Mexico. MATERIAL AND METHODS: A cross-sectional descriptive study. Data was recorded on blood bank forms, and risk factors and illnesses were studied in the 7,056 blood donors at the General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Guanajuato, Mexico, over a period of two years (from July 1998 to June 2000. A sample of 4,010 donors was obtained, each of whom underwent serological tests for HBV, HCV and HIV, serotypes 1 and 2, using an enzymatic immunoassay of third generation in serum or human plasma; seroprevalence rate of seropositive donors was calculated and stratified by age and sex. RESULTS: The combined seroprevalence for HBV, HCV and HIV was 2.5% (101; HCV was 1.14% (46, HBV, 1.12% (45, and HIV, 0.24% (10. In males, HBV was 1.04% (33, HCV 1.07% (34, and HIV, 0.28% (9. In females, HBV was 1.42% (12, HCV was 1.42% (12, and HIV was 0.11% (1. Seropositive males had a 2.4 higher rate as compared to females. CONCLUSIONS: The seroprevalence of viral markers was greater than that reported in previous studies carried out in Mexico, which suggests that sexual transmission was the principal mechanism of infection; this reflects poor health education and the need to carefully select potential donors.

  13. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy

    Directory of Open Access Journals (Sweden)

    Laura Camoni

    2010-03-01

    Full Text Available We estimated the prevalence of HIV, HBV and HCV infections among injecting and non-injecting drug users treated within public drug-treatment centres in Italy to determine the correlates of infection. In the sample of 1330 drug users, the prevalence of HIV was 14.4% among drug injectors and 1.6% among non-injectors; the prevalence of HBV was 70.4% among injecting drug users and 22.8% among non-injectors and of HCV was 83.2% among injecting drug users and 22.0% among non-injectors. Old age, unemployment, and intravenous drug use were significantly correlated with each of the infections, as well as a longer history of injecting drug use. The results indicate that these infections continue to circulate among drug users, highlighting the need for monitoring of this group in Italy.

  14. New Anti-HBV C-Boivinopyranosyl Flavones from Alternanthera philoxeroides

    Directory of Open Access Journals (Sweden)

    Bin Li

    2016-03-01

    Full Text Available C-boivinopyranosyl flavones have rarely been isolated from nature. In the search for anti-HBV (hepatitis b virus constituents of Alternanthera philoxeroides, two new compounds, luteolin-6-C-β-d-boivinopyranosyl-3′-O-β-d-glucopyranoside (1 and chrysoeriol-6-C-β-d-boivinopyranosyl-4′-O-β-d-glucopyranoside (2, along with three known C-boivinopyranosyl flavones (compounds 3–5 were isolated. Their structures were determined by spectroscopic analyses including 1D and 2D NMR, HR-ESI-MS, IR spectra. Compounds 1, 2 and 3 showed significant anti-HBV activities through specifically inhibiting the secretion of HBsAg in HepG2.2.15.

  15. Occult hepatitis B virus infection and cryptogenic chronic hepatitis in an area with intermediate prevalence of HBV infection

    Institute of Scientific and Technical Information of China (English)

    Mohammad Javad Kaviani; Behzad Behbahani; Mohammad Jafar Mosallaii; Fatemeh Sari-Aslani; Seyed Alireza Taghavi

    2006-01-01

    AIM: To assess the possible role of occult HBV infection in the pathogenesis of chronic hepatitis in Iranian patients.METHODS: After exclusion of autoimmune, metabolic and viral etiologies, 104 consecutive adult patients with histologic and biochemical features of chronic hepatitis and negative HBsAg were enrolled in the study.Qualitative PCR with a sensitivity of 150 × 103 copies/L,using two primers for Pre-S and core regions was applied to measure presence of HBV DNA in serum of the patients.RESULTS: All 104 patients completed the study.Qualitative HBV DNA was positive in two patients (1.9%).CONCLUSION: Occult HBV infection has negligible role in the pathogenesis of cryptogenic chronic hepatitis in Iranian patients.

  16. Dried blood spot sampling for hepatitis B virus serology and molecular testing.

    Directory of Open Access Journals (Sweden)

    Sofiane Mohamed

    Full Text Available BACKGROUND AIMS: Dried blood spots (DBS on filter paper have been successfully used to diagnose and monitor several infectious diseases. The aim was to investigate the performance of DBS in hepatitis B virus (HBV diagnosis using commercial tests in comparison to standard methods. METHODS: Paired DBS and plasma samples were collected from 200 patients: 100 patients with HBsAg negative status and 100 patients with HBsAg positive status. In the latter patient, HBeAg reactivity was tested. Ten samples of anti-HBs were collected from people vaccinated against HBV. We also studied 50 patients with positive HBV DNA viral load in plasma and 10 HBV DNA negative patients. HBV genotypes and gene polymerase mutations were determined in 10 randomly selected HBV-infected patients. The DBS sample consisted of 50 µL of whole blood, i.e. a 12-mm paper card. RESULTS: The sensitivity thresholds of HBsAg and anti-HBs antibody were 0.30 ± 0.08 IU/mL and 18.11 ± 6.05 IU/mL, respectively, for DBS with 98% sensitivity and 100% specificity. Sensitivity was 98% and specificity 100% for the detection of HBV DNA on a blotter, considering an HBV DNA threshold of 914.1 ± 157.8 IU/ml. Ten patients had an HBeAg positive status in plasma, all were detected positive using DBS. HBV genotyping and mutation detection were successfully performed on DBS, with full concordance between the 10 paired DBS and plasma samples. CONCLUSION: This study shows DBS is a reliable alternative to plasma specimens for quantifying and detecting HBsAg, anti-HBs, HBeAg and genotyping. DBS may increase the opportunities for HBV testing and treatment follow-up in hard-to-reach individuals.

  17. 乙肝病毒携带孕妇检出病毒阳性年龄及疫苗接种调查%Investigation on detection age of positive HBV and vaccine inoculation of HBV - infected pregnant women

    Institute of Scientific and Technical Information of China (English)

    陈红; 任群

    2011-01-01

    目的:了解乙型肝炎病毒母婴和父婴传播中垂直传播和水平传播的比例和乙肝病毒携带孕妇乙肝疫苗接种情况.方法:对父母也为乙肝病毒携带者的乙型肝炎病毒携带孕妇的乙肝病毒检出年龄进行调查,并对乙肝病毒携带孕妇乙肝病毒检出前乙肝疫苗接种情况也进行了调查.结果:①165例被调查乙肝病毒携带孕妇中,否认在检出乙肝病毒阳性前家庭有乙肝病毒接触史72例,占43.64%.有非家庭乙肝病毒接触史11例,占6.67%.家庭中有乙肝病毒携带者76例,占46.06%,其中母亲为乙肝病毒携带者42例,占25.45%,父亲为乙肝病毒携带者21例,占12.73%,丈夫为乙肝病毒携带者13例,占7.88%.做过外科手术6例,占3.64%.②母亲为乙肝病毒携带者加父亲为乙肝病毒携带者63例中,4例1岁以前检出乙肝病毒阳性,占6.35%,1岁以后检出乙肝病毒阳性59例,占93.65%,差异有统计学意义(X2=96.032,P=0.000).其中6例7岁以前检出乙肝病毒阳性,占9.52%,其余57例均在7岁以后检出乙肝病毒阳性,占90.48%,经统计学处理,7岁以前与7岁以后检出乙肝病毒阳性差异仍有统计学意义(X2=76.222,P=0.000).③165例被调查乙肝病毒携带孕妇中有98例明确自己检出乙肝病毒阳性前是否接种过乙肝疫苗,占被调查乙肝病毒携带孕妇的59.39%.其中检出乙肝病毒阳性前接种过乙肝疫苗者39例,占39.80%,但均未在检出前3年内接种乙肝疫苗.未接种过乙肝疫苗者59例,占60.20%.结论:乙肝病毒母婴传播和父婴传播中水平传播多于垂直传播.全程接种乙肝疫苗后不可能终生免疫,乙肝病毒密切接触者需要定期检测乙肝保护性抗体定量,及时加强免疫.%Objective: To understand the ratio of vertical transmission and horizontal transmission in mother - to - fetus transmission and father - to - fetus transmission of hepatitis B virus ( HBV ) and the vaccine inoculation situation of HBV

  18. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].

    Science.gov (United States)

    Sayan, Murat; Buğdacı, Mehmet Sait

    2013-07-01

    The hepatitis B virus (HBV) polymerase (pol) gene completely overlaps with the envelope (S) gene. Nucleos(t)ide analogue (NA) resistance mutations in the pol gene of HBV, either from selection of primary or secondary resistance mutations, typically result in changes in the overlapping hepatitis B surface antigen (HBsAg). Recent studies have conferred a new acronym to these HBV pol/S gene overlap mutants; ADAPVEMs, for antiviral drug-associated potential vaccine-escape mutants. The present report aimed to assess the determined multiple HBV vaccine-escape mutants in a Turkish patient with chronic hepatitis B (CHB), undergoing NAs treatment. The liver biopsy of HBsAg positive, HBeAg negative 53-year old female patient with CHB, revealed a score as histological activity index; 9 and fibrosis; 2 according to Ishak classification. NA treatment backgrounds consisted of 24 months lamivudine, followed by 18 months entacavir and lastly 3 months tenofovir monotherapies. Since HBV DNA load was determined as 7.030.000 IU/ml at the 4th month of tenofovir therapy, entecavir was added as current treatment regimen, and tenofovir + entecavir therapy decreased the HBV DNA load (400 IU/ml). Sequence analysis was performed for HBV pol/S gene and overlapping pol/S gene amino acid substitutions, primary/compensatory NA resistance mutations and antiviral drug-associated potential vaccine-escape mutations (ADAPVEM) were analysed. The patient isolate was identified as genotype D/subgenotype D1 of HBV. Primary drug resistance mutations (rtV173L + rtL180M + rtM204V) to lamivudine and telbivudine and a compensatory mutation (rtQ215H) to lamivudine and adefovir were described in the HBV pol gene sequence. However, multiple HBV vaccine-escape mutations (sS143T + sD144E + sG145R + sE164D + sI195M) have been determined on the HBV overlapping pol/S gene region. Lamivudine and telbivudine which are the frequently preferred drugs for the treatment of CHB in Turkey, have the potential to lead to

  19. Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation

    Institute of Scientific and Technical Information of China (English)

    Xiao-Mou Peng; Lin Gu; Xue-Juan Chen; Jian-Guo Li; Yang-Su Huang; Zhi-Liang Gao

    2005-01-01

    AIM: To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control.To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CDPCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection. RESULTS: The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to10 μmol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain indepe ndent of the amount of templates and the number of PCRcycles. Its detection limit was 103 copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg. CONCLUSION: Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.

  20. HBV Infection Trend in Iranian Disabled Children; Is It really Worrying?

    Directory of Open Access Journals (Sweden)

    Mohammad Hossein Khosravi

    2017-01-01

    Full Text Available We read with a great interest the article written by Davoodbeglou and colleagues entitled “Evaluation of Hepatitis B Infection Prevalence in Institutionalized Intellectually Disabled Children” which is recently published in your prestigious journal1. The authors concluded that HBV infection is more prevalent among institutionalized disabled children and that we should change our health policies for HBV infection management in this population. They have conducted a valuable study with an important subject in a high risk population for hepatitis. Despite our interest to the findings of Davoodbeglou et al. study there are some challenging points about their work; so we think that some comments may be of benefit. The first, authors have claimed a higher prevalence of HBV infection among vaccinated children in comparison with those with no or undetermined vaccination history. While there are studies in which the efficacy of neonatal HBV immunization has been proven2. How the authors justify this finding?In addition the authors have not mentioned the sampling method of their study which is the crucial factor of prevalence studies. This may seriously affect the results of study. Also the time period in which the study was conducted has not been determined by the authors. Was it after or before distribution of national vaccination program for hepatitis B? In this regard we should be aware of the maximum age of disabled individuals included in the study.In conclusion we appreciate the valuable effort of the authors; however we were wondering if we could kindly ask them to interpret better our concerns.

  1. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations

    Directory of Open Access Journals (Sweden)

    Sawai Hiromi

    2012-06-01

    Full Text Available Abstract Background A recent genome-wide association study (GWAS using chronic HBV (hepatitis B virus carriers with and without hepatocellular carcinoma (HCC in five independent Chinese populations found that one SNP (rs17401966 in KIF1B was associated with susceptibility to HCC. In the present study, a total of 580 HBV-derived HCC cases and 1351 individuals with chronic hepatitis B (CHB or asymptomatic carrier (ASC were used for replication studies in order to evaluate the reported association with HBV-derived HCC in other East Asian populations. Results We did not detect any associations between rs17401966 and HCC in the Japanese cohorts (replication 1: OR = 1.09, 95 % CI = 0.82-1.43; replication 2: OR = 0.79, 95 % CI = 0.54-1.15, in the Korean cohort (replication 3: OR = 0.95, 95 % CI = 0.66-1.36, or in the Hong Kong Chinese cohort (replication 4: OR = 1.17, 95 % CI = 0.79-1.75. Meta-analysis using these cohorts also did not show any associations with P = 0.97. Conclusions None of the replication cohorts showed associations between rs17401966 and HBV-derived HCC. This may be due to differences in the genetic diversity among the Japanese, Korean and Chinese populations. Other reasons could be the high complexity of multivariate interactions between the genomic information and the phenotype that is manifesting. A much wider range of investigations is needed in order to elucidate the differences in HCC susceptibility among these Asian populations.

  2. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation

    Institute of Scientific and Technical Information of China (English)

    Xiao Cui; Zhao Li; Peng-Ji Gao; Jie Gao; Ji-Ye Zhu

    2015-01-01

    BACKGROUND:Glypican-3 (GPC-3) is frequently overexpressed in hepatocellular carcinoma (HCC). Recent studies have shown that GPC-3 is a highly efifcient diagnostic biomarker of HCC and an indicator of poor prognosis in HCC patients who have undergone hepatectomy. However, its prognostic value in pa-tients with HBV-associated HCC after liver transplantation (LT) is not clear. The present study is to evaluate the prognostic value of GPC-3 in patients with HBV-associated HCC after LT. METHODS:A cohort of 104 HCC patients with HBV-associ-ated cirrhosis who had undergone LT at our hospital between 2002 and 2011 were enrolled in this study. Samples of HCC were taken from these patients. GPC-3 protein expression was detected in parafifn-embedded specimens using immunohis-tochemistry. All related clinical data were obtained from the China Liver Transplant Registry. The relationship between GPC-3 expression and clinicopathological parameters was analyzed. Univariate and multivariate Cox-regression analyses were used to identify risk factors for poor prognosis. RESULTS:GPC-3 was expressed in samples from 74 (71.2%) of the 104 patients. GPC-3 was expressed only in HCC cells. Positive staining was correlated with tumor size (P=0.004), encapsulation (P=0.018), pathological stage (P=0.027), portal vein invasion (P=0.043), tumor differentiation (P=0.002) and the Milan criteria (P=0.016). The 5-year survival rate and dis-ease-free survival rate of patients with GPC-3-positive were lower than those (38.2% vs 75.4%,P CONCLUSION:GPC-3 is a potential biomarker for poor prog-nosis after LT in HCC patients with HBV-associated cirrhosis.

  3. Anti-HBV Activities of Three Compounds Extracted and Purified from Herpetospermum Seeds

    Directory of Open Access Journals (Sweden)

    Pu-Yang Gong

    2016-12-01

    Full Text Available The goal of this research was to evaluate the anti-hepatitis B virus (HBV activities of three compounds extracted and purified from Herpetospermum seeds (HS on HepG2.2.15 cells. Herpetin (HPT, herpetone (HPO, and herpetfluorenone (HPF were isolated from HS and identified using HR-ESI-MS and NMR. Different concentrations of the drugs were added to the HepG2.2.15 cells. Cell toxicity was observed with an MTT assay, cell culture supernatants were collected, and HBsAg and HBeAg were detected by ELISA. The content of HBV DNA was determined via quantitative polymerase chain reaction (PCR with fluorescent probes. The 50% toxicity concentration (TC50 of HPF was 531.48 μg/mL, suggesting that this species is less toxic than HPT and HPO. HPT and HPF showed more potent antiviral activities than HPO. The 50% inhibition concentration (IC50 values of HPF on HBsAg and HBeAg were 176.99 and 134.53 μg/mL, respectively, and the corresponding therapeutic index (TI values were 2.66 and 3.49, respectively. HPT and HPF were shown to significantly reduce the level of HBV DNA in the HepG2.2.15 culture medium compared to the negative control. This initial investigation of the anti-HBV constituents of HS yielded three compounds that revealed a synergistic effect of multiple components in the ethnopharmacological use of HS.

  4. Oral mucosa alterations in chronic hepatitis and cirrhosis due to HBV or HCV infection.

    Science.gov (United States)

    Sulka, Agnieszka; Simon, Krzysztof; Piszko, Paweł; Kalecińska, Ewa; Dominiak, Marzena

    2006-03-01

    The aim of the study was to evaluate the character of lesions within oral mucosa in patients suffering from chronic hepatitis and cirrhosis of the liver due to either HBV or HCV infection. A total of 74 patients treated at the Clinic of Infectious Diseases in Wrocław for chronic hepatitis B (20 patients, group I) and for chronic hepatitis C (23 patients group III) and cirrhosis of the liver due to HBV (15 patients , group II) and HCV (16 patients, group IV) infection. The control group comprised 29 healthy subjects. Lesions within the oral mucosa found on clinical examinations were confirmed with a histopathological evaluation. Patients suffering from chronic hepatitis B revealed leukoplakia (1/20), melanoplakia (1/20), petechiae (1/20), 17 patients from this group did not show any changes. Patients suffering from chronic hepatitis C revealed leukoplakia (6/23), Delbanco's disease (2/23), melanoplakia (1/23), lichen planus (1/23), petechiae (1/23), 12 patients from this group did not show any changes. Patients suffering from cirrhosis of the liver due of HBV infection revealed leukoplakia (3/15) petechiae (2/15), Delbanco's disease (1/15), angular cheilitis (1/15), aphthae (1/15), 7 patients from this group did not reveal any changes. Patients suffering from cirrhosis of the liver due of HCV infection revealed petechiae (2/16), melanoplakia (1/16), candidosis (1/16), labial herpes (1/16), 11 patients from this group did not reveal any changes. In control group we observed leukoplakia (3/29), Delbanco's disease (1/29), labial herpes (1/29), petechiae (1/29), and 23 subjects did not present pathological lesions within the oral mucosa. Results indicate the lack of connection between chronic HBV and HCV infection as well as the stage of the disease with the incidence and character of oral lesions in oral mucosa.

  5. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment

    Institute of Scientific and Technical Information of China (English)

    Chang-Zheng Ke; Yue Chen; Zuo-Jiong Gong; Zhong-Ji Meng; Li Liu; Ze-Jiu Ren; Zuo-Hua Zhou

    2006-01-01

    AIM: To study the dynamic changes of hepatits B virus (HBV) DNA in serum and peripheral blood mononuclear cells (PBMCs) of patients after lamivudine therapy.METHODS: A total of 72 patients with chronic HBV infection were included in this study. All patients were confirmed to have the following conditions: above 16 years of age, elevated serum alanine amonotransferase (ALT), positive hepatitis B e antigen (HBeAg), positive HBV DNA in serum and PBMCs, negative antibodies against HAV, HCV, HDV, HEV. Other possible causes of chronic liver damages, such as drugs, alcohol and autoimmune diseases were excluded. Seventy-two cases were randomly divided into lamivudine treatment group (n = 42) and control group (n = 30). HBV DNA was detected both in serum and in PBMCs by fluorescence quantitative polymerase chain reaction (PCR), during and after lamivudine treatment.RESULTS: In the treatment group, HBV DNA became negative both in serum and in PBMC, of 38 and 25 out of 42 cases respectively during the 48 Wk oflamivudine treatment, the negative rate was 90.5% and 59.5% respectively. In the control group, the negative rate was 23.3% and 16.7% respectively. It was statistically significant at 12, 24 and 48 wk as compared with the control group (P < 0.005). The average conversion period of HBV DNA was 6 wk (2-8 wk) in serum and 16 wk (8-24 wk) in PBMC.CONCLUSION: Lamivudine has remarkable inhibitory effects on HBV replication both in serum and in PBMCs.The inhibitory effect on HBV DNA in PBMCs is weaker than that in serum.

  6. Genotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, China

    Directory of Open Access Journals (Sweden)

    Juan Feng

    2011-06-01

    Full Text Available Abstract The hepatitis B virus (HBV has been classified into eight genotypes (A-H based on intergenotypic divergence of at least 8% in the complete nucleotide sequence or more than 4% in the S gene. To facilitate the investigation of the relationship between the efficacy of drug treatment and the mutation with specific genotype of HBV, we have established a new genotyping strategy based on a fragment of the HBV DNA polymerase gene. Pairwise sequence and phylogenetic analyses were performed using CLUSTAL V (DNASTAR on the eight (A-H standard full-length nucleotide sequences of HBV DNA from GenBank (NCBI and the corresponding semi-nested PCR products from the HBV DNA polymerase gene. The differences in the semi-nested PCR fragments of the polymerase genes among genotypes A through F were greater than 4%, which is consistent with the intergenotypic divergence of at least 4% in HBV DNA S gene sequences. Genotyping using the semi-nested PCR products of the DNA polymerase genes revealed that only genotypes B, C, and D were present in the 50 cases, from Shenyang, China, with a distribution of 11 cases (22%, 25 cases (50%, and 14 cases (28% respectively. These results demonstrate that our new genotyping method utilizing a fragment of the HBV DNA polymerase gene is valid and can be employed as a general genotyping strategy in areas with prevalent HBV genotypes A through F. In Shenyang, China, genotypes C, B, and D were identified with this new genotyping method, and genotype C was demonstrated to be the dominant genotype.

  7. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice

    OpenAIRE

    2013-01-01

    ABSTRACTBackground: Patients with chronic hepatitis B virus (HBV) infection are at a high risk to develop hepatocellular carcinoma (HCC). Recently, metabolic syndrome has been found to carry a risk for HCC development. Considering the limitation of chemotherapeutic drugs for HCCs, the development of chemopreventive agents for high risk chronic HBV carriers is urgently demanded. In this study, we used combined silymarin and resveratrol extract which have been shown to exhibit biologic effects ...

  8. Correlation study of serum markers and HBV-DNA levels in hepatitis B patients%乙型肝炎患者血清标志物与HBV-DNA含量的相关性研究

    Institute of Scientific and Technical Information of China (English)

    赵卫; 周盛杰

    2013-01-01

    Objective To investigate the correlation of serum markers and HBV-DNA levels in hepatitis B patients and its clinical significance. Methods Two hundred and fifty-eight hepatitis B patients was detected for serum markers by ELISA and HBV-DNA levels by quantitative fluorescent polymerase chain reaction (QF-PCR).The correlation between serum markers and HBV-DNA levels were investigated. Results In HBsAg+/HBeAg+ group and HBsAg+/ HBeAg+/anti-HBc+ group, the positive rate of HBV-DNA and the levels of HBV-DNA were the highest. For the five infection modes of HBsAg7anti-HBe7anti-HBc+, HBsAg+/HBc+, anti-HBs+/anti-HBe+/ anti-HBc+, anti-HBe+/anti-HBc+, an-ti-HBs+, the HBV-DNA positive rates were 62.96%, 52.94%, 37.50%, 27.27%, 4.35%, respectively. Conclusion There is a correlation between the positive rate of HBV-DNA and the serum markers in hepatitis B patients. The detection serum markers combined with the quantitative detection of HBV-DNA can accurately reflect the extent of virus replication and infection intensity, which is of great significance for the early diagnosis, treatment and prognosis of hepatitis B.%目的 探讨乙型肝炎患者血清标志物与HBV-DNA定量检测之间的关系及其临床意义.方法 选择258例经我院确诊的乙肝患者,采用酶联免疫吸附试验法检测患者体内血清标志物,采用荧光定量聚合酶链反应检测HBV-DNA含量,比较血清标志物与HBV-DNA检测量之间的关系.结果 HBsAg+/HBeAg+组与HBsAg+/HBeAg+/抗-HBc+组HBV-DNA阳性检出率与含量最高;HBsAg+/抗-HBe+/抗-HBc+、HBsAg+/HBc+、抗-HBs+抗HBe+/抗-HBc+、抗-HBe+/抗-HBc+、抗-HBs+5种感染模式下HBV-DNA阳性检测率分别为62.96%、52.94%、37.50%、27.27%、4.35%.结论 乙肝患者血清HBV-DNA阳性率与血清标志物存在相关性;同时进行血清标志物的检测与HBV-DNA定量检测能较准确直接地反应病毒复制程度及传染强度,对于早期诊断、治疗及预后判断具有指导意义.

  9. Risk factors from HBV infection among blood donors:A systematic review

    Institute of Scientific and Technical Information of China (English)

    Giuseppe La Torre; Rosella Saulle

    2016-01-01

    Objective:To perform a systematic review of the scientific literature to identify risk factors associated with hepatitis B viruses(HBV) infection among blood donors.Methods:The literature search was carried out on Pub Med and Scopus databases using the keywords "risk factors" "HBV infection" and "blood donors".No date or language restrictions were applied to the search.This literature review was completed in March2014.The selection process and the reporting of the review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement.The Newcastle Ottawa scale was using to evaluate the quality of each single primary study.Results:Out of 172 records resulted in the search,5 papers were included in the final analysis because they are within acceptance criteria.Two of the selected studies were cross-sectional and three of them were case-control studies.Significant association resulted with some demographic and behavioral risk factors,such as marital status,dental treatment/procedure history,no stable relationship or multiple partners and family history of HBV infection.Conclusions:The systematic review performed encourages to conduct further research among blood donors in order to fully understand risk factors among donors in more extensive thus to provide valuable information about surveillance.

  10. Telbivudine (Sebivo in patients with hepatitis B virus (HBV chronic infection

    Directory of Open Access Journals (Sweden)

    Viola Sacchi

    2008-12-01

    Full Text Available Hepatitis B is the most common serious liver infection in the world, with about 350 million people who are infected with the hepatitis B virus (HBV and about 1 million deaths annually.Hepatitis B is characterized by an acute and a chronic phase, if the subject fails to produce adequate immune response.About 5-10% of adults infected with HBV go on to develop chronic infection and become chronic carriers (CHB; moreover, the liver damage, if not stopped, continues until cirrhosis or hepatocellular carcinoma. In the natural history of HBV infection, the most important event is HBeAg seroconversion, characterized by loss of HBeAg (a specific antigen of the virus and development of anti-HBe antibodies (HBeAg-positive patients. If the seroconversion has occurred early (when liver damage is not already significant and is maintained, long-term prognosis is excellent. The disease can follow a more aggressive course if active viral replication persists despite anti-HBe positivity. This state, characterized by continuing viral replication, has been termed as HBeAg-negative CHB, and is the most prevalent form in Italy. At the moment, there are 4 approved antiviral drug classes, with different antiviral efficacy, for the treatment of chronic hepatitis B: interferons, nucleoside analogues, nucleotide analogues, and cyclopents.The primary target of the treatment is a prolonged suppression of viral replication, in order to avoid long term complications and increase survival.

  11. Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Shi, Yang, E-mail: yangshi_xz@126.com; Song, Qingwei; Hu, Dianhe; Zhuang, Xiaohu; Yu, Shengcai

    2015-05-22

    Hepatocellular carcinoma (HCC) is one of the most common cancers and can be induced by chronic HBV infection. The role of HBV-specific immune responses in mediating tumorigenesis and HCC prognosis is debated. The effect of intratumoral microenvironment on tumor-infiltrating lymphocytes (TILs) is also unclear. Here, we examined resected tumor tissue from 36 patients with HBV-induced HCC. We categorized study cohort based on ex vivo IL-10 secretion by tumor cells into high IL-10-secreting (Hi10) and low IL-10-secreting (Lo10) groups, and found that the Lo10 group was less sensitive to TLR ligand stimulation. TILs from the Lo10 group contained higher frequencies of HBV-specific IFN-g-producing cells and total IFN-g-producing cells, and possessed higher proliferative capacity. Moreover, the proliferative capacity of TILs from the Hi10 group was negatively correlated with IL-10 secretion from tumor cells. Together, our data demonstrated that low IL-10-producing capacity in HBV-induced HCC tumors is associated with enhanced TIL activity. - Highlights: • We examined intratumoral IL-10 production in HBV-induced HCC. • We grouped HCC tumors into Hi10 and Lo10 groups based on their IL-10 production. • Lo10 groups had better IFN-g response by TILs. • Lo10 groups had better TIL proliferative capacity. • Lo10 group tumor cells were refractory to TLR ligand stimulation.

  12. Antihepatitis B Virus Activity of a Protein-Enriched Fraction from Housefly (Musca domestica in a Stable HBV-Producing Cell Line

    Directory of Open Access Journals (Sweden)

    Xuemei Lu

    2014-01-01

    Full Text Available Hepatitis B virus (HBV infection remains a major public health problem. Although several vaccines and therapeutic strategies are currently being implemented to combat HBV virus, effective antiviral therapy against HBV infection has not been fully developed. Alternative strategies and new drugs to combat this disease are urged. Insects and insect derivatives are a large and unexploited source of potentially useful compounds for modern medicine. In the present study, we investigated the first anti-HBV activity of a protein-enriched fraction (PE from the larvae of the housefly (Musca domestica in a stable HBV-producing cell line. HBsAg and HBeAg in the culture medium were measured by enzyme-linked immunosorbent assay. HBV-DNA was quantified by fluorescent quantification PCR. HBV core protein was assayed by immunofluorescent staining. Results indicate PE treatment inhibited both HBsAg, HBeAg secretion, and HBV-DNA replication. Furthermore, PE could also suppress HBV core protein expression. PE could be a potential candidate for the development of a novel and effective drug for the treatment of HBV infection.

  13. Antihepatitis B virus activity of a protein-enriched fraction from housefly (Musca domestica) in a stable HBV-producing cell line.

    Science.gov (United States)

    Lu, Xuemei; Jin, Xiaobao; Wang, Jie; Chu, Fujiang; Zhu, Jiayong

    2014-01-01

    Hepatitis B virus (HBV) infection remains a major public health problem. Although several vaccines and therapeutic strategies are currently being implemented to combat HBV virus, effective antiviral therapy against HBV infection has not been fully developed. Alternative strategies and new drugs to combat this disease are urged. Insects and insect derivatives are a large and unexploited source of potentially useful compounds for modern medicine. In the present study, we investigated the first anti-HBV activity of a protein-enriched fraction (PE) from the larvae of the housefly (Musca domestica) in a stable HBV-producing cell line. HBsAg and HBeAg in the culture medium were measured by enzyme-linked immunosorbent assay. HBV-DNA was quantified by fluorescent quantification PCR. HBV core protein was assayed by immunofluorescent staining. Results indicate PE treatment inhibited both HBsAg, HBeAg secretion, and HBV-DNA replication. Furthermore, PE could also suppress HBV core protein expression. PE could be a potential candidate for the development of a novel and effective drug for the treatment of HBV infection.

  14. 乙肝病毒表面抗原定量与HBV-DNA含量的相关性分析%HBV Surface Antigen Quantitation of DNA Content Analysis

    Institute of Scientific and Technical Information of China (English)

    刘添皇; 何宗运

    2013-01-01

      目的探讨HBV表面抗原(HBsAg)定量与HBV-DNA含量的相关性,为乙型肝炎的预防和治疗提供帮助。方法选取2011年6月至2012年8月间在我院门诊及住院的诊断为乙型肝炎的患者180例,同时进行HBsAg和HBV-DNA定量检测,分析两者之间的相关性。结果 HBsAg浓度在20~200 ng/mL时,HBV-DNA的阳性率上升较明显,表明在该时期体内有大量乙肝病毒复制,具有传染性,并可能对机体具有一定的破坏性。随着HBsAg含量的升高,HBV-DNA阳性率也随着不断增高。结论在临床诊断、治疗中,联合检测HBsAg和HBV-DNA有助于乙肝患者的病情观察、用药、评估疗效及判断预后。%  Objective Explore the correlation analysis of the Quantitative DNA content of HBV surface antigen, and help to prevent and treat of hepatitis B. Methods June 2011 to August 2012 in our hospital outpatient and inpatient diagnosis of 180 cases of hepatitis B patients, while giving the quantitative detection of HBsAg and HBV-DNA analysis of the correlation between the two. Results HBsAg concentration of 20-200 ng/mL, HBV-DNA positive rate increased more significantly in the period, a large number of hepatitis B virus replication, the virus of the body has a certain destructive and infectious. HBV-DNA positive rate of HBsAg content increased, along with the constant increase.Conclusion During the clinical diagnosis and treatment, combined detection of HBsAg and HBV-DNA can help patients with hepatitis B disease observation, medication, predict efficacy and prognosis.

  15. 酵母双杂交系统筛选HBV PreS1相互作用蛋白%Screening the hepatitis B virus PreS1 associated proteins in yeast two-hybrid system

    Institute of Scientific and Technical Information of China (English)

    叶峰; 张曦; 邸莹; 王小清; 刘小静; 孔颖; 赵英仁; 陈天艳; 刘敏

    2012-01-01

    Objective To screen the interacted protein hepatitis B virus (HBV) PreSl with human hepatocytes from normal human liver cDNA library by sos-recruitment system (SRS) and explore the mechanism of HBV endocylosis. Methods PCR was performed to amplify the gene of HBV PreSl from the plasmid PCP10/ HBV ayw subtype containing the whole fragment of HBV;the PCR product was cloned into yeast expression plasmid pSos. and reconstituted plasmid was tested by auto-sequencing assay and named pSos- PreSl. The pSos-PreSl fusion protein expressed in the yeast cells was confirmed by Western blot after pSos- PreSl was transfected into the yeast cell cdc25.Self-activation of the bait protein was determined by cotransformation of pSos- PreSl and pMyr-Lamin C, and the cytoplasmic localization of the bait protein was verified by cotransformation of pSos- PreSl and pMyr SB. Yeast cells co-transfected with pSos- PreSl and the normal human liver cDNA library grew in selective nutrition and temperature. The true positive clones were submitted for sequencing. The results were submitted to the BLAST notebook of NCBI to seek homologous sequence. Results The yeast expression vector of HBV PreSl gene was constructed successfully and its expression in yeast was verified. The recombinant bait plasmid did not have self-activation and toxicity to yeast cdc25H cells. Furthermore, the cytoplasmic localization of the bait protein was verified correctly. After yeast cells were co-transfected with pSos-PreSl and the normal human liver cDNA library, 5 clones were positive and showed high homology with KCMF1, cyt C, vitamin D binding protein, Homo sapiens albumin (ALB) and Homo sapiens asialoglycoprotein receptor (ASGPR). Conclusion We obtained 5 proteins which may interact with HBV PreSl protein by SRS. This is helpful for exploring the mechanism of HBV endocytosis.%目的 利用Sos招募系统(SRS),构建含HBV PreS1基因的酵母双杂交诱饵载体,筛选人肝细胞与HBV PreS1蛋白相互作用的

  16. acute onset Pancreatitis in the third trimester of Pregnancy in HBV Carrier Women taking telbivudine for Blocking Mother-to-Infant transmission

    Institute of Scientific and Technical Information of China (English)

    Hao-feng Xiong; Jing-yuan Liu; Hao-dong Cai; Jun Cheng

    2014-01-01

    Acute pancreatitis in pregnancy (APIP) is rare and the reasons for APIP are biliary disease and congenital or acquired hypertriglyceridemia, which could occur during any trimester but more than 50% cases happened during the third trimester. In this report, one case of a young pregnant woman, a HBV carrier in her 37th week+5 d of gestation, was admitted to Emergency Department due to acute abdominal pain, vomiting and diarrhea. The patient was in antiretroviral treatment with telbivudine from 28 weeks of gestation to prevent mother-to-child transmission of HBV. Laboratory tests demonstrated hypertriglyceridemia, abdominal computed tomography scan revealed peripancreatic edema. Hyperlipidemic pancreatitits was primary diagnosed and the patient was admitted to the intensive care unit. Considering the possible role in the pathogenesis of pancreatitis, telbivudine was interrupted after birth giving. After supportive treatment, her condition gradually improved. Since it is the ifrst description of APIP during treatment with telbivudine, the association between pregnancy, hyperlipidemia, telbivudine and acute pancreatitis has been well investigated.

  17. A Turbidity Test Based Centrifugal Microfluidics Diagnostic System for Simultaneous Detection of HBV, HCV, and CMV

    Directory of Open Access Journals (Sweden)

    Hung-Cheng Chang

    2015-01-01

    Full Text Available This paper presents a LAMP- (loop-mediated isothermal amplification- based lab-on-disk optical system that allows the simultaneous detection of hepatitis B virus, hepatitis C virus, and cytomegalovirus. The various flow stages are controlled in the proposed system using different balance among centrifugal pumping, Coriolis pumping, and the capillary force. We have implemented a servo system for positioning and speed control for the heating and centrifugal pumping. We have also successfully employed a polymer light-emitting diode section for turbidity detection. The easy-to-use one-click system can perform diagnostics in less than 1 hour.

  18. Performance and diagnostic usefulness of commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and HCV in India

    Directory of Open Access Journals (Sweden)

    Maity Susmita

    2012-11-01

    Full Text Available Abstract Background HIV, HBV and HCV pose a major public health problem throughout the world. Detection of infection markers for these agents is a major challenge for testing laboratories in a resource poor setting. As blood transfusion is an important activity saving millions of live every year, it also carries a risk of transfusion transmissible infections caused by these fatal blood borne pathogens if the quality of testing is compromised. Conventional ELISA is regarded as the mostly used screening technique but due to limitations like high cost, unavailability in many blood banks and testing sites, involvement of costly instruments, time taking nature and requirement of highly skilled personnel for interpretation, rapid tests are gaining more importance and warrants comparison of performance. Results A comparative study between these two techniques has been performed using commercially available diagnostic kits to assess their efficacy for detection of HIV, HBV and HCV infections. Rapid kits were more efficient in specificity with synthetic antigens along with high PPV than ELISA in most cases. Comparison between different ELISA kits revealed that Microlisa HIV and Hepalisa (J. Mitra & Co. Pvt. Ltd.; ERBA LISA HIV1 + 2, ERBA LISA Hepatitis B and ERBA LISA HCV (Transasia Bio-medicals Ltd. gives uniform result with good performance in terms of sensitivity, specificity, PPV, NPV and efficiency, whereas, Microlisa HCV (J. Mitra & Co. Pvt. Ltd., Microscreen HBsAg ELISA and INNOVA HCV (Span Diagnostics Ltd. did not perform well. Rapid kits were also having high degree of sensitivity and specificity (100% except in HIV Comb and HCV Comb (J. Mitra & Co. Pvt. Ltd.. The kit efficiency didn’t vary significantly among different companies and lots in all the cases except for HCV ELISA showing statistically significant variation (p  Conclusions ELISA is a good screening assay for markers of HIV, HBV and HCV infections. Rapid tests are useful for

  19. Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis Prevalência dos genótipos do vírus da hepatite B em imigrantes na Itália com hepatite crônica ativa pelo vírus B

    Directory of Open Access Journals (Sweden)

    Emilio Palumbo

    2007-03-01

    Full Text Available BACKGROUND: The genetic heterogeneity of the HBV genome has been established and eight genotypes can be classified according to the criterion of >8% differences in the complete nucleotide sequence of the viral genome. AIMS: To evaluate the prevalence of HBV-infection in a population of immigrants and to determine in patients with detectable serum HBV-DNA the HBV-genotypes. METHODS: Between January 2005 and December 2005 a total of 556 immigrants were tested for HBsAg. In HBsAg positive patients the biochemical and virological activity of infection and the possible presence of co-infections (HCV, HDV, HIV were evaluated. In patients with detectable serum HBV DNA, the HBV-genotype was determined by INNOLiPA. RESULTS: Among the 556 subjects tested, 60 (10.7% resulted HBsAg positive. All were men, and 42 (70% come from Africa, 10 (16.6% from Asia and 9 (14.4% from East-Europe. 28/60 (46.6% patients presented normal ALT levels (RACIONAL: A heterogeneidade do genoma do vírus da hepatite B (VHB foi estabelecida e oito genótipos podem ser classificados de acordo com o critério de diferenças de percentagem maior ou igual a 8 na seqüência completa do nucleotídeo do genoma vira!. OBJETIVOS: Verificar a prevalência da infecção pelo vírus da hepatite B (VHB em uma população de imigrantes na Itália e determinar os genótipos do VHB em pacientes com níveis séricos detectáveis do VHB-DNA. MÉTODOS: Entre janeiro e dezembro de 2005, o total de 556 imigrantes foram testados para o HbsAg. Se positivos, a atividade bioquímica e viral da infecção e a possível presença de co-infecções (HVC, HVD e HIV foram examinadas. Nos pacientes positivos para o VHB-DNA, o genótipo do VHB foi determinado pelo método INNOLiPA. RESULTADOS: Entre os 556 pacientes, 60 (10,7% tinham HbsAg positivo. Todos eram do sexo masculino e 42 (70%, provenientes da África, 10 (16,6% da Ásia e 9 (14,4% do Leste Europeu. 28/60 (46,6% apresentaram níveis de ALT normais

  20. Variations in the core promoter/pre-core region in HBV genotype C in Japanese and Northern Vietnamese patients.

    Science.gov (United States)

    Truong, Bui Xuan; Yano, Yoshihiko; Seo, Yasushi; Phuong, Tran Minh; Tanaka, Yasuhito; Kato, Hirotaka; Miki, Akira; Utsumi, Takako; Azuma, Takeshi; Trach, Nguyen Khanh; Mizokami, Masashi; Hayashi, Yoshitake; Kasuga, Masato

    2007-09-01

    Hepatitis B virus (HBV) subgenotypes Cs (C1) and Ce (C2) are common in East Asia. To investigate the genomic difference of HBV genotype C between two separated regions, 50 subgenotype Cs-infected Vietnamese and 70 subgenotype Ce-infected Japanese patients were enrolled for analysis. The patients were categorized to either a hepatocellular carcinoma group (HCC) or a non-HCC group including liver cirrhosis, chronic hepatitis, and asymptomatic carriers. HBV serology, HBV-DNA level, and variations in core promoter/pre-core region were examined. Phylogenetic analysis based on the full genome sequences and nucleotide sequences partly in the S gene and in the P gene revealed that all Japanese strains (70/70) were subgenotype Ce, and nearly all of the Vietnamese strains (50/51) were subgenotype Cs, excluding one subgenotype C5. C1858 and G1775 were common in the Vietnamese (64% and 40%) but not in the Japanese (0%). The prevalence of C/A1753 in Vietnamese was higher than that in the Japanese (32% vs. 17.1%), however the frequency of A1896 in the Japanese was significantly higher (32.9% vs. 12%, P HBV-DNA, the Japanese HCC had a relatively low level. In the Vietnamese, C/A1753 and C1858 were associated closely with T1762A1764, higher HBV-DNA levels and higher HCC incidence. The multivariate analysis revealed that male, T1653 and C/A1753 were independent risk factors for HCC. The subgenotypes and unique mutations of HBV genotype C in the Vietnamese and Japanese differed, and C/A1753 and C1858 variants might play a role in the pathogenesis of liver disease in Vietnamese patients.

  1. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo

    Institute of Scientific and Technical Information of China (English)

    Chang-Qing Li; Yu-Tong Zhu; Feng-Xue Zhang; Lin-Chun Fu; Xiao-Hui Li; Yi Cheng; Xiang-Yang Li

    2005-01-01

    AIM: To study the anti-HBV effect of liposome-encapsulated matrine (Lip-M) in vitro and in vivo.METHODS: 2.2.15 cell line was cultured in vitro to observe the effect of Lip-M and matrine on the secretion of HBsAg and HBeAg. The toxicity of Lip-M and matrine to 2.2.15 cell line was also studied by MTT method. In in vivo study,drug treatment experiment was carried out on the 13th day after ducks were infected with duck hepatitis B virus (DHBV). The ducks were randomly divided into 4 groups with 5-6 ducks in each group. Lip-M and matrine were given to DHBV-infected ducks respectively by gastric perfusion. Four groups were observed: group of Lip-M (20 mg/kg), group of Lip-M (10 mg/kg), group of matrine (20 mg/kg) and group of blank model. The drug was given once daily for 20 d continuously, and normal saline was used as control. The blood was drawn from the posterior tibial vein of all ducks before treatment (T0), after the medication for 5 (T5), 10 (T10), 15 (T15), 20 (T20) d and withdrawl of the drug for 3 d (P3). The serum samples were separated and stored at -70 ℃, DHBV-DNA was detected by the dot-blot hybridization.RESULTS: After addition of Lip-M and matrine to 2.2.15cell line for eleven d, the median toxic concentration (TC50)of Lip-M and matrine was 7.29 mg/mL and 1.33 mg/mL respectively. The median concentration (IC50) of Lip-M to inhibit HBsAg and HBeAg expression was 0.078 mg/mL and 3.35 mg/mL respectively. The treatment index (TI)value of Lip-M for HBsAg and HBeAg was 93.46 and 2.17respectively, better than that of matrine. The DHBVinfected duck model treatment test showed that the duck serum DHBV-DNA levels were markedly reduced in the group of Lip-M (20 mg/kg) after treated by gastric perfusion for 10, 15 and 20 d (0.43±0.22 vs0.95±0.18,t= 4.70, P= 0.001<0.01.0.40±0.12 vs0.95±0.18, t= 6.34,P= 0.000<0.01. 0.22±0.10 vs 0.95±0.18, t= 8.30,P = 0.000<0.01), compared to the group of matrine (20 mg/kg) (0.43±0.22 vs0.79±0.19, t= 3.17, P= 0.01<0

  2. Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression

    Institute of Scientific and Technical Information of China (English)

    Rosa; Zampino; Adriana; Boemio; Aldo; Marrone; Luciano; Restivo; Maria; Chiara; Fascione; Riccardo; Nevola; Luigi; Elio; Adinolfi; Nicola; Coppola; Carmine; Minichini; Mario; Starace; Evangelista; Sagnelli; Grazia; Cirillo; Emanuele; Miraglia; del; Giudice; Maria; Stanzione; Emanuele; Durante-Mangoni; Giovanna; Salzillo

    2014-01-01

    AIM:To evaluate steatosis,insulin resistance(IR)and patatin-like phospholipase domain-containing 3(PNPLA3) and their relation to disease progression in hepatitis B and C viruses(HCV-HBV) coinfected patients.METHODS:Three hundred and thirty patients with biopsy proven chronic hepatitis were enrolled:66 had HBV-HCV,66 HBV and 198 HCV infection.Prevalence of steatosis,IR and PNPLA3 polymorphisms and their relation to anthropometric,biochemical,virological and histological parameters were evaluated.RESULTS:Prevalence of steatosis in group HBV-HCV was similar to that in HCV(47.0% vs 49.5%,respec-tively);group HBV showed the lowest steatosis(33.3%).Group HBV-HCV had a lesser degree of steatosis than HCV(P = 0.016),lower HCV RNA levels(P = 0.025) and lower prevalence and degree of IR(P = 0.01).PNPLA3 polymorphisms were associated with steatosis.Group HBV-HCV showed higher levels of liver fibrosis than group HCV(P = 0.001),but similar to that ob-served in HBV group.In HBV-HCV group,liver fibrosis was not associated with steatosis,IR or PNPLA3.HBV infection was the independent predictor of advanced liver fibrosis.CONCLUSION:HBV-HCV co-infected patients have lower degree of hepatic steatosis,IR and HCV RNA than HCV mono-infected;co-infected patients showed a more rapid liver fibrosis progression that seems to be due to the double infection and/or HBV dominance.

  3. 乙肝病毒携带产妇血清标志物模式与血清及乳汁HBV-DNA相关性研究%Study on the hepatitis B serum markers and the correlation between serum and milk HBV-DNA in HBV-infectious pregnant women

    Institute of Scientific and Technical Information of China (English)

    朱珉之; 杭双熊; 申红玉

    2014-01-01

    目的:通过检测分析乙肝病毒携带产妇血清学标志物与血清、乳汁HBV-DNA阳性率的关系,以及产妇血清与乳汁中HBV-DNA含量之间的相关性,旨在指导母乳喂养。方法选取96例乙肝病毒携带产妇,将其分为大三阳组(54例)、小三阳组(25例)、HbsAg和HbeAg均阳性组(8例)及HbsAg和HbcAb均阳性组(9例)。另选取12例乙肝两对半全阴的产妇作为对照组。ELISA法检测乙肝病毒携带产妇乙肝免疫血清学标志物,实时荧光定量PCR法分别检测产妇血清与乳汁中HBV-DNA含量,并对所有检测指标进行相关性分析。结果大三阳组产妇血清和乳汁HBV-DNA阳性率明显高于其他三组(P0.05)。根据乙型肝炎血清学标志物HBeAg是否阳性将96例产妇分为HBeAg阳性组(62例)和HBeAg阴性组(34例),血清HBeAg阳性产妇的血清和乳汁中HBV-DNA阳性率均明显高于HBeAg阴性产妇,差异具有统计学意义(P0.05). The HBV-DNA positive rates in serum and milk in HBeAg positive groups were obvious-ly higher than that in HBeAg-negative group (P<0.01). However, HBV-DNA in serum and milk were also detected in part of the HBeAg-negative pregnancy women. The HBV-DNA content in serum had positive relation with HBV-DNA content in milk (r=0.891, P<0.05). Conclusion In HBV- infectious pregnant women, it is found that the HBV-DNA positive rate in milk was less than that in serum, and the content of HBV-DNA in milk was increased along with that increased in serum. Therefore, it is more reliable to determine the risk of hepatitis B virus transmission from mother to infant by quantitative measurement of HBV-DNA in serum and milk. It is helpful in interrupting HBV trans-mission, deciding the mode of breast-feeding, and guiding breast-feeding, so as to decrease the infectious rate of baby.

  4. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

    DEFF Research Database (Denmark)

    Weber, Rainer; Sabin, Caroline; Reiss, Peter;

    2010-01-01

    Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals.......Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals....

  5. Phylogenetic analysis of complete genome sequences of hepatitis B virus from an Afro-Colombian community: presence of HBV F3/A1 recombinant strain

    Directory of Open Access Journals (Sweden)

    Alvarado-Mora Mónica V

    2012-10-01

    Full Text Available Abstract Background Hepatitis B virus (HBV infection is one of the most prevalent viral infections in humans and represents a serious public health problem. In Colombia, our group reported recently the presence of subgenotypes F3, A2 and genotype G in Bogotá. The aim of this study was to characterize the HBV genotypes circulating in Quibdó, the largest Afro-descendant community in Colombia. Sixty HBsAg-positive samples were studied. A fragment of 1306 bp (S/POL was amplified by nested PCR. Positive samples to S/POL fragment were submitted to PCR amplification of the HBV complete genome. Findings The distribution of HBV genotypes was: A1 (52.17%, E (39.13%, D3 (4.3% and F3/A1 (4.3%. An HBV recombinant strain subgenotype F3/A1 was found for the first time. Conclusions This study is the first analysis of complete HBV genome sequences from Afro-Colombian population. It was found an important presence of HBV/A1 and HBV/E genotypes. A new recombinant strain of HBV genotype F3/A1 was reported in this population. This fact may be correlated with the introduction of these genotypes in the times of slavery.

  6. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.

    Science.gov (United States)

    Geng, Lei; Lin, Bing-Yi; Shen, Tian; Guo, Hua; Ye, Yu-Fu; Zheng, Shu-Sen

    2016-06-01

    Anti-virus prophylactic therapy may be not necessary for the prevention of hepatitis B virus (HBV) recurrence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globulin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis B e antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver disease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after withdrawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months; one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data suggested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  7. YMDD variants of HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation

    Institute of Scientific and Technical Information of China (English)

    Fei Pei; Jun-Yu Ning; Jiang-Feng You; Jing-Pin Yang; Jie Zheng

    2005-01-01

    AIM: To look for a rapid low-cost technique for the detection of HBV variants.METHODS: Two patients who underwent orthotopic liver transplantation (OLT) for HBV infection were treated with lamivudine (100 mg daily) and HBV infection recurred in the grafted livers. The patients were monitored intensively for liver enzymes, hepatitis B surface antigen (HBsAg) and HBV DNA in serum. Liver biopsy was performed regularly. HBV DNA in a conserved polymerase domain (the YMDD locus) was amplified from serum of each patient by PCR and sequenced. HBV genotypes were analyzed by restriction fragment length polymorphism (RFLP) of the PCR products generated from a fragment of the polymerase gene.RESULTS: YMDD wild-type HBV was detected in one patient by PCR-RFLP and DNA sequencing 19 mo after OLT, and YIDD mutant-type HBV in the other patient, 16 mo after OLT.CONCLUSION: PCR-RFLP assay is an accurate and simple method for genotyping lamivudine-resistant HBV variants.

  8. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

    Directory of Open Access Journals (Sweden)

    Schmit Jean-Claude

    2011-05-01

    . Conclusions Despite the existing national risk-reduction strategies implemented since 1993, high prevalence of HCV and HBV infections in injecting drug users is observed. Our study showed that implementing risk-prevention strategies, including immunisation remains difficult with PDUs. Improvement should be looked for by the provision of field healthcare structures providing tests with immediate results, advice, immunisation or treatment if appropriate.

  9. Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    Chao-Pin Li; Li-Fa Xu; Qun-Hong Liu; Chao Zhang; Jian Wang; Yu-Xia Zhu

    2004-01-01

    AIM: To explore an ideal method for extracting protoporphyrin disodium (PPN) from unanticoagulated animal blood, and to study the inhibitory effects of PPN on HBV-DNA duplication and its cytotoxicity to 2.2.15 cell strain.METHODS: Protoporphyrin methyl ester and other intermediate products were prepared with protoheme separated from protein hydrolysates of coagulated animal blood, which were finally made into PPN and detected quantitatively with an ultraviolet fluorescent analyzer.Ten μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml of PPN-aqueous solution were added into culture medium for 2.2.15 cells respectively. Eight days later, the drug concentration in supernatant from the culture medium was detected when inhibition rate of HBeAg, cell Survival rate when inhibition rate of HBeAg was 50% (ID50), and when survival cells in experimental group were 50% of those in control group (CD50), and the therapeutic index (TI) was also detected. PPN with different concentration of 10 μg/ml,20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml was respectively mixed and cultivated with HepG2 2.2.15 cell suspension,and then the inhibition of PPN against HBV-DNA was judged by PCR.RESULTS: The extract of henna crystal was identified to be PPN. When the concentrations of PPN were 160 μg/ml and 80 μg/ml, the inhibition rates of HBeAg were 89.8% and 82.4%, and the cell survival rates were 98.7% and 99.2%.CONCLUSION: It is suggested that PPN can be extracted from unanticoagulated animal blood. PPN can inhibit HBV-DNA expression and duplication ih vitro, and has no cytotoxicity to liver cells. Further study and application of PPN are warranted.

  10. Epidemiology of hepatitis C virus infection in highly endemic HBV areas in China.

    Directory of Open Access Journals (Sweden)

    Duan Li

    Full Text Available BACKGROUND: Wuwei City has the highest prevalence of hepatitis B virus (HBV in China. From 2007 to 2011, the average reported incidence rate of hepatitis B was 634.56/100,000 people. However, studies assessing the epidemic features and risk factors of HCV in the general population of Wuwei City are limited. METHODS: A total of 7189 people were interviewed and screened for HCV antibodies. HCV RNA and HCV genotypes were analyzed by PCR. Relevant information was obtained from the general population using a standardized questionnaire, and association and logistic regression analyses were conducted. RESULTS: The anti-HCV prevalence was 1.64% (118/7189, and HCV-RNA was detected in 37.29% (44/118 of the anti-HCV positive samples. The current HCV infection rate was 0.61% (44/7189 in the Wuwei general population. Hepatitis C infection rate was generally higher in the plains regions (χ(2 = 27.54,P<0.05, and the most predominant HCV genotypes were 2a (59.1% and 1b (34.1%. The concurrent HCV and HBV infection rate was 1.37%, and a history of blood transfusion (OR = 17.9, 95% CI: 6.1 to 52.6, p<0.001 was an independent risk factor for HCV positivity. CONCLUSIONS: Although Wuwei is a highly endemic area for HBV, the anti-HCV positive rate in the general population is low. More than one-third of HCV-infected people were unaware of their infection; this may become an important risk factor for hepatitis C prevalence in the general population. Maintaining blood safety is important in order to help reduce the burden of HCV infection in developing regions of China.

  11. Detection of HBV, PCNA and GST-π in hepatocellular carcinoma and chronic liver diseases

    Institute of Scientific and Technical Information of China (English)

    Li-Juan Shen; Hua-Xian Zhang; Zong-Ji Zhang; Jin-Yun Li; Ming-Qin Chen; Wei-Bo Yang; Run Huang

    2003-01-01

    AIM: To investigate the change of HBV DNA, PCNA and GST-π in chronic liver disease and hepatocellular carcinoma (HCC).METHODS: Hepatitis B surface antigen (HBsAg), proliferating cell nuclear antigen (PCNA) and glutathione S-transferases (GST-π) were detected by immunohistochemical staining and HBV DNA was detected by in situ hybridization (ISH) in formalin-fixed and paraffin-embedded sections with a total of 111 specimens of chronic hepatitis, liver cirrhosis,paratumorous tissue, HCC and normal liver tissue.RESULTS: The positive rates of HBsAg and HBVDNA were 62.5 %(15/24) and 75.0 %(12/16) in chronic hepatitis,64.0 %(16/25) and 83.3 %(15/18) in liver cirrhosis, 72.7 %(16/22) and 85.7 %(12/14) in the paratumorous tissu and 45.0 %(14/31) and 64.3 %(9/14) in HCC. The positive HBVDNA granules in chronic hepatitis, liver cirrhosis and the paratumorous tissue were more intense than that in HCC.The positive rates of PCNA and GST-π were 34.8 %(8/23)and 25.0 %(4/16) in chronic hepatitis, 73.7 %(14/19) and 17.6 %(3/17) in liver cirrhosis, 86.7 %(13/15) and 53.3 % (8/15) in the paratumorous tissue, 100 %(15/15) and 60.0 %(9/15) in HCC, respectively, and the positive rate of GST-πin the paratumorous tissue was significantly higher than that in the liver cirrhosis without tumor (P<0.05), but same as that in HCC(P>0.05).CONCLUSION: The HBV infection may increase expression of PCNA and GST-π. The paratumor cirrhosis may be a sequential lesion of precancerous cirrhosis around HCC.

  12. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression

    Institute of Scientific and Technical Information of China (English)

    Bozena Walewska-Zielecka; Kazimierz Madalinski; Joanna Jablonska; Paulina Godzik; Joanna Cielecka-Kuszyk; Bogumila Litwinska

    2008-01-01

    AIM: To study the composition of liver inflammatory infiltrate in biopsy material from patients chronically infected with hepatotropic viruses and to evaluate the correlation of inflammatory infiltrate with hepatitis B virus (HBV) and hepatitis C virus (HCV) viral antigen expression in chronic B and C hepatitis.METHODS: The phenotype of inflammatory cells was evaluated by the EnVision system, using a panel of monoclonal antibodies. HBV and HCV antigens were detected with the use of monoclonal anti-HBs, poly-clonal anti-HBc and anti-HCV antibodies, respectively.RESULTS: The cellular composition of liver inflammatory infiltrate was similar in the patients with B and C hepatitis: ~50%-60% of cells were T helper lymphooltes. Approximately 25% were T cytotoxic lymphocytes; B lymphocytes comprised 15% of inflammatory infiltrate; other cells, including NK, totalled 10%. Expression of HLA antigens paralleled inflammatory activity. Portal lymphadenoplasia was found more often in hepatitis C (54.5%) than in hepatitis B (30.6%). Expression of HB-cAg was found more often in chronic B hepatitis of moderate or severe activity. Overall inflammatory activity in HBV-infected cases did not correlate with the intensity of HBsAg expression in hepatooltes. Inflammatory infiltrates accompanied the focal expression of HCV anti-gens. A direct correlation between antigen expression and inflammatory reaction in situ was noted more often in hepatitis C than B.CONCLUSION: Irrespective of the etiology and activity of hepatitis, components of the inflammatory infiltrate in liver were similar. Overall inflammatory activity did not correlate with the expression of HBsAg and HCVAg; HBcAg expression, however, accompanied chronic hepatitis B of moderate and severe activity.

  13. Study on the relationship between level of CD58 expression in peripheral blood mononuclear cell and severity of HBV infection

    Institute of Scientific and Technical Information of China (English)

    XIE Ming; WANG Xiang-ling; JI Yu-qiang; LI Jie; MENG Zhao-jun; SHI Lin; YUAN Yu-kang

    2005-01-01

    Background As one of the intercellular adhesion molecules, CD58 plays important roles in promotion of the adhesion between T cells and target cells, hyperplasia, activation of T cells and natural killer cells, and balance between Th1 and Th2. We studied the relationship between the levels of CD58 expression in peripheral blood mononuclear cells (PBMCs) and severity of HBV infection. Methods The levels of CD58 mRNA in PBMCs were detected using quantitative reverse transcription PCR. The percentage of CD58 positive cells was detected by flow cytometry in patients and healthy controls. Results The levels of CD58 mRNA and the percentage of CD58 positive cells in patients infected with HBV were significantly higher than that in the control. Based on severity of HBV infection, the patients were classified into four groups. The expression of CD58 increased significantly in an order from mild chronic, moderate chronic, severe chronic to severe hepatitis groups. The levels of CD58 mRNA and the percentage of CD58 positive cells in PBMCs from patients with HBV infection were both positively correlated with serum levels of ALT and AST.Conclusion The level of CD58 expression is related with the severity of HBV infection and the degree of liver damage.

  14. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine

    Institute of Scientific and Technical Information of China (English)

    Hee Bok Chae; Hie-Won Hann

    2007-01-01

    AIM: To identify the factors associated with virologic breakthrough and to select a subgroup of patients who respond well to lamivudine without developing virologic breakthrough (VBT).METHODS: Of 79 patients who had received lamivudine therapy for 9-57 mo, 34 were HBeAg-positive and 45 were HBeAg-negative, 24 developed virologic breakthrough and 55 did not. Clinical and virologic factors were compared between the two groups.RESULTS: The median duration of therapy was 25 (9-57)mo. Virologic breakthrough was defined as a > 1 log HBV DNA increase following initial suppression. When several factors, including gender, duration of infection, baseline HBV DNA, and baseline ALT in HBeAg-positive chronic hepatitis patients were analyzed by logistic regression,the most important predictor of virologic breakthrough was the baseline HBV DNA (r2 = 0.12, P < 0.05). When HBeAg-postitive chronic hepatitis patients were divided into two groups by a point of 6.6 log HBV DNA, the incidence of virologic breakthough between two groups was significantly different.CONCLUSION: Lamivudine may remain an effective first line therapy for those HBeAg-positive patients with a baseline HBV DNA < 6.6 log10 copies/mL.

  15. Khmer American Mothers’ Knowledge about HPV and HBV Infection and Their Perceptions of Parenting: My English Speaking Daughter Knows More

    Science.gov (United States)

    Lee, Haeok; Kiang, Peter; Tang, Shirely S.; Chea, Phala; Peou, Sonith; Semino-Asaro, Semira; Grigg-Saito, Dorcas C.

    2016-01-01

    SUMMARY Purpose The purpose of this study is to explore and describe Khmer mothers’ understanding of HBV and HPV prevention as well as their perception of parenting on health and health education of their daughters in the US. Methods The qualitative pilot study guided by the revised Network Episode Model and informed by ethnographic analysis and community-based purposive sampling method were used. Face-to-face audiotaped interviews with eight Khmer mothers were conducted by bilingual female middle-aged community health leaders who spoke Khmer. Results The findings revealed that Khmer mothers clearly lacked knowledge about HBV and HPV infection prevention and had difficulty understanding and educating their daughters about health behavior, especially on sex-related topics. The findings showed that histo-sociocultural factors are integrated with the individual factor, and these factors influenced the HBV and HPV knowledge and perspective of Khmer mothers’ parenting. Conclusion The study suggests that situation-specific conceptual and methodological approaches that take into account the uniqueness of the sociocultural context of CAs is a novel method for identifying factors that are significant in shaping the perception of Khmer mothers’ health education related to HBV and HPV prevention among their daughters. The communication between mother and daughter about sex and the risk involved in contracting HBV and HPV has been limited, partly because it is seen as a “taboo subject” and partly because mothers think that schools educate their children regarding sexuality and health. PMID:26160247

  16. Baseline characteristics of HIV & hepatitis B virus (HIV/HBV co-infected patients from Kolkata, India

    Directory of Open Access Journals (Sweden)

    Jayeeta Sarkar

    2016-01-01

    Results: HIV/HBV co-infected patients had proportionately more advanced HIV disease (WHO clinical stage 3 and 4 than HIV mono-infected individuals (37.1 vs. 19.9%. The co-infected patients had significantly higher serum bilirubin, alanine aminotransferase (ALT, alkaline phosphatase and ALT/platelet ratio index (APRI. CD4 count was non-significantly lower in co-infected patients. Majority (61.5% were HBeAg positive with higher HIV RNA (P<0.05, HBV DNA (p<0.001 and APRI (p<0.05 compared to those who were HBeAg negative. HBV/D was the predominant genotype (73.2% and D2 (43.7% was the commonest subgenotype. Interpretation & conclusions: HIV/HBV co-infected patients had significantly higher serum bilirubin, ALT, alkaline phosphatase and lower platelet count. HBeAg positive co-infected patients had higher HIV RNA and HBV DNA compared to HBeAg negative co-infected patients. Prior to initiation of antiretroviral treatment (ART all patients should be screened for HBsAg to initiate appropriate ART regimen.

  17. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues

    Institute of Scientific and Technical Information of China (English)

    Zhuo-Lun Song; Yu-Jun Cui; Wei-Ping Zheng; Da-Hong Teng; Hong Zheng

    2012-01-01

    Nucleos(t)ide analogues (NA) are a breakthrough in the treatment and management of chronic hepatitis B.NA could suppress the replication of hepatitis B virus (HBV) and control the progression of the disease.However,drug resistance caused by their long-term use becomes a practical problem,which influences the long-term outcomes in patients.Liver transplantation is the only choice for patients with HBV-related end-stage liver disease.But,the recurrence of HBV after transplantation often caused by the development of drug resistance leads to unfavorable outcomes for the recipients.Recentiy,the multi-drug resistance (MDR) has become a common issue raised due to the development and clinical application of a variety of NA.This may complicate the antiviral therapy and bring poorly prognostic outcomes.Although clinical evidence has suggested that combination therapy with different NA could effectively reduce the viral load in patients with MDR,the advent of new antiviral agents with high potency and high genetic barrier to resistance brings hope to antiviral therapy.The future of HBV researches relies on how to prevent the MDR occurrence and develop reasonable and effective treatment strategies.This review focuses on the diagnostic and therapeutic progress in MDR caused by the anti-HBV NA and describes some new research progress in this field.

  18. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line.

    Science.gov (United States)

    Cavallone, Daniela; Moriconi, Francesco; Colombatto, Piero; Oliveri, Filippo; Bonino, Ferruccio; Brunetto, Maurizia Rossana

    2013-04-01

    The Gunther's vector-free method (GM), using PCR-amplified full length HBV-DNA (fl-HBV-DNA), is currently the best in vitro HBV replication system despite the low intracellular HBV-DNA production. The replication efficiency and HBsAg secretion of 12 isolates from HBsAg/HBeAg positive sera by GM, Monomer-Linear-Sticky-Ends-DNA (MLSE) and Monomer-Circular-Closed (MCC) were compared in HuH7 cells. Eight of twelve genomes (67%) were replication competent by GM; however direct sequencing (DS) showed that more than 80% of input DNA was undigested in spite of SapI treatment. Replication Intermediates (RI) were detected earlier (24 vs. 48h) and in higher amounts (2.51±0.32 and 6.43±0.43 fold) by MCC than GM or MLSE. By MCC 10 of 12 genomes (83%) were replication competent and 7 produced high RI levels. RI and HBsAg kinetics correlated positively in MCC (R=0.696, p=0.017 overall; R=0.928, p=0.008), but not in GM (R=-0.437, p=0.179 overall; R=-0.395, p=0.439) in genotype D isolates. In conclusion, HBV-DNA circularization prior transfection improves in vitro viral replication and replication competent HBsAg production, mimicking better the in vivo conditions.

  19. [Whole-sequence Analyses for 12 HBV C/D Recombinants from a Population in Tibet (China)].

    Science.gov (United States)

    Liu, Tiezhu; Shen, Liping; Yin, Wenjiao; Wang, Feng; Wang, Fuzhen; Zhang, Guomin; Zheng, Hui; Dunzhu, Duoji; Bi, Shengli; Cui, Fuqiang

    2016-03-01

    We wished to undertake molecular genetic typing and evaluate recombinants of the hepatitis-B virus (HBV) in Tibet (China). Multistage random sampling was used to collect HBsAg-positive samples. Nested polymerase chain reactions were used to amplify the whole sequence of the HBV. DNAstar, MEGA6 and SimPlot were used to assemble sequences, create phylogenetic trees, and undertake recombination analyses. Twelve whole sequences of the HBV of a Tibetan population were collected using these methods. Results showed that all 12 strains were C/D recombinants. Nine of the recombinations were at nt750, and the other three at nt1526. Therefore, the 12 strains could be divided into two types of recombinants: C/Da and C/Db. Analyses of the sequence of the whole genome revealed that the 12 strains belonged to genotype C, and that the nucleotide distance was > 4% between the 12 strains and sub-genotypes C1 to C15 in Genbank. The most likely sub-genotype was C1. Individuals with C/Da were from central and northern Tibet (e.g., Lasa, Linzhi, Ali) and those with C/Db recombinants were from Shannan in southern Tibet. These data suggest that the two types of recombinants had a good distribution in Tibet. Also, they can provide important information for studies on HBV recombination, gene features, virus evolution, as well as the control and prevention of HBV infection in Tibet.

  20. Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Chiara Viola; Tarik Asselah; Didier Samuel; Fran(c)ois Durand; Hamza Boudjema; Dominique Vaila; Patrick Marcellin

    2006-01-01

    We described a 59-year-old male patient who underwent liver transplantation in 1989 for hepatocellular carcinoma (HCC) complicating hepatitis B virus (HBV) cirrhosis. In 2001 (12 years after liver transplantation), he developed a lung metastasis of HCC without intrahepatic recurrence and the resection was done. In July 2003, he was symptom free without any recurrence. HCCmetastasis can develop even after a very long time of liver transplantation. Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater thanthat of those who do not receive immunosuppressive therapy.

  1. Characteristics of S gene mutation in patients with occult HBV infection

    Directory of Open Access Journals (Sweden)

    Jian-hong CHEN

    2015-04-01

    Full Text Available Objective To analyze characteristics of HBV S gene mutation in one patient with occult hepatitis B virus infection, who was positive for serum HBV DNA for long term, but negative for HBsAg in order to reveal the correlation between S gene mutation and development of OBI as well as the progression of the liver disease. Methods Four serum samples were collected at different time-points for the use of amplifying HBV S gene and performing cloning-sequencing. The representative S mutants were selected to construct recombinant vectors for phenotype analysis. Results Several S-gene mutational patterns were detected in the samples, including pre-S1 large fragment deletion, s126-127 "RPCMNCTI" insertion, sQ129N, s131-133 TSM→NST, and classical sG145R mutations. In sequential 4 samples, s131-133 TSM→NST mutation was detected in 0%, 26%, 59% and 74% of viral clones, respectively. The pre-S1 large fragment deletion was constantly found in the 4 serum samples, accounting for 26%, 17%, 15% and 21% of detected viral clones, respectively. Phenotypic analysis showed that sQ129N and s131-133 TSM → NST mutations reduced the affinity of the antibody to HBsAg and increased the secretion of virus particles. Compared with the wild-type strain, the replication capacity and surface antigen promoter Ⅱ (SPⅡ activity of large fragment-deleted (nt 3046-3177 deletion strain were decreased by 43.7% and 97.2%, respectively. In addition, sG145R-induced impairment to secretion capacity of viral particles was verified. Conclusions Clinical presentations of long-term OBI of this HBV-infected patient could be caused by multiple S-gene mutants. Some S-gene mutations influence viral phenotypic characteristics, which might closely be related to the progression of liver disease. DOI: 10.11855/j.issn.0577-7402.2015.03.02

  2. The study on the relativity among HBeAg, HBV-DNA and PreS1-antigen%乙型肝炎血清前S1抗原与HBV-DNA和HBeAg相关性分析

    Institute of Scientific and Technical Information of China (English)

    邓芝云; 董菊子; 朱发仁; 张方信

    2011-01-01

    Objective To study the clinical application value of Presl-antigen. Methods The HBV markers and Presl-antigen were detected by enzyme linked immunosorbent assay ( ELISA) and the HBV-DNA was detected by fluorescent quantitation poly-merase chain reaction (FQ-PCR) in 365 patients with hepatitis B. Results The positive rates of the HBV-DNA and Presl were 86.4% and 89.1% in 110 patients of HBsAg+ , HBeAg+ and HBcAb + ; 36.4% and 40.9% in 66 patients of HBsAg+ ,HBeAb + and HBcAb + ;32.4% and 41.7% in 37 patients of HBsAg + and HBcAb + ;15.4% and 15.4% in 39 patients of HeAg + and HBcAb + ;5.3% and 8.0% in 113 patients of HBsAb +. The positive rates of HBeAg and PreSlAg increased with increasing HBV-DNA, PreS1 Ag was increased significantly compared with HBeAg ( P < 0.05 ). Conclusion Presl and HBV-DNA are the sensitive index for HBV replication, though PreSlAg and HBeAg Presl increased with increasing HBV-DNA, PreSlAg is more sensitive than HBeAg, and it is valuable in clinical application.%目的 探讨乙型肝炎血清前S1抗原(PreS1Ag)临床应用的价值.方法 对365例乙型肝炎患者血清,采用酶联免疫吸附试验(ELISA)检测HBV血清标志物和PreS1 Ag,用荧光定量聚合酶链反应(FQ-PCR)方法 检测HBV-DNA.结果 HBV-DNA和PreS1Ag的阳性率在110例HBV大三阳中,分别为86.4%和89.1%;在66例HBV小三阳中,分别为36.4%和40.9%;在37例HBsAg、HBcAb中,分别为32.4%和41.7%;在39例HBeAg、HBcAb阳性中,分别为15.4%和15.4%;在113例HBsAb阳性中,分别为5.3%和8.0%.HBeAg、PreS1Ag阳性率随不同载量HBV-DNA升高而增高,但PreS1Ag比HBeAg增高更明显(P<0.05).结论 PreS1 Ag和HBV-DNA一样都是乙型肝炎病毒复制的敏感指标,虽然PreS1Ag和HBeAg都随HBV-DNA载量增加而升高,但PreS1Ag较HBeAg更能敏感,因此PreS1 Ag具有重要的临床应用价值.

  3. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: Exploratory screening reveals high frequency of occult HBV infection

    Institute of Scientific and Technical Information of China (English)

    Prasun Bhattacharya; Partha Kumar Chandra; Sibnarayan Datta; Arup Banerjee; Subhashish Chakraborty; Krishnan Rajendran; Subir Kumar Basu; Sujit Kumar Bhattacharya; Runu Chakravarty

    2007-01-01

    AIM: To evaluate the prevalence of markers of hepatitis B virus (HBV) and hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among blood donors in Kolkata, Eastern India for two consecutive years and to conduct a pilot study to explore the presence of HBV DNA among hepatitis B surface antigen (HBsAg) negative but anti-HBc positive blood donors.METHODS: Seroprevalence of HBsAg, anti-HCV and anti-HIV was studied among 113051 and 106695 voluntary blood donors screened in 2004 and 2005,respectively. Moreover, a pilot study on 1027 HBsAg negative donors was carried out for evaluating the presence of HBV DNA by PCR on HBsAg negative/antiHBc positive donors.RESJLTS: A statistically significant increase in the prevalence of HBV (1448 vs 1768, P < 0.001), HIV (262vs 374, P < 0.001), HCV (314 vs 372, P = 0.003) and syphilis (772 vs 853, P = 0.001) infections was noted among blood donors of Kolkata West Bengal in 2005 as compared to 2004. Moreover, the exploratory study on 1027 HBsAg negative donors revealed that 188 (18.3%) of them were anti-HBc positive out of which 21% were positive for HBV DNA.CONCLUSION: The findings of this study underscore the significantly increasing endemicity of hepatitis viruses, syphilis and HIV among the voluntary blood donors of our community. The pilot study indicates a high rate of prevalence of HBV DNA among HBsAg negative/anti-HBc positive donors and thus emphasizes the need for a more sensitive and stringent screening algorithm for blood donations.

  4. Distribution of hepatitis B virus genotypes: Phylogenetic analysis and virological characteristics of Genotype C circulating among HBV carriers in Kolkata, Eastern India

    Institute of Scientific and Technical Information of China (English)

    Arup Banerjee; Sibnarayan Datta; Partha K Chandra; Susanta Roychowdhury; Chinmoy Kumar Panda; Runu Chakravarty

    2006-01-01

    AIM: To evaluate the genotype distribution of hepatitis B virus (HBV) in Eastern India and to clarify the phylogenetic origin and virological characteristics of the recently identified genotype C in this region.METHODS: Genotype determination, T1762/A1764mutation in the basal core promoter (BCP) and A1896mutation in the precore region of 230 subjects were determined by restriction fragment length polymorphism method (RFLP) and the result was confirmed by direct sequencing.RESULTS: The predominant genotypes D (HBV/D) and A (HBV/A) were detected in 131/230 (57%) and 57/230(25%) samples. In addition, genotype C (HBV/C) was detected in 42/230 (18%) isolates. Surface gene region was sequenced from 45 isolates (27 HBV/C, 9 HBV/A and 9 HBV/D). Phylogenetic analysis revealed that all of the HBV/C sequences clustered with South East Asian subgenotype (HBV/Cs). The sequence data showed remarkable similarity with a Thai strain (AF068756) (99.5%± 0.4% nucleotide identities) in 90% of the genotype C strains analyzed. T1762/A1764 mutation in BCP region, associated with high ALT was significantly higher in HBeAg negative isolates than HBeAg positive isolates.Frequency of A1896 mutation leading to HBeAg negativity was low.CONCLUSION: The present study reports the genotypic distribution and the characteristics of partial genome sequences of HBV/C isolates from Eastern India. Low genetic diversity and confinement of HBV/C in Eastern India possibly indicate a recent, limited, spread in this region. Genotype C with T1762/A1764 mutation has been reported to increase the risk for hepatocellular carcinoma; therefore genotype C carriers in Eastern India should be carefully monitored.

  5. Detection of Mutations Resistant to Lamivudine or Adefovir in HBV and Its Management

    Institute of Scientific and Technical Information of China (English)

    2013-01-01

    Objective Nucleos(t)ide analogues (NAs) na?ve chronic hepatitis B(CHB) patients were given rescue combination therapy after drug resistance to lamivudine or adefovir. Evolution of HBV mutation patterns and its impact on antiviral effects were studied. Methods Total of 142 na?ve CHB patients treated with lamivudine were randomly divided into two groups when lamivudine resistance occurred. One group was added with adefovir, the other was switched to entecavir and adefovir. Seventy-two na?ve CHB patients treated with adefovir were randomly divided into two groups when adefovir resistance occurred. One group was added with lamivudine, the other was added with entecavir. HBV polymerase reverse transcriptase mutations associated with resistance were analyed before and after 48 weeks of rescue therapy, respectively. Results The mutation patterns of M204V/I, M204V+L180M were predominantly found in CHB patients after lamivudine resistance. Meanwhile, the entecavir resistance mutation patterns were also detected. Therefore, patients with lamivudine resistance could develop more diverse drug resistance mutations if they were switched to entecavir and adefovir. The mutation patterns of rtA181 were predominantly found in CHB patients after adefovir resistance and rescure therapy with add-on entecavir was more effective than with add-on lamivudine Conclusions Resistance mutation analysis chould help to choose NAs, reduce resistance and ehance antiviral effects.

  6. HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids

    Science.gov (United States)

    Su, Pei-Yi; Yang, Ching-Jen; Chu, Tien-Hua; Chang, Chih-Hsu; Chiang, Chiayn; Tang, Fan-Mei; Lee, Chih-Yin; Shih, Chiaho

    2016-01-01

    Capsid assembly and stability of hepatitis B virus (HBV) core protein (HBc) particles depend on balanced electrostatic interactions between encapsidated nucleic acids and an arginine-rich domain (ARD) of HBc in the capsid interior. Arginine-deficient ARD mutants preferentially encapsidated spliced viral RNA and shorter DNA, which can be fully or partially rescued by reducing the negative charges from acidic residues or serine phosphorylation of HBc, dose-dependently. Similarly, empty capsids without RNA encapsidation can be generated by ARD hyper-phosphorylation in insect, bacteria, and human hepatocytes. De-phosphorylation of empty capsids by phosphatase induced capsid disassembly. Empty capsids can convert into RNA-containing capsids by increasing HBc serine de-phosphorylation. In an HBV replicon system, we observed a reciprocal relationship between viral and non-viral RNA encapsidation, suggesting both non-viral RNA and serine-phosphorylation could serve as a charge balance buffer in maintaining electrostatic homeostasis. In addition, by comparing the biochemistry assay results between a replicon and a non-replicon system, we observed a correlation between HBc de-phosphorylation and viral replication. Balanced electrostatic interactions may be important to other icosahedral particles in nature. PMID:27958343

  7. Study the Three Extraction Methods for HBV DNA to Use in PCR

    Directory of Open Access Journals (Sweden)

    N. Sheikh

    2004-07-01

    Full Text Available Diagnosis of Hepatitis B is important because of the its high prevalence. Recently PCR method , has found greater interest among different diagnostic methods. Several reports emphasis on some false negative results in those laboratories using PCR. The aim of this study was to compare three different procedures for HBV DNA extraction. A total 30 serum samples received from Shariati hospital. Sera was taken from patients having chronic Hepatitis with HBs antigen positive and HBe antigen negative. The sensitivity of guanidium hydrochloride method for extracting the HBV DNA from serum were evaluated and compared with phenol–chloroform and boiling methods. Diagnostic PCR kit was obtained from Cynagene contained taq polymerase, reaction mixture, dNTP, and buffer for reaction. A 353 bp product were amplified by amplification program provided in used PCR protocol. The comparison of results indicated that procedure was successful for amplification of the designed products from Hepatitis B in sera. Number of positive results were 16,19,23 and number of negative result were 14,11,7 for the boiling, phenol-chloroform and guanidium-hydrochloride extraction methods respectively.PCR method is the fastest diagnosis method and the most accurate procedure to identify Hepatitis B. Guanidium hydrochloride method was the most successful procedure studied in this survey for viruses.

  8. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression.

    Directory of Open Access Journals (Sweden)

    Bouchra Kitab

    Full Text Available BACKGROUND: Hepatitis B virus (HBV is one of the most common human pathogens that cause aggressive hepatitis and advanced liver disease (AdLD, including liver cirrhosis and Hepatocellular Carcinoma. The persistence of active HBV replication and liver damage after the loss of hepatitis B e antigen (HBeAg has been frequently associated with mutations in the pre-core (pre-C and core promoter (CP regions of HBV genome that abolish or reduce HBeAg expression. The purpose of this study was to assess the prevalence of pre-C and CP mutations and their impact on the subsequent course of liver disease in Morocco. METHODS/PRINCIPAL FINDINGS: A cohort of 186 patients with HBeAg-negative chronic HBV infection was studied (81 inactive carriers, 69 with active chronic hepatitis, 36 with AdLD. Pre-C and CP mutations were analyzed by PCR-direct sequencing method. The pre-C stop codon G1896A mutation was the most frequent (83.9% and was associated with a lower risk of AdLD development (OR, 0.4; 95% CI, 0.15-1.04; p = 0.04. HBV-DNA levels in patients with G1896A were not significantly different from the other patients carrying wild-type strains (p = 0.84. CP mutations C1653T, T1753V, A1762T/G1764A, and C1766T/T1768A were associated with higher HBV-DNA level and increased liver disease severity. Multiple logistic regression analysis showed that older age (≥ 40 years, male sex, high viral load (>4.3 log(10 IU/mL and CP mutations C1653T, T1753V, A1762T/G1764A, and C1766T/T1768A were independent risk factors for AdLD development. Combination of these mutations was significantly associated with AdLD (OR, 7.52; 95% CI, 4.8-8; p<0.0001. CONCLUSIONS: This study shows for the first time the association of HBV viral load and CP mutations with the severity of liver disease in Moroccan HBV chronic carriers. The examination of CP mutations alone or in combination could be helpful for prediction of the clinical outcome.

  9. HBV-INFECTION DE NOVO AFTER ORTHOTOPIC LIVER TRANSPLANTATION: CLINICAL AND VIROLOGICAL CHARACTERISTICS, ASSESSMENT OF ANTIVIRUS THERAPY EFFECTIVENESS

    Directory of Open Access Journals (Sweden)

    O. I. Malomuzh

    2012-01-01

    Full Text Available We studied 11 cases of HBV-infection de novo in patients after orthotopic liver transplantation performed because of non-viral cirrhosis. Serum НBeAg, was revedled in all patients. In most cases clinical course of HBV-infection was benign. Treatment with entecavir was more effective than lamivudin, and brought to НBsAg elimination in 4 patients. Treatment with lamivudin led to descrease viral load in all patients and HBsAg elimination in one case. 

  10. Epidemiological profile and risk factors of HIV and HBV/HCV co-infection in Fujian Province, southeastern China.

    Science.gov (United States)

    Wu, Shouli; Yan, Pingping; Yang, Tianfei; Wang, Zhenghua; Yan, Yansheng

    2017-03-01

    This study aimed to investigate the epidemiological features of HIV-infected subjects co-infected with HBV/HCV in Fujian Province, southeastern China, and identify the risk factors. Blood samples were collected from 2,028 HIV antibody-positive subjects in Fujian Province. Serum HBsAg and anti-HCV antibody were detected, and CD4(+) T cell count was measured. Of the 2,028 subjects, the prevalence of HIV-HBV, HIV-HCV, and HIV-HBV-HCV co-infections was 16.22%, 3.7%, and 0.79%, respectively. Man (OR = 1.912, 95% CI: 1.371-2.667), key population (OR = 0.756, 95% CI: 0.57-0.976) and detainee (OR = 0.486, 95% CI: 0.259-0.909) were risk factors of HIV-HBV co-infection, and man (OR = 2.227, 95% CI: 1.096-4.525), minority (OR = 5.04, 95% CI: 1.696-14.98), junior high school or lower education (OR = 2.32, 95% CI: 1.071-5.025), intravenous drug use (OR = 38.46, 95% CI: 11.46-129.11) and detainee (OR = 5.687, 95% CI: 2.44-13.25) were risk factors of HIV-HCV co-infection. In addition, a lower mean CD4(+) T cell count was measured in HIV/HBV and HIV/HCV co-infected subjects than in HIV-infected subjects among the untreated individuals, while in the treated populations, a higher mean CD4(+) T cell count was detected in HIV/HBV and HIV/HCV co-infected subjects than in HIV-infected subjects. HIV co-infection with HBV or HCV, notably HIV-HBV co-infection, is widespread in southeastern China. Hepatitis virus screening should be included in monitoring of HIV infection, and HIV and hepatitis virus co-infection should be considered during the development of HIV antiretroviral therapy scheme. J. Med. Virol. 89:443-449, 2017. © 2016 Wiley Periodicals, Inc.

  11. Proifle, spectrum and signiifcance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China

    Institute of Scientific and Technical Information of China (English)

    Jing You; Bao-Zhang Tang; Hutcha Sriplung; Virasakdi Chongsuvivatwong; Alan Geater; Lin Zhuang; Jun-Hua Huang; Hong-Ying Chen; Lan Yu

    2008-01-01

    BACKGROUND:There are signiifcant variations in the geographical distribution of hepatitis B virus (HBV) genotypes throughout the world, and some genotypes are associated with different clinical outcomes. Eight genotypes of human HBV (designated A-H) have been reported. The present study was designed to examine the distribution of HBV genotypes among patients at various stages of chronic type B liver disease in Yunnan Province, China, and to explore its signiifcance and the relationship of HBV genotype with gender and age, clinical spectrum of chronic HBV infection, and viral replicative activity. METHODS:Serum samples from 126 patients with chronic HBV infection from Yunnan Province, including 26 chronic asymptomatic HBV carriers (ASC), 61 patients with chronic hepatitis B (CHB) (21 mild, 30 moderate and 10 severe), 20 patients with chronic fulminant hepatic failure (CFHF), 12 patients with HBV-related liver cirrhosis (LC) and 7 patients with HBV-related hepatocellular carcinoma (HCC) were analyzed using reverse dot blot (RDB) methodology, which is based on the reverse hybridization principle for HBV genotyping. The relations of HBV genotype with gender and age, clinical patterns, and serological data of the patients were analyzed. RESULTS: In this series, genotypes A, B, C, and D were found. 38.1%patients (48/126) belonged to B, 54.8%(69/126) to C, 0.8%(1/126) to D, 1.6%(2/126) to a mixture of B and C, and 1.6%(2/126) to a mixture of A and C. 3.2%patients (4/126) had unknown genotypes. No other genotypes (E, F, G, and H) were found. Genotypes B and C were predominant. There was a statistically signiifcant difference in the distributions of genotypes C and B (χ2=7.04, P=0.008), and C was the dominant genotype in all patient categories. The rate of genotype B in the mild CHB group was signiifcantly higher than that in the moderate and severe groups (χ2=12.16, P=0.0001; χ2=11.98, P=0.001, respectively), the ASC group (χ2=5.46, P=0.02), the CFHF group (χ2

  12. Frequencies of dendritic cells and Toll-like receptor 3 in neonates born to HBsAg-positive mothers with different HBV serological profiles.

    Science.gov (United States)

    Guo, J; Gao, Y; Guo, Z; Zhang, L R; Wang, B; Wang, S P

    2015-01-01

    To investigate the frequencies of dendritic cells (DCs) and Toll-like receptor 3 (TLR3) in neonates of HBsAg-positive mothers with different HBV serological profiles, we conducted a study in Taiyuan, China. The study included 144 HBsAg-positive mothers and their neonates. The frequencies of DCs and TLR3 were determined using four-colour flow-cytometric analysis. DC and TLR3 frequencies were not related to HBV intrauterine transmission, maternal HBeAg positivity, maternal HBV DNA positivity and HBeAg/HBV DNA double-positivity. The plasmacytoid dendritic cell (pDC) frequencies in neonates whose maternal HBV DNA was >5 × 107 copies/ml decreased significantly compared to that in neonates whose maternal HBV DNA was ⩽5 × 107 copies/ml (Z = - 2·170, P = 0·03) or whose maternal HBV DNA was negative (Z = - 1·981 P = 0·048). This study suggests that neonatal pDC frequencies decrease when maternal HBV DNA loads are >5 × 107 copies/ml.

  13. Downregulation of the AU-rich RNA-binding protein ZFP36 in chronic HBV patients: implications for anti-inflammatory therapy.

    Directory of Open Access Journals (Sweden)

    Wen-Jing Jin

    Full Text Available Inflammation caused by chronic hepatitis B virus (HBV infection is associated with the development of cirrhosis and hepatocellular carcinoma; however, the mechanisms by which HBV infection induces inflammation and inflammatory cytokine production remain largely unknown. We analyzed the gene expression patterns of lymphocytes from chronic HBV-infected patients and found that the expression of ZFP36, an AU-rich element (ARE-binding protein, was dramatically reduced in CD4(+ and CD8(+ T lymphocytes from chronic HBV patients. ZFP36 expression was also reduced in CD14(+ monocytes and in total PBMCs from chronic HBV patients. To investigate the functional consequences of reduced ZFP36 expression, we knocked down ZFP36 in PBMCs from healthy donors using siRNA. siRNA-mediated silencing of ZFP36 resulted in dramatically increased expression of multiple inflammatory cytokines, most of which were also increased in the plasma of chronic HBV patients. Furthermore, we found that IL-8 and RANTES induced ZFP36 downregulation, and this effect was mediated through protein kinase C. Importantly, we found that HBsAg stimulated PBMCs to express IL-8 and RANTES, resulting in decreased ZFP36 expression. Our results suggest that an inflammatory feedback loop involving HBsAg, ZFP36, and inflammatory cytokines may play a critical role in the pathogenesis of chronic HBV and further indicate that ZFP36 may be an important target for anti-inflammatory therapy during chronic HBV infection.

  14. An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers.

    Directory of Open Access Journals (Sweden)

    Xiao Zhu

    Full Text Available BACKGROUND: Our previous study indicated that a common variant (rs430397 G>A in the intron 5 of glucose-regulated protein 78 (GRP78 gene was associated with risk and prognosis of primary hepatocellular carcinoma (HCC, including HBV- and cirrhosis-related HCC. rs430397 polymorphism may be a contributing factor or biomarker of HBV infection or HBV-related cirrhosis. METHODOLOGY/PRINCIPAL FINDINGS: 539 non-HBV-infected individuals, 205 self-limited infection and 496 persistent HBV infection were recruited between January 2001 and April 2005 from the hospitals in Southern China. Genomic DNA was genotyped for rs430397. The associations between the variation and susceptibility to liver cirrhosis (LC in persistent HBV infection were examined. We observed that individuals carrying allele rs430397A were more likely to become HBV-related LC. When persistently infected patients were divided into four subgroups, patients with phase IV had an increased allele A and genotype AG compared with phase I and/or phase III. Decreased serum albumin and prolonged plasma prothrombin time (PT were showed in LC patients carrying genotype AA. Furthermore, rs430397 genotype had an increased susceptibility to LC with dose-dependent manners (P-trend = 0.005, and the genotype did constitute a risk factor for the development of advanced LC (Child-Pugh classification C and B, P-trend = 0.021. CONCLUSIONS/SIGNIFICANCE: rs430397 polymorphism may be a contributing factor to LC in persistent HBV carriers.

  15. Relationship between HBV DNA and HBeAg in serum and HBcAg and inflammation grad in liver tissue among patients with chronic hepatiti B

    Institute of Scientific and Technical Information of China (English)

    刘兴祥

    2014-01-01

    Objective To investigate the relationship between HBV DNA and HBeAg in serum and HBcAg and inflammation grade in liver tissue among chronic hepatitis B(CHB)patients.Methods A retrospective analysis was performed on 250 CHB patients who underwent liver biopsy.These patients were divided into three groups according to serum levels of HBV

  16. The Knowledge, Attitude and Practices regarding HBV Infection of Married Women in the Reproductive Age Group living in Cantonment Area, Sunjawan, Jammu

    Directory of Open Access Journals (Sweden)

    Rashmi Sharma, C.L. Sharma, Ruchi Khajuria

    2004-07-01

    Full Text Available The present study was conducted to know the knowledge, attitude and practices of 300 marriedwomen in the reproductive age group living in the cantonment area Sunjawan, Jammu regardingHBV infection. Only 20% of the women were found aware of the mode of transmission of HBV.However, 50% of the women were having the misconceptions regarding mode of transmission ofHBV. 4% of women, 30% of children up to 5 years and 15% of children above 5 years were fullyimmunized with hepatitis B vaccine. 80% of children up to 5 years and 75% of children above 5years were fully immunized as per universal immunization programme. Hence, the results of thestudy clearly indicated the low immunization rate with vaccine against HBV than that under universalimmunization programme and further potentiated the need for implementation of therecommendations in 9th five year plan of India regarding introduction of immunization againstHBV in universal immunization programme at the earliest .

  17. MOLECULAR EPIDEMIOLOGY FEATURES OF HBV/HDV CO-INFECTION IN KYRGYZSTAN

    Directory of Open Access Journals (Sweden)

    A. V. Semenov

    2016-01-01

    Full Text Available One of the most serious health problems in the world are hepatotropic viruses that cause chronic liver disease. Hepatitis B virus is distributed globally; around 5% of the carriers are also infected with hepatitis delta virus. Co-infection or superinfection of hepatitis viruses B and D significantly associated with a much more severe liver disease, compared with infection only hepatitis B virus. However, examination of hepatitis virus B carriers for the presence of hepatitis D virus in most regions of the world is not mandatory. It should be noted that the complete genotype mapping of viruses hepatitis B and D isolated on the territory of the CIS and the countries of the former Soviet Union, there is not yet, despite the constantly ongoing works devoted genotyping hepatotropic virus in the territory of the Russian Federation and neighboring countries. Due to the fact that one of the prospective ways of spreading viruses is the “labor migration” the inhabitants of Central Asia in other countries, including the Russian Federation, there is a need to pay attention to the situation of viral hepatitis in the region. The aim of our study was to estimate the prevalence of genetic variants and characteristics of molecular epidemiology of chronic viral hepatitis co-infection B + D in Kyrgyzstan. The study involved 30 plasma samples from patients with chronic viral hepatitis B and D from different regions of Kyrgyzstan. Based on the phylogenetic analysis of the isolates showed that among patients examined HBV identified only D genotype. Based on the phylogenetic analysis of the isolates indicated that among the examined patients with chronic viral hepatitis B revealed only genotype D. It is shown prevalence of HBV subtype D1 (73.34% compared to the HBV subtype D2 (3.33% and D3 (23.33%. Revealed HDV genotype I with highly variable region of the gene encoding the delta antigen. The high similarity of some isolates with strains specific to neighboring

  18. Is Universal HBV Vaccination of Healthcare Workers a Relevant Strategy in Developing Endemic Countries? The Case of a University Hospital in Niger

    Science.gov (United States)

    Pellissier, Gérard; Yazdanpanah, Yazdan; Adehossi, Eric; Tosini, William; Madougou, Boubacar; Ibrahima, Kaza; Lolom, Isabelle; Legac, Sylvie; Rouveix, Elisabeth; Champenois, Karen; Rabaud, Christian; Bouvet, Elisabeth

    2012-01-01

    Background Exposure to hepatitis B virus (HBV) remains a serious risk to healthcare workers (HCWs) in endemic developing countries owing to the strong prevalence of HBV in the general and hospital populations, and to the high rate of occupational blood exposure. Routine HBV vaccination programs targeted to high-risk groups and especially to HCWs are generally considered as a key element of prevention strategies. However, the high rate of natural immunization among adults in such countries where most infections occur perinatally or during early childhood must be taken into account. Methodology/Principal Findings We conducted a cross sectional study in 207 personnel of 4 occupational groups (medical, paramedical, cleaning staff, and administrative) in Niamey’s National Hospital, Niger, in order to assess the prevalence of HBV markers, to evaluate susceptibility to HBV infection, and to identify personnel who might benefit from vaccination. The proportion of those who declared a history of occupational blood exposure ranged from 18.9% in the administrative staff to 46.9% in paramedical staff. Only 7.2% had a history of vaccination against HBV with at least 3 injections. Ninety two percent were anti-HBc positive. When we focused on170 HCWs, only 12 (7.1%) showed no biological HBV contact. Twenty six were HBsAg positive (15,3%; 95% confidence interval: 9.9%–20.7%) of whom 8 (32%) had a viral load >2000 IU/ml. Conclusions/Significance The very small proportion of HCWs susceptible to HBV infection in our study and other studies suggests that in a global approach to prevent occupational infection by bloodborne pathogens, a universal hepatitis B vaccination of HCWs is not priority in these settings. The greatest impact on the risk will most likely be achieved by focusing efforts on primary prevention strategies to reduce occupational blood exposure. HBV screening in HCWs and treatment of those with chronic HBV infection should be however considered. PMID:22970218

  19. 携带乙型肝炎病毒产妇血清及乳汁HBV-DNA含量的研究%The contents of MBV-DNA in breast milk and serum of HBV positive pregnant patients

    Institute of Scientific and Technical Information of China (English)

    杨可吟; 朱桂莲

    2011-01-01

    目的 了解乙型肝炎血清学指标阳性母亲的血清与乳汁中HBV排泄率之间的关系,以及新生儿血清乙型肝炎病毒标志物(HBVM)表达的特点.方法 选择携带乙型肝炎病毒产妇97例,采用电化学发光原理检测产妇及其新生儿血清学标志物;采用实时荧光定量PCR法测定产妇血清及其乳汁中HBV-DNA含量.结果 携带乙型肝炎病毒产妇的乳汁中约10.0%存在潜在危险性;HBeAg阳性的血清和乳汁HBV-DNA阳性率明显高于阴性者,差异有统计学意义(P<0.05);HBeAg阳性母亲所生新生儿90.0%HBeAg也呈阳性,可能存在宫内感染.结论 对产前HBVM阳性的孕妇有条件均应检测血清HBV-DNA,对血清HBV-DNA阳性的产妇需进一步检测乳汁及新生儿HBV-DNA来指导母乳喂养.%OBJECTIVE To understand the relationship between serum markers of hepatitis B positive mothers in the serum and the excretion rate of HBV, and to make clear of the expression of neonatal serum HBVM features.METHODS A total of 97 cases of mothers carrying Hepatitis B virus were selected, and then the mothers and their neonates were detected by using electrochemiluminescence principle of maternal and neonatal serum markers; The real time quantitative PCR method was adopted for the determination and the maternal serum HBV-DNA content in breast milk. RESULTS Of the milk of mothers carrying hepatitis B virus, approximately 10. 0% of which were potentially dangerous. HBeAg positive HBV-DNA in serum and breast milk were significantly higher than that of the negative, the difference was statistically significant (P<0. 05). 90. 0% of the neonates of HBeAg positive mothers were also positive, there may be intrauterine infection. CONCLUSION HBVM-positive pregnant women should be performed the detection of HBV-DNA in serum in prenatal period, HBV-DNA positive in serum of maternal and newborn breast milk needs to be further detected to guide the breastfeeding.

  20. Relationship between mannose-binding protein gene polymorphisms and disease progression and HBV DNA in patients with chronic HBV infection%慢性HBV感染者甘露糖结合蛋白基因多态性与疾病进展及与HBV DNA相关性的研究

    Institute of Scientific and Technical Information of China (English)

    郑瑞丹; 陈哲; 陈建能; 高建平; 庄群瑛; 朱青川; 卢燕辉; 林震群; 洪伍华; 李庆端

    2012-01-01

    Objective To determine the influences of Mannose binding protein (MBP) gene polymorphisms on HBV DNA loads and on the progression of liver disease in patients with chronic HBV infeclion.Method The Codons on 54 MBP gene polymorphisms and HBV DNA loads in a cohort of 395 patients with chronic HBV infection,including 244 with chronic hepatitis B (CHB),151 with liver cirrhosis(LC) and 88 normal controls were examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and fluorescent quantitative PCR (FQ-PCR).Result The MBP genotype frequencies of GGC/GAC and alleles genetic frequencies of GAC in CHB group showed no significant differences comparing to the normal control group ( P > 0.05 ).The MBP genotype frequencies of GGC/GAC and alleles genetic frequencies of GAC on CHB group (severe),compensation phase of LC group and decompensation phase of LC group were higher than those in the normal control group (P < 0.05 ),the genetic polymorphism of decompensation of LC was 36.5 %,highest of all.The MBP genotype frequencies of GGC/GAC and alleles genetic frequencies of GAC of patients with chronic HBV infection were not changed with the differences of HBV-DNA loads.Conclusion The codes on 54 MBP gene polymorphisms is not closely related to HBV DNA loads,but was associated with the progression of hepatitis B infection.%目的 探讨慢性HBV感染者甘露糖结合蛋白(MBP)基因多态性对慢性乙型肝炎患者疾病进展的影响及与HBV DNA载量的关系.方法 采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法和实时荧光定量PCR(FQ-PCR)技术对244例慢性乙型肝炎患者、151例肝硬化患者和88名正常对照者的MBP基因第54号密码子多态性和血清HBV DNA载量进行检测.结果 CHB轻、中度组患者MBP基因GGC/GAC基因型频率和GAC等位基因频率与正常对照组比较差异无统计学意义(P>0.05);CHB重度组、代偿性LC组、失代偿性LC组MBP基因GGC/GAC

  1. Correlation analysis between HBsAg,HbeAg,HbeAb and HBcAb with HBV DNA in Lanzhou area and its clinical value%兰州地区 HBsAg、HBeAg、HBeAb、HBcAb 与 HBV DNA 的相关分析及临床价值

    Institute of Scientific and Technical Information of China (English)

    李彩东; 吴斌; 陈锡莲

    2014-01-01

    Objective To investigate the relationship between HBV DNA load with the serological markers(HB-M)HBsAg, HBeAg,HBeAb,HBcAb in the persons infected by chronic hepatitis B virus (HBV)in Lanzhou.Methods The real-time fluores-cent quantitative PCR was used to detect the HBV DNA load and the double antibody sandwich chemiluminesent immunoassay was used to measure the serum HBsAg,HbeAg,HbeAb and HbcAb levels in 724 cases of HBVinfection.Results The HBsAg level was positively correlated with the HBV DNA load in chronic HBV infection in Lanzhou area(r=0.342,P <0.05),there was an ob-vious positive correlation between HBeAg and HBV DNA load(r=0.463,P <0.05),the HBeAb level and HBV DNA load had the negative correlation (r=-0.227,P =0.001),the HBcAb level and HBV DNA load had no significantly correlation (r=-0.062, P =0.366).Conclusion There is obvious positive correlation between HBV DNA load with HBsAg,HBeAg in chronic HBV infec-tion in Lanzhou area,which indicating that the observation by combining HBsAg and HBeAg with HBV DNA can judge the infec-tious degree of the patients more accurately.%目的:探讨兰州地区慢性乙型肝炎病毒(HBV)感染者血清乙型肝炎病毒脱氧核糖核酸(HBV DNA)载量与乙型肝炎病毒血清学标志物(HBV-M)HBsAg、HBeAg、HBeAb、HBcAb 的相关性。方法724例 HBV 感染者分别利用实时荧光定量PCR 法检测 HBV DNA 载量,运用双抗体夹心化学发光免疫分析法检测血清 HBsAg、HBeAg、HBeAb、HBcAb 水平。结果兰州地区慢性 HBV 感染者 HBsAg 水平与 HBV DNA 载量呈正相关关系(r=0.342,P <0.05),HBeAg 水平与 HBV DNA 载量呈正相关关系(r=0.463,P <0.05),HBeAb 水平与 HBV DNA 载量之间呈负相关关系(r =-0.227,P =0.001),HBcAb 水平与HBV DNA 载量变化无相关性(r=-0.062,P =0.366)。结论兰州地区慢性 HBV 感染者 HBV DNA 载量和 HBsAg、HBeAg均有明显的正相关

  2. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil

    Directory of Open Access Journals (Sweden)

    M.L.A. Oliveira

    1999-09-01

    Full Text Available Viral hepatitis constitutes a major health issue, with high prevalence among injecting drug users (IDUs. The present study assessed the prevalence and risk determinants for hepatitis B, C and D viruses (HBV, HCV and HDV infections among 102 IDUs from Rio de Janeiro, Brazil. Serological markers and HCV-RNA were detected by enzyme immunoassay and nested PCR, respectively. HCV genotyping was determined by restriction fragment length polymorphism analysis (RFLP. HBsAg, anti-HBc and anti-HBs were found in 7.8, 55.8 and 24.7% of IDUs, respectively. In the final logistic regression, HBV infection was independently associated with male homosexual intercourse within the last 5 years (odds ratio (OR 3.1; 95% confidence interval (CI 1.1-8.8. No subject presented anti-delta (anti-HD. Anti-HCV was detected in 69.6% of subjects, and was found to be independently associated with needle sharing in the last 6 months (OR 3.4; 95% CI 1.3-9.2 and with longer duration of iv drug use (OR 3.1; 95% CI 1.1-8.7. These data demonstrate that this population is at high risk for both HBV and HCV infection. Among IDUs from Rio de Janeiro, unprotected sexual intercourse seems to be more closely associated with HBV infection, whereas HCV is positively correlated with high risk injecting behavior. Comprehensive public health interventions targeting this population and their sexual partners must be encouraged.

  3. Serum C-reactive protein predicts early mortality in hospitalized patients with HBV-related decompensated cirrhosis.

    Science.gov (United States)

    Zhu, ShaoMing; Waili, Yulituzi; Qi, XiaoTing; Chen, YueMei; Lou, YuFeng; Chen, Bo

    2017-01-01

    The serum C-reactive protein (CRP) is an inflammatory marker. The aim of the present study was to elucidate whether CRP could serve as a potential surrogate marker for 30-day mortality in hospitalized patients with HBV-related decompensated cirrhosis (HBV-DeCi).This was a retrospective cohort study that included 140 patients with HBV-DeCi. All patients were followed up for 1-month. A panel of clinical and biochemical variables were analyzed for potential associations with outcomes using multiple regression models.The serum CRP was significantly higher in nonsurviving patients than in surviving patients. Multivariate analysis demonstrated that CRP levels (odds ratio: 1.047, P = 0.002) and the model for end-stage liver disease score (odds ratio: 1.370, P = 0.001) were independent predictors for mortality.Serum CRP is a simple marker that may serve as an additional predictor of 1-month mortality in hospitalized patients with HBV-DeCi.

  4. Determination of HBV Genotypes among Hbs Ag Positive Blood Donors in Tehran, Iran Using PCR-RFLP

    Directory of Open Access Journals (Sweden)

    S Milani

    2009-03-01

    Full Text Available Background: Hepatitis B virus (HBV is one of the major causative agents of acute and chronic liver disease worldwide and is believed to be responsible for a million deaths annually. On the basis of a comparison of complete genomic se­quences, HBV has been classified into eight genotypes A-H which show a geographical distribution. Some genotypes are associ­ated with different clinical outcomes. Identification of HBV genotypes is important to begin and follow up the treat­ment."nMethods: In this cross-sectional study, the serum samples of blood donors were collected from Tehran Blood Transfusion Cen­ters in period during "2005-2006". Sera of 55 blood donors who were positive for hepatitis B surface antigen were se­lected. DNA was extracted using commercial kit and the S gene sequence was amplified by nested-PCR. PCR products were then analyzed for restriction enzymes that would be genotype specific."nResults: Genotype D was found the only type in all HBV DNA positive serum samples, in Tehran."nConclusion: Genotype D is dominant among Tehran's blood donors, which is consistent with Iran and the Middle East domi­nant genotype.  

  5. 献血人群血清anti-HBC和HBV DNA检测的意义

    Institute of Scientific and Technical Information of China (English)

    朱紫苗; 谢步飞

    2014-01-01

    目的 探讨无偿献血者乙型肝炎病毒核心抗体与隐匿性感染的关系.方法 收集无偿献血者样本9 100份,采用ELISA法进行HBsAg和anti-HBC血清学筛查,对anti-HBC阳性血清PCR检测乙肝病毒核酸.结果 911份(10.01%)标本为anti-HBC阳性,其中820份(90.01%)HBsAg阴性,34例血清HBV DNA阳性.结论 常规检测对于献血者筛查具有重要意义.

  6. Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011

    DEFF Research Database (Denmark)

    Christensen, Peer Brehm; Clausen, Mette Rye; Krarup, Henrik Bygum;

    2012-01-01

    The Danish Society of Infectious Diseases and Danish Society of Gastroenterology and Hepatology set up a committee in 2007 to produce national guidelines for treatment of viral hepatitis B and C. The 2011 version of the guidelines have been endorsed by the scientific societies and are presented...... is not common in Denmark. The prevalence has not been determined by national surveys, but it is estimated that 10,000-15,000 patients are chronically infected with hepatitis B and 15,000-20,000 with chronic hepatitis C. The majority of patients with HBV infection in Denmark are emigrants from high endemic...... for their chronic viral hepatitis. Clinical care: According to the Danish National Board of Health, patients with chronic viral hepatitis should be followed with regular intervals, at clinics specialized in either infectious diseases or gastroenterology/hepatology. The primary aim is to identify patients...

  7. Subfulminant hepatitis B after infliximab in Crohn's disease:Need for HBV-screening?

    Institute of Scientific and Technical Information of China (English)

    Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel

    2006-01-01

    Infections are a major adverse effect during the treatment with anti-TNF-α. While exclusion of any bacterial infection and screening for tuberculosis are mandatory before initiating a therapy with anti-TNFα-antibodies, there are no guidelines whether to screen for or how to deal with chronic viral infections such as hepatitis B. In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state. He recovered completely after lamivudine therapy was started, but this severe adverse event could have been prevented if screening for HBV and pre-emptive therapy with lamivudine would have been started prior to infliximab.We therefore strongly argue in favor of extended screening recommendations for infectious diseases including viral infections before considering a therapy with infliximab.

  8. Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011

    DEFF Research Database (Denmark)

    Christensen, Peer Brehm; Clausen, Mette Rye; Krarup, Henrik;

    2012-01-01

    The Danish Society of Infectious Diseases and Danish Society of Gastroenterology and Hepatology set up a committee in 2007 to produce national guidelines for treatment of viral hepatitis B and C. The 2011 version of the guidelines have been endorsed by the scientific societies and are presented...... is not common in Denmark. The prevalence has not been determined by national surveys, but it is estimated that 10,000-15,000 patients are chronically infected with hepatitis B and 15,000-20,000 with chronic hepatitis C. The majority of patients with HBV infection in Denmark are emigrants from high endemic...... below. Annual updates will be available at the websites of the societies. As this present English version has been written six months after the Danish 2011 version, it contains minor changes that will be integrated in the Danish 2012 version, available at the end this year. Epidemiology: Viral hepatitis...

  9. DNA immunization with fusion genes containing HCV core region and HBV core region

    Institute of Scientific and Technical Information of China (English)

    杨莉; 刘晶; 孔玉英; 汪垣; 李光地

    1999-01-01

    The eucaryotic expression plasmids were constructed to express the complete (HCc191) or the truncated (HCc69 and HCc40) HCV core genes, solely or fused with the HBV core gene (HBc144). These constructions were transiently expressed in COS cells under the control of the CMV promoter. The antigenicity of HBc and HCc could be detected in the expression products by ELISA and Western blot. The mice immunized with these expression plasmids efficiently produced the anti-HCc antibodies, and also anti-HBc antibodies when the plasmids contained the fusion genes. In addition, the antibodies induced by the fusion genes were more persistent than those induced by the non-fusion HCV core genes. These indicate that the fusion of HCc genes to HBc gene is in favor of the immunogenicity of HCc, while the immunogenicity of HBc is not affected.

  10. Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents – A Longitudinal Study in Real Life

    Science.gov (United States)

    Pawłowska, Małgorzata; Smok, Beata; Rajewski, Paweł; Wietlicka-Piszcz, Magdalena; Halota, Waldemar; Tretyn, Andrzej

    2016-01-01

    This study evaluated the long-term (up to 4 years) efficacy and safety of entecavir ETV treatment and analysed the significance of baseline and on-treatment factors in long-term ETV outcomes in adolescents with chronic hepatitis B (CHB). We determined the cumulative virological and serological outcomes of 44 adolescents with CHB receiving ETV for up to 4 years. To investigate the dynamics of HBV DNA, ALT activity and hepatitis B e antigen (HBeAg) seroconversion over time and their associations with the considered factors, generalized estimating equation (GEE) models were used. The cumulative rates of undetectable HBV DNA (<20 IU/ml) and HBeAg seroconversion after 4 years were 89.7% and 55.4%, respectively. In the study group, we showed that having undetectable HBV DNA at the 6th or 12th month of therapy predicted the achievement of a sustained response rate (SRR, defined as the loss of HBV DNA, loss of HBeAg and ALT normalization) at year 3 of ETV therapy (P = 0.048, OR = 5.83; P = 0.012; OR = 14.57, respectively). The GEE analysis indicated that of the different factors, the duration of ETV therapy had a strong impact on the achievement of virological suppression, HBeAg seroconversion and SRR in adolescents. Each month after the initiation of therapy, the odds of loss of HBV DNA increased by approximately 5% (OR = 1.05, P<0.0001), on average. Additionally, the GEE analysis revealed that adolescents with an age at infection of ≥10 years had 3 times higher odds of achieving undetectable HBV DNA than patients with a younger infection age (OR = 3.67, P = 0.028). None of the ETV-treated patients reported significant adverse effects. ETV is an effective and safe treatment option for adolescents with CHB. Undetectable HBV DNA in the 6th and/or 12th month of ETV treatment and older age at infection could predict maintained virological suppression. PMID:27685782

  11. Test

    DEFF Research Database (Denmark)

    Bendixen, Carsten

    2014-01-01

    Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers.......Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers....

  12. Epidemiological determinants of occupational exposure to HIV, HBV and HCV in health care workers

    Directory of Open Access Journals (Sweden)

    Hadadi A

    2007-10-01

    Full Text Available Background: Health care workers (HCWs are at substantial risk of acquiring bloodborne pathogen infections through contact with blood and other potentially infectious materials. The main objectives of this study were to determine the epidemiological characteristics of occupational exposure to blood/body fluids, related risk factors of such exposure, and hepatitis B vaccination status among HCWs."nMethods: This cross-sectional study was conducted from December 2004 to June 2005 at three university hospitals in Tehran, Iran. Using a structured interview, we questioned HCWs who had the potential for high-risk exposure during the year preceding the study."nResults: With a total number of 467 exposures (52.9% and an annual rate of 0.5 exposures per HCW, 391 (43% of the 900 HCWs had at least one occupational exposure to blood and other infected fluids during the previous year. The highest rate of occupational exposure was found among nurses (26% and the housekeeping staff (20%. These exposures most commonly occurred in the medical and emergency wards (23% and 21%, respectively. The rate of exposure in HCWs with less than five years of experience was 54%. Percutaneous injury was reported in 280 participants (59%. The history of hepatitis B vaccination was positive in 85.93% of the exposed HCWs. Sixty-one percent had used gloves at the time of exposure. Hand washing was reported in 91.4% and consultation with an infectious disease specialist in 29.4%. There were 72 exposures to HIV, HBV and HCV; exposure to HBV was the most common. In 237 of the enrolled cases, the source was unknown. Job type, years of experience and hospital ward were the risk factors for exposure."nConclusion: Education, protective barriers and vaccination are important in the prevention of viral transmission among HCWs.

  13. The hydrological response of the Ourthe catchment to climate change as modelled by the HBV model

    Directory of Open Access Journals (Sweden)

    T. L. A. Driessen

    2009-11-01

    Full Text Available The Meuse is an important river in western Europe, and almost exclusively rain-fed. Projected changes in precipitation characteristics due to climate change, therefore, are expected to have a considerable effect on the hydrological regime of the river Meuse. We focus on an important tributary of the Meuse, the Ourthe, measuring about 1600 km2. The well-known hydrological model HBV is forced with three high-resolution (0.088° regional climate scenarios, each based on one of three different IPCC CO2 emission scenarios: A1B, A2 and B1. To represent the current climate, a reference model run at the same resolution is used. Prior to running the hydrological model, the biases in the climate model output are investigated and corrected for. Different approaches to correct the distributed climate model output using single-site observations are compared. Correcting the spatially averaged temperature and precipitation is found to give the best results, but still large differences exist between observations and simulations. The bias corrected data are then used to force HBV. Results indicate a small increase in overall discharge for especially the B1 scenario during the beginning of the 21st century. Towards the end of the century, all scenarios show a decrease in summer discharge, partially because of the diminished buffering effect by the snow pack, and an increased discharge in winter. It should be stressed, however, that we used results from only one GCM (the only one available at such a high resolution. It would be interesting to repeat the analysis with multiple models.

  14. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Xiao-Hong Liu; Jing Lin; Shu-Hui Zhang; Shun-Min Zhang; Mark A Feitelson; Heng-Jun Gao; Ming-Hua Zhu

    2008-01-01

    AIM:To investigate the hepatitis B virus (HBV) x gene (HBx) state in the tissues of HBV-related hepatocellular carcinoma (HCC) in Chinese patients and whether there were particular HBx mutations.METHODS:HBx gene was amplified and direct sequencing was used in genomic DNA samples from 20HCC and corresponding non-cancerous liver tissues from HBsAg-positive patients.HBV DNA integration and HBx deleted mutation were validated in 45 HCC patients at different stages by Southern blot analysis and polymerase chain reaction methods.RESULTS:The frequencies of HBx point mutations were significantly lower in HCC than their corresponding non-cancerous liver tissues (11/19 vs 18/19,P = 0.019).In contrast,deletions in HBx gene were significantly higher in HCC than their non-cancerous liver tissues (16/19 vs 4/19,P<0.001).The deletion of HBx COOH-terminal was detected in 14 HCC tissues.A specific integration of HBx at 17p13 locus was also found in 8 of 16 HCC,and all of them also exhibited full-length HBx deletions.Integrated or integrated coexistence with replicated pattern was obtained in 45.5% (20145)-56.8% (25145)tumors and 40.9% (18/45)-52.3% (23/45) non-tumor tissues.CONCLUSION:HBx deletion,especially the COOH-terminal deletion of HBx is a frequent event in HBV-associated HCC tissues in China.HBV integration had also taken place in partial HCC tissues.This supporting the hypothesis that deletion and probably integrated forms of the HBx gene may be implicated in liver carcinogenesis.

  15. Preparation of DNA Template Library for HBV Infected Person%HBV感染者DNA模板库的制备

    Institute of Scientific and Technical Information of China (English)

    邓春青; 冯珊珊

    2015-01-01

    Objective:To extract human genomic DNA with HBV infection,and preparation of DNA template for studying the genetic polymorphism of HBV infection.Method:HBV infection of human anticoagulant whole blood were collected,Human genomic DNA was extracted by Miller’s Method.Result:DNA template in HBV infected person included asymptomatic carrier,chronic hepatitis,severe hepatitis,liver cirrhosis and hepatocellular carcinoma,and part of a healthy blood donors were collected at the same time.Conclusion:The template library is mainly HBV persistent infection,extracted DNA with Miller’s Method has high purity and stability.%目的:提取乙型肝炎病毒感染人群基因组DNA,并制备成DNA模板供予HBV感染相关的基因多态性研究之用。方法:收集HBV感染人群抗凝全血,采用盐析法提取基因组DNA。结果:收集的HBV感染人群包括无症状携带者、慢性肝炎、重型肝炎、肝硬化以及肝癌,同时收集了一部分健康献血员病例。结论:模板库中主要为HBV持续感染病例,采用盐析法提取的DNA纯度高且稳定。

  16. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes

    Directory of Open Access Journals (Sweden)

    Francisco Campello do Amaral Mello

    2012-05-01

    Full Text Available The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil. Here, hepatitis B virus (HBV DNA positivity, drug resistance mutations and their association with HBV genotypes were evaluated in chronically HBV-infected patients under different drug regimens in Brazil. The study involved 129 patients under interferon or nucleos(tide analogue therapy for a median treatment time of 12 months. One hundred and five (81% of these patients were treated with lamivudine (LAM, either in monotherapy or in combination with newer drugs, such as entecavir (ETV or tenofovir (TDF. High (37.5-100% rates of HBV DNA positivity were observed with all but one drug regimen (LAM + ETV. However, patients that were treated with ETV alone, TDF alone or with LAM combination therapies had a mean viral load that was 3-4 log lower than patients treated with LAM monotherapy. Of the patients treated with LAM, 47% developed resistance mutations. HBV genotypes A (59.1%, D (30.3% and F (9.1% were found. There was no association between the presence of LAM resistance mutations and genotypes, HBeAg status or treatment duration. Nevertheless, the rtM204V mutation was observed more frequently (12/13, 92% in genotype A than in the others (p = 0.023. Six out of nine isolates that contained the rtM204I mutation belonged to genotype D and half of them displayed a single mutation. Genotype D isolates with the rtM204V variant preferentially displayed a triple mutation, while genotype A preferentially displayed a double mutation (p = 0.04.

  17. Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment

    Institute of Scientific and Technical Information of China (English)

    Li Minran; Xi Hongli; Wang Qinhuan; Hou Fengqin; Huo Na; Zhang Xiaxia; Li Fang

    2014-01-01

    Background Knowledge on Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B (CHB) patients with longterm adefovir dipivoxil (ADV) treatment is limited.The aims of this study were to investigate HBsAg kinetics in patients with chronic hepatitis B virus (HBV) infection treated with long-term ADV and to evaluate different characteristics between patients with and without HBsAg loss.Methods We retrospectively evaluated HBsAg kinetics in 24 Chinese patients with chronic HBV infection who achieved continuous virologic suppression during ADV therapy.HBV genotype was determined at baseline.Liver biochemistry,hepatitis B e antigen status,serum HBV DNA,and HBsAg levels were measured at baseline,6 months,and once every year thereafter.Results Of these 24 patients,3,1,and 20 patients were followed up for 3,5,and 6 years,respectively.Baseline serum HBsAg level had a moderate correlation with baseline HBV DNA level (r=0.52,P=0.01).The median rate of HBsAg reduction during the therapy period was 0.08 Ig IU·ml-1·y-1.Baseline serum HBsAg level was significantly higher than other time points (P ranges from 0.046 to 0.002).The HBsAg reduction rate during the first year was similar to that in other years (P>0.05).The HBsAg reduction rate during the first year in patients with eventual HBsAg loss was significantly faster than that in patients without HBsAg loss (P=0.005).Conclusions Serum HBsAg levels in Chinese CHB patients receiving long-term ADV demonstrated a gradual reduction.Patients with eventual HBsAg loss had a significantly faster HBsAg reduction rate during the first year than those without HBsAg loss.

  18. Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART.

    Directory of Open Access Journals (Sweden)

    Jennifer Audsley

    Full Text Available BACKGROUND: Previous studies have demonstrated that hepatitis B virus (HBV infection increases the risk for ALT elevations in HIV-HBV co-infected patients during the first year of HAART; however, there is limited data on the prevalence of ALT elevations with prolonged HAART in this patient group. METHODS/PRINCIPAL FINDINGS: To identify factors associated with ALT elevations in an HIV-HBV co-infected cohort receiving prolonged HAART, data from 143 co-infected patients on HAART enrolled in an international HIV-HBV co-infected cohort where ALT measurements were obtained every 6 months was analysed. A person-visit analysis was used to determine frequency of ALT elevation (≥ 2.5×ULN at each visit. Factors associated with ALT elevation were determined using multivariate logistic regression with generalized estimating equations to account for correlated data. The median time on HAART at the end of follow-up was 5.6 years (range 0.4-13.3 years. During follow-up, median ALT was 36 U/L with 10.6% of person-visits classified as having ALT elevation. Most ALT elevations were grade 2 (86.5%, with only 13.5% of all ALT elevations grade 3 or higher. Univariate associations with ALT elevation (p1 year of HAART was uncommon, and severe ALT elevations were rare. HIV-HBV co-infected patients on long-term HAART who are either HBeAg positive or have a CD4 count of <200 cells/ml are at increased risk for ALT elevations.

  19. 乙型肝炎病毒感染产妇乳汁中乙型肝炎病毒DNA载量对母乳喂养的指导意义%Instructional significance of HBV-DNA load in maternal milk on breasffeeding of postpartum women infected with HBV

    Institute of Scientific and Technical Information of China (English)

    何佳英; 张迎华; 张永乐; 黄荷凤

    2011-01-01

    目的 探讨乙型肝炎病毒(HBV)感染产妇乳汁中HBV-DNA病毒载量对母乳喂养的指导意义.方法 对2008-2010年在某院住院的152例HBV感染产妇,采用荧光PCR技术检测其外周血清及乳汁中HBV-DNA病毒载量水平,并以1.0×103 U/ml为判断临界值,分析血清和乳汁中HBV-DNA病毒载量之间的关系.结果 152例HBV感染产妇血清和乳汁中HBV-DNA载量大于1.0×103 U/ml者分别占50.66% (77/152)和36.18%(55/152).血清和乳汁HBV DNA载量与乙肝病毒e抗原(HBeAg)是否阳性相关,HBeAg阳性时血清和乳汁中HBV-DNA载量大于1.0×103 U/ml者分别占95.38%( 62/65)和76.92%( 50/65),HBeAg阴性时分别为17.24%(15/87)和5.75%(5/87).血清HBV-DNA与乳汁HBV-DNA载量存在相关性,当血清HBV-DNA载量为3~4 lg U/ml时,乳汁中HBV-DNA检出率仅为20.00% (5/25),在血清HBV-DNA载量大于5 lg U/ml时,乳汁中HBV-DNA检出率达96.15%( 50/52).结论 HBV感染产妇乳汁中HBV-DNA载量随着血清中HBV-DNA载量升高而升高,当乳汁中存在HBV-DNA病毒大于1.0×103 U/ml时,应避免母乳喂养.%Objective To study the instructional significance of HBV-DNA load in maternal milk on breastfeeding of postpartum women infected with HBV.Methods HBV-DNA levels in serum and breast milk were detected by FQ-PCR in 152 postpartum women infected with HBV,and HBV-DNA ≥ 1.0 × 103 U/ml was defined as HBV positive.Correlation analysis was also conducted to estimate if there were relations in HBV levels in serum and breast milk.Results HBV-DNA positive rate were 50.66% (77/152) and 36.18% (55/152) in serum and breast milk,respectively.When HBeAg was positive,HBV-DNA positive rate were 95.38% (62/65)and 76.92% (50/65)in serum and breast milk; however when HBeAg was negative,HBV-DNA positive rate were 17.24% (15/87) and 5.75% ( 5/87 ) in serum and breast milk.When the concentration of HBV-DNA was 3 -4 lg U/ml in serum,HBV-DNA positive rate was 20.00% ( 5/25 ) in breast

  20. Influence of Paternal Serum HBV-DNA Load Levels and Pregnant Women's HBsAb on Paternal Vertical Transmission of Hepatitis B Virus%父亲血清HBV-DNA载量和孕母HBsAb对HBV父婴垂直传播的影响

    Institute of Scientific and Technical Information of China (English)

    陈顺萍; 张荣莲; 任坤海

    2014-01-01

    目的 探讨父亲血清HBV-DNA载量和孕母HBsAb对乙肝病毒(HBV)父婴垂直传播发生的影响,以期寻找阻断HBV父婴垂直传播的有效方法.方法 在患者知情同意的前提下,以HBsAg及HBV-DNA为指标筛检父亲HBsAg阳性、孕母HBVM全阴或者仅HBsAb阳性及HBV-DNA均为阴性的121个家庭作为研究对象,依据其新生儿脐带血HBV-DNA检测结果作为分组标准,将HBV-DNA检测阳性23例作为病例组,阴性98例作为对照组,进行病例对照研究.结果 ①新生儿脐带血HBV-DNA阳性率为19.0% (23/121);②父亲血清HBV-DNA载量与新生儿脐带血HBV-DNA阳性率存在剂量反应关系(趋势x2=60.108,P=0.000),受试者工作特征曲线(ROC曲线)分析表明:父亲血清HBV-DNA载量106拷贝/mL是预测HBV垂直传播发生较好的分界点;③孕母HBsAb阳性组与HBsAb阴性组其新生儿脐带血HBV-DNA阳性率差异有统计学意义(x2=12.399,P=0.000),当父亲血清HBV-DNA载量≥107拷贝/mL时,两组新生儿脐带血HBV-DNA阳性率差异无统计学意义(P>0.05).结论 父亲血清HBV-DNA阳性和孕母HBsAb阴性是HBV父婴垂直传播的危险因素,父亲血清HBV-DNA载量106拷贝/mL是较好的垂直传播发生的预测指标.

  1. Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS.

    Science.gov (United States)

    He, X; Wang, Y; Zhang, W; Li, H; Luo, R; Zhou, Y; Liao, C Li M; Huang, H; Lv, X; Xie, Z; He, M

    2014-01-01

    Hepatocellular carcinoma(HCC) is serious condition associated with a high morbidity and mortality. Therefore is an urgent need to develop novel noninvasive techniques for early diagnosis, particularly for patients with AFP-negative [AFP(-)] HCC. In this study, iTRAQ-MALDI-MS/MS was used to identify differentially expressed proteins in AFP(-) HBV-related HCC compared with non-cancerous hepatitis B virus (HBV) and healthy controls subjects.Serum was obtained from 18 patients with AFP(-) HBV-related HCC, 18 matched patients with HBV without HCC and 18 healthy control subjects. High abundance proteins were removed from serum and the differentially expressed proteins from the three groups were screened out using iTRAQ-MALDI-MS/MS. The Gene Ontology (GO) function and the interaction networks of differentially expressed proteins were then analyzed. A total of 24 expressed differential proteins associated with AFP(-) HBV-related HCC were screened out, 15 proteins were up-regulated and 9 down-regulated. The most common molecular function of the 24 differentially expressed proteins was enzyme inhibition. Interaction network of the 24 differentially expressed proteins showed that 14 proteins (C5, KNG1, FN1, LRG1, HRG, SERPINC1, CRP, APOB, SAA1, APCS, C4BPA, CFI, CFB and GSN) were central to the functional network. The expression levels of the GSN protein were down-regulated in AFP(-) HBV-related HCC subjects compared with healthy controls and the HBV group (pAFP(-) HBV-related HCC appeared at the fulcrum of the functional network and were differentially expressed compare to HBV and healthy controls suggesting a possible association with HCC progression.

  2. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2015-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  3. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2016-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  4. HBx及其截短体在乙型肝炎病毒复制中的作用%Role of HBx and truncated HBx in HBV replication

    Institute of Scientific and Technical Information of China (English)

    杨旋; 何松

    2012-01-01

    HBV感染作为引起慢性乙型肝炎、乙肝后肝硬化、原发性肝癌(hepatocellular carcinoma,HCC)的起始因素,已成为世界性的健康问题.据统计,目前世界上已有超过5亿人感染HBV,每年有1百万人死于乙肝相关疾病.HBx蛋白作为HBV的一个多功能调节蛋白,已被证实在HCC的发生过程中起了重要作用.近年来,关于乙肝病毒X蛋白(HBV X protein,HBx)影响HBV的复制研究也有了一定的进展.同时,越来越多的HBx截短体在肝病发展过程中的作用也被重视.本文将对HBx及其截短体在HBV复制中的作用作一综述.%As one of the principal causes of liver diseases, such as chronic hepatitis B, hepatic cirrhosis and hepatocellular carcinoma (HCC), hepatitis B virus (HBV) infection has been a major health problem worldwide. It is estimated that more than 500 million individuals have been infected with HBV worldwide and 1 million die of HBV infection-associated diseases annually. HBV X protein (HBx) is a multifunctional protein that can modulate various cellular processes and plays a crucial role in the pathogenesis of HCC. In recent years, the role of HBx in HBV replication has been more or less confirmed. In addition, more and more natural HBx truncated mutants and their roles in HBV replication have been found. This review aims to elucidate the roles of HBx and truncated HBx in HBV replication.

  5. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule

    Directory of Open Access Journals (Sweden)

    Collard Alix

    2010-10-01

    Full Text Available Abstract Background Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheria-tetanus-whole cell pertussis vaccine combined with hepatitis B and Haemophilus influenzae type b vaccines, containing a reduced amount of polyribosyl-ribitol-phosphate (PRP and a DTPw component manufactured at a different site (DTPw-HBV/Hib2.5 [Kft]. The primary aim of this study was to demonstrate that DTPw-HBV/Hib2.5 [Kft] was not inferior to the licensed DTPw-HBV/Hib (Tritanrix(tm-HepB/Hiberix(tm vaccine or the DTPw-HBV/Hib2.5 vaccine, also containing a reduced amount of PRP, with respect to the immune response to the PRP antigen, when administered to healthy infants, according to the Expanded Programme for Immunization (EPI schedule at 6, 10 and 14 weeks of age. Methods 299 healthy infants were randomised to receive either DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib2.5 or DTPw-HBV/Hib according to the 6-10-14 week EPI schedule. Blood samples were analysed prior to the first dose of study vaccine and one month after the third vaccine dose for the analysis of immune responses. Solicited local and general symptoms such as pain, redness and swelling at the injection site and drowsiness and fever, unsolicited symptoms (defined as any additional adverse event and serious adverse events (SAEs were recorded up to 20 weeks of age. Results One month after the third vaccine dose, 100% of subjects receiving DTPw-HBV/Hib2.5 [Kft] or DTPw-HBV/Hib and 98.8% of subjects receiving DTPw-HBV/Hib2.5 vaccine had seroprotective levels of anti-PRP antibodies (defined as anti-PRP antibody concentration ≥0.15 μg/ml. Seroprotective antibody concentrations were attained in over 98.9% of subjects for diphtheria, tetanus and hepatitis B. The vaccine response rate to pertussis antigen was at least 97.8% in each group. Overall, the DTPw-HBV/Hib2.5 [Kft

  6. HBV相关慢加亚急性肝衰竭患者中Th17细胞、Treg细胞的变化及其与肝功能和HBV-DNA载量间的研究%Change of Th17 cell, Treg cell in patients with HBV-associated acute-on-chronic liver failure and its relationship with liver function and HBV-DNA load

    Institute of Scientific and Technical Information of China (English)

    沈敏; 林明强; 冯奇桃; 吕友凯; 李永武

    2016-01-01

    Objective To detect the levels of Th7 and Treg cells in patients with hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) and to analyze the effect of Th7 and Treg cells in the pathogenesis of HBV-ACLF. Methods The frequency of Th17 and Treg cells in peripheral blood of 22 patients with HBV-ACLF (HBV-ACLF group), 24 patients with chronic hepatitis B (CHB group) and 20 healthy controls (HC group) were deter-mined by flowcytometry. HBV-DNA loads were measured by fluorescent PCR. Finally, the correlations among Th17, Treg, Th17/Treg, alanine aminotransferase (ALT), aspertate aminotransferase (AST), total bilirubin (TB) and HBV-DNA loads were analyzed. Results The levels of Th17, Treg and Th17/Treg in HBV-ACLF group were significantly higher than those in CHB group and HC group, and the levels in CHB group were significantly higher than those in HC group (P0.05). Conclusion Th17 and Treg may be in a balanced state in healthy people, and such state might be broken in patients with CHB and HBV-ACLF, which indicates that Th17 and Treg are involved in the occurrence and development of CHB and HBV-AVLF. Th17 cell could be used as an immunological marker for determination of the liver damage degree in HBV-ACLF. Th17, Treg have no correlation with the load of HBV-DNA.%目的:通过检测乙型肝炎病毒(HBV)相关慢加亚急性肝衰竭(HBV-ACLF)患者外周血中的Th17细胞、Treg细胞的水平,探讨Th17、Treg细胞在HBV-ACLF发病机制中的作用。方法流式细胞术检测22例HBV-ACLF患者、24例慢性乙型肝炎患者(CHB)以及20例健康对照者(HC)外周血Th17、Treg细胞的频率,荧光定量PCR法检测患者外周血HBV-DNA水平,同时分析Th17细胞、Treg细胞、Th17/Treg与谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TB)及HBV-DNA载量间的相关性。结果 HBV-ACLF组患者的Thl7细胞、Treg细胞、Th17/Treg较CHB组和HC组明显增高,CHB组又较HC组Th17细胞、Treg细胞、Th17

  7. 乙型肝炎病毒核酸检测试剂临床应用的分析%Evaluation of multiplex nucleic acid testing assays for screening of hepatitis B virus DNA in blood donation process

    Institute of Scientific and Technical Information of China (English)

    周诚; 吴星; 黄维金; 蓝海云; 辜文洁; 祁自柏; 梁争论; 李河民

    2008-01-01

    Objective To evaluate the multiplex nucleic acid testing (NAT) assays for HBV,HCV and HIV in detecting HBV DNA in plasma samples. Methods 534 plasma samples collected form several areas were detected with Abbott Architect i2000 HBsAg, ani-HBs, HBeAg, anti-HBe, anti-HBc and anti-HBc IgM diagnostic kits. HBV DNA levels of those samples were detected with Roche COBAS AmpliPrep/ COBAS TaqMan HBV Test. Two kinds of multiplex NAT assays for HBV, HCV and HIV were used to test HBV DNA of those 534 samples. Results of serology-markers and quantitative HBV DNA levels with results of NAT were compared. Results HBV DNA was positive in all 81 HBsAg, HBeAg and anti-HBc positive samples,detected by both of NAT assays. HBV DNA was positive in 11 and 19 of 200 HBsAg negative samples when detected with the two kinds of NAT assays separately. Compared with the quantitative results detected by Roche COBAS AmpliPrep/COBAS TaqMan HBV Test, the HBV DNA positive rates were 96.9% and 94.3% in 193 samples of HBV DNA levels over 500 IU/ml while 40.2% and 45.3% in 117 samples of HBV DNA levels below 500